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Abstract 
During the course of this PhD, methodology for the synthesis of a series of novel, highly fluorescent 
pyridine-derived α-amino acids was developed. Enone-derived α-amino acids were subjected to an 
inverse electron demand hetero-Diels-Alder cycloaddition and aromatisation reaction, which led to 
a twelve-membered library of pyridine analogues. The optical properties of these compounds were 
analysed, with several exhibiting interesting fluorescent characteristics. One of the analogues was 
incorporated into a cell penetrating pentapeptide via solid phase peptide synthesis. The resulting 
hexapeptide was incubated with human fibroblast cells and fluorescence microscopy was used to 
show accumulation of the peptide in the cells.  
 
 
 
The total syntheses of piperidine containing natural products, spruce alkaloid and (+)-241D were 
also examined during this PhD. A short nine-step linear sequence was developed giving spruce 
alkaloid and (+)-241D in 21% and 19% overall yield, respectively. A base mediated 6-endo-trig 
cyclisation was employed as the key-step followed by stereoselective ketone reduction to complete 
the total syntheses. The scope of the cyclisation and reduction was examined with a range of enone 
side-chains resulting in a small library of novel 4-hydroxy-2,6-disubstituted piperidines. 
 
 
2 
 
Table of Contents 
Abstract ............................................................................................................................................... 1 
Table of Contents ................................................................................................................................ 2 
Acknowledgements ............................................................................................................................. 5 
Author’s Declaration ........................................................................................................................... 6 
Abbreviations ...................................................................................................................................... 7 
1.0 Introduction ................................................................................................................................ 11 
1.1 α-Amino Acids ......................................................................................................................... 11 
1.2 Fluorescent α-Amino Acids ..................................................................................................... 12 
1.3 Natural α-Amino Acids and Fluorescent Analogues ............................................................... 12 
1.4 Coumarin-Derived Fluorescent α-Amino Acids....................................................................... 17 
1.5 Xanthone and Acridone-Derived Fluorescent α-Amino Acids ................................................ 21 
1.6 Flavone-Derived Fluorescent α-Amino Acids .......................................................................... 23 
1.7 BODIPY-Derived Fluorescent α-Amino Acids .......................................................................... 25 
1.8 Aminophthalimide- and Aminonaphthyl-Derived Fluorescent α-Amino Acids ...................... 29 
1.9 Polyaromatic-Derived Fluorescent α-Amino Acids ................................................................. 35 
1.10 Summary ............................................................................................................................... 41 
2.0 Synthesis of Novel Fluorescent Heterocyclic-Derived α-Amino Acids ........................................ 43 
2.1 Previous Work in the Sutherland Group ................................................................................. 43 
2.2 Proposed Research ................................................................................................................. 44 
2.3 Synthesis of Pyridine-Derived α-Amino Acids ......................................................................... 45 
2.3.1 Synthesis of N-Trityl Protected Enone-Derived α-Amino Acids ....................................... 45 
2.3.2 Synthesis of N-Cbz Protected Enone-Derived α-Amino Acids ......................................... 47 
2.3.3 Synthesis of N-Boc Protected Enone-Derived α-Amino Acids ......................................... 48 
2.3.4 Inverse Electron Demand Hetero-Diels-Alder (HDAINV) Cycloaddition ............................ 50 
2.3.5 Synthesis of N-Cbz Protected Pyridine-Derived α-Amino Acids ...................................... 53 
2.3.6 Deprotection to Form the Parent Pyridine-Derived α-Amino Acids ................................ 55 
2.4 Optical Properties of Pyridine-Derived α-Amino Acids ........................................................... 56 
2.4.1 Absorption and Emission Data for Neutral and Electron-Rich Pyridine Derivatives ........ 56 
2.4.2 Absorption and Emission Data for Electron-Poor Pyridine Derivatives ........................... 58 
2.4.3 Methoxyphenyl 151 and Naphthyl 152 Dilution Study .................................................... 60 
2.4.4 Methoxyphenyl 151 pH Study .......................................................................................... 63 
2.4.5 Other Optical Properties .................................................................................................. 65 
2.4.6 Summary .......................................................................................................................... 66 
2.5 Synthesis of Second Generation Pyridine-Derived α-Amino Acids ......................................... 67 
3 
 
2.5.1 Synthesis of N-Cbz Protected Enone-Derived α-Amino Acids ......................................... 67 
2.5.2 Inverse Electron Demand Hetero-Diels-Alder (HDAINV) Cycloaddition ............................ 68 
2.5.3 Synthesis of N-Cbz Protected Pyridine-Derived α-Amino Acids ...................................... 68 
2.5.4 Aryl Nitro Reduction with Tin(II) Chloride Dihydrate ....................................................... 69 
2.5.5 Deprotection to Form the Parent Pyridine-Derived α-Amino Acids ................................ 69 
2.6 Optical Properties of Second Generation Pyridine-Derived α-Amino Acids ........................... 70 
2.6.1 Absorption and Emission Data for Second Generation Pyridine Derivatives .................. 70 
2.6.2 Other Optical Properties .................................................................................................. 73 
2.6.3 Summary .......................................................................................................................... 74 
2.7 Synthesis of Fmoc Protected Pyridine-Derived α-Amino Acids .............................................. 75 
2.7.1 Solid Phase Peptide Synthesis .......................................................................................... 75 
2.7.2 SPPS - Boc Protection Method ......................................................................................... 75 
2.7.3 SPPS - Fmoc Protection Method ...................................................................................... 75 
2.7.4 Synthesis of N-Fmoc Protected Pyridine-Derived α-Amino Acids ................................... 76 
2.8 Synthesis of Novel Fluorescent Cell Penetrating Hexapeptide ............................................... 76 
2.8.1 SPPS of Cell Penetrating Pentapeptide VPTLK ................................................................. 76 
2.8.2 Synthesis of Hexapeptide 181 .......................................................................................... 79 
2.9 Cell Study with Hexapeptide 181 ............................................................................................ 80 
2.10 Synthesis of Pyrimidine-Derived α-Amino Acids................................................................... 85 
2.10.1 Initial Synthesis of Pyrimidine-Derived α-Amino Acids.................................................. 85 
2.10.2 Alternative Synthesis Towards Pyrimidine-Derived α-Amino Acids .............................. 87 
2.11 Future Work .......................................................................................................................... 89 
2.11.1 Proposed Synthesis of Pyrimidine-Derived α-Amino Acids ........................................... 89 
2.11.2 Proposed Synthesis of β-Carboline-Derived α-Amino Acids .......................................... 90 
2.11.3 Proposed Synthesis of Benzotriazole-Derived α-Amino Acids ....................................... 91 
2.13 Conclusions ........................................................................................................................... 93 
3.0 Total Syntheses of 4-Hydroxy-2,6-Disubstituted Piperidine Natural Products ........................... 94 
3.1 Previous Work in the Sutherland Group ................................................................................. 94 
3.2 Proposed Research ................................................................................................................. 95 
3.3 Previous Synthesis of Spruce Alkaloid .................................................................................... 96 
3.4 Previous Syntheses of (+)-241D .............................................................................................. 98 
3.5 Towards the Total Synthesis of Spruce Alkaloid ................................................................... 100 
3.5.1 First Approach Towards the Total Synthesis of Spruce Alkaloid .................................... 100 
3.5.2 Revised Approach Towards the Total Synthesis of Spruce Alkaloid .............................. 104 
3.6 Total Synthesis of Spruce Alkaloid and (+)-241D .................................................................. 106 
3.6.1 Synthesis of Enones ....................................................................................................... 106 
4 
 
3.6.2 6-Endo-Trig Cyclisation of Enones 258 and 259 ............................................................. 108 
3.6.3 Stereoselective Reduction ............................................................................................. 109 
3.7 Expanding the Scope of 4-Hydroxy-2,6-Disubstituted Piperidine Synthesis ........................ 110 
3.7.1 Synthesis of Enones ....................................................................................................... 110 
3.7.2 Scope of 6-Endo-Trig Cyclisation .................................................................................... 111 
3.7.3 Selective NOE Assignments ............................................................................................ 111 
3.7.4 Stereoselective Reduction ............................................................................................. 112 
3.7.5 Selective NOE Assignments ............................................................................................ 113 
3.8 Stereoselective Acid Mediated 6-Endo-Trig Cyclisation ....................................................... 114 
3.9 Future Work .......................................................................................................................... 117 
3.10 Conclusions ......................................................................................................................... 118 
4.0 Experimental ............................................................................................................................. 119 
4.1 General Experimental ........................................................................................................... 119 
4.2 Experimental Procedures ...................................................................................................... 119 
4.3 Experimental for the Synthesis of Hexapeptide 181 ............................................................ 199 
4.4 Cell-Hexapeptide 181 Study .................................................................................................. 201 
5.0 References ................................................................................................................................ 202 
6.0 Appendices ................................................................................................................................ 209 
Appendix 1 - Genetically Encoded Proteinogenic α-Amino Acids .............................................. 209 
Appendix 2 - Pentapeptide Test Cleavage Data .......................................................................... 210 
Appendix 3 - Fluorescence Lamp Settings .................................................................................. 211 
 
  
5 
 
Acknowledgements 
First off, I would like to thank my supervisor Dr Andy Sutherland for giving me the opportunity to 
work in his group. Throughout my PhD, he has provided me with a limitless amount of knowledge 
and expertise allowing me to get the most out of this experience. Whether it was practical work, 
report writing or presentation preparation he always had constructive opinions on how to improve. 
I would also like to thank my second supervisor Professor Richard Hartley for providing me with 
invaluable advice regarding annual report feedback. Thanks to the EPSRC and Cancer Research UK 
for funding my research. 
 
A big thank you to all the staff working in stores (Ted, Bruce and Paul), the mass spectroscopy 
service (Jim, Andy and Harry), the NMR service (Dr Adams) and the IT service (Stuart and Arlene) 
for their support. Massive thanks to Dr Astrid Knuhtsen, Dr Andrew Jamieson, Carol-Anne Smith 
and Dr Mathis Riehle. Without their help and expertise in the final months of my PhD I would not 
have had the positive ending I had been striving for. 
 
Of course, I must thank all of the Sutherland group members past and present for all the laughs and 
making the experience so much more enjoyable. To Mark, Lynne, Ewen, Filip, Salaheddin, Nikki, 
Tomas, Mohamed, Kerry, Tim, Réka, Marytn, Maria, and last but not least Team Big BoysAJ (Lewis 
and Jonny), cheers! Same goes for the other half of the Loudon lab, thanks to all the past and 
present members of the Hartley group. A big thanks to the two ERASMUS students Ariyada 
Souvanlasy and Laetitia Baud, and MSci student Christina Bell, all of whom assisted my projects. 
Thanks to everyone who was part of the 14/15 Alchemist Committee, making it an enjoyable and 
rewarding experience. 
 
A massive thank you to my parents, Sally and Jim, for supporting me throughout my PhD, even 
although they still have no idea what I have been up to. Thanks to my other family members who 
have helped in one way or another during my PhD, my brother Andrew, Aunt Christine, cousin Peter 
and my late gran. I also appreciated the time spent out of the lab playing for Westerlands AFC or 
with my good friends Stevie and Richard as well as the other lads from back home when we had 
the chance to get together. 
 
Finally, thanks to my lovely girlfriend Kim for putting up with me over the years, coming home late 
and constantly whining about my research not working. She has always been there for me and has 
been massively supportive and understanding since I started my PhD, very much appreciated.  
 
“Boys can do anything, when they put their mind to it.” - Sally Harkiss 
6 
 
Author’s Declaration 
I declare that, except where explicit reference is made to the contribution of others, this thesis 
represents the original work of Alexander H. Harkiss and has not been submitted for any other 
degree at the University of Glasgow or any other institution. The work upon which is based was 
carried out at the University of Glasgow in the Loudon laboratory under the supervision of Dr 
Andrew Sutherland between October 2013 and May 2017. Aspects of the work described herein 
have previously been published elsewhere as stated below.  
 
L. Gilfillan, R. Artschwager, A. H. Harkiss, R. M. L. Liskamp and A. Sutherland, Synthesis of Pyrazole 
Containing α-Amino Acids via a Highly Regioselective Condensation/Aza-Michael Reaction of β-Aryl 
α,β-Unsaturated Ketones, Org. Biomol. Chem., 2015, 13, 4514–4523. 
 
 
Signature 
 
Printed name ALEXANDER HUGH HARKISS 
 
  
7 
 
Abbreviations 
°C Degrees centigrade 
9-BBN 9-Borabicyclo[3.3.1]nonane 
Ac Acetyl 
Anap 3-[(6-Acetyl-2-naphthalenyl)amino] alanine 
Ar Aromatic 
BADAN 6-Bromoacetyl-2-dimethylaminonaphthalene 
BINAP 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene 
Boc tert-Butyloxycarbonyl 
BODIPY Boron-dipyrromethene 
br Broad 
c Concentration 
CaM Calmodulin 
Cbz Carboxybenzyl 
CI Chemical ionisation 
COSY Correlated spectroscopy 
CPME Cyclopentyl methyl ether 
CPP Cell penetrating peptide 
d Doublet 
DAPA Dimethylaminophthalimide 
DAST Diethylaminosulfur trifluoride 
DCC N,N'-Dicyclohexylcarbodiimide 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEPT Distortionless enhancement polarisation transfer 
DHFR Dihydrofolate reductase 
DIAD Diisopropyl azodicarboxylate 
DIBAL-H Diisobutylaluminium hydride 
DIC N,N′-Diisopropylcarbodiimide 
DIPEA Diisopropylethylamine 
DMA Dimethylacetamide 
DMAP 4-Dimethylaminopyridine 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EI Electron impact 
8 
 
EPL Expressed protein ligation 
ESI Electrospray ionisation 
ESIPT Excited state intramolecular proton transfer 
Et Ethyl 
FAB Fast atom bombardment 
FBS Fetal bovine serum 
Fmoc Fluorenylmethyloxycarbonyl 
FRET Förster resonance energy transfer 
g Grams 
GFP Green fluorescent protein 
GMO Genetically modified organism 
h Hour 
HBTU (2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate) 
HCTU O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate  
HDA Hetero-Diels-Alder 
HDAINV Inverse electron demand hetero-Diels-Alder 
HeLa Human epithelial cells 
HIV Human immunodeficiency virus 
HOMO Highest occupied molecular orbital 
HPLC High-performance liquid chromatography 
HSQC Heteronuclear single quantum correlation spectroscopy 
hTERT Human telomerase reverse transcriptase 
HWE Horner-Wadsworth-Emmons 
Hz Hertz 
IC50 Half maximal inhibitory concentration 
IR Infrared 
J NMR spectra coupling constant 
Kd Dissociation constant 
KHMDS Potassium hexamethyldisilazane 
KR Lysine and arginine rich peptide 
LC-MS Liquid chromatography-mass spectroscopy  
LiHMDS Lithium hexamethyldisilazane 
LUMO Lowest unoccupied molecular orbital 
m Multiplet 
M Molar 
9 
 
m- Meta- 
m/z Mass to charge 
Mcm 7-methoxycoumarinylalanine 
Me Methyl 
mg Milligrams 
MHz Megahertz 
mL Millilitres 
mM Millimolar 
mmol Millimole 
mol Mole 
MOM Methoxymethyl 
Ms Mesyl 
MW Microwave 
NBD 4-Fluoro-7-nitrobenzofurazan 
NBS N-Bromosuccinimide 
NHS N-Hydroxysuccinimide 
NIR Near-infrared 
NMM N-Methyl morpholine 
NMP N-Methyl-2-pyrrolidone 
NOE Nuclear Overhauser effect 
NOESY Nuclear Overhauser effect spectroscopy 
Ns Nitrobenzenesulfonyl 
NVOC Nitroveratryloxycarbonyl 
o- Ortho- 
p- Para- 
PAF26 Peptide AntiFungal 26 
PBS Phosphate-buffered saline 
PC Phosphatidylcholine 
PDC Pyridinium dichromate 
pdCpa 5’-Phospho-2’-deoxyribocytidylriboadenosine 
PET Positron emission tomography 
Ph Phenyl 
Pr Propyl 
PTC Phase transfer catalysis 
PTP Protein tyrosine phosphate 
pTyr Phosphotyrosine 
10 
 
q Quartet 
QY Quantum yield 
RBCs Red blood cells 
rt Room temperature 
s Singlet 
SNAr Nucleophilic aromatic substitution 
SPPS Solid phase peptide synthesis 
t Triplet 
Tat-TAR Trans-activator of transcription-trans-activating response 
TBAF Tetra-n-butylammonium fluoride 
TBD 1,5,7-Triazabicyclo[4.4.0]dec-5-ene 
TBDMS tert-Butyldimethylsilyl 
TBS Tris-buffered saline 
TEA Triethylamine 
Tf Triflyl 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIPS Triisopropylsilane 
TLC Thin layer chromatography 
tRNA Transfer ribonucleic acid 
Ts Tosyl 
TTET Triplet-triplet energy transfer 
UV Ultraviolet 
VMR Vinylogous Mannich-type reaction 
Δ Reflux 
μM Micromolar 
 
  
11 
 
1.0 Introduction 
1.1 α-Amino Acids 
α-Amino acids are small organic molecules that contain both amino (–NH2) and carboxylic acid (–
CO2H) functionality. They exist as zwitterions and possess amphoteric properties, meaning they can 
act as an acid and a base. They commonly exist in nature as their ʟ-isomeric form, whereby the α-
carbon is chiral. These α-amino acids can join to one another to form short peptide chains, longer 
polypeptides or proteins of varying size. There are 22 genetically encoded proteinogenic amino 
acids that are incorporated biosynthetically into proteins during translation, 20 in the standard 
genetic code (Appendix 1) and two of which, selenocysteine and pyrrolysine can be incorporated 
via special translation mechanisms (Figure 1).1 
 
 
Figure 1: Selenocysteine and pyrrolysine. 
 
There are many known non-proteinogenic amino acids and even although they occur in nature they 
are not used by the translational machinery to assemble proteins. These non-coded amino acids 
are important, as intermediates of these can be formed during biosynthesis and then the amino 
acids are synthesised post-translationally within proteins.1 
 
Proteins are central to almost every biological process, performing a vast array of functions such as 
catalysing metabolic reactions, replicating DNA, transporting molecules and responding to stimuli. 
Unnatural amino acids have been designed in laboratories to provide an important approach to 
probing the structure and function of proteins and also their medicinal applications.2 
 
There are two main methods for unnatural amino acid incorporation to study proteins, residue-
specific and site-specific incorporation. The current labelling methods for the latter approach 
include incorporation of unnatural amino acids with biorthogonal handles that can be modified via 
chemoselective reactions once incorporated.3 Another approach includes the incorporation of 
fluorescent unnatural amino acids and this will be the focus of this chapter, whereby recent 
syntheses of fluorescent unnatural amino acids will be described in detail and their applications 
briefly elucidated.3 
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1.2 Fluorescent α-Amino Acids 
Fluorescent spectroscopy is a highly sensitive and selective analytical and diagnostic tool, 
facilitating the development of a number of research fields such as molecular and cellular biology, 
biophysics, biotechnology, and medicine. It also has a rapid response time and can utilise countless 
small molecular probes that possess tuneable photophysical properties. Due to the importance of 
proteins and our understanding of their structure and function, fluorescent spectroscopy can be 
utilised using a number of strategies.4 
  
Expression of the protein of interest could be achieved by using a naturally occurring fluorescent 
protein (GFP)5 or naturally occurring α-amino acids within the protein itself (tyrosine or 
tryptophan).6 These approaches are hampered by limitations. Once a fluorescent protein has been 
attached to the protein of interest, the presence of this fluorescent protein may alter the form and 
function of the protein being investigated. In order for the second procedure to work there must 
be an abundance of the natural α-amino acids in the protein of interest. This might not be possible 
and combined with the fact that multiple residues may occur in a variety of regions in the protein, 
the spectroscopy can become complex.6 
 
An alternative pathway would be to design and synthesise unnatural fluorescent α-amino acid 
derivatives and incorporate these into proteins via solid phase peptide synthesis (SPPS), expressed 
protein ligation (EPL) or unnatural amino acid mutation.7 There have been several recent reviews 
that discuss significant developments regarding the design and synthesis of unnatural fluorescent 
α-amino acids and peptides. Katritzky described the specific structural features required for the use 
of fluorescent α-amino acids as effective molecular probes.8 Krueger and Imperiali reported the 
successful incorporation of unnatural fluorescent α-amino acids into peptides and proteins and 
their application in chemical biology studies.7 In this chapter, recent syntheses of novel fluorescent 
α-amino acids will be described along with their fluorescent properties and applications. Each α-
amino acid will also be classified with regard to the type of side-chain fluorophore residue it 
possesses. 
 
1.3 Natural α-Amino Acids and Fluorescent Analogues 
The use of naturally occurring α-amino acids, ʟ-phenylalanine, ʟ-tyrosine and ʟ-tryptophan (Figure 
2) for fluorescence imaging reduces the conformational changes in protein structure that may be 
observed when using unnatural α-amino acids.9 Regardless of this advantage, the poor optical 
properties of these natural α-amino acids have limited their use. These residues have distinct 
absorption and emission wavelengths and differ in quantum yields. The fluorescence quantum yield 
(QY) value is used to determine the emission efficiency of a given fluorophore. The calculation is 
13 
 
based on the number of photons emitted divided by the number of photons absorbed. Tryptophan 
is much more fluorescent then either tyrosine or phenylalanine. Due to tryptophan’s greater molar 
extinction coefficient, higher quantum yield and resonance energy transfer, the fluorescence 
spectrum of a protein containing the three amino acids usually resembles that of tryptophan. This 
is the main reason for the design and synthesis of novel unnatural fluorescent α-amino acids that 
have greater emission efficiency and fluoresce in the visible region (380–750 nm) of the 
electromagnetic spectrum.10 
 
 
Figure 2: Structures and optical properties of ʟ-phenylalanine, ʟ-tryptophan and ʟ-tyrosine. 
 
Derivatives of these naturally occurring amino acids have been investigated thoroughly. Tyrosine 
derived fluorescent α-amino acids were investigated by Wang and co-workers.11 Following 
protection of the amine and carboxylic acid groups, 3-iodo-ʟ-tyrosine 1 and 3,5-diiodo-ʟ-tyrosine 2 
were subjected to mono and double Heck couplings between a variety of styrene derivatives to 
form tyrosine analogues bearing stilbene backbones (Scheme 1). A library of thirteen analogues 
were synthesised in high yield with varying functionality on the styrene aryl group. The two with 
the most interesting optical properties were 3 and 4. The mono-methoxy compound 3 fluoresced 
at 400 nm and had a high QY of 0.87. The di-methoxy compound 4 had an equally impressive QY of 
0.94 and had two emission bands at 420 and 438 nm. This library of tyrosine derived amino acids 
displayed extended conjugation from the aryl side chain through the vinyl linker to the central 
phenol ring. The methoxy groups in particular are efficient electron donating groups and this is why 
3 and 4 have such desirable optical properties. 
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Scheme 1: Synthesis of tyrosine stilbene methoxy analogues. 
 
An Fmoc derivative of 4 was synthesised and incorporated into a small cell penetrating 
pentapeptide (sequence: 4-VPALK) using SPPS. To assess the cell permeability and fluorescent 
properties of the hexapeptide 5 (Figure 3), it was incubated with a human epithelial cell line (HeLa) 
and mouse fibroblast cells (NIH 3T3) for 3 h and visualised using laser scanning confocal microscopy. 
The images showed that the CPP could accumulate in the cells, suggesting that these types of amino 
acids could be applied in chemical biology studies as fluorescent probes. 
 
 
Figure 3: Cell penetrating hexapeptide 5.  
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There has also been novel tryptophan derived fluorescent α-amino acids recently synthesised by 
Hecht and co-workers. His laboratory has reported the synthesis of three novel cyanotryptophans 
and two quinoline derived tryptophan α-amino acids.12,13 Both syntheses use similar methodology, 
taking advantage of the Schöllkopf auxiliary to introduce chirality once the fluorophore portion of 
the molecule was synthesised (Scheme 2). 6-Cyanoindole was used as the starting material for the 
synthesis of the fluorophore side-chain and after five transformations produced chloride 6 in 39% 
overall yield. The lithium enolate of Schöllkopf auxiliary 7 was reacted with 6 to form adduct 8 with 
high diastereoselectivity. Mild hydrolysis of the auxiliary was followed by protecting the amine as 
NVOC carbamate 9. Sequential N-detosylation, methyl ester hydrolysis and cyanomethyl ester 
formation afforded 10 in 44% over three steps. The optical properties of compound 10 were 
measured in its N-acetylated methyl ester form, to mimic the predicted behaviour in a 
peptide/protein. It displayed an emission maximum value of 370 nm and a QY of 0.53. It should be 
noted that it possesses an emission maximum wavelength with a substantial red-shift compared 
with tryptophan. This suggests that the emission signal could be isolated from the natural 
tryptophan residues found in proteins, making this unnatural α-amino acid a potential imaging 
agent. 
 
 
Scheme 2: Schöllkopf bis-lactim amino acid synthesis of 10. 
 
Hecht and co-workers also investigated the potential use of the cyanotryptophan α-amino acid 
derivative 11 as a Förster resonance energy transfer (FRET) pair with ʟ-(7-hydroxycoumarin-4-
yl)ethylglycine 12 (Figure 4).12 As discussed, 11 has an emission maximum at 370 nm and 12 has 
emission maxima values of 345 and 440 nm. Both were incorporated with good efficiency into two 
different positions (11 Trp74 and 12 Trp17) of Escherichia coli dihydrofolate reductase (ecDHFR). 
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Previous studies suggested the cyanotryptophan derivatives introduction to position 74 were 
tolerated as well as small fluorescent α-amino acid incorporation into position 17. Calculations 
determined that the distance between the donor 11 and acceptor 12 pairing was suitable for FRET 
experiments. Incorporation was done by decoding a four-base codon CGGG with the coumarinyl-
tRNACCCG and the nonsense codon UAG with cyanotryptophanyl-tRNACUA 13. The modified DHFR 
was then excited at 310 nm and an efficient FRET signal was recorded at 460 nm proving that 11 
could be used as a FRET partner for studying protein-nucleic acid interactions. 
 
 
Figure 4: Donor 11 and acceptor 12 FRET pairing, and tRNACUA with 11 incorporated (13). 
 
Phenylalanine derived unnatural α-amino acids have been recently synthesised, particularly by Zotti 
et al.14 The synthesis starts with the alkylation of Nα-benzylidene-ᴅʟ-Ala-NH2 14 with 4-
(bromomethyl)benzonitrile using phase transfer catalysis (PTC) to give 15 (Scheme 3). The 
benzylidene group was hydrolysed to form the racemic amino amide 16. A genetically modified 
organism (GMO), Ochrobactrum anthropi, was utilised to resolve the racemic mixture, producing 
the desired phenylalanine derivative 18 and amino amide 17. Amino acid 18 was incorporated into 
the decapeptide, trichogin GA IV a membrane active peptaibiotic, to mimic the Aib amino acid 
commonly found in these types of peptides. The helical conformation was maintained and through 
exploitation of the p-cyanophenyl moiety, the peptide had an emission maximum of 295–305 nm 
allowing the group to study the interaction of this modified lipopeptaibiotic with model 
membranes.  
 
17 
 
 
Scheme 3: Synthesis of 4-cyanobenzyl chromophores 17 and 18. 
 
1.4 Coumarin-Derived Fluorescent α-Amino Acids 
2H-Chromen-2-ones or coumarins are fragrant organic chemical compounds in the benzopyrone 
chemical class (Figure 5). They have a characteristic ring system that has been used for optical 
imaging due to the possession of desirable properties such as high quantum yields, an extensive 
spectroscopic range, photostability and solubility in a variety of solvents.10,8 
 
 
Figure 5: Basic structure of coumarin. 
 
Multiple groups have developed synthetic methodology to access the coumarin ring system and 
one of the most popular methods to construct coumarin-derived α-amino acids was developed by 
Garbay and co-workers.15 They managed to synthesise 7-methoxycoumarin α-amino acid 
derivatives by applying a Pechmann condensation reaction to construct the ring system. Since then, 
a number of groups have adopted this Pechmann condensation methodology to prepare coumarin 
derived α-amino acids.16 The Yao group synthesised a self-immobilising and fluorogenic 
phosphotyrosine (pTyr) mimic and used SPPS to incorporate it into peptide-based probes.17 Fmoc-
ʟ-aspartic acid 4-tert-butyl ester 19 was used as the starting material for the synthetic route 
(Scheme 4). Following manipulation of the carboxylic acid protecting groups, compound 20 was 
treated with Meldrum’s acid to form β-ketoester 21, the substrate for coumarin synthesis. The 
Pechmann condensation was carried out with resorcinol under acidic conditions to yield 7-hydroxy 
coumarin α-amino acid derivative 22. Formylation using the Duff reaction, followed by 
phosphorylation with bis(o-nitrobenzyl) phosphorochloridate produced 23. A two-step aldehyde 
reduction and fluorination procedure was used to install the benzylic fluorine 24. Phenylsilane and 
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Pd(PPh3)4 were then used to remove the allyl protecting group before a mixture of TEA/thiophenol 
was employed to remove one of the 2-nitrobenzyl groups to give 25. No explanation was provided 
as to why the selected conditions did not remove both 2-nitrobenzyl groups.   
 
 
Scheme 4: Synthesis of fluorogenic coumarin-derived α-amino acid 25. 
 
Yao’s group wanted to study the role of protein tyrosine phosphates (PTP), which play an important 
role in controlling signal transduction processes and regulating the phosphoproteome network.17 
PTP investigations at a molecular level provide unprecedented knowledge of how enzymes work 
under physiological settings. Once the fluorogenic coumarin derived α-amino acid 25 was 
synthesised they then incorporated it into three different CPPs via SPPS. Previous work on these 
localisation peptides have been shown to successfully deliver enzyme inhibitors into subcellular 
organelles of live cells.18 A four residue glycine (Gly4) linker connected the unnatural α-amino acid 
to the CPP to reduce any interference with the CPP and PTP. CPP 26 was one of the resulting peptide 
based probes synthesised during this study (Figure 6). It was used to deliver the pTrp mimic to the 
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membrane of HeLa cells in order to visualise PTP activities. Successful visualisation was possible via 
confocal microscopy.  
 
 
Figure 6: Membrane specific pTrp mimic peptide 26. 
 
Work carried out by Häußler and Gütschow also focussed on coumarin derived α-amino acids, 
specifically a 6,7-dimethoxy coumarin analogue.19 They wanted to synthesise and investigate a 
route to a coumarin derived α-amino acid with bisbenzamidine functionality in the structure. Due 
to the benzamidine moiety being capable of binding in the protein active sites via anionic and 
hydrogen bond interactions it has become of great interest.20 Bisbenzamidines possess antifungal 
and antiprotozoal properties because the benzamidine residues can interact with adenine/thymine 
sites of DNA via insertion into the minor groove.21,22 These types of interactions could be 
investigated by using an efficient fluorophore with bisbenzamidine functionality installed and use 
of fluorescence microscopy for visualisation. Similar conditions as described above were utilised to 
synthesise 27 using the Pechmann condensation reaction (Scheme 5).19 The next objective was to 
install the bisbenzamidine moieties. Carboxylic acid 27 was activated using N-methylmorpholine 
and isobutyl chloroformate followed by subsequent reaction with 4-aminomethylbenzonitrile to 
form the amino amide. Deprotection of the amine with hydrochloric acid gave HCl salt 28. The 
amine salt was treated with DIPEA and 4-cyanobenzenesulfonyl chloride producing the sulfonyl 
amide and installing the second nitrile group. The Pinner reaction was used to form imidate 29. 
Ammonium acetate was used to furnish the desired bisbenzamidine functional groups. Preparative 
HPLC, treatment with TFA and freeze drying led to the final bisbenzamidine-TFA salt 30. The 
excitation maximum for the compound was 350 nm and its emission maximum, 422 nm. Future 
biological studies are expected to be carried out looking at its interaction with adenine/thymine 
rich double stranded DNA. 
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Scheme 5: Synthesis of bisbenzamidine 6,7-dimethoxy coumarin-derived α-amino acid 30. 
 
An alternative approach to synthesising coumarin derived α-amino acids was recently developed 
by Kazmaier and co-workers.23 They synthesised coumarin-derived allylic carbonates and subjected 
them to a palladium catalysed allylic alkylation with a chelated glycine enolate intermediate 
(Scheme 6). 4-Methyl derived coumarin 31 was synthesised via Pechmann condensation and o-
methylation of resorcinol. The methyl group was oxidised using selenious acid, forming 4-
formylcoumarin 32. Reaction with vinylmagnesium bromide led to the allylic alcohol which was 
directly acylated with ethyl chloroformate to synthesise allylic carbonate 33. Chelated glycine 
enolate 34 was generated by deprotonating the protected glycine using lithium 
hexamethyldisilazide and zinc as the chelating counter ion. Palladium catalysed allylic alkylation 
completed the synthesis, fusing the coumarin ring with the glycine moiety to give 35. These 
coumarin derived allylic carbonates are suitable electrophiles for this final step and when using 
terminal allylic carbonates, these furnished a single regioisomer and the E-alkene exclusively. So far 
only the racemic approach has been developed but future studies will investigate a stereoselective 
protocol so that fluorescent labelling of peptides and natural products could be explored.  
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Scheme 6: Synthesis of coumarin-derived α-amino acids via a Pd-catalysed allylic alkylation.  
 
1.5 Xanthone and Acridone-Derived Fluorescent α-Amino Acids 
Xanthone derivatives are made up of three fused rings with bridging ketone and ether groups 
(Figure 7). The structure of acridone is very similar but instead of an oxygen/ether linker, there is 
an amine bridge. Both have a rich conjugated donor-acceptor relationship within the central B ring. 
This push-pull motion of electrons allows these fluorophores to exhibit desirable optical properties. 
 
 
Figure 7: Structures of xanthone and acridone. 
 
There have been recent reports detailing the synthesis of fluorescent α-amino acids with xanthone 
and acridone frameworks.24,25 Braun and co-workers designed a synthetic route towards Fmoc and 
Boc protected α-amino acids with xanthone as the side chain (Scheme 7).24 Their fluorescent 
properties were also examined. A xanthone derived α-amino acid was required to investigate the 
folding mechanisms in polypeptides. A fluorescence triplet-triplet energy transfer (TTET) 
mechanism takes place between xanthone and naphthylalanine residues in close proximity to one 
another. In order to study this interaction further an Fmoc or Boc protected xanthone α-amino acid 
analogue is required, so that direct incorporation can be carried out smoothly, with no post 
synthesis modifications or protecting groups. To start the synthesis, an Ullmann coupling between 
2-bromobenzoic acid and 4-methoxyphenol gave diarylether 2-(4-methoxyphenoxy)benzoic acid 
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36. Copper triflate benzene complex (2.5 mol%) was the optimal source of copper and 4-
dimethylaminopyridine (2.5 mol%) was used as a ligand. The reaction could be scaled up to 40 mmol 
by switching solvent to toluene, maintaining an excellent 89% yield. Concentrated sulfuric acid was 
used to form the ring and demethylate the methoxy group to give 37. Treatment with triflic 
anhydride led to triflate 38, necessary for the cross-coupling step. The Negishi coupling proceeded 
with the organozinc amino acid derivative and Pd[P(o-tol)3]2Cl2 (5.4 mol%) producing the xanthone-
derived α-amino acid 39. A Boc-protected organozinc coupling partner was also used and gave the 
corresponding coupled product in 40% yield. Both Fmoc and Boc protected compounds were 
hydrolysed using acidic and enzymatic conditions, respectively. The excitation maximum for the 
Boc protected acid was 340 nm and had a broad emission maximum at 380 nm. 
 
 
Scheme 7: Synthesis of xanthone-derived α-amino acid 39. 
 
A five step, high yielding and scaleable route was optimised by Mehl and Petersson’s respective 
groups for the synthesis of an acridone-derived α-amino acid capable of being utilised in ribosomal 
biosynthesis.25 This efficient synthetic route started with ʟ-tryptophan, which was fully protected 
using standard conditions and treated with phenyl triflimide to provide the substrate 40 for the 
Buchwald-Hartwig coupling (Scheme 8).26 A solvent, temperature, base and Pd/ligand ratio screen 
was then carried out to find optimal conditions for the coupling. Palladium acetate, rac-BINAP and 
caesium carbonate, in cyclopentyl methyl ether (CPME) gave the highest yields of the desired 
product 41. Toluene was used as the solvent at 135 °C when reactions were carried out on larger 
scales. A Friedel-Crafts cyclisation was then employed to construct the acridone ring system using 
concentrated sulfuric acid. This final step also removed the methyl ester and Boc protecting groups 
to give 42, with an overall yield of 87%. A route to 42 had already been previously published, 
however large quantities of the final compound were required for bacterial culture studies, so a 
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more cost effective route was established.27,28 The absorption maxima for 42 was 383 and 402 nm, 
with an emission maxima of 420 and 445 nm and a QY of 0.74 when using methanol as the solvent. 
 
 
Scheme 8: Synthesis of acridone-derived α-amino acid 42.  
 
Fluorescent acridone-derived α-amino acid 42 was paired with the common fluorophore 7-
methoxycoumarinylalanine (Mcm) for a FRET application.25 The absorption value for Mcm is around 
325 nm and once irradiated it fluoresces at 400 nm. If 42 is in close proximity to Mcm when this 
occurs it can subsequently be excited and emit at a longer wavelength. The group incorporated 
both amino acids into calmodulin (CaM) of Escherichia coli to study the conformational changes 
associated with the binding of helical peptides to CaM. 
 
1.6 Flavone-Derived Fluorescent α-Amino Acids 
Flavones are a class of flavonoids based on the backbone of 2-phenylchromen-4-one (Figure 8). 
There are a vast number of natural and synthetic flavones.  Several methods exist to synthesise 
their structure such as the Allan-Robinson reaction,29 the Auwers synthesis30 and the Baker-
Venkataraman rearrangement.31 Flavones have antioxidant, anti-proliferative and anti-
inflammatory activities and have been an important moiety for the development of new 
therapeutics.32 
 
 
Figure 8: Basic structure of flavone. 
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Work carried out by the Mély group has focussed on the synthesis of flavone derived α-amino acids 
and their applications.33 They described the synthesis of a furyl analogue in the 2-position of the 
flavone and potential for it to be a tryptophan residue mimic. The six-step synthesis started with ʟ-
tyrosine which was treated with acetyl chloride to form the phenolic ester, which then underwent 
a Fries rearrangement in the presence of AlCl3 (Scheme 9). Subsequent Boc-protection led to the 
hydroxy acetophenone 43. This compound was then condensed with furfural to produce chalcone 
44 in a 95% yield. The key step in this synthesis was the formation of the flavone backbone where 
the Algar-Flynn-Oyamada reaction was utilised. Oxidative cyclisation occurred under strong basic 
and oxidative conditions giving a modest yield of 20% for flavone 45. The final steps were a 
deprotection-reprotection procedure to give the final Fmoc protected flavone derived α-amino acid 
46. The optical properties of the Boc-protected flavone were measured showing that it had an 
absorption maximum of 350 nm and two emission bands at 420 and 525 nm with methanol as the 
solvent. Using SPPS, 46 was incorporated into the NC(11−55), which is the zinc finger domain of the 
HIV-1 nucleocapsid protein and displays nucleic acid assembly/disassembly properties.33 Trp37 and 
Ala30 were the residues substituted for 46 and although Trp37 plays a key role in the structure and 
activity of NC(11−55), the fluorescent derivative managed to maintain the folding and chaperone 
activities of the peptide. Therefore, this flavone-derived α-amino acid has proven to be a 
tryptophan residue mimic in this particular biological study. 
 
 
Scheme 9: Synthesis of flavone-derived α-amino acid 46. 
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The Mély group went on to make several other analogues using the same synthetic route and apply 
them to similar biological studies (Figure 9). Compound 47, a dimethylaminophenyl derivative was 
incorporated into melitten, a membrane active peptide.34 The fluorescent analogue replaced Leu9 
and Trp19 residues of this peptide. It displayed dual fluorescence bands at 470 and 570 nm via 
excited state intramolecular proton transfer (ESIPT). Similarly to the furyl analogue, Mély 
incorporated a methoxyphenyl flavone derivative 48 into a HIV-1 nucleocapsid peptide.35 A long-
lived fluorescence lifetime was observed because of the ESIPT complex and the binding partners of 
the labelled peptides were visualised through two photon fluorescence lifetime imaging.  
 
 
Figure 9: Dimethylaminophenyl 47 and methoxyphenyl 48 flavone-derived α-amino acids and 
ESIPT reaction in 3-hydroxyflavones. 
 
1.7 BODIPY-Derived Fluorescent α-Amino Acids 
Boron-dipyrromethene, commonly known as BODIPY, is dipyrromethene complexed with a 
disubstituted boron atom, usually a BF2 unit (Figure 10). Derivatives of BODIPY are known to have 
small Stokes shifts, high quantum yields, sharp absorption and emission peaks, and high solubility 
in many organic solvents.36 This combination of properties makes BODIPY fluorophore an excellent 
imaging agent. There have been several reviews covering the synthesis and application of BODIPY 
compounds.36,37 The general method used to construct BODIPY analogues is treating 
dipyrromethene with boron trifluoride etherate and a tertiary amine. The dipyrromethene is 
synthesised from the corresponding pyrroles via the Knorr pyrrole protocol and subsequent 
oxidation. 
 
 
Figure 10: Unsubstituted BODIPY core structure. 
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Due to the desirable optical properties associated with BODIPY derivatives, several groups have 
synthesised BODIPY derived α-amino acids and used them in biological studies.38 Guzow and co-
workers reported the synthesis of a BODIPY-derived α-amino acid with a benzoxazole moiety linking 
the fluorophore with an alanine derivative.39 Starting with N-Boc-3-nitro-ʟ-tyrosine methyl ester, 
the nitro group was reduced using standard catalytic hydrogenation conditions, followed by 
treatment with terephthalaldehyde which furnished Schiff base 49 (Scheme 10).40 Lead(IV) acetate 
was used as the oxidising agent, inducing cyclisation to benzoxazole 50. 
 
 
Scheme 10: Synthesis of benzoxazole-derived α-amino acid 50.  
 
The next stage in the synthesis was construction of the BODIPY core.39 Compound 50 was 
condensed with two equivalents of 2,4-dimethyl-1H-pyrrole in the presence of TFA to give 
dipyrromethane derivative 51 (Scheme 11). p-Chloranil, a quinone oxidant was used to generate 
dipyrromethene 52. Upon treatment with boron trifluoride etherate and triethylamine, this gave 
the final BODIPY derivative 53, in a 21% yield over 3 steps. The spectral and photophysical 
properties of 53 were described in detail using methanol as the solvent. A strong absorption band 
was observed at 501 nm with an additional band at 310 nm, resulting from the benzoxazole 
functionality. When excited at 501 nm it produced an emission band at 516 nm and had a quantum 
yield of 0.26. The group envisage this BODIPY-derived α-amino acid 53 being incorporated into 
peptides for biological studies. 
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Scheme 11: Synthesis of BODIPY-derived α-amino acid 53. 
 
Another very recent example of a fluorescent BODIPY derived α-amino acid was published by Lavilla 
and Vendrell’s respective groups.41,42,43 They have developed methodology that allows the efficient 
arylation of the indole C2 position of tryptophan through the use of a palladium catalysed C-H 
activation strategy. In order to utilise this procedure, they synthesised two iodinated BODIPY 
derivatives, m-iodophenyl-BODIPY (41%) 54 and p-iodophenyl-BODIPY (29%) 55 (Figure 11).44 
Standard BODIPY synthesis conditions were employed, 3-iodobenzene/4-iodobenzene and 
dimethylpyrrole condensation, DDQ oxidation and BF3OEt2/TEA treatment. 
 
 
Figure 11: BODIPY iodine substrates for the Pd-catalysed C-H activation reaction. 
 
Fmoc-ʟ-tryptophan was subjected to the C-H activation conditions using 54 as the coupling partner, 
Pd(OAc)2 as the palladium(II) source, in the presence of AgBF4 and TFA, both were critical for the 
catalytic cycle (Scheme 12).44 The reaction was assisted by microwave irradiation, 80 °C for 20 
minutes, which made gram-scale synthesis of 55 possible in a high 74% yield. The absorption and 
emission maximum values for 55 were 503 and 517 nm respectively. 
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Scheme 12: Synthesis of Trp-BODIPY-derived α-amino acid 55. 
 
Amino acid 55 was incorporated into Peptide AntiFungal 26 (PAF26).44 PAF26 is a synthetic 
antimicrobial hexapeptide with high affinity for fungal cells and selectivity over bacterial and 
mammalian cells. The C-terminal has a hydrophobic domain (Trp-Phe-Trp) and an N-terminal 
cationic domain (Arg-Lys-Lys), both essential for its antifungal properties. As there are two 
tryptophan residues in this peptide, they decided to use SPPS to synthesise fluorogenic derivatives 
of PAF26, substituting Trp for Trp-BODIPY 55. They wanted to assess the impact of 55 in the 
different positions of the hexapeptide, so four PAF26 analogues were constructed (e.g. Figure 12). 
The peptides activity towards the fungal pathogen Aspergillus fumigatus, various bacterial strains 
and human red blood cells (RBCs) were determined. Surprisingly, three of the fluorogenic 
hexapeptides displayed a higher affinity for A. fumigatus than the non-labelled PAF26. These results 
suggest that this novel labelling approach can report the interaction of PAF26 with A. fumigatus 
and does not disrupt the expected molecular interaction between the peptide and fungus. 
 
 
Figure 12: Trp-BODIPY derivative of hexapeptide PAF26. 
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1.8 Aminophthalimide- and Aminonaphthyl-Derived Fluorescent α-
Amino Acids 
4-Aminophthalimide is a derivative of phthalic anhydride and 2-naphthylamine is an aromatic 
amine derived from naphthalene (Figure 13). Careful consideration and design of α-amino acid 
derivatives of these compounds have led to the synthesis of highly sensitive probes for biological 
processes. Fluorophores bearing push-pull electronic properties are of great interest and there 
have been several syntheses and subsequent biological studies carried out on aminophthalimide 
and aminonaphthyl derived α-amino acids, due to this functionality.  
 
 
Figure 13: Basic structures of 4-aminophthalimide and 2-naphthylamine. 
 
Imperiali has reported the synthesis of several phthalimide based α-amino acids. 4-
Aminophthalimide was of interest because it was recognised as an environmentally sensitive 
fluorophore that responds to changes in polarity and viscosity.45 It exhibits solvatochromism and 
due to its small size, could potentially mimic natural α-amino acids. With that in mind, the synthesis 
towards a 4-aminophthalimide-derived α-amino acid was developed starting with 
diaminopropionic acid derivative 56 (Scheme 13).46 The carboxylic acid group was protected to give 
allyl ester 57 and following treatment with TFA gave amine 58. Coupling partner 59 was synthesised 
from 4-aminophthalic acid via reductive amination and sublimation under reduced pressure. The 
phthalimide synthesis conditions required activation of the acid intermediate using HBTU and HOBt 
under basic conditions leading to phthalimide 60. The allyl ester group was removed quantitatively 
using Pd(PPh3)4 and phenylsilane, producing aminophthalimide-derived α-amino acid 61. 
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Scheme 13: Synthesis of 4-dimethylaminophthalimide-derived α-amino acid 61. 
 
The biological system of interest was the 14-3-3 proteins which are involved in phosphoserine-
dependant signalling and essential for cell signal regulation.46 These proteins are known to bind 
short phosphopeptides efficiently, therefore compound 61 was incorporated into a short 
phosphopeptide (14-3-3bp) via standard SPPS protocols (Figure 14). The absorption maximum 
value for peptide 62 was 395 nm and it had an emission maximum of 510 nm. The fluorescently 
labelled 14-3-3bp-DAPA peptide was incubated with the 14-3-3 protein. Solutions of the protein-
peptide mixture were tested for their fluorescent properties and it was noted that there was a 
fluorescence intensity increase as well as a blue-shifted emission maximum value from 570 nm (14-
3-3bp-DAPA only) to 531 nm upon protein binding. As the peptide binds to the protein, the 
fluorescent amino acid enters a more hydrophobic environment and is shielded from surrounding 
water molecules allowing for the observed 6-fold increase in fluorescence intensity. The 
consequence of the blue-shift suggests that 61 is a highly sensitive fluorescent side-chain that 
exhibits variable optical properties in different environments. 
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Figure 14: Fluorescently labelled phosphopeptide 14-3-3bp-DAPA 62. 
 
Imperiali has synthesised several aminophthalimide-derived α-amino acids including a novel 4-N,N-
dimethylamino-1,8-naphthalimide fluorophore.47 This short synthesis began with anhydride-
derived aryl bromide 63 which was transformed to the corresponding dimethylamino compound 
64 using 3-dimethylaminopropionitrile in 3-methyl-1-butanol.48 Anhydride 64 was then condensed 
with Boc-Dap-OH to form dimethylaminophthalimide 65. A trivial deprotection/reprotection 
procedure followed to give Fmoc protected α-amino acid derivative 66, with an overall yield of 46% 
over the four steps. 
 
 
Scheme 14: Synthesis of dimethylaminophthalimide-derived α-amino acid 66. 
 
Amino acid 66 was incorporated into a lysine and arginine rich peptide, termed KR in order to 
measure its susceptibility to SPPS, rate of hydrolysis, and optical properties.47 The results were 
compared with the other previously synthesised dimethylaminophthalimide α-amino acids (4-
DMAP and 6-DMN) prepared by Imperiali as well as other known solvatochromic fluorophores, 
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BADAN (6-bromoacetyl-2-dimethylaminonaphthalene), dansyl chloride and NBD (4-fluoro-7-
nitrobenzofurazan) (Figure 15).49,50 The previously reported dimethylaminophthalimides were 
susceptible to hydrolysis when subjected to nucleophilic bases such as the standard base used in 
SPPS, piperidine. HPLC analysis suggested that there was no reaction for KR4DMN when treated with 
20% 4-methylpiperidine/DMF whereas KR4DMAP and KR6DMN had several other peaks, meaning side 
reactions were taking place. At high pH levels 4-DMAP and 6-DMN have a tendency for the imide 
ring to hydrolyse over time. A comparison between KR4DMAP and KR4DMN suggested that 4-DMN is 
able to stay intact whereas 4-DMAP eventually hydrolyses. This was measured via fluorescence 
spectroscopy as a non-fluorescent by-product is formed from 4-DMAP upon hydrolysis. The 
solvatochromic properties of 4-DMN were also measured using water and dioxane to investigate 
the effect of polar and non-polar solvents on the fluorophore.47 Again the KR peptide motif was 
utilised to ensure solubility was maintained in both solvent systems. 18-Crown-6 was also present 
in the dioxane samples to complex with the protonated primary amines on the lysine residues and 
N-terminus, guaranteeing solubility. The difference in emission maximum values between solvents 
for all the fluorophores tested was staggering. All dimethylaminophthalimide samples in tris-
buffered saline (TBS) displayed no emission maximum bands whereas in dioxane, there were 1200–
4500 fold increases in fluorescence intensity. This is attributed to the extremely low fluorescence 
quantum yields displayed by these dimethylaminophthalimides in polar protic solvents. Overall, the 
utility of 66 as a fluorescent tag has been demonstrated in this report. It is able to exhibit desirable 
properties with very few compromises. Excellent attributes include excitation in the visible region, 
short synthesis of the Fmoc derivative and that 4-DMN is more stable than the previously 
synthesised dimethylaminophthalimides. However, it is still able to maintain the switch-like 
fluorescent properties typical for this compound series. 
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Figure 15: KR peptide sequence and the three dimethylaminophthalimide side-chains. 
 
α-Amino acids with aminonaphthyl side-chains have also been investigated extensively. Anap, a 
known unnatural α-amino acid, synthesised by Schultz and co-workers, was incorporated into yeast 
proteins with high efficiency and specificity with response to the amber codon.51 It was also site-
specifically incorporated into E. coli glutamine binding proteins and used to probe structural 
changes caused by ligand binding.51 However, it was prepared via an inefficient 8-step racemic 
synthesis with an overall yield of 8.1%. An improved stereospecific synthesis was reported by Wang 
and co-workers.52 This began with 6-hydroxy-2-acetylnaphthyl which was subjected to a one-pot 
alkylation-Smiles rearrangement-hydrolysis sequence, inspired by Mizuno and Yamano’s phenol to 
aniline protocol (Scheme 15).53 The alkylating agent used was 2-bromo-2-methylpropanamide. 
After formation of intermediate 67, the Smiles rearrangement was employed under basic 
conditions to give amide 68. Acidic conditions were used to induce hydrolysis and subsequent 
protection with an o-nitrobenzenesulfonyl group produced protected aniline 69. The key step in 
this synthesis was the Fukuyama-Mitsunobu reaction which was used to couple the fluorophore 
and amino acid moieties together to furnish 70. The final steps in the synthesis were the removal 
of all protecting groups to provide the parent α-amino acid 71. This approach is not only higher 
yielding (overall yield of 51%) but also required fewer steps and allowed the synthesis of the 
bioactive ʟ-enantiomer. The absorption and emission maximum values for 71 were 350 and 575 nm 
respectively, with a quantum yield of 0.48 using ethanol as the solvent. 
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Scheme 15: Synthesis of aminonaphthyl-derived α-amino acid 71. 
 
Fowler et al have also synthesised a dimethylaminonaphthyl-derived α-amino acid with a 
conjugated enone group connecting the fluorophore to the α-amino acid.54 The synthesis began 
with a chiral pool starting material, ʟ-aspartic acid which was fully protected to give N-trityl 
dimethyl ester 72 (Scheme 16). Dimethyl methylphosphonate was deprotonated using butyl lithium 
and added to dimethyl ester 72 which transformed into the corresponding β-ketophosphonate 
ester 73. The key step in this synthesis was the HWE (Horner-Wadsworth-Emmons) reaction which 
was used to form a new E-alkene between the dimethylaminonaphthyl aldehyde and 73 to furnish 
enone 74. To complete the synthesis a deprotection/reprotection strategy was used to isolate the 
Boc protected amine 75. Final methyl ester hydrolysis and Boc group removal led to the 
dimethylaminonaphthyl derived α-amino acid 76. Compound 76 was tested in a variety of solvents 
for its optical properties. In water, a polar protic solvent, it exhibited an emission band at 552 nm 
but in a non-polar solvent like toluene, a hypsochromic shift was observed and emission was 
recorded at 506 nm. Compound 76 is solvatochromic because it has the ability to change colour 
due to changes in solvent polarity. It was envisaged that this compound could be used as a 
fluorescent biomarker, being incorporated into peptides/proteins for biological studies. 
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Scheme 16: Synthesis of dimethylaminonaphthyl-derived α-amino acid 76. 
 
1.9 Polyaromatic-Derived Fluorescent α-Amino Acids 
Another class of fluorescent α-amino acids that has been widely investigated has been the use of 
conjugated polyaromatic groups as the α-amino acid side chain. The optical properties of these 
polyaromatic side chains may stay consistent when using polar and non-polar solvents, which 
potentially limits their value as reporting probes. However, their use as standard fluorescent tags 
is desirable because the fluorescence can be tuned through variation in the functional groups 
present in the aryl side-chains as well as making the framework of the compound more rigid via the 
use of fused ring systems. The standard approach involves coupling the fluorescent polyaromatic 
side chain to an activated amino acid core. Mohite and Bhat developed a Knoevenagel 
condensation-reductive decarboxylation strategy using aspartic and glutamic acid derivatives to 
form novel keto α-amino acids with various aromatic side chains such as the pyrene derivative 77 
(Figure 16).55 Ferreira et al used a rhodium-catalysed conjugate addition reaction to make β-
arylalanine derivatives with fluorescent groups attached such as phenanthrene analogue 78.56 An 
approach towards constrained analogues of phenylalanine was designed by Kotha and Meshram.57 
A Diels-Alder cycloaddition was employed to join the fluoranthene-fused sultine to methyl 2-
acetamidoacrylate yielding conformationally constrained fluoranthene α-amino acid derivative 79. 
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Figure 16: Polyaromatic-derived α-amino acids.  
 
Work carried out by Göbel and his co-workers led to the synthesis of enantiopure α-amino acids 
with aromatic and heteroaromatic side chains.58 The synthesis began with ʟ-methionine which was 
reduced to the alcohol and converted to vinylglycinol 80 via a thermal syn elimination reaction 
previously reported in the literature (Scheme 17).59 The key step in this synthesis was the Heck 
coupling which was used to fuse the pyrene framework to the amino acid moiety. The optimised 
conditions involved quaternary ammonium salts which act as the catalyst promoter. No other 
ligands were used and high yields were obtained across the substrate scope for this procedure. 
Furthermore, exclusive formation of E-alkene 81 was observed in all cases. Transfer hydrogenation 
was used to reduce the styrene double bond and remove the Cbz protecting group, without any 
aromatic side chain reduction. Silyl protecting group removal and subsequent Fmoc amine 
protection followed to give primary alcohol 82. The final synthetic step was PDC oxidation to furnish 
the carboxylic acid 83. 
 
 
Scheme 17: Synthesis of pyrene-derived α-amino acid 83. 
 
37 
 
The Fmoc protected amino acid was incorporated into a tripeptide 84, flanked by two arginine 
residues due to their crucial role in Tat-TAR binding (Figure 17).58 Previous work in the group has 
shown that cationic tripeptides can bind to the viral RNA element TAR derived from HIV-1.60 The 
complexation of these tripeptides with RNA disrupts the Tat-TAR moiety, which is a molecular 
switch that regulates the transcriptional efficiency in HIV, effectively halting the spread of HIV in 
cell culture studies. RNA binding assays were carried out and the IC50 and Kd values were obtained 
for 84 and the other analogues synthesised in this current study. A rhodamine and fluorescein 
tagged Tat peptide was also used as a binding site competitor as they are able to efficiently quench 
dyes when RNA is absent. Peptide 84 had an IC50 of 0.9 μM which was the lowest value measured 
and a Kd value of 50 nM. This biological study has proven that tripeptide 84 is one of the most potent 
small molecule ligands for TAR to date. 
 
 
Figure 17: Tripeptide 84. 
 
A popular method for constructing fluorescent polyaromatic α-amino acids is using the Suzuki-
Miyaura cross coupling reaction. An example of this is the work carried out by Hecht and co-
workers.61 They describe the synthesis of four biphenyl-phenylalanine derivatives which employ the 
palladium catalysed coupling reaction as their key synthetic step. The synthesis began with N-Boc-
3-iodophenylalanine which was esterified with iodomethane under basic conditions to give methyl 
ester 85 (Scheme 18). Suzuki-Miyaura conditions were then used to couple 4-biphenylboronic acid 
to aryl iodide 85. An excellent yield of 95% was obtained, generating terphenylalanine analogue 86. 
The Boc group was removed with TFA followed by reprotection to produce pentenoyl protected 
amine 87. Methyl ester hydrolysis with lithium hydroxide ensued and the corresponding carboxylic 
acid was activated as a cyanomethyl ester 88. Treatment with a solution of tris-
(tetrabutylammonium) salt of pdCpA (5’-Phospho-2’-deoxyribocytidylriboadenosine) led to 
aminoacetyl pdCpA terphenylalanine derivative 89. The optical properties of this analogue were 
measured using the N-pentenoyl-protected amino acid giving an absorption and emission band at 
280 and 342 nm respectively. A high emission efficiency of 0.67 was also calculated. All four of the 
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terphenylalanine derivatives were used to activate tRNA transcripts after being incorporated into 
multiple positions of ecDHFR.61 Efficient incorporation into position 16 was possible and for all four 
modified proteins the rate of NADPH consumption doubled when compared with the wild type. The 
sterically accessible position 49 was also targeted and this led to comparable catalytic function of 
the four modified proteins with the wild type. A folded region of the protein was of interest to 
investigate whether the sizeable biphenyl-phenylalanine derivatives could be incorporated with 
minimal perturbation towards the functionality of DHFR. Two of the four modified proteins were 
accommodated at the sterically demanding position 115 and 89 was incorporated to one of the 
proteins that did not perform well in this position. It was hypothesised that aryl groups substituted 
at the para position of the phenylalanine ring introduced the least amount of steric hindrance in 
proximity to the protein backbone. The group also incorporated these novel fluorescent α-amino 
acids into ecDHFR along with a 7-hydroxycoumarin α-amino acid. They managed to demonstrate 
that these compounds can effectively transfer energy to this coumarin via a FRET mechanism. 
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Scheme 18: Synthesis of biphenyl-phenylalanine-derived α-amino acid 89. 
 
Gilfillan et al managed to utilise the α,β-unsaturated ketone functionality on a series of enone 
derivatives to construct a small five-membered library of pyrazole derived α-amino acids.62 The 
synthesis proceeded with ʟ-aspartic acid and a five-step protocol previously developed was 
employed to access the Cbz protected amine 90 (Scheme 19). Enone 90 was reacted with 
phenylhydrazine under acidic conditions which efficiently led to the 2-pyrazoline intermediate 91. 
Immediate reaction with DDQ oxidised the ring to the fully unsaturated and aromatic pyrazole 
moiety 92. Deprotection to the parent α-amino acid was possible using 6 M hydrochloric acid under 
reflux, producing 93 in an excellent 97% yield. The optical properties for this library of novel α-
amino acids were measured. The nitrophenyl derivative 93 had an absorption maximum of 303 nm 
and displayed an emission band at 415 nm in the visible region of the electromagnetic spectrum. A 
naphthyl derivative 94 absorbed at 249 nm and emitted strong fluorescence at 356 nm that was 
blue-shifted in comparison with the nitrophenyl analogue 93. Naturally occurring tryptophan has 
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an emission maximum value of 352 nm which is very similar to that of 94, meaning the potential to 
use this α-amino acid as a fluorescent probe is limited because it would be difficult to distinguish 
between the natural and unnatural α-amino acid residues. This is not the case for 93 as it has a red-
shifted wavelength in comparison to tryptophan. 
 
 
Scheme 19: Synthesis of pyrazole-derived α-amino acids. 
 
Due to the promising optical properties displayed by the nitrophenyl derivative 93, investigation 
into further functionalisation of this compound was examined. α-Amino acids with sulfonyl fluoride 
functionality have shown to act as electrophilic traps for the inhibition of protease enzymes.63 A N-
Cbz protected tetrapeptide with a sulfonyl fluoride moiety managed to demonstrate antimalarial 
activity.64 With this in mind, experiments were carried out to investigate whether 92 could be 
transformed into a multi-functional compound that could be used as a fluorescent probe as well as 
a protease enzyme inhibitor. Methyl ester 92 was reduced using sodium borohydride to the primary 
alcohol and subsequently treated with mesyl chloride to form mesylate 95 (Scheme 20). Cesium 
thioacetate was generated in situ which displaced the mesylate group forming thioacetate 96. 
Oxidation with hydrogen peroxide formed the sodium sulfonate salt. The sulfonyl fluoride 97 was 
generated through the use of triethylamine trihydrofluoride and deoxofluorination agent, 
XtalFluor-M®. The target compound was converted from 92 in an excellent 48% overall yield. This 
synthesis has demonstrated the potential for further functionalisation of these pyrazole derived α-
amino acids to make duel action fluorescent probes. 
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Scheme 20: Synthesis of sulfonyl fluoride α-amino acid derivative 97. 
 
1.10 Summary 
The synthesis and biological application of fluorescent unnatural α-amino acids has increased 
considerably over the last 10–15 years, demonstrating their importance in chemical, biological and 
medicinal research. This is exemplified by the number of recent reviews on the design of novel 
fluorescent α-amino acids and their applications.8,7,65 
 
Palladium-catalysed coupling reactions have been one of the most popular ways to fuse the 
conjugated fluorophore to the α-amino acid portion. There have also been examples where 
construction of the chromophore occurs initially which is followed by late stage asymmetric 
protocols to introduce the stereocentre, methods such as the Schöllkopf bis-lactim amino acid 
synthesis. Another favourable method is using readily available chiral pool α-amino acids as starting 
materials and performing various synthetic transformations to essentially build the novel 
fluorophores with the α-amino acid unit present throughout the synthesis.  
 
The novel fluorescent α-amino acids described here have exhibited a range of optical properties. 
Some have blue-shifted emission maximum bands showing up in the UV and purple/blue regions 
of the electromagnetic spectrum. Many of these fluorophores are easily tuneable through 
functional groups transformations or extending conjugation through aryl group additions or fusing 
ring together to increase rigidity. This allows for bathochromic shifts to take place with regards to 
absorption and fluorescence, allowing emission maximum values to occur in the green and red 
areas of the visible spectrum, with some even managing to exhibit in the near-infrared (NIR) region 
(750–2500 nm). 
 
42 
 
Many of these unnatural α-amino acids have been used as tyrosine and tryptophan mimics allowing 
a fluorescent tag to be present in peptide and proteins with minimal disruption to structure and 
conformation. Donor and acceptor FRET pairings allow the investigation into the mechanism of 
enzymes and a variety of cellular processes.  
 
Optical properties such as sharp absorption and emission peaks in the visible region that are 
tuneable, with high quantum yield values are the most sought after characteristics of a novel 
fluorophore. A rapid and high yielding route towards an Fmoc α-amino acid derivative that can be 
easily incorporated into peptides and proteins is another excellent property. Research is still 
underway to develop new fluorophores that exhibit all the desirable properties expected of a 
fluorescent probe to be used for new applications in medical research.66 
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2.0 Synthesis of Novel Fluorescent Heterocyclic-Derived α-
Amino Acids 
2.1 Previous Work in the Sutherland Group 
Previous work carried out by Lindsay Fowler showed that an efficient four-step synthesis towards 
enone-derived α-amino acids was possible.54,67 A large substrate scope was carried out to test the 
robustness of the Horner-Wadsworth-Emmons (HWE) reaction used to form the α,β-unsaturated 
ketone (Figure 18). Good to excellent yields were achieved using a range of commercially available 
aryl and alkyl aldehydes. A highly fluorescent dimethylaminonaphthyl analogue 76 was also 
synthesised during that portion of the research and displayed excellent optical properties. 
However, the enones were found to be unstable on long-term storage. 
 
 
Figure 18: Selection of protected enone-derived α-amino acids and fluorophore 76. 
 
Lynne Gilfillan was tasked with the challenge of utilising the enone functionality to make a small 
library of more stable pyrazole-derived α-amino acids (Figure 19).62,68 Synthesising a more stable 
heterocycle in place of the reactive enone, as well as extending the conjugation was advantageous. 
The optical properties of the compounds were tested and results showed that naphthyl 94 and 
nitrophenyl 93 were the most fluorescent. 
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Figure 19: Five-membered library of pyrazole-derived α-amino acids. 
 
2.2 Proposed Research 
The aim of this project was to synthesise libraries of heterocyclic α-amino acid derivatives by 
exploring the reactivity of the corresponding enone functional group (Scheme 21). In order to fully 
understand the reactivity and scope of these enone derivatives, the idea was to subject them to 
further heterocycle forming reactions. Heterocycles such as pyridines,69 functionalised pyridines,70 
pyrimidines,71 pyridones72 and functionalised pyrazoles73 were of interest. 
 
 
Scheme 21: Retrosynthesis of novel fluorescent α-amino acid derivatives. 
 
Once libraries of these heterocycle-derived α-amino acids were synthesised, they were to be fully 
analysed with respect to their optical properties. Any that displayed interesting and comparable 
data to known unnatural α-amino acids that have been exploited as fluorescent probes in biological 
studies, were to be Fmoc protected. SPPS would be employed to couple the novel fluorescent α-
amino acid onto a small CPP. Biological studies using fluorescence microscopy would follow to 
investigate whether the fluorophore-CPP conjugate could enter and accumulate in cells. 
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2.3 Synthesis of Pyridine-Derived α-Amino Acids 
2.3.1 Synthesis of N-Trityl Protected Enone-Derived α-Amino Acids 
The synthesis towards the enone derivatives began with the commercially available chiral pool 
starting material, ʟ-aspartic acid. The carboxylic acid groups were protected using thionyl chloride 
and methanol to form dimethyl ester hydrochloride salt 98 in quantitative yield (Scheme 22). The 
primary amine was then protected with a bulky trityl group using standard conditions and excellent 
yields of 93% were achieved for N-trityl dimethyl ester 72. Addition of the anion of dimethyl 
methylphosphonate to a solution of 72 in THF at −78 °C led to the regioselective formation of β-
keto phosphonate ester 73 in an 86% yield. The reaction gives β-keto phosphonate ester 73 as the 
sole product due to protection of the α-methyl ester by the steric bulk of the N-trityl protecting 
group. The first key step of this synthesis was the HWE reaction. Previously optimised conditions 
led to the use of potassium carbonate as the base and acetonitrile as the polar aprotic solvent.74 
The reactions were performed at 50 °C and from one to seven days. 
 
 
Scheme 22: Synthesis of β-keto phosphonate ester 73 and HWE reaction conditions. 
 
β-Keto phosphonate ester 73 was subjected to the HWE conditions with various aldehydes used as 
the coupling partner. This led to a twelve-membered library of N-trityl enone-derived α-amino acids 
(Figure 20). The exclusive formation of the E-isomer was observed, in good to excellent yield. The 
identification of the E-enone was straightforward due to a vicinal coupling constant of 
approximately 16.2 Hz in the 1H NMR spectra for these compounds. A range of different aldehydes 
were submitted to the reaction conditions which included electron-donating/withdrawing aryl 
groups, a biaryl system, a heterocycle and two alkyl groups. Yields greater than 69% were observed 
for all analogues apart from 107 which was obtained with a moderate yield of 40%. This was due to 
the reaction only being attempted once on a small-scale. 
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Figure 20: Substrate scope for N-trityl protected enone-derived α-amino acids. 
 
The mechanism for the HWE reaction starts with the deprotonation of the most acidic hydrogen 
atom of the β-keto phosphonate ester (Scheme 23).75 Reversible, stepwise attack of the phosphoryl 
stabilised carbanion 110 on benzaldehyde generates interchangeable oxyanions 111 and 112. The 
pathway to the anti-addition intermediate 112 is faster compared to the syn-addition intermediate 
111. Reactive four-membered oxaphosphonates 113 and 114 are then generated, whereby the 
trans-intermediate 113 decomposes leading to the major thermodynamic E-alkene product. Both 
trans 113 and cis 114 pathways are slow to decompose. Due to the stereoselective nature of this 
olefination reaction the cis pathway must be considerably slower as no Z-alkene is observed. 
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Scheme 23: Mechanism of the HWE olefination. 
 
The majority of the aldehydes used were commercially available, except the aldehyde used to make 
biaryl analogue 106. The Suzuki-Miyaura cross-coupling reaction was used to synthesise 4-(3’-
nitrophenyl)benzaldehyde 115 in quantitative yield from 4-bromobenzaldehyde and 3-
nitrophenylboronic acid (Scheme 24). This protocol had already been reported in the literature.76 
 
 
Scheme 24: Synthesis of 4-(3’-nitrophenyl)benzaldehyde 115. 
 
2.3.2 Synthesis of N-Cbz Protected Enone-Derived α-Amino Acids 
Now that a library of enone-derived α-amino acids had been synthesised, the next step was to 
prepare intermediates that could be used in heterocycle forming reactions. Previous work had 
shown that N-trityl derivatives were too sterically hindered to allow reactions at the enone. 
Therefore, to ensure that heterocycle synthesis was efficient with no side-reaction occurrence, the 
next step was to remove the acid labile trityl group and reprotect with the Cbz protecting group 
(Scheme 25). The enone derivatives were treated with trifluoroacetic acid at room temperature, 
which cleanly removed the trityl group to form the intermediate TFA salt. Hünig's base was then 
used to neutralise the TFA, followed by benzyl chloroformate addition which led to the N-Cbz 
derivatives. This was a very rapid and clean reaction, allowing good to high yields for the two-step 
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procedure. The substrate scope for this reaction focussed mainly on aryl side-chains. These aryl 
groups would allow conjugation with the resulting heterocycles giving good potential optical 
properties. A range of aryl side-chains with electron rich/poor functional groups were investigated. 
Propyl derivative 123 was also examined to prove that it is possible to subject alkyl side-chain 
analogues to this protocol. 
 
 
Scheme 25: Deprotection/reprotection procedure to form N-Cbz protected enone-derived α-
amino acids. 
 
2.3.3 Synthesis of N-Boc Protected Enone-Derived α-Amino Acids 
It was hypothesised that these N-Cbz protected enone derivatives would be stable towards the 
proposed heterocycle forming conditions. However, as a contingency plan, N-Boc protected 
derivatives were also synthesised. A two-step deprotection/reprotection procedure was employed, 
similar to that of the N-trityl to N-Cbz sequence. TFA was used to remove the acid labile trityl group 
which was followed by N-Boc protection using di-tert-butyl dicarbonate and TEA (Scheme 26). Aryl 
group side chains were the main focus of the substrate scope for the N-Boc protected series of 
enones. Yields ranging from 62–82% were achieved across the seven-membered library apart from 
furan derivative 130 which had only been synthesised once on a small-scale. 
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Scheme 26: Deprotection/reprotection procedure to form N-Boc protected enone-derived α-
amino acids. 
 
4-Fluoro-3-nitrophenyl derivative 128 was of interest as it could potentially be used in a nucleophilic 
aromatic substitution (SNAr) reaction to install fluorine-18 (18F), a radioactive fluorine isotope 
commonly used in positron emission tomography (PET) imaging.77 Upon heterocycle synthesis, in 
this example a functionalised pyridine, the SNAr reaction and incorporation of the 18F radioisotope 
could be achieved using 18F potassium fluoride and 2.2.2-cryptand (Scheme 27).77 The resulting 
compound could be used as a dual action imaging agent being used in fluorescence or PET imaging. 
 
 
Scheme 27: Proposed conditions and mechanism for SNAr 18F-radiolabelling of 4-fluoro-3-
nitrophenyl analogue. 
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2.3.4 Inverse Electron Demand Hetero-Diels-Alder (HDAINV) Cycloaddition 
The second key synthetic step was an inverse electron demand hetero-Diels-Alder (HDAINV) reaction 
catalysed by a lanthanide Lewis acid catalyst. This work originated from Danishefsky and Bednarski 
who developed this type of Diels-Alder reaction, employing various lanthanide complexes such as 
Eu[fod]3 and Yb[fod]3 to catalyse the procedure (Scheme 28). Initial work reported the use of 
Danishefsky’s diene 131 that underwent the HDA reaction with various aldehydes.78 Focus then 
shifted to the cycloaddition of α,β-unsaturated aldehydes 132 and vinyl ethers.79 The protocol was 
also showcased as a key step in the total synthesis of various natural products such as vineomycin 
B2 algycon.80 
 
 
Scheme 28: Initial use of lanthanide catalysts for the HDA reaction.  
 
Throughout all of these literature reports, high endo selectivity was observed for this HDA 
cycloaddition. With that in mind, the next stage in this project was to subject the α,β-unsaturated 
enones to these conditions. The N-Cbz protected enone-derived α-amino acids were chosen as the 
preferred library for this cycloaddition, due to the ability of the Cbz protecting groups to withstand 
high temperature and pressure. The enones were heated to 105 °C in neat ethyl vinyl ether with a 
5 mol% catalyst loading of Yb[fod]3 (Scheme 29). The enones acted as the electron-withdrawing 
diene and ethyl vinyl ether was used as the electron-rich dienophile. The reaction provided good to 
excellent yields of the dihydropyran α-amino acid derivatives. Eight N-Cbz protected dihydropyran 
analogues were synthesised using this procedure with the substrate scope consisting of electron-
rich/poor aryl groups, a biaryl system as well as a short alkyl group. Longer reaction times were 
necessary for the electron rich compounds, methoxyphenyl 134 and dimethylaminonaphthyl 136. 
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Scheme 29: General procedure for HDAINV reaction and substrate scope. 
 
This HDAINV reaction furnished two new stereocentres and although the next step in this synthetic 
sequence results in the loss of both due to aromatisation, it is important to fully understand and 
predict why the mechanism and resulting regio- and stereoselectivity are observed. The effect of 
the Lewis acid catalyst was also considered. Standard Diels-Alder reactions involve an electron-rich 
diene and electron-poor dienophile, whereby two new chemical bonds and a six-membered ring 
are formed. The roles are reversed for an inverse electron demand Diels-Alder (DAINV) reaction, 
where the diene is electron-poor and dienophile electron-rich.81 During a DAINV reaction, three π-
bonds are broken, and two σ-bonds and one new π-bond are formed. The regiochemistry can be 
predicted by considering the best HOMO-LUMO interaction. The LUMO (lowest unoccupied 
molecular orbital) of the heterodiene reacts with the HOMO (highest occupied molecular orbital) 
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of the dienophile (Figure 21). The orbitals will align to maximise the bonding interactions and 
subsequently minimising the anti-bonding interactions. Theoretically, the DAINV obeys a general 
endo selection rule. The DAINV favours an endo orientation of the electron-donating substituents on 
the dienophile as it approaches the diene. This endo approach helps maximise secondary orbital 
overlap.82 The orbital overlap occurs between the carbonyl carbon of the diene and the ethoxy 
oxygen of the ethyl vinyl ether dienophile. With the reaction proceeding through the endo pathway, 
the dienophile could approach from the top or bottom face of the diene (Figure 21). The Yb[fod]3 
Lewis acid cooridinates to the carbonyl oxygen of the diene, consequently lowering the LUMO 
energy. A six-membered transition state could also be forming due to the close proximity of the 
amino group simultaneously coordinating to the Lewis acid. This transition state could be 
minimising the free rotation around the methylene bridge, locking the conformation in place and 
blocking the top face of the diene. For all analogues subjected to the HDAINV conditions there was 
a major product observed, generally with a 9:1 dr. The proposed transition state could explain the 
observed diastereoselectivity. However, as the next step involved aromatisation, full 
characterisation was never carried out to determine the major diastereomer. 
 
 
Figure 21: HDAINV potential transition state. 
 
The lanthanide complex used in this reaction was tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-
octanedionato)ytterbium (Yb[fod]3) which consists of three bidentate acetylacetonate ligands 
bound to the metal(III) centre (Figure 22).83,84 The Lewis acid lowers the LUMO energy, resulting in 
a smaller energy gap between the HOMO/LUMO and a faster reaction. It also increases the LUMO 
polarisation allowing for a more regioselective reaction.  
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Figure 22: Structure of Yb[fod]3. 
 
2.3.5 Synthesis of N-Cbz Protected Pyridine-Derived α-Amino Acids 
Following the synthesis of the dihydropyran-derived α-amino acid analogues, the aromatisation 
step was next investigated. This step combined with the HDAINV reaction was developed by Ciufolini 
and Byrne, and termed as a modified Knoevenagel-Stobbe condensation reaction. They first 
reported it for the preparation of 2,4-disubstituted pyridines 141 (Scheme 30).85 
 
 
Scheme 30: Initial use of the two-step HDAINV/pyridine synthesis procedure. 
 
Ciufolini described multiple total and formal syntheses of various natural products that contain 
substituted pyridine rings using this approach (Figure 23). He reported the formal synthesis of 
lavendamycin methyl ester, a streptonigrin congener.86 Cystodytin A was also synthesised along 
with multiple cystodytin natural product analogues.87,88 This approach was also used to prepare a 
series of pyridoacridine alkaloids and shermilamine B.89,90  
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Figure 23: Pyridine-containing natural products synthesised by the Ciufolini group. 
 
Using this approach, each dihydropyran from the eight-membered library was treated with 
hydroxylamine hydrochloride in acetonitrile and heated to 70 °C overnight to form the desired 
pyridine heterocycle (Scheme 31). Moderate to good yields were achieved. However, lower yields 
were observed for the electron-poor nitrophenyl 146, fluorophenyl 147 and biaryl 148 analogues. 
Dimethylaminonaphthyl 145 displayed the lowest yield across the series, but its synthesis was only 
attempted once on a very small-scale. Repeat reactions were carried out on all the other analogues 
to optimise their yields. Silica chromatography was not the ideal purification method due to 
retention of these pyridines on the acidic silica. This was also the case when 1% triethylamine was 
used in the eluting solvents. Neutral alumina was then attempted and proved to be a much more 
suitable stationary phase for flash column chromatography to purify this series of compounds. 
 
 
Scheme 31: General conditions for the aromatisation procedure. 
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During this transformation, the ethoxy oxygen is protonated and the formation of an oxonium 
species results in the elimination of ethanol (Scheme 32). Subsequent nuclephilic attack of the 
hydroxylamine to the electrophilic oxonium ion, proton transfer and ring opening furnishes an 
oxime/enol intermediate. Tautomerisation of the oxime and enol to their respective enamine and 
ketone functional groups leads to nucleophilic attack of the enamine nitrogen to the carbonyl 
group. This is followed by rapid loss of two molecules of water, resulting in the formation of the 
stable pyridine ring.91 The driving force of this reaction is the dehydration and ethanol elimination 
steps, as well as the formation of a stable aromatic ring. 
 
 
Scheme 32: Possible mechanism for the synthesis of N-Cbz protected pyridine-derived α-amino 
acids. 
 
2.3.6 Deprotection to Form the Parent Pyridine-Derived α-Amino Acids 
The final step in this synthetic sequence towards the target molecules was deprotection of the 
amine and carboxylic acid protecting groups. Acid mediated deprotection using 6 M hydrochloric 
acid was used to generate the final α-amino acids (Scheme 33). Excellent yields across this series of 
compounds were obtained.  
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Scheme 33: Deprotection conditions to form the parent α-amino acids. 
 
2.4 Optical Properties of Pyridine-Derived α-Amino Acids 
With the parent α-amino acids available, the next stage of this study was to fully analyse the optical 
properties of these compounds, including absorption and emission maximum values, molar 
extinction coefficients and quantum yields. Determination of these properties would allow 
correlation between structure and fluorescence, generating an understanding of how this 
information could be used to design further analogues for biological studies. 
 
2.4.1 Absorption and Emission Data for Neutral and Electron-Rich Pyridine Derivatives 
The neutral and electron-rich pyridine derivatives displayed the most interesting optical properties. 
Phenyl analogue 150 had an absorption maximum of 263 nm and an emission maximum of 332 nm 
(Figure 24). Methyloxyphenyl 151 had an absorption value of 283 nm (Figure 25) and naphthyl 152 
a blue-shifted absorption maximum value of 259 nm (Figure 26). When both of these compounds 
were irradiated at their respective excitation wavelengths, at the standard concentrations, the 
emission bands were too intense and were off the scale. This suggests that both compounds are 
highly fluorescent and should be investigated further. Propyl 157 was irradiated at its absorption 
maximum value of 267 nm and gave a very weak emission maximum of 311 nm (Figure 27). This 
was predicted due to the limited conjugation of this analogue. 
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Figure 24: Phenyl 150 absorption and emission data. 
 
 
Figure 25: Methoxyphenyl 151 absorption and emission data.  
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Figure 26: Naphthyl 152 absorption and emission data. 
 
 
Figure 27: Propyl 157 absorption and emission data. 
 
2.4.2 Absorption and Emission Data for Electron-Poor Pyridine Derivatives 
The optical properties for the electron-poor pyridine analogues were not as promising after 
comparison with the electron-rich series. Nitrophenyl 154 had an absorption value of 277 nm and 
very weak fluorescence at 381 nm (Figure 28). Fluorophenyl 155 displayed an absorption band at 
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268 nm and emission at 325 nm (Figure 29). Finally, biaryl 156 had an intense absorption value of 
276 nm (Figure 30). Upon irradiation however, a weak emission maximum of 373 nm was observed. 
The optical properties for this set of compounds was expected due to the electron-deficient 
properties associated with the aryl side-chains. Generally, good fluorophores exhibit a push-pull 
electronic relationship but these compounds possess electron-deficient nitro and fluoro functional 
groups. 
 
 
Figure 28: Nitrophenyl 154 absorption and emission data. 
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Figure 29: Fluorophenyl 155 absorption and emission data. 
 
 
Figure 30: Biaryl 156 absorption and emission data. 
 
2.4.3 Methoxyphenyl 151 and Naphthyl 152 Dilution Study 
Due to the intense emission spectra observed for methoxyphenyl 151 and naphthyl 152 when using 
10 μM sample concentrations, a dilution study was carried out to investigate the emission 
maximum values for these analogues. Sample concentrations of 5, 1 and 0.1 μM were analysed 
268 325
0
10
20
30
40
50
60
70
80
90
0
0.05
0.1
0.15
0.2
0.25
0.3
227 277 327 377 427 477 527
Fl
u
o
re
se
n
ce
 I
n
te
n
si
ty
A
b
so
rp
ti
o
n
Wavelength (nm)
Absorption Emission
276
373
0
5
10
15
20
25
30
35
40
45
50
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
233 283 333 383 433 483
Fl
u
o
re
se
n
ce
 I
n
te
n
si
ty
A
b
so
rp
ti
o
n
Wavelength (nm)
Absorption Emission
61 
 
using UV/visible and fluorescence spectroscopy. The absorption maximum value for 
methoxyphenyl 151 was 283 nm for all three concentrations (Figure 31). Upon irradiation at 283 
nm, the 5 μM and 1 μM samples were still too concentrated and the reading was off the scale 
(Figure 32). The most dilute sample however, displayed an emission maximum value of 366 nm. 
These results suggest methoxyphenyl 151 exhibits intense emission with a maximum value of 366 
nm, which is in the UV-A region of the electromagnetic spectrum. 
 
 
Figure 31: Methoxyphenyl 151 absorption data.  
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Figure 32: Methoxyphenyl 151 emission data. 
 
The absorption maximum value for naphthyl 152 at the three concentrations was 259 nm (Figure 
33). Excitation at this wavelength for each sample followed. The 5 μM sample had two emission 
maximum bands at 380 and 452 nm (Figure 34). The same result was obtained for the 1 μM sample. 
However, at 0.1 μM there appeared to be a single emission band at 383 nm. It is unknown why 
there was a dual band observed for the more concentrated samples. The data obtained from the 
most dilute sample would be used in future investigations using naphthyl 152 as it was considered 
the most accurate and reasonable result. 
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Figure 33: Naphthyl 152 absorption data.  
 
 
Figure 34: Naphthyl 152 emission data.  
 
2.4.4 Methoxyphenyl 151 pH Study 
Due to the intense fluorescence displayed by methoxyphenyl 151, a pH study was carried out to 
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addition of concentrated hydrochloric acid and sodium hydroxide was used to acidify and basify the 
stock solutions of methanol to pH 1 and 12 respectively. A red-shifted absorption maximum value 
of 338 nm was observed for the acidic solution and a minimal blue-shifted absorption maximum of 
274 nm for the basic solution. 
 
 
Figure 35: Methoxyphenyl 151 absorption data for pH study. 
 
These samples were then irradiated at their respective absorption maximum values. The neutral 
sample had the predicted emission value of 368 nm due to previous investigations (Figure 36). 
Much like the absorption value for the basic solution, a blue-shifted emission maximum reading of 
351 nm was obtained, which was considerably less intense than the neutral solution. The acidic 
solution on the other hand had a predicted emission maximum with a bathochromic shift on 
comparison with the neutral solution. An emission maximum of 428 nm was observed with about 
half the fluorescence intensity of the neutral solution. This red-shifted wavelength is located in the 
purple area of the visible spectrum. The neutral and basic solutions fluoresce in the UV-A region. 
Upon acidification, the emission band red-shifts to the purple/visible area of the electromagnetic 
spectrum. These results suggest that methoxyphenyl 151 could potentially be used as a fluorescent 
pH probe especially when pH levels in the environment switch from neutral/basic to acidic.  
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Figure 36: Methoxyphenyl 151 emission data for pH study. 
 
2.4.5 Other Optical Properties  
A number of other spectroscopic properties were determined for the library of pyridine-derived α-
amino acids using the absorption and emission data. The Stokes shift is the difference in wavelength 
between the emission and absorption maximum values. It is fundamental to the sensitivity of 
fluorescence techniques if the Stokes shift is large because it allows emission photons to be 
detected against a low background, isolated from excited photons.92 The molar extinction 
coefficient is the capacity for light absorption at a specific wavelength and is defined by the Beer-
Lambert law, A = εcl (A = absorbance, ε = extinction coefficient, c = molar concentration, l = optical 
pathlength). Fluorescence quantum yield is defined as the number of fluorescence photons emitted 
per excitation photons absorbed. Experimentally, relative fluorescence quantum yields can be 
determined by measuring the fluorescence of a fluorophore of known quantum yield with the same 
experimental parameters as the substance in question. The final property calculated was the 
brightness or fluorescence output per fluorophore. This is proportional to the product of the 
extinction coefficient and the fluorescence quantum yield. All of the pyridine derivatives displayed 
high extinction coefficient values in excess of 16,000 cm−1 M−1 (Table 1). Biaryl 156 had a molar 
extinction coefficient of 47,310 cm−1 M−1, the highest for this series of compounds. This is due to 
the conjugation extending over three aryl rings. A good fluorescence quantum yield of 0.18 was 
observed for naphthyl 152 and an excellent 0.46 was calculated for methoxyphenyl 151. The results 
for these two compounds suggest that it is crucial for potential fluorophores to not only have 
extended conjugation but for electron-donating groups to be present. For propyl 157 and biaryl 
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156, the fluorescence quantum yields and brightness were not measured due to their extremely 
low intensity emission graphs. 
 
 
Table 1: Optical properties summary for pyridine-derived α-amino acid library. 
 
2.4.6 Summary 
Based on the results from the optical properties investigation, it is clear that the most promising 
pyridine derivatives that could potentially be used as fluorescent probes are methoxyphenyl 151 
and naphthyl 152 (Figure 37). It is apparent that a direct correlation exists between the electron-
rich nature of the α-amino acid side-chains and desirable fluorescent properties such as the 
quantum yield.  
 
 
Figure 37: Pyridine-derived fluorophores 151 and 152. 
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2.5 Synthesis of Second Generation Pyridine-Derived α-Amino Acids 
Having developed an efficient route to pyridine-derived α-amino acids and the synthesis of a seven-
membered library of compounds, the next stage of this project was to introduce more electron-
donating functionality into the aryl groups. An attempt to improve the optical properties was the 
main aim. It was hypothesised that a second electron-donating group present on the aryl side-chain 
might result in a substantial red-shift, with regards to the absorption and emission maximum 
values, as well as an increase of the fluorescence intensity. Therefore, a library of five compounds 
was targeted to produce a second generation of pyridine analogues. 
 
2.5.1 Synthesis of N-Cbz Protected Enone-Derived α-Amino Acids 
A range of novel enones were prepared using the already developed HWE reaction (Scheme 22). 
Two electron-donating aldehydes and one electron-withdrawing aldehyde were used to make a 
small library of enone-derived α-amino acids with disubstituted aryl group functionality (Scheme 
34). Long reaction times were required for the HWE reaction with electron rich aldehydes 2,4-
dimethoxybenzaldehyde and piperonal, which led to the corresponding enones 158 and 159. On 
the contrary, a very short reaction time of 1 h was needed for the 2,4-dinitrobenzaldehyde example, 
160. The standard deprotection/reprotection strategy was used to generate N-Cbz protected 
enones 161, 162, and 163.  
 
 
Scheme 34: Synthesis of N-trityl and N-Cbz protected enone-derived α-amino acids. 
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2.5.2 Inverse Electron Demand Hetero-Diels-Alder (HDAINV) Cycloaddition 
The next step in the synthetic sequence was the HDAINV cycloaddition (Scheme 35). Extended 
reaction times were imperative for the reaction to reach completion and good yields were achieved 
for all three analogues.  
 
 
Scheme 35: HDAINV reaction conditions and analogues synthesised. 
 
2.5.3 Synthesis of N-Cbz Protected Pyridine-Derived α-Amino Acids 
The second part in this two-step procedure was the modified Knoevenagel-Stobbe condensation 
reaction used to construct the functionalised pyridine ring (Scheme 36). A similar trend was 
observed regarding the yield obtained for electron-rich and deficient analogues when compared to 
the first generation pyridine library. Good yields were obtained for the electron donating 
dimethoxyphenyl 167 and piperonyl 168 whereas a lower 38% yield was acquired for the electron-
withdrawing dinitrophenyl derivative 169. This lower yield could be due to the polar nature of 169 
as it was particularly difficult to handle and isolate via column chromatography. 
 
 
Scheme 36: Pyridine formation conditions and analogues synthesised.  
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2.5.4 Aryl Nitro Reduction with Tin(II) Chloride Dihydrate 
In order to boost the number of pyridine-derived α-amino acids with electron rich aryl side chains, 
an approach to reducing both nitrophenyl 146 and dinitrophenyl 169 analogues to their 
corresponding anilines was investigated (Scheme 37). The selective reduction of aromatic nitro 
groups in the presence of other reducible or acid sensitive groups is possible through the use of 
tin(II) chloride dihydrate in non-acidic and non-aqueous solvents.93 Therefore, nitrophenyl 146 was 
subjected to these mild conditions which resulted in clean conversion to aminophenyl 170 in 65% 
yield. Dinitrophenyl 169 was also converted to diaminophenyl 171 and a consistent 63% yield was 
achieved. 
 
 
Scheme 37: Aryl nitro to aniline reduction conditions. 
 
2.5.5 Deprotection to Form the Parent Pyridine-Derived α-Amino Acids 
The final stage in the synthesis of the second generation of pyridine-derived α-amino acids was the 
deprotection of amine and carboxylic acid protecting groups. The same conditions used for the 
phase I pyridines was employed, 6 M hydrochloric acid under reflux (Scheme 38). A two day reaction 
for dimethoxyphenyl 167 and piperonyl 168 resulted in a complex mixture of products, as 
confirmed by 1H NMR spectroscopy. It is likely that the methoxy and the acetal functional groups 
were removed along with the Cbz and methyl ester during a long reaction time. Shortening the 
reaction time to 16 h generated 172 and 173 cleanly.  
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Scheme 38: Deprotection to form the parent α-amino acid derivatives. 
 
2.6 Optical Properties of Second Generation Pyridine-Derived α-Amino 
Acids 
The optical properties of the second generation of pyridine derivatives were investigated. This was 
to see if any of the disubstituted analogues had considerably better fluorescent properties than the 
first generation of pyridines. The analogues with the best combination of emission maximum range 
and fluorescence intensity would be selected for incorporation into a small CPP and used for 
subsequent biological investigations. 
 
2.6.1 Absorption and Emission Data for Second Generation Pyridine Derivatives 
Dimethoxyphenyl 172 had an absorption maxima at 275 nm and a shoulder peak at 298 nm (Figure 
38). Upon irradiation at 275 nm a broad emission band appeared with a maximum value of 384 nm. 
However, when it was excited at 298 nm, a similar emission spectrum was recorded with exactly 
the same maximum value of 384 nm but it was considerably more intense than irradiation at 275 
nm. This was an unforeseen result as it was predicted that due to the red-shift in absorption 
maximum, a red-shift in emission maximum was expected. The absorption maximum for piperonyl 
173 was 303 nm and it had a red-shifted emission maximum of 460 nm (Figure 39). This was an 
excellent result as the emission band is located in the blue area of the visible region which expands 
the potential use of this compound if it was used as a fluorescent probe. Piperonyl 173 does not 
have comparable fluorescence intensity to methoxyphenyl 151, naphthyl 152 or dimethoxyphenyl 
172. The only electron-deficient analogue in this library was dinitrophenyl 174. It had an absorption 
maximum of 265 nm and weak fluorescence intensity, with an emission maximum of 304 nm (Figure 
40). Results for the electron-rich aminophenyl 175 were promising. It displayed an absorption 
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maximum of 315 nm and a red-shifted emission maximum of 433 nm upon irradiation (Figure 41). 
This was very interesting as the emission band is located in the purple area of the visible spectrum. 
Finally, diaminophenyl 176 had an absorption maximum of 328 nm (Figure 42). However, even with 
an extra amino group donating electrons to the aromatic system it displayed a substantial reduction 
in fluorescence intensity in comparison with aminophenyl 175. It was hypothesised that this would 
have the opposite effect and improve the fluorescent properties. The emission maximum value was 
485 nm but due to the poor intensity associated with this analogue it was not further investigated.  
 
 
Figure 38: Dimethoxyphenyl 172 absorption and emission data.  
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Figure 39: Piperonyl 173 absorption and emission data. 
 
 
Figure 40: Dinitrophenyl 174 absorption and emission data. 
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Figure 41: Aminophenyl 175 absorption and emission data. 
 
 
Figure 42: Diaminophenyl 176 absorption and emission data. 
 
2.6.2 Other Optical Properties 
Similar to the first library of pyridine derivatives, the next stage was to calculate the Stokes shift, 
molar extinction coefficient, quantum yield and brightness for each of the second generation 
pyridine analogues. The most promising derivatives from this library were dimethoxyphenyl 172 
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and piperonyl 173. A good quantum yield of 0.19 was calculated for 172 and it displayed broad and 
intense fluorescence (Table 2). Even though piperonyl 173 did not exhibit intense fluorescence 
which was exemplified with a low quantum yield of 0.06, it did however fluoresce in the visible 
region which would expand the potential for application. The quantum yields and brightness for 
dinitrophenyl 174 and diaminophenyl 176 were not measured due to the weak emission that each 
analogue displayed. 
 
 
Table 2: Optical properties summary for second generation pyridine-derived α-amino acids. 
 
2.6.3 Summary 
From the second generation of pyridine-derived α-amino acids, the most interesting compounds 
were dimethoxyphenyl 172 and piperonyl 173 (Figure 43). These two compounds along with the 
first generation methoxyphenyl 151 and naphthyl 152 analogues were the four pyridine derivatives 
that exhibited the most desirable optical properties. This is likely due to the fact that these four 
compounds have electron-rich side-chain aryl groups allowing them to possess a push-pull 
relationship throughout the extended conjugation. They have the most potential to be 
incorporated into a small CPP and utilised in subsequent cell study investigations. 
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Figure 43: Pyridine-derived fluorophores with interesting optical properties. 
 
2.7 Synthesis of Fmoc Protected Pyridine-Derived α-Amino Acids 
2.7.1 Solid Phase Peptide Synthesis 
Solid phase peptide synthesis (SPPS) was pioneered by Merrifield in 1963 and it is now the standard 
method for synthesising peptides and proteins in the laboratory.94 It allows the synthesis of natural 
peptides that can be difficult to express in bacteria, the incorporation of unnatural amino acids, 
peptide/protein backbone modification and the synthesis of proteins that consist of ᴅ-amino acids. 
Porous beads are treated with functional linkers, where peptide chains can be built from. Repeated 
cycles of deprotection-wash-deprotection-wash take place until the desired peptide has been 
synthesised. The superiority of this technique is due to the ability to perform wash cycles after each 
reaction, filtering off excess liquid-phase reagents and by-products while the growing peptide of 
interest remains covalently attached to the insoluble resin.95 
 
2.7.2 SPPS - Boc Protection Method 
The original method for the synthesis of peptides and proteins relied upon the Boc group to protect 
the α-amino group, supressing its nucleophilicity. Acid mediated deprotection with TFA is generally 
used to remove the N-terminal Boc protecting group, prior to coupling each amino acid to the 
growing peptide chain. Upon synthesis of the target peptide, the deprotection strategy to remove 
the side-chain protecting groups, usually benzyl-based groups, requires treatment with hydrogen 
fluoride. This is extremely hazardous to work with and a harsh final cleavage reagent which can 
ultimately degrade the peptide. A milder, base labile method for SPPS was developed as an 
alternative to the Boc protection method.95 
 
2.7.3 SPPS - Fmoc Protection Method 
The Fmoc protection method allows for a milder deprotection strategy using piperidine to remove 
the Fmoc group, exposing the α-amino group for subsequent coupling. The Fmoc group is stable 
under acidic conditions which allow the use of mild acid labile protecting groups to protect the side-
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chain residues, generally tert-butyl based. This orthogonal protecting group strategy is preferred 
over the Boc method because it is easier to cleave from the resin support. Side-chain protecting 
group removal and cleavage from the resin is carried out with TFA in the presence of cation 
scavengers. However, it is less atom economical as the fluorenyl group is much larger than the tert-
butyl group.95 
 
2.7.4 Synthesis of N-Fmoc Protected Pyridine-Derived α-Amino Acids  
As previously described in the first chapter, a popular application of unnatural fluorescent α-amino 
acids is incorporation into a peptide or protein to study biological mechanisms via fluorescence 
microscopy. In order for α-amino acid incorporation to occur via SPPS, the fluorescent analogue 
must be transformed into a N-Fmoc protected derivative. Methoxyphenyl 151 and piperonyl 173 
exhibited excellent optical properties and were chosen to be protected as N-Fmoc derivatives. 
Fluorenylmethyloxycarbonyl chloride was used under basic conditions to form methoxyphenyl 177 
and piperonyl 178 N-Fmoc protected analogues (Scheme 39).96 Consistent yields of 40% were 
achieved for both reactions.   
 
 
Scheme 39: Synthesis of N-Fmoc protected pyridine-derived α-amino acids. 
 
2.8 Synthesis of Novel Fluorescent Cell Penetrating Hexapeptide 
As the N-Fmoc protected analogues had been successfully synthesised, the next stage of this project 
was to incorporate them into a known CPP. These fluorescently tagged CPPs would be incubated 
with cell lines and visualised via fluorescence microscopy to study whether the fluorophore-CPP 
conjugate could accumulate in the cells.  
 
2.8.1 SPPS of Cell Penetrating Pentapeptide VPTLK 
Cheruku et al synthesised a series of tyrosine-derived stimuli responsive, fluorescent α-amino 
acids.11 During this study they incorporated a novel α-amino acid with the most promising optical 
properties into a cell penetrating Bax-inhibiting pentapeptide using SPPS.97 Hexapeptide 5 was 
successfully synthesised and investigations were carried out to assess the cell permeability and 
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fluorescent properties of this peptide (Figure 44). It was incubated with a human epithelial cell line 
(HeLa) and mouse fibroblast cells (NIH 3T3) for 3 h. Laser scanning confocal microscopy was used 
to visualise and confirm that hexapeptide 5 could enter and accumulate in these cell lines. This 
demonstrates the potential utility of this novel fluorescent α-amino acid proving that it could be 
used to image cellular processes. Inspired by this work, a known CPP would be selected, synthesised 
and coupled with N-Fmoc protected methyoxyphenyl analogue 177. This particular pyridine-
derived α-amino acid was chosen due to its intense fluorescence as well as its high quantum yield 
and molar extinction coefficients.  
 
 
 
Figure 44: Cell penetrating hexapeptide 5. 
 
CPPs are a group of peptides that have the ability to penetrate the plasma membrane of living 
cells.98–101 Cell penetrating pentapeptides are derived from the protein Ku70 and designed on the 
Bax-binding domain of Ku70. Ku70 is a multifunctional protein involved in non-homologous end-
joining DNA repair and cell-death regulation. Matsuyama and co-workers have developed a series 
of cell penetrating peptides that were designed based on the Bax-binding domain of Ku70 of various 
species which include human, rat and mouse.102 Pentapeptide VPTLK 179 was designed from human 
Ku70 and displayed excellent cell penetration activity (Figure 45).97 It was therefore selected as the 
preferred small CPP that was to be synthesised and coupled with α-amino acid 177. 
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Figure 45: Structure of cell penetrating pentapeptide VPTLK 179. 
 
Dr Astrid Knuhtsen and Dr Andrew Jamieson provided invaluable knowledge and expertise when 
this portion of work was undertaken. SPPS was carried out using Rink Amide ChemMatrix® as the 
polymer-support. The ChemMatrix® Rink Amide resin does not have any protecting group on the 
linker therefore the first step was swelling of the resin followed by coupling with Fmoc-ʟ-Lys(Boc)-
OH, the C-terminal amino acid (Scheme 40). Following coupling and thorough washing, the resin 
was subjected to 20% piperidine in DMF to remove the Fmoc-protecting group on the N-terminus. 
The resin was washed again after which the next amino acid was coupled. These steps were 
repeated until the synthesis of pentapeptide VPTLK was complete. A test cleavage was carried out 
on a small amount of resin, in which the resin bound peptide 180 was treated with a TFA/TIPS/H2O 
(95:2.5:2.5) cleavage cocktail. This cleaved the peptide from the resin as well as removing the lysine 
and threonine residue side-chain protecting groups. Triisopropylsilane (TIPS) was used as a cation 
scavenger, preventing reactive tert-butyl cations from generating undesired products. A sample of 
the resulting Fmoc protected peptide was analysed on the LC-MS to confirm the synthesis of N-
terminus Fmoc protected pentapeptide VPTLK. This result suggested that the crude pentapeptide 
had been successfully synthesised to >95% purity using the peptide synthesiser (Appendix 2).  
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Scheme 40: SPPS of resin bound pentapeptide 180. 
 
2.8.2 Synthesis of Hexapeptide 181 
In order to couple methoxyphenyl 177 to resin bound pentapeptide 180 the peptide synthesiser 
was not used. Instead, manual peptide coupling was employed due to the amounts of the novel 
fluorescent α-amino acid available. Resin bound pentapeptide 180 was treated with 20% piperidine 
in DMF to remove the N-terminal Fmoc protecting group (Scheme 41). The coupling conditions 
were the same as above however, only two equivalents of methoxyphenyl 177 were used due to 
the amount available. Following this manual coupling, a second test cleavage was carried out on a 
small amount of the resin bound hexapeptide using the same test cleavage conditions as before to 
ensure the desired fluorophore tagged peptide had formed. Upon LC-MS confirmation that 
successful coupling had taken place, the Fmoc protected hexapeptide was subjected to 20% 
piperidine in DMF to form the N-terminus free amine. After which, the N-terminus was acetylated 
using acetic anhydride/DIPEA/DMF (1:1:8). The final step was cleaveage of the hexameric peptide 
from the polymer-support and removal of the amino acid side-chain protecting groups, tBu and Boc 
under acidic conditions. Preparative HPLC was used to isolate hexapeptide 181 to >95% purity. Full 
characterisation was carried out which included analysis by HRMS (Table 4, Figure 53, Figure 54).  
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Scheme 41: Synthesis of hexapeptide 181. 
 
2.9 Cell Study with Hexapeptide 181 
The final aspect of this project following the successful synthesis of hexapeptide 181 was to carry 
out a biological investigation, aided by Carol-Anne Smith and Dr Mathis Riehle. Suitable cells would 
be grown and subsequently incubated with hexapeptide 181 diluted to a known concentration with 
appropriate growth media. Fluorescence microscopy would then be used to visualise whether 181 
manages to enter and accumulate in the cells. Human foreskin fibroblast cells immortalised with 
hTERT (human telomerase reverse transcriptase) were used for this cell study. The cells were 
applied and grown on ibidi® μ-Slide VI 0.4 plates for 72 h before visualisation or addition of 
hexapeptide 181. Images of control cells with no prior peptide-growth media incubation were taken 
for comparison (Figure 46). Separate images of each cell were taken with the fluorescence lamp off 
and again immediately after the fluorescence lamp was turned on (Appendix 3). An overlay of these 
images is also displayed. 
 
81 
 
 
Figure 46: Control cells not incubated with hexapeptide 181. 
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Cells were then incubated at room temperature with 120 μL of 100 μM hexapeptide 181 in 
Dulbecco’s Modified Eagle’s Medium (DMEM). Like the control cells, two images were taken. One 
with the fluorescence lamp off and the other with it on, an overlay of these two images was also 
processed. Pictures were taken from immediate application up to a 70 minute incubation period. 
The fluorescence on pictures displays a bright, concentrated assembly of hexapeptide 181 (Figure 
47, Figure 48, Figure 49 and Figure 50). By superimposing the fluorescence off and on pictures it is 
clear that hexapeptide 181 has entered the cells. The peptide appears to have entered the cell 
membrane and accumulated in the cytoplasm, congregating outside the nucleus. By comparing 
these with the control images there is a considerable difference as there are no bright portions seen 
in any of the control cells. This excellent result proves that the fluorescently tagged hexapeptide 
181 has cell penetrating properties and can be visualised using fluorescence microscopy due to the 
presence of the novel fluorescent α-amino acid incorporated into the peptide. 
 
 
Figure 47: Cells incubated with hexapeptide 181 for 60 minutes. 
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Figure 48: Cells incubated with hexapeptide 181 for 65 minutes. 
 
 
Figure 49: Cells incubated with hexapeptide 181 for 70 minutes. 
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Figure 50: Cells incubated with hexapeptide 181 for 10 minutes (enlarged and cropped). 
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2.10 Synthesis of Pyrimidine-Derived α-Amino Acids 
2.10.1 Initial Synthesis of Pyrimidine-Derived α-Amino Acids 
In order to fully understand the reactivity of the enone-derived α-amino acids, a variety of 
heterocycle forming reactions were considered and an investigation into the synthesis of 
pyrimidine-derivatives was undertaken. Treating enones with various amidines under acidic103 or 
basic104 conditions can lead to substituted pyrimidine rings. However, there have been no previous 
syntheses of pyrimidine-derived α-amino acids using an enone substrate.  
 
Phenyl enone 116 and nitrophenyl enone 90 were used as the model substrates and subjected to a 
number of various reaction conditions in an attempt to synthesise the desired pyrimidine ring 
(Scheme 42 and Table 3). For entries 1 and 2, sodium carbonate was used as the base which was 
required to neutralise the HCl salt of benzamidine hydrochloride. Acetonitrile and methanol were 
used as the respective solvents under reflux. Unfortunately, a complex mixture of products formed 
for both reactions. Benzamidine hydrochloride 182 was treated with 1 M NaOH to form 
benzamidine 183 as the corresponding free amine. This was used as the amidine reagent for entry 
3 with methanol as the solvent and no base. Again decomposition took place. It was hypothesised 
that pyrimidine ring formation was not taking place due to the electron-rich nature of benzamidine 
and that switching to a more electron-deficient amidine coupling partner would help the reaction 
proceed. Acetamidine hydrochloride 184 was used for the next attempt along with sodium 
carbonate and methanol but no reaction took place (entry 4). The formation of acetamidine 185 as 
the free amine was carried out and used for the next reaction (entry 5). All the starting material 
was consumed but there was no formation of any major products. For the next attempt, potassium 
carbonate and benzamidine hydrochloride 182 was used in toluene under reflux (entry 6). All the 
reactions used polar protic or aprotic solvents so an attempt with non-polar toluene was 
investigated but decomposition ensued (entry 6). Lewis acids have been employed in heterocycle 
forming reactions such as a ytterbium triflate catalysed method for the preparation of substituted 
imidazoles.105 Ytterbium triflate was used catalytically along with potassium carbonate, 
benzamidine hydrochloride 182 in THF under reflux (entry 7). Nitrophenyl enone 90 was also used 
as the substrate for this reaction (entry 7) as no phenyl enone 116 remained due to the number of 
previous test reactions. A major product had formed however, the methyl ester group had also 
hydrolysed. Therefore, the crude reaction mixture was treated with thionyl chloride and methanol 
and, the desired product 186 was isolated in 44% yield. 
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Scheme 42: General conditions for pyrimidine ring synthesis. 
 
 
Table 3: General conditions for pyrimidine ring synthesis. a Phenyl 116 as starting material enone b 
Nitrophenyl 90 as starting material enone. 
 
The reaction conditions were repeated in an attempt to improve the yield of this two-step 
procedure (Scheme 43). The synthesis of nitrophenyl pyrimidine 186 proceeded with a 47% yield. 
A second analogue was synthesised, naphthyl pyrimidine 187 from the corresponding enone. 
Unfortunately a low 11% yield was observed for this compound and after several attempts, no 
improvement to the yield was achieved. A potential reason for the observed low yields for this 
reaction is due to the amidine reagent hydrolysing the methyl ester protecting group. With the free 
carboxylic acid moiety unprotected, side-reactions could be taking place leading to a complex 
mixture of intermediates and eventual decomposition. It was observed by Bartlett and co-workers 
that a guanidine/ethanol mixture was able to hydrolyse the methyl ester present in their 
substrate.106 Due to this finding and the results so far, investigations towards the synthesis of 
pyrimidine-derived α-amino acids using this particular synthetic route was halted. 
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Scheme 43: Synthesis of pyrimidine-derived α-amino acids 186 and 187. 
 
2.10.2 Alternative Synthesis Towards Pyrimidine-Derived α-Amino Acids 
Due to the inefficient synthesis of the naphthyl 187 derivative using the conditions described, an 
alternative approach was investigated. An alternative functional group and protection strategy was 
investigated due to the earlier problems with hydrolysis of the methyl ester by the amidine 
reagents. ʟ-Aspartic acid was used as the starting material for the new synthetic route (Scheme 44). 
The β-acid was protected as a methyl ester and subsequent Boc-protection led to carboxylic acid 
188.107,108 The α-acid was activated using N-hydroxysuccinimide and N,N'-dicyclohexylcarbodiimide 
followed by reduction with sodium borohydride to furnish primary alcohol 189.109 It was then 
protected to form tert-butyldimethylsilyl ether 190.110 Now that the methyl ester had been replaced 
with a silyl ether moiety, the next step was to synthesise the corresponding β-keto phosphonate 
ester 191 using the standard conditions previously described in this chapter.111,112 Benzaldehyde 
was used in the HWE reaction along with 191 to synthesise E-alkene 192 in an excellent 89% yield.  
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Scheme 44: Synthesis of enone derivative 192. 
 
With phenyl enone 192 available, the next step was to subject it to pyrimidine synthesis conditions. 
Unfortunately no reaction was observed when using potassium carbonate, THF and ytterbium 
triflate. In an attempt to force the reaction, the free base of benzamidine was formed and treated 
with the enone in ethanol under reflux (Scheme 45). The reaction yielded the desired pyrimidine 
193 in 10%, but due to the scale of the reaction only characterisation via 1H NMR spectroscopy and 
mass spectrometry was possible. Therefore this only proves the concept of this proposed synthesis. 
Upon reaction optimisation, 193 could be treated with TBAF to remove the silyl protecting group, 
forming primary alcohol 194.113 Oxidation with TEMPO and sodium hypochlorite could provide 
carboxylic acid 195 and trivial Boc-removal with TFA could furnish the parent α-amino acid 196. A 
number of analogues could be synthesised by differentiating the side-chain aryl groups as well as 
varying the amidine coupling partner used. There are a range of commercially available amidines 
such as benzamidine, acetamidine and guanidine. If successful, there would be three aryl groups in 
conjugation and by strategically placing electron-donating functional groups in optimal positions 
these compounds could have the potential to display interesting optical properties. 
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Scheme 45: Pyrimidine ring formation conditions, proposed synthesis to parent α-amino acid 196 
and potential pyrimidine-derived α-amino acid analogues. 
 
2.11 Future Work 
2.11.1 Proposed Synthesis of Pyrimidine-Derived α-Amino Acids 
The potential synthesis of pyrimidine derived α-amino acids was discussed earlier in this chapter. If 
the ring forming reaction was optimised and a guanidine derivative 197 was synthesised, there 
could be potential to brominate para to the amino group using NBS, creating a brominated 
derivative 198.114 A commercially available or synthetically modified boronic acid could then be 
cross coupled with 198 to form arylated 199 or 200.115 If unsubstituted 199 was formed then the 
standard deprotection procedure could be used to form the parent α-amino acid. However, if the 
chlorinated or brominated derivative 200 was synthesised then an intramolecular C-H activation 
reaction could be investigated to fuse both aryl groups together to form tetracycle 201.116,117 An 
appropriate catalyst such as palladium acetate could potentially undergo oxidative addition with 
the aryl halide moiety and after approach of the other aryl side-chain a concerted metalation-
deprotonation transition state could form. Subsequent reductive elimination would then take place 
forming a new carbon-carbon bond. This would rigidify the overall structure and in this example 
there are two electron-donating groups (methoxy and amino) and one electron-withdrawing nitro 
group. Effective fluorophores display this push-pull electronic relationship. Investigation into this 
proposed route could lead to a library of highly fluorescent derivatives that could exhibit emission 
bands further into the visible region of the electromagnetic spectrum. This increases their potential 
to be used as fluorescent probes and a variety of biological mechanisms could be explored.  
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Scheme 46: Proposed halogenation-Suzuki coupling-intramolecular C-H activation sequence on 
pyrimidine α-amino acid analogues.  
 
2.11.2 Proposed Synthesis of β-Carboline-Derived α-Amino Acids 
Synthesis towards β-carboline-derived α-amino acids was proposed and an initial proof of concept 
investigation was carried out. Robinson and co-workers synthesised 2,3,4,6-tetrasubstituted 
pyridine 203 by condensing enone 202 with acetophenone derivatives (Scheme 47).118 
 
 
Scheme 47: Synthesis of 2,3,4,6-tetrasubstituted pyridine 203.  
 
Using this literature precedent as inspiration, 2-bromophenyl enone 121 was subjected to the 
reported conditions. 2-Aminoacetophenone hydrochloride was acetylated prior, using acetic 
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anhydride under basic conditions to form 204.119 Unfortunately there was no observed product 
after 18 h at 50 °C and decomposition started to take place when the temperature was increased. 
If the reaction had been successful then 205 could be subjected to an intramolecular Buchwald-
Hartwig coupling to fuse the pyridine and aryl group together to form the desired β-carboline 
206.120 
 
 
Scheme 48: Proposed synthesis of β-carboline-derived α-amino acid 206. 
 
A second attempt was carried out with phenyl enone 116 using a catalytic amount of zinc bromide 
and toluene under reflux (Scheme 49). The desired 2,3,4,6-tetrasubstituted pyridine 207 was not 
observed however, 2,4,6-trisubstituted pyridine 208 was isolated albeit with a low 7% yield after a 
single small-scale attempt. An efficient synthesis of 2,3,4,6-tetrasubstituted pyridines could be 
possible following optimisation of the Lewis acid and solvent. Buchwald-Hartwig coupling 
conditions could then be used to access the β-carboline framework. A series of analogues would 
then be synthesised with particular focus on electron-donating groups. 
 
 
Scheme 49: Attempted synthesis of 2,3,4,6-tetrasubstituted pyridine 207. 
 
2.11.3 Proposed Synthesis of Benzotriazole-Derived α-Amino Acids 
In unrelated research to this fluorescent α-amino acid project, Nikki Sloan from the group 
developed a one-pot iodination of aryl amines via stable diazonium salts.121 The standard method 
for the synthesis of aryl iodides is through diazonium salt formation of aryl amines by using 
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Sandmeyer-type reaction conditions.122 Harsh acidic conditions are often required for the 
preparation of diazonium salts and unwanted side-reactions can occur due to this. Therefore a new 
general method for the iodination of aryl compounds that could use a wide array of commercially 
available starting materials as well as mild reaction conditions was developed. However, during the 
project an unusual result was observed. Aniline 209 was treated with p-toluenesulfonic acid in the 
presence of polymer-supported nitrite reagent (Scheme 50). Sodium iodine was used as the 
iodinating reagent which was supposed to displace the diazonium salt and furnish aryl iodine 210. 
However, a competing intramolecular reaction took place whereby the secondary amine ortho to 
the aryl amine attacked the diazonium salt species and gave benzotriazole 211 in 40% yield.  
 
 
Scheme 50: Unexpected benzotriazole cyclisation. 
 
A proposed route towards the synthesis of benzotriazole-derived α-amino acids was devised that 
would utilise this unexpected cyclisation. ʟ-Asparagine would be used as the chiral pool starting 
material which would be Boc-protected initially to give carboxamide 212 (Scheme 51).123 A 
Hofmann rearrangement could then be employed, using a reagent such as (diacetoxyiodo)benzene 
to form amine 213.124 Treatment with TMSCHN2/MeOH would produce methyl ester 214.125 Various 
1-fluoro-2-nitrobenzene derivatives could then be used in nucleophilic aromatic substitution 
reactions with amine 214 to construct a library of aryl nitro derivatives.126 Aryl nitro reduction using 
Pd/C or tin(II) chloride dihydrate would furnish aniline 215, the substrate for the cyclisation 
reaction. Preparation of the corresponding diazonium salt intermediate 216 would follow, whereby 
the intramolecular cyclisation would take place to form benzotriazole 217. Deprotection to parent 
α-amino acid 218 would conclude the synthesis. This seven-step proposed synthesis could access 
novel benzotriazole-derived α-amino acids that could potentially have interesting optical 
properties. Numerous SNAr coupling partners are commercially available which could lead to late-
stage synthesis of a large library of analogues. 
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Scheme 51: Proposed synthesis of benzotriazole-derived α-amino acids. 
 
2.13 Conclusions 
A synthetic route was developed and optimised for the synthesis of pyridine-derived α-amino acids. 
An initial seven-membered library was constructed with a varied substrate scope. An in-depth 
analysis of their optical properties was investigated, which resulted in two analogues being 
considered for further analysis, methoxyphenyl 151 and naphthyl 152. A second generation of 
analogues was also synthesised, focussing mainly on electron-rich targets. This was based on the 
correlation observed between good fluorescent properties and electron-donating side-chain aryl 
groups. The optical properties were measured for these compounds and interesting fluorescent 
characteristics was exhibited by dimethoxyphenyl 172 and piperonyl 173. An N-Fmoc derivative of 
methoxyphenyl 151 was synthesised and SPPS was carried out to construct a cell penetrating 
hexapeptide tagged with the fluorescent α-amino acid. Human fibroblast cells were incubated with 
this fluorophore tagged peptide and visualisation of the peptide in the cells was possible using 
fluorescence microscopy. This project shows that by carefully constructing α-amino acid side-chains 
with conjugated aryl groups and strategically placing electron-rich functional groups in positions 
that boost the charge transfer of the compound, it is possible to incorporate them into CPPs and 
confirm cell penetration via fluorescence microscopy. Potential future work has also been proposed 
that takes advantage of the enone functionality. This could lead to more α-amino acid derivatives 
that possess highly fluorescent side-chains and display red-shifted absorption and emission maxima 
as well as excellent quantum yield values. 
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3.0 Total Syntheses of 4-Hydroxy-2,6-Disubstituted 
Piperidine Natural Products 
3.1 Previous Work in the Sutherland Group 
Previous work carried out by Lindsay Fowler showed the first stereoselective synthesis of 2,6-trans-
6-substituted-4-oxo-ʟ-pipecolic acids using a tandem reductive amination/6-endo-trig cyclisation 
(Scheme 52).127,67 The sequential reduction and cyclisation mediated by sodium cyanoborohydride 
allowed the preparation of a series of highly functionalised 6-alkyl and 6-aryl analogues. During the 
6-endo-trig cyclisation, it was proposed that the enones adopted a Zimmerman-Traxler chair-like 
transition state with both the R and N-benzyl groups in equatorial positions.128 
 
 
Scheme 52: Reductive amination/6-endo-trig cyclisation.  
 
Following on from this portion of work, Mark Daly managed to develop conditions that could switch 
the stereochemical outcome of the 6-endo-trig cyclisation to provide an efficient synthesis of 2,6-
cis-6-substituted-4-oxo-ʟ-pipecolic acids (Scheme 53).129,130 A more direct intramolecular conjugate 
addition reaction took place that proceeded under basic conditions. Using a free amine, it was 
believed an alternative Zimmerman-Traxler chair-like conformer was generated with the R and 
methyl ester groups occupying pseudoequatorial positions, which essentially controlled the 
cyclisation. Molecular modelling of this cyclisation allowed some insight as to how these 
compounds were formed.  
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Scheme 53: Base mediated 6-endo-trig cyclisation. 
 
3.2 Proposed Research 
The aim of this research was to showcase the previously developed base-mediated 6-endo-trig 
cyclisation as a key-step in the synthesis of 4-hydroxy-2,6-disubstituted piperidines natural 
products (Scheme 54).129 Spruce alkaloid and (+)-241D were the targeted natural products, as both 
contain a 2,4,6-cis substitution pattern which could be easily accessed using the 6-endo-trig 
cyclisation followed by subsequent functional group manipulations. 
 
 
Scheme 54: Retrosynthesis of natural products spruce alkaloid and (+)-241D. 
 
On optimisation of cyclisation conditions, the next challenge would be the reduction of the methyl 
ester to the methyl group with as few synthetic steps as possible. This was to ensure that a rapid 
and efficient synthetic route was possible to these natural products with a low step count and high 
overall yield. The scope of this cyclisation would be explored further to discover if more complex 
frameworks and natural products intermediates could be accessed. 
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3.3 Previous Synthesis of Spruce Alkaloid 
Spruce alkaloid was identified as a trace alkaloid in extracts from the Colorado blue spruce, Picea 
pungens by Stermitz and co-workers.131 The structure and relative configuration was determined 
via NOESY and by comparing NMR spectra with other known alkaloids with similar structures. The 
only previous synthesis of spruce alkaloid was carried out by Gnamm et al.132,133 The total synthesis 
started with the known iridium-catalysed amination of trans-crotyl methyl carbonate with N-Boc 
formamide (Scheme 55).134 Treatment with potassium hydroxide removed the formyl group to 
furnish Boc-protected amine 219. Hydroboration/oxidation and subsequent Swern oxidation 
produced aldehyde 220. (+)-B-Allyldiisopinocampheylborane was employed at low temperatures 
to give a 93:7 mixture of homoallylic alcohols anti-221 and syn. The desired alcohol anti-221 was 
then subjected to a cross-metathesis reaction with biscarbonate 222 to yield a 9:1 E/Z mixture of 
allylic carbonate 223. Cleavage of the Boc protecting group gave cyclisation precursor 224.  
 
 
Scheme 55: Synthesis of cyclisation precursor 224. 
 
The next stage of the synthesis was initiated with another iridium-catalysed cyclisation of amine 
224 which proceeded smoothly to form compound 225 in 90% yield and dr of 98:2 (Scheme 56). 
Acetyl and Cbz protecting groups were employed to protect the secondary alcohol and amine 
respectively to give carbamate 226. Ozonolysis was used to cleave the alkene to form aldehyde 227. 
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A Wittig olefination was employed to introduce the two extra carbon atoms needed for the propyl 
chain found in the natural product. Alkene 228 was subjected to hydrogenation conditions which 
removed the Cbz protecting group and reduced the alkene. Finally, basic conditions were used to 
remove the acetyl protecting group to yield the natural product, spruce alkaloid 229. The group 
also managed to synthesise (+)-241D from compound 226. Cross metathesis with 1-nonene, 
hydrogenation and treatment with sodium hydroxide produced (+)-241D. This fourteen-step 
synthesis of spruce alkaloid was possible in a 24% overall yield. Excellent selectivity was observed 
for the iridium-catalysis steps and homoallylic alcohol formation steps. However, the reagents 
needed to perform these asymmetric induction reactions are very expensive and difficult to handle, 
particularly the air sensitive iridium catalyst. There were no examples of selective substrate 
controlled reactions and there were a number of protecting group removal and reprotection steps 
which was detrimental to the step count and overall yield. 
 
 
Scheme 56: Synthesis of spruce alkaloid 229.  
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3.4 Previous Syntheses of (+)-241D 
Alkaloid (+)-241D was isolated by Daly and co-workers, from skin extracts of Dendrobates speciosus, 
a rare poison frog located in the highlands of western Panama.135,136 A racemic synthesis was carried 
out by Daly and his group a few years later and the compound was found to be a potent inhibitor 
of the binding of [3H]perhydrohistrionicotoxin to nicotinic acetylcholine receptor channels.137 Since 
then (+)-241D has become a very popular natural product, with numerous groups reporting their 
total synthesis of this small 4-hydroxy-2,6-disubstituted piperidine alkaloid.138–144 Troin and co-
workers reported the first enantioselective synthesis of (+)-241D and the C-4 epimer.145 He reported 
another total synthesis of this natural product years later to showcase the scope and limitations of 
the diastereoselective preparation of 2,6-cis and 2,6-trans disubstituted piperidines through an 
intramolecular reaction of chiral β’-carbamate-α,β-unsaturated ketones.112 
 
A recent synthesis of (+)-241D was reported by Yang.146 A general method to assemble multi-
substituted chiral piperidines was developed which was inspired by the biosynthesis of piperidine 
natural products. A stereoselective three-component vinylogous Mannich-type reaction (VMR) of 
1,3-bis-trimethylsilyl enol ether 230 was investigated (Scheme 57). To ensure stereoselective 
control in the VMR, the commercially available chiral α-methyl benzylamine 231 was used to form 
chiral aldimines in situ. The three-component VMR between benzylamine 231, bis-trimethylsilyl 
enol ether 230 and decanal proceeded smoothly to form acyclic intermediate 232, which upon 
treatment with a catalytic amount of acetic acid cyclised to produce the desired chiral adduct 233 
in 76% yield. Palladium catalysed hydrogenation was used to remove the chiral auxiliary and reduce 
the enone to the corresponding saturated alcohol, completing the total synthesis of (+)-241D 234. 
This is a very concise two-stage synthesis of (+)-241D, with an overall yield of 55%. A number of 
other alkaloid natural products were generated using this protocol such as (−)-241D, isosolenopsin 
A and (−)-epimyrtine.  
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Scheme 57: Yang’s synthesis of alkaloid (+)-241D 234. 
 
The most recent synthesis of (+)-241D was carried out by Prasad and co-workers.147 They reported 
the synthesis of β-amino-substituted enones with excellent selectivity, via the addition of silyl enol 
ethers to chiral sulfinimines. Further synthetic manipulations led to the total synthesis of several 
natural products. The synthesis of (+)-241D began with enone 235 which was transformed into the 
corresponding silyl enol ether 236 and immediately treated with sulfinimine 237 to form β-
sulfinamido ketone 238 in 62% yield (Scheme 58). Acidic conditions were required to remove the 
sulfinyl group. Upon cleavage, TEA was used to induce the cyclisation to form piperidinone 239 in 
82% yield as a single diastereomer. Standard conditions to reduce the ketone were employed to 
furnish (+)-241D 234. An overall yield of 43% was achieved for this three-step total synthesis of (+)-
241D. The synthesis of (+)-lasubine II and (−)-lasubine I were also described. A surprising aspect 
surrounding this report was the result obtained for the cyclisation reaction. Prasad’s group only 
observe a single diastereomer 239 and with a high isolated yield of 82%. The only functional group 
providing any facial selectivity is the methyl group. It is highly unlikely that the small group would 
induce diastereoselectivity of this magnitude. Inspired by this finding, an attempt to recreate this 
highly diastereoselective cyclisation, particularly the base-mediated step, in our laboratory was 
unsuccessful. Only a 1:1 dr was achieved after numerous attempts. These findings will be described 
in detail later in this chapter. 
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Scheme 58: The Prasad group synthesis of alkaloid (+)-241D 234. 
 
3.5 Towards the Total Synthesis of Spruce Alkaloid 
3.5.1 First Approach Towards the Total Synthesis of Spruce Alkaloid 
The first stage towards the total synthesis of spruce alkaloid was to use the previously developed 
β-keto phosphonate ester synthesis followed by the HWE reaction to install the appropriate alkyl 
side-chain. The synthesis began with ʟ-aspartic acid which was protected to form dimethyl ester 
hydrochloride salt (Scheme 59). Amine protection followed to give N-trityl 72. β-Keto phosphonate 
ester 73 was then synthesised and used as a substrate for the HWE reaction with butyraldehyde, 
producing E-alkene 108 in an excellent 85% yield. This compound was then treated with 2 M 
hydrochloric acid to remove the acid labile trityl group, forming the HCl salt.129 The reaction mixture 
was basified (pH 8/9) by addition of Hünig's base. This induced the 6-endo-trig cyclisation to 
produce cis-piperidinone 240 and trans-piperidinone 241 as a 3:1 mixture of diastereomers. The 
major product of this stereoselective 6-endo-trig cyclisation, the desired cis diastereomer 240 was 
isolated in 56% yield. The synthesis of this compound had previously been developed by Mark 
Daly.129,130 Compounds 240 and 241 1H and 13C NMR spectra were an exact match to the data 
already published in the Sutherland group. 
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Scheme 59: Synthesis of cyclised piperidinone derivatives 240 and 241. 
 
With the desired cis-piperidinone 240 available, the next stage was to reduce the ketone to the 
alcohol. Secondary amine 240 was Boc-protected, furnishing N-Boc piperidinone 242 in 70% yield 
(Scheme 60). The following step involved stereoselective reduction of the ketone to the 
corresponding alcohol. Substrate control and class of reducing agent was used to dictate the facial 
selectivity of the reductant. In this case sodium borohydride was chosen and the reaction was 
carried out at −10 °C in methanol to produce 4-hydroxy-2,6-disubstituted piperidine 243 with high 
diastereoselectivity (94:6 dr). Although no selective NOE experiments were used to confirm the 
relative stereochemistry of 243, work reported by Renault shows that a tert-butyl ester analogue 
of 243 was reduced using the same conditions to form the corresponding 4-hydroxy-2,6-
disubstituted piperidine with a 9:1 dr and in 84% yield.148 Due to the similar result obtained in our 
laboratory, we were satisfied that the relative stereochemistry was correct. The resulting secondary 
alcohol 243 was protected using bromomethyl methyl ether in the presence of DIPEA to yield O-
MOM protected piperidinol 244. 
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Scheme 60: Synthesis of protected 4-hydroxy-2,6-disubstituted piperidine 244. 
 
As all the stereocentres were set in the correct configuration for the natural product, the next stage 
was reduction of the methyl ester to the methyl group before removal of the protecting groups to 
complete the total synthesis of spruce alkaloid. Attempts to directly reduce the methyl ester to 
methyl group were unsuccessful. For example, attempted reduction of 244 with B(C6F5)3 and 
triethylsilane showed no reaction. Reduction with B(C6F5)3 of aldehydes, acyl chlorides, esters and 
carboxylic functional groups with hydrosilanes was reported by Gevorgyan and Yamamoto.149,150 
These reports only show examples of this methodology working with simple substrates, not 
complex natural product intermediates such as 244. Instead, methyl ester 244 was treated with 
two equivalents of diisobutylaluminium hydride (DIBAL-H) which effectively reduced the ester to 
the corresponding primary alcohol 245 in 77% yield (Scheme 61). Attempts to tosylate the resulting 
alcohol only returned starting material. A possible reason is due to steric hinderance. The chair-like 
conformation of the 6-membered ring may bring both bulky protecting groups (Boc and MOM) in 
close proximity to the primary alcohol, restricting access to it. It was decided instead to use the 
smaller mesyl chloride reagent. Alcohol 245 was treated with mesyl chloride and TEA for 24 h. 
Analysis of the reaction by NMR spectroscopy revealed that none of the desired mesylate 246 was 
present however, there was a major product, which was isolated. The 1H NMR spectrum of this 
product showed that there was no singlet tert-butyl peak from the Boc group present. This 
unknown compound was fully characterised and analysis showed that a cyclisation had taken place 
to form carbamate 247 in 60% yield.  
 
103 
 
 
Scheme 61: Attempted mesylation which led to cyclised carbamate 247. 
 
A plausible mechanism for this unexpected cyclisation was proposed involving a SN2 intramolecular 
displacement (Scheme 62). Benedetti and co-workers have shown that when the hydoxy group of 
chiral N-Boc-β-amino alcohols is converted into a suitable leaving group, cyclisation to 
oxazolidinones can take place with inversion of configuration.151 Gao and Renslo applied this 
reaction for the practical synthesis of differentially protected 2-(hydroxymethyl)piperazines.152 
Primary alcohol 245 was activated and intramolecular SN2 displacement by the carbonyl oxygen of 
the neighbouring carbamate took place to form oxazolidinone 247, after concomitant loss of 
isobutene. 
 
 
Scheme 62: Proposed intramolecular cyclisation mechanism. 
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3.5.2 Revised Approach Towards the Total Synthesis of Spruce Alkaloid 
Due to this outcome, an alternative approach was developed. A major change in this route was 
proposed, which involved switching the secondary amine protecting group from a carbamate to a 
benzyl group. This was in order to avoid any unwanted side-reactions. The 2,6-cis piperidinone 240 
was protected with the benzyl group on treatment with benzyl bromide under basic conditions 
(Scheme 63). This gave 248 in 82% yield. An attempt to reduce both the ketone and methyl ester 
groups to diol 249 was unsuccessful after reaction with DIBAL-H. A complex mixture of products 
was observed after serval attempted reactions. Sodium borohydride in methanol was then 
employed to reduce the ketone however, poor diastereoselectivity was observed and an 
inseparable mixture of diastereomers was produced.   
 
 
Scheme 63: N-Benzyl protection and unsuccessful ketone/ester reductions.  
 
Due to the lack of selectivity of ketone reduction using the N-benzyl protecting group, a change in 
the reaction sequence was investigated. Directly reducing ketone 240 led to secondary alcohol 250 
in 60% yield with a 9:1 dr (Scheme 64). Although no selective NOE experiments were used to 
confirm the relative stereochemistry of 250, work previously developed in the Sutherland group 
reported the stereoselective reduction of an isopropyl analogue of 250 using sodium 
tris(acetoxy)borohydride to produce the corresponding 4-hydroxy-2,6-disubstituted piperidine 
with similar results.129,130 Conditions to install the benzyl group were employed, leading to N-benzyl 
251. Lithium borohydride was then used to reduce methyl ester 251 to the corresponding primary 
alcohol 252, in 72% yield. 
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Scheme 64: Synthesis of diol 252. 
 
With a route to diol 252 now established, the next step was to selectively transform the primary 
alcohol into a leaving group in the presence of the secondary alcohol.153 The first proposed 
approach was the conversion of primary alcohol 252 to iodide 253 using the Appel reaction. The 
newly iodinated compound would then be subjected to catalytic hydrogenation conditions to 
generate the methyl group as well as remove the benzyl protecting group.154,155 This would 
complete the total synthesis of spruce alkaloid 229. Unfortunately the iodination was unsuccessful 
and no reaction took place (Scheme 65). Switching from THF to the higher boiling point solvent, 
1,4-dioxane and heating the reaction to 80 °C was not enough to force the reaction. Due to the 
large size of the resulting phosphonium iodide salt formed as well as the benzyl protecting group 
being in close proximity to the primary alcohol, steric clashes between the substrate and reagent 
may have hindered any reaction taking place. With this in mind, a final attempt to transform the 
primary alcohol into a leaving group was carried out. Standard conditions to mesylate alcohol 252 
were attempted but no reaction took place to form mesylate 254. If successful, lithium aluminium 
hydride reduction followed by hydrogenation could have completed the total synthesis.156 Due to 
the failed attempts to reduce the alcohol to the methyl group, a completely revised synthetic route 
was devised to work around the impeding reduction issue. 
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Scheme 65: Unsuccessful attempts to iodinate and mesylate diol 252. 
 
3.6 Total Synthesis of Spruce Alkaloid and (+)-241D 
The next stage of this total synthesis project was to design a new route that would successfully 
access the desired natural products, spruce alkaloid and (+)-241D. Instead of utilising the 6-endo-
trig methodology early in the synthesis and attempting to perform late stage methyl ester to methyl 
group reduction, the plan was to form the methyl group during the early stages of the synthesis 
and then cyclise towards the end of the route (Scheme 66). 
 
 
Scheme 66: Retrosynthesis of natural products spruce alkaloid and (+)-241D. 
 
3.6.1 Synthesis of Enones 
The revised route started with ʟ-aspartic acid which was treated with thionyl chloride and methanol 
at −10 °C to selectively protect the more accessible β-carboxylic acid (Scheme 67).107 Subsequent 
N-Boc protection led to 89% yield of 188.108 Compound 188  was reacted with N-
hydroxysuccinimide and N,N'-dicyclohexylcarbodiimide to form the activated ester, which was 
rapidly reduced upon treatment with sodium borohydride to yield primary alcohol 189.109 Mild 
Appel reaction conditions were employed to convert alcohol 189 to iodide 255 in 90% yield.157 An 
attempt to use the crude material from the iodination reaction for direct hydrogenation was 
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unsuccessful. It was necessary for iodide 255 to be isolated prior to hydrogenation. Standard 
catalytic hydrogenation conditions under neutral conditions did not furnish the desired methyl 
derivative 256. Hydrogenation under pressure was also unsuccessful. Reports in the literature state 
that in order to cleave an alkyl C-I bond, the presence of base is pivotal for the reaction to 
proceed.154,155 It was proposed that the formation of HI poisons the palladium catalyst rendering it 
inactive. Under basic conditions, the HI is neutralised allowing the reaction to proceed. Therefore, 
Hünig's base was added to the reaction mixture, which allowed clean formation of methyl 
derivative 256 in an excellent 99% yield. Formation of the β-keto phosphonate ester 257 was carried 
out using a previously developed protocol.111,112 An efficient 6-step synthesis of the β-keto 
phosphonate ester 257 was optimised with an overall yield of 64%.     
 
 
Scheme 67: Synthesis of β-keto phosphonate ester 257. 
 
With the β-keto phosphonate ester 257 available, the next phase of this project was to synthesise 
E-enones that have the required alkyl side-chains that correspond to the targeted natural products. 
Therefore, butyraldehyde was used in the first HWE reaction and an 87% yield of enone 258 was 
achieved (Scheme 68). Enone 259 was synthesised in 78% yield from the HWE reaction between β-
keto phosphonate ester 257 and decanal. 
 
 
Scheme 68: HWE reaction conditions and synthesis of enone derivatives 258 and 259. 
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3.6.2 6-Endo-Trig Cyclisation of Enones 258 and 259 
The problematic step in the earlier attempts to synthesise the natural products was the formation 
of the methyl group at a late stage in the synthesis. One of the main objectives of the revised route 
was to efficiently access methyl-derived enones 258 and 259 as early as possible. The final key-
steps in the total synthesis would be the 6-endo-trig cyclisation followed by ketone reduction to 
produce the natural products. With enones 258 and 259 available, the next step was to apply the 
6-endo-trig cyclisation that had previously been developed in the Sutherland group.129 Enones 258 
and 259 were treated with TFA, allowing clean Boc protecting group removal and formation of the 
TFA salt intermediates (Scheme 69). The crude material was then dissolved in methanol and DIPEA 
was added to induce the 6-endo-trig cyclisation. Propyl derivatives 260 and 261 were synthesised 
with good isolated yields of 43% for the cis and 42% for the trans diastereomer. There have been 
no reports in the literature regarding the synthesis of these two compounds, therefore selective 
NOE experiments were carried out to confirm the relative configuration of each diastereomer. The 
selective NOE spectrum confirmed that compound 260 was in fact the cis diastereomer and no NOE 
enhancement was observed for 261 which was predicted due to the hydrogen atoms not being in 
close proximity to one another. Similar yields were obtained for the nonyl derivatives. Cis-239 was 
isolated in 45% yield and trans-262 in 44% yield. Compound 239 has been previously synthesised 
by Hurvois and co-workers.144 The 1H and 13C NMR spectra recorded in our laboratory matched the 
literature data exactly. Unfortunately there was no substrate controlled stereoselectivity observed 
for both compounds. The previously described method (Scheme 59) had a larger methyl ester 
substituent that induced the lower energy Zimmerman-Traxler transition state, which led to the cis 
diastereomer predominating. With a smaller methyl group there is no stereoselectivity as a 1:1 dr 
is observed. However, high isolated yields for both diastereomers were achieved upon 
optimisation. Although cis isomers 260 and 239 would be used to complete the total syntheses, the 
trans compounds 261 and 262 could also be used to access the natural product epimers. 
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Scheme 69: Base mediated 6-endo-trig cyclisation of 258 and 259 and selective NOE data. 
 
3.6.3 Stereoselective Reduction 
As an efficient cyclisation procedure had been optimised to access the 2,6-cis piperidinone 
derivatives, the final step to complete the total syntheses was the stereoselective reduction of the 
ketone to the corresponding secondary alcohol. Ketones 260 and 239 were treated with sodium 
borohydride in methanol at −15 °C (Scheme 70). A substrate and reagent controlled stereoselective 
reduction took place and a diastereomeric ratio of 9:1 was observed for both reactions. High 
isolated yields of the natural products were achieved, 87% for spruce alkaloid 229 and 84% for (+)-
241D 234. The 1H and 13C spectra for these compounds matched the literature data for spruce 
alkaloid132,133 and (+)-241D,144 confirming the synthesis of the correct structures and relative 
stereochemistry. 
 
 
Scheme 70: Stereoselective reduction to spruce alkaloid 229 and (+)-241D 234. 
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3.7 Expanding the Scope of 4-Hydroxy-2,6-Disubstituted Piperidine 
Synthesis 
As both natural products had been synthesised successfully, focus turned to the preparation of a 
small library of cyclised 4-hydroxy-2,6-disubstituted piperidine derivatives. The sole aim of this was 
to expand the substrate scope of the cyclisation and reduction steps to examine whether various 
side-chain aryl groups could be tolerated. 
 
3.7.1 Synthesis of Enones 
β-Keto phosphonate ester 257 was reacted with a number of aldehydes under the previously 
optimised HWE reaction conditions (Scheme 71). Various electron-rich and electron-poor 
analogues were synthesised as well as phenethyl 268 and methyl 269 derivatives. This gave good 
to high yields for all of the examples and displayed a clear trend between reaction time and 
electronic nature of the aldehyde used. Electron-poor nitrophenyl 266 and pyridine 267 took 6 h 
and 24 h respectively. Significantly longer reaction times were required for the more electron-rich 
phenyl 263, methoxyphenyl 264 and naphthyl 265 derivatives. 
 
 
Scheme 71: HWE conditions and seven-membered library of enones. 
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3.7.2 Scope of 6-Endo-Trig Cyclisation 
With access to a small library of E-enones, the next stage was to submit these compounds to the 6-
endo-trig cyclisation conditions (Scheme 72). A 1:1 dr for each example was observed, comparable 
to the propyl and nonyl side-chain analogues that were used in the natural product syntheses 
project. Aryl groups were well tolerated and very consistent overall yields of 80–86% were achieved 
for each example. The isolation of each diastereomer was difficult but after extensive TLC solvent 
elution investigations, clean separation was possible using column chromatography. Methyl-
derived enone 269 was cyclised under the standard conditions giving the two products in a 1:1 dr 
however, an attempt to separate the diastereomers was unsuccessful. 
 
 
Scheme 72: Cyclisation conditions and twelve-membered library of 2,6-substituted 4-piperidinone 
derivatives. 
 
3.7.3 Selective NOE Assignments 
Selective NOE experiments were carried out to confirm the relative stereochemistry of each 
diastereomer. Compound 270 has been previously synthesised by Davis and co-workers.139 The 1H 
and 13C NMR spectra recorded in our laboratory matched the literature data exactly. The other 2,6-
piperidinones were examined to confirm that the correct diastereomers had been identified (Figure 
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51). All of the 2,6-cis compounds displayed NOE enhancements when each hydrogen atom was 
individually irradiated confirming their close proximity to one another. No NOE enhancements were 
observed between the two hydrogen atoms in question for the 2,6-trans compounds when each 
was irradiated respectively. This data provides further confirmation that each diastereomer had 
been correctly assigned.  
 
 
Figure 51: Selective NOE data for the 2,6-cis piperidinone library (d8 acquisition parameter for all 
compounds was 0.300 seconds). 
 
3.7.4 Stereoselective Reduction 
The final stage of this investigation was the stereoselective reduction of the 4-piperidinones using 
the previously developed conditions (Scheme 73). The six-membered library of 2,6-cis 
piperidinones were subjected to these conditions which led to the synthesis of the corresponding 
4-hydroxy-2,6-disubstituted piperidine analogues. A very good 9:1 diastereoselectivity was 
achieved along with isolated yields of 68–91% for the major diastereomers. 
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Scheme 73: Reduction conditions and six-membered library of 4-hydroxy-2,6-disubstituted 
piperidine derivatives. 
 
3.7.5 Selective NOE Assignments 
Selective NOE experiments were carried out to confirm the relative stereochemistry of each 
compound. Piperidinol 282 has been previously synthesised by the Ma and Davis groups.138,158 
Compound 287 has also been reported in the literature by Yang.146 The 1H and 13C NMR spectra 
recorded in our laboratory matched both sets of literature data. The other 4-hydroxy-2,6-
disubstituted piperidines were examined to confirm that the correct diastereomers had been 
identified (Figure 52). Compounds 283 and 286 displayed distinctive signals in the 1H NMR spectrum 
for the C-2, C-4 and C-6 hydrogen atoms. Upon irradiation at each hydrogen signal, there were NOE 
enhancements for the other two hydrogen atoms in close proximity. For compounds 284 and 285, 
the hydrogen signals at the 4 and 6 positions overlapped therefore selective NOE was only possible 
for the C-2 hydrogen atom and the C-4/6 overlap signal. This data establishes further confirmation 
that each diastereomer had been correctly assigned regarding the relative stereochemistry. 
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Figure 52: Selective NOE data for the 4-hydroxy-2,6-disubstituted piperidine library (d8 
acquisition parameter for all compounds was 0.300 seconds). 
 
3.8 Stereoselective Acid Mediated 6-Endo-Trig Cyclisation 
While attempting to synthesise natural products spruce alkaloid and (+)-241D, a recent paper by 
Reddy et al reported a highly selective 6-endo-trig cyclisation that was used in their total synthesis 
of (+)-241D.147 β-Sulfinamido ketone 238 was treated with hydrochloric acid in methanol to remove 
the sulfinyl group (Scheme 74). Neutralisation with TEA induced the 6-endo-trig cyclisation to 
produce cis-piperidinone 239 as a single diastereomer in 84% yield. In an attempt to replicate this 
excellent result in our laboratory, enone 258 was subjected to the same reaction conditions as 
described above, to form the expected cis-piperidinone 260. However, when following the first 
stage of this reaction via TLC, two new spots started to appear above the starting material. The 
expected baseline spot indicating that the Boc group had been cleaved and that the HCl salt had 
formed was not present. 1H NMR spectroscopy clearly showed that the tert-butyl singlet peak was 
still present and that cyclisation had taken place. Silica chromatography was used to isolate both 
spots together in order to get an accurate diastereomeric ratio and an overall yield. A 6-endo-trig 
cyclisation had taken place to form trans-piperidinone 288 and cis-piperidinone 289 with a 2:1 dr 
and 58% overall yield. The structure of cis-piperidinone 289 was confirmed by comparison with the 
literature NMR data.159 Therefore, an acid-mediated 6-endo-trig cyclisation had converted enone 
258 into piperidinone diastereomers but selectively for trans-N-Boc protected piperidinone 288. 
Major compound 288 was then isolated in 40% yield and fully characterised.  
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Scheme 74: Acid mediated 6-endo-trig cyclisation. 
 
A proposed mechanism for this cyclisation is shown in Scheme 75. A stoichiometric amount of acid 
was added and likely acted as a Brønsted acid. The proton could have coordinated to the enone 
oxygen, making the alkene more electrophilic and susceptible to conjugate addition. The 6-endo-
trig cyclisation then took place and a similar Zimmerman-Traxler transition state that was 
previously described (Scheme 52) induced the diastereoselective nature of this cyclisation. Both the 
propyl and N-Boc groups would prefer equatorial positions, the N-Boc group particularly due to its 
size. The resulting enol would then rapidly tautomerise to its keto form 288.  
 
 
Scheme 75: Proposed mechanism for 6-endo-trig cyclisation. 
 
In order to ensure one equivalent of hydrochloric acid was being added, commercially available 2 
M ethereal hydrochloric acid was used in subsequent reactions. Several other alkyl side-chain 
analogues were subjected to these conditions (Scheme 76). Nonyl-derived enone 259 was 
converted to the corresponding cyclised products with a 1.5:1 dr in favour of trans-piperidinone 
290 which was isolated in 53% yield. By comparing the 1H NMR spectrum of the crude reaction 
116 
 
mixture with the cis-piperidinone that has previously been published, it was clear that the major 
product was 2,6-trans piperidinone 290.142 A 1.5:1 dr was observed after phenethyl-derived enone 
268 was transformed into the piperidinone analogues. A 44% isolated yield was achieved for the 
major product, trans-piperidinone 291. A selective NOE experiment was carried out to prove that 
the isolated compound was trans-piperidinone 291. Upon irradiation of the C-2 and C-6 hydrogen 
atoms, there were no corresponding NOE enhancements, suggesting they are not in close proximity 
to one another. This confirms that the relative stereochemistry is correct. Methyl-derived enone 
269 was also subjected to the acid mediated cyclisation and a 1.5:1 dr was observed however, 
attempts to separate the cyclised products via column chromatography were unsuccessful. 
 
 
Scheme 76: Cyclisation conditions and trans-piperidinone major compounds. 
 
Phenyl-derived enone 263 was also subjected to these conditions in an attempt to investigate 
whether enones with aryl side-chains would also cyclise (Scheme 77). Unfortunately no reaction 
took place and when the reaction was heated to try and force the cyclisation to work, Boc 
protecting group removal ensued. A plausible reason for no reaction occurring for the aryl side-
chain analogues is due to more stable, less reactive, highly conjugated aryl enone. Although the sp2 
secondary amino group is nucleophilic enough to undergo conjugate addition with the activated 
alkyl-derived enones, it appears to not possess the nucleophilicity to disrupt the conjugated aryl-
enone, resulting in no reaction taking place. 
 
 
Scheme 77: Attempt to cyclise aryl-derived enone derivative 263.  
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3.9 Future Work 
Having successfully utilised the base mediated 6-endo-trig cyclisation as a key-step in the total 
synthesis of spruce alkaloid and (+)-241D, the future work in this project will involve the 
optimisation and application of the acid mediated cyclisation. The substrate scope for this 
procedure will be thoroughly investigated and natural products with trans-piperidinone 
functionality will be targeted. Natural products such as (+)-myrtine 296 could be accessed using the 
acid mediated 6-endo-trig cyclisation as a key-step.160,161 β-Keto phosphonate ester 257 could be 
converted to enone 292 using the HWE reaction (Scheme 78). Acid mediated cyclisation would then 
be used and trans-piperidinone 293 isolated. The Boc group would be removed to give secondary 
amine 294 which would then be alkylated with allyl bromide to form tertiary amine 295. Ring closing 
metathesis and hydrogenation would be employed to complete the total synthesis of (+)-myrtine 
296. (−)-Lasubine I162,163 and (+)-subcosine I164,165 are also natural products that contain a 2,6-trans 
piperidinone ring system and could also be targeted for total synthesis. 
 
 
Scheme 78: Proposed synthesis of (+)-myrtine 295 and other potential targets. 
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3.10 Conclusions 
Spruce alkaloid 229 and (+)-241D 234 were synthesised from cheap commercially available starting 
materials. There are three stereocentres present in these compounds, two of which were 
constructed from substrate controlled reactions and the third was already present in the chiral pool 
starting material, ʟ-aspartic acid. After the initial unsuccessful attempts to synthesise spruce 
alkaloid, a new approach was taken which included formation of the methyl group early on in the 
synthesis and late stage base mediated 6-endo-trig cyclisation to construct the 2,6-cis piperidinone 
framework. Throughout the syntheses there was no need for expensive reagents such as 
catalyst/ligand combinations to generate the stereocentres, or the use of over-elaborate protocols. 
The syntheses began with ʟ-aspartic acid and a total of nine synthetic steps were required to reach 
spruce alkaloid 229 and (+)-241D 234 with overall yields of 21% and 19%, respectively. The key-step 
in the syntheses was the 6-endo-trig cyclisation. Although no stereoselectivity was observed in 
favour of the desired cis diastereomer during the cyclisation, the high isolated yields for both cis 
and trans compounds would allow access to the natural product epimers upon reduction of the 
trans isomer. A small substrate scope was also carried out to display that a variety of substrates 
could tolerate the cyclisation conditions. A serendipitous result also allowed access to 2,6-trans 
piperidinones diastereoselectively using acidic conditions. Once this procedure has been optimised, 
a substrate scope will be investigated and the reaction will be used as a key-step in the total 
synthesis of multiple natural products. 
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4.0 Experimental 
4.1 General Experimental 
All reagents and starting materials were obtained from commercial sources and used as received. 
Dry solvents were purified using a PureSolv 500 MD solvent purification system. All reactions were 
performed under an atmosphere of argon unless otherwise mentioned. Brine refers to a saturated 
solution of sodium chloride. Flash column chromatography was carried out using Fisher matrix silica 
60. Macherey-Nagel aluminium-backed plates pre-coated with silica gel 60 (UV254) were used for 
thin layer chromatography and visualised by staining with KMnO4, vanillin or ninhydrin. 1H NMR 
and 13C NMR spectra were recorded on a Bruker DPX 400 or 500 spectrometer with chemical shift 
values in ppm relative to TMS (δH 0.00 and δC 0.0), or residual chloroform (δH 7.26 and δC 77.2), 
dimethylsulfoxide (δH 2.50 and δC 39.52) or methanol (δH 3.31 and δC 49.00) as standard. Proton 
and carbon assignments are based on two-dimensional COSY and DEPT experiments, respectively. 
Mass spectra were obtained using a JEOL JMS-700 spectrometer for EI and CI or Bruker Microtof-q 
for ESI. Infrared spectra were obtained neat using a Shimadzu IR Prestige-21 spectrometer. Melting 
points were determined on a Reichert platform melting point apparatus. Optical rotations were 
determined as solutions irradiating with the sodium D line (λ= 589 nm) using an Autopol V 
polarimeter. [α]D values are given in units 10−1 deg cm2 g−1. UV-Vis spectra were recorded on a 
Pekin Elmer Lamda 25 instrument. Fluoresence spectra were recorded on a Shimadzu RF-
5301PC spectrofluorophotometre. Emission data were measured using an excitation slit width 
of 3 nm and emission slit width of 5 nm. Quantum yield data were measured using anthracene 
and ʟ-tryptophan as standard references. Emission data were measured using an excitation slit 
width of 3 nm and emission slit width of 3 nm. Fluoresence microscopy was carried out using a 
Zeiss Axiovert 200 M fluorescence microscope. 
 
4.2 Experimental Procedures 
Dimethyl (2S)-2-aminobutandioate hydrochloride (98)166 
 
 
 
To a suspension of ʟ-aspartic acid (5.00 g, 37.6 mmol) in dry methanol (100 mL) at 0 °C under argon 
was added thionyl chloride (3.80 mL, 52.6 mmol). The mixture was allowed to warm to room 
temperature and stirred under reflux for 3 h. The solution was allowed to cool to room temperature 
and concentrated in vacuo, azeotroping with toluene-dichloromethane to produce dimethyl (2S)-
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2-aminobutandioate hydrochloride (98) (7.41 g, 100%) as a white solid. Mp 115–116 °C (lit.,166 Mp 
114–115 °C); [α]D24 +22.0 (c 1.0, MeOH); δH (400 MHz, DMSO-d6) 2.99 (1H, dd, J 18.0, 5.5 Hz, 3-HH), 
3.05 (1H, dd, J 18.0, 5.5 Hz, 3-HH), 3.66 (3H, s, OCH3), 3.74 (3H, s, OCH3), 4.35 (1H, t, J 5.5 Hz, 2-H), 
8.72 (3H, s, CHNH3+); δC (100 MHz, DMSO-d6) 34.0 (CH2), 48.4 (CH), 52.2 (CH3), 53.0 (CH3), 168.7 (C), 
169.6 (C); m/z (CI) 162 (MH+, 100%), 148 (5), 102 (20). 
 
Dimethyl (2S)-2-(tritylamino)butandioate (72)167  
 
 
 
To a suspension of dimethyl (2S)-2-aminobutandioate hydrochloride (98) (7.41 g, 37.5 mmol) in 
dichloromethane (300 mL), at 0 °C under argon was added triethylamine (11.0 mL, 78.8 mmol) 
dropwise, followed by triphenylmethyl chloride (12.6 g, 45.0 mmol). The mixture was allowed to 
warm to room temperature and stirred for 6 h. The mixture was diluted with dichloromethane (50 
mL), washed with 2 M citric acid (300 mL), water (150 mL), brine (150 mL), dried (MgSO4) and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 30% diethyl ether in petroleum ether (40–60) to produce dimethyl (2S)-2-
(tritylamino)butandioate (72) (14.1 g, 93%) as a white solid. Mp 71–72 °C (lit.,167 Mp 70–71 °C); Rf 
0.15 (30% diethyl ether in petroleum ether); [α]D24 +36.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.51 
(1H, dd, J 14.7, 7.0 Hz, 3-HH), 2.66 (1H, dd, J 14.7, 5.4 Hz, 3-HH), 2.93 (1H, d, J 10.1 Hz, NH), 3.25 
(3H, s, OCH3), 3.67 (3H, s, OCH3), 3.68–3.73 (1H, m, 2-H), 7.15–7.20 (3H, m, 3 × ArH), 7.23–7.28 (6H, 
m, 6 × ArH), 7.46–7.51 (6H, m, 6 × ArH); δC (100 MHz, CDCl3) 39.0 (CH2), 50.5 (CH), 50.7 (CH3), 52.4 
(CH3), 69.9 (C), 125.2 (3 × CH), 126.6 (6 × CH), 127.5 (6 × CH), 144.4 (3 × C), 169.7 (C), 172.6 (C); m/z 
(EI) 403 (M+, 1%), 326 (35), 243 (100), 165 (30), 83 (70). 
 
Methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (73)167  
 
 
 
To a solution of dimethyl methylphosphonate (9.44 mL, 87.5 mmol) in dry tetrahydrofuran (70 mL) 
at −78 °C under argon was added n-butyllithium (34.3 mL, 85.8 mmol, 2.5 M in hexanes) dropwise. 
After stirring at −78 °C for 1 h, the solution was added via cannula to a stirring solution of dimethyl 
(2S)-2-(tritylamino)butandioate (72) (14.1 g, 35.0 mmol) in dry tetrahydrofuran (100 mL) at −78 °C. 
After stirring at −78 °C under argon for 3 h, the reaction was quenched by the addition of a saturated 
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solution of ammonium chloride (80 mL). The solution was then concentrated in vacuo, redissolved 
in ethyl acetate (200 mL), washed with water (100 mL), brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 90% ethyl acetate in petroleum ether (40–60) to produce methyl (2S)-5-
(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (73) (14.9 g, 86%) as a white solid. Mp 
117–118 °C (lit.,167 Mp 117–118 °C); Rf 0.20 (90% ethyl acetate in petroleum ether); [α]D24 +31.1 (c 
1.0, CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 16.7, 6.9 Hz, 3-HH), 2.85–2.95 (2H, m, 3-HH and NH), 
3.06 (2H, d, JH–C–P 22.7 Hz, 5-H2), 3.29 (3H, s, OCH3), 3.65–3.73 (1H, m, 2-H), 3.76 (3H, s, OCH3), 3.79 
(3H, s, OCH3), 7.15–7.21 (3H, m, 3 × ArH), 7.24–7.28 (6H, m, 6 × ArH), 7.45–7.49 (6H, m, 6 × ArH); δC 
(100 MHz, CDCl3) 41.8 (d, JC–P 128 Hz, CH2), 48.7 (CH2), 52.0 (CH3), 52.9 (CH3), 53.0 (CH3), 53.1 (CH), 
71.2 (C), 126.5 (3 × CH), 127.9 (6 × CH), 128.7 (6 × CH), 145.6 (3 × C), 174.0 (C), 199.2 (C); m/z (CI) 
496 (MH+, 1%), 301 (5), 254 (90), 243 (100), 237 (55), 167 (45). 
 
Methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99)  
 
 
 
Methyl (2S)-5-(dimethoxyphosphoryl)-4-oxo-2-(tritylamino)pentanoate (73) (0.598 g, 1.21 mmol) 
was dissolved in anhydrous acetonitrile (12 mL) and potassium carbonate (0.200 g, 1.45 mmol) was 
added. The mixture was stirred at room temperature for 0.5 h followed by addition of benzaldehyde 
(0.246 mL, 2.42 mmol). The temperature was increased to 50 °C and the mixture was stirred for 72 
h. Once the reaction was complete, the solution was concentrated in vacuo, redissolved in ethyl 
acetate (20 mL) and washed with water (2 × 15 mL) and brine (15 mL). The organic layer was dried 
over MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 30% diethyl ether in petroleum ether (40–60) to produce 
methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) (0.546 g, 95%) as a yellow oil. Rf 
0.17 (30% diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3023 (NH), 2950 (CH), 1737 (C=O), 
1657 (C=C), 1608, 1205; [α]D25 +111.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.80 (1H, dd, J 15.2, 7.0 Hz, 
3-HH), 2.88–2.97 (2H, m, 3-HH and NH), 3.28 (3H, s, OCH3), 3.79–3.89 (1H, m, 2-H), 6.69 (1H, d, J 
16.2 Hz, 5-H), 7.14–7.29 (10H, m, 6-H and 9 × ArH), 7.37–7.41 (3H, m, 3 × ArH), 7.44–7.53 (8H, m, 8 
× ArH); δC (100 MHz, CDCl3) 43.6 (CH2), 50.0 (CH3), 51.7 (CH), 69.2 (C), 124.5 (3 × CH), 125.7 (6 × CH), 
126.1 (CH), 126.3 (2 × CH), 127.4 (6 × CH), 127.8 (2 × CH), 128.6 (CH), 133.0 (C), 141.3 (3 × C), 143.7 
(CH), 172.4 (C), 195.5 (C); m/z (FAB) 476.2231 (MH+. C32H30NO3 requires 476.2226), 398 (15%), 259 
(6), 243 (100), 232 (25), 166 (23), 132 (24). 
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Methyl (2S,5E)-6-(4’-methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (100)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.495 g, 1.00 mmol) and 4-methoxybenzaldehyde (0.25 mL, 
2.00 mmol) for 72 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-6-(4’-
methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (100) (0.384 g, 76%) as a colourless oil. Rf 0.20 
(30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3320 (NH), 2951 (CH), 1736 (C=O), 1595 
(C=C), 1510, 1447, 1252, 1171, 1028; [α]D23 +54.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 
15.0, 7.0 Hz, 3-HH), 2.84–2.99 (2H, m, 3-HH and NH), 3.27 (3H, s, OCH3), 3.71–3.93 (4H, m, 2-H and 
OCH3), 6.59 (1H, d, J 16.1 Hz, 5-H), 6.92 (2H, d, J 8.7 Hz, 2 × ArH), 7.11–7.35 (9H, m, 9 × ArH), 7.39–
7.59 (9H, m, 6-H and 8 × ArH); δC (100 MHz, CDCl3) 45.7 (CH2), 52.0 (CH3), 54.0 (CH), 55.4 (CH3), 71.3 
(C), 114.5 (2 × CH), 124.3 (CH), 126.6 (3 × CH), 127.1 (C), 128.0 (6 × CH), 128.9 (6 × CH), 130.2 (2 × 
CH), 143.2 (CH), 145.9 (3 × C), 161.8 (C), 174.6 (C), 197.5 (C); m/z (FAB) 506.2329 (MH+. C33H32NO4 
requires 506.2331), 428 (5%), 262 (11), 243 (100), 162 (18), 86 (5). 
 
Methyl (2S,5E)-6-(naphthalen-2’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (101)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (1.09 g, 2.20 mmol) and 2-naphthaldehyde (0.687 g, 4.40 mmol) 
for 72 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
30% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(naphthalen-2’-yl)-4-
oxo-2-(tritylamino)hex-5-enoate (101) (1.03 g, 89%) as a yellow solid. Mp 62–63 °C; Rf 0.15 (30% 
diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3055 (NH), 2982 (CH), 1734 (C=O), 1655 (C=C), 
1604, 1593, 1489, 1172; [α]D24 +64.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.84 (1H, dd, J 15.1, 7.0 Hz, 
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3-HH), 2.92–3.00 (2H, m, 3-HH and NH), 3.29 (3H, s, OCH3), 3.79–3.86 (1H, m, 2-H), 6.80 (1H, d, J 
16.2 Hz, 5-H), 7.15–7.30 (9H, m, 9 × ArH), 7.50–7.55 (8H, m, 6’-H, 7’-H and 6 × ArH), 7.62–7.69 (2H, 
m, 6-H and 3’-H), 7.84–7.89 (3H, m, 4’-H, 5’-H and 6’-H), 7.94 (1H, br s, 1’-H); δC (100 MHz, CDCl3) 
45.9 (CH2), 52.1 (CH), 54.0 (CH3), 71.4 (C), 123.6 (CH), 126.6 (CH), 126.6 (3 × CH), 126.9 (CH), 127.6 
(CH), 128.0 (CH), 128.0 (6 × CH), 128.2 (CH), 128.7 (CH), 128.9 (6 × CH), 130.7 (CH), 132.0 (C), 133.4 
(C), 134.5 (C), 143.5 (CH), 145.9 (3 × C), 174.6 (C), 197.6 (C); m/z (FAB) 526.2388 (MH+. C36H32NO3 
requires 526.2382), 448 (7%), 273 (8), 243 (100), 181 (19), 165 (24). 
 
Methyl (2S,5E)-6-[4’-(dimethylamino)naphthalen-1’-yl]-4-oxo-2-(tritylamino)hex-5-enoate (74)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.451 g, 0.911 mmol) and 4-dimethylamino-1-naphthaldehyde 
(0.363 g, 1.82 mmol) for 96 h. The crude product was purified via flash column chromatography on 
silica gel, eluting with 40% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-
[4’-(dimethylamino)naphthalen-1’-yl]-4-oxo-2-(tritylamino)hex-5-enoate (74) (0.372 g, 72%) as an 
orange oil. Rf 0.18 (40% diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3448 (NH), 3019, 2947 
(CH), 1737 (C=O), 1651 (C=C), 1569, 1449, 1390; [α]D18 +73.7 (c 0.4, CHCl3); δH (400 MHz, CDCl3) 2.83 
(1H, dd, J 14.8, 6.8 Hz, 3-HH), 2.88–3.04 (8H, m, 3-HH, NH and NMe2), 3.30 (3H, s, OCH3), 3.78–3.88 
(1H, m, 2-H), 6.71 (1H, d, J 15.7 Hz, 5-H), 7.04 (1H, d, J 8.0 Hz, 3’-H), 7.14–7.29 (9H, m, 9 × ArH), 
7.49–7.60 (8H, m, 8 × ArH), 7.74 (1H, d, J 8.0 Hz, 2’-H), 8.13–8.26 (2H, m, 2 × ArH), 8.30 (1H, d, J 15.7 
Hz, 6-H); δC (101 MHz, CDCl3) 44.9 (2 × CH3), 45.8 (CH2), 52.0 (CH3), 54.0 (CH), 71.3 (C), 113.4 (CH), 
123.6 (CH), 125.2 (CH), 125.3 (CH), 125.4 (C), 125.8 (CH), 126.5 (3 × CH), 126.6 (CH), 126.9 (CH), 
127.9 (6 × CH), 128.4 (C), 128.9 (6 × CH), 133.1 (C), 140.2 (CH), 145.9 (3 × C), 153.8 (C), 174.7 (C), 
197.4 (C); m/z (FAB) 569.2799 (MH+. C38H37N2O3 requires 569.2804), 491 (3%), 460 (4), 325 (52), 243 
(100), 224 (19), 85 (56). 
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Methyl (2S,5E)-6-(4’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (102)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (2.17 g, 4.38 mmol) and 4-nitrobenzaldehyde (1.32 g, 8.76 
mmol) for 48 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-6-(4’-
nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (102) (1.64 g, 72%) as an off-white solid. Mp 139–
141 °C; Rf 0.33 (30% ethyl acetate in petroleum ether); νmax (neat)/cm–1 2951 (CH), 1742 (C=O), 1712 
(C=O), 1490, 1509, 1341; [α]D25 +43.3 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 2.80 (1H, dd, J 15.5, 6.9 Hz, 
3-HH), 2.91 (1H, dd, J 15.5, 5.1 Hz, 3-HH), 2.95 (1H, br s, NH), 3.31 (3H, s, OCH3), 3.81 (1H, m, 2-H), 
6.77 (1H, d, J 16.2 Hz, 5-H), 7.17–7.51 (16H, m, 6-H and 3 × Ph), 7.66 (2H, d, J 8.8 Hz, 2’-H and 6’-H), 
8.26 (2H, d, J 8.8 Hz, 3’-H and 5’-H); δC (101 MHz, CDCl3) 46.2 (CH2), 52.1 (CH3), 53.7 (CH), 71.3 (C), 
124.3 (CH), 126.6 (3  CH), 128.0 (6  CH), 128.8 (6  CH), 128.9 (2  CH), 129.6 (2  CH), 139.9 (CH), 
140.6 (C), 145.7 (3  C), 148.6 (C), 174.3 (C), 197.0 (C); m/z (FAB + NaI) 543.1903 (MNa+. 
C32H28NO5Na requires 543.1896), 443 (9%), 413 (9), 351 (19), 243 (100), 176 (78). 
 
Methyl (2S,5E)-6-(4’-fluoro-3’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (103) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.466 g, 0.941 mmol) and 4-fluoro-3-nitrobenzaldehyde (0.318 
g, 1.882 mmol) for 120 h. The crude product was purified via flash column chromatography on silica 
gel, eluting with 50% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(4’-
fluoro-3’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (103) (0.391 g, 69%) as a pale yellow 
solid. Mp 54–57 °C; Rf 0.13 (50% diethyl ether in petroleum ether); νmax/cm−1 (neat) 3545 (NH), 2985 
(CH), 1612 (C=O), 1537 (C=C), 1350, 1084, 707; [α]D26 +9.3 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 2.77 
(1H, dd, J 15.4, 7.0 Hz, 3-HH), 2.87–2.98 (2H, m, 3-HH and NH), 3.32 (3H, s, OCH3), 3.80 (1H, dt, J 
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9.3, 7.0 Hz, 2-H), 6.68 (1H, d, J 16.2 Hz, 5-H), 7.17–7.21 (3H, m, 3 × ArH), 7.24–7.28 (7H, m, 7 × ArH), 
7.34 (1H, dd, J 10.2, 8.7 Hz, 5’-H), 7.41 (1H, d, J 16.2 Hz, 6-H), 7.47–7.52 (5H, m, 5 × ArH), 7.76 (1H, 
ddd, J 8.7, 4.1, 2.3 Hz, 6’-H), 8.20 (1H, dd, J 7.0, 2.3 Hz, 2’-H); δC (126 MHz, CDCl3) 46.4 (CH2), 52.2 
(CH3), 53.8 (CH), 71.5 (C), 119.4 (d, JC-C-F 21.4 Hz, CH), 125.5 (d, JC-C-C-F 2.3 Hz, CH), 126.8 (3 × CH), 
128.1 (6 × CH), 128.5 (d, JC-C-C-C-F 2.1 Hz, C), 128.9 (CH), 128.9 (6 × CH), 131.9 (d, JC-C-F 4.4 Hz, C), 134.8 
(d, JC-C-C-F 8.8 Hz, CH), 138.9 (CH), 145.8 (3 × C), 156.3 (d, JC-F 269.7 Hz, C), 174.4 (C), 196.8 (C); m/z 
(ESI) 561.1773 (MNa+. C32H27FN2NaO5 requires 561.1796). 
 
Methyl (2S,5E)-6-(4-fluorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (104)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.571 g, 1.15 mmol) and 4-fluorobenzaldehyde (0.247 mL, 2.30 
mmol) for 72 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 40% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(4-
fluorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (104) (0.391 g, 69%) as a yellow oil. Rf 0.25 (40% 
diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3057 (NH), 2950 (CH), 1738 (C=O), 1612, 1598, 
1233; [α]D25 +128.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.78 (1H, dd, J 15.2, 7.0 Hz, 3-HH), 2.87–2.95 
(2H, m, 3-HH and NH), 3.28 (3H, s, OCH3), 3.78–3.85 (1H, m, 2-H), 6.61 (1H, d, J 16.1 Hz, 5-H), 7.05–
7.11 (2H, m, 3’-H and 5’-H), 7.15–7.19 (3H, m, 3 × ArH), 7.21–7.29 (7H, m, 7 × ArH), 7.44 (1H, d, J 
16.1 Hz, 6-H), 7.47–7.53 (7H, m, 7 × ArH); δC (100 MHz, CDCl3) 44.9 (CH2), 51.1 (CH3), 52.9 (CH), 70.4 
(C), 115.3 (d, JC-C-F 22.1 Hz, 2 × CH), 125.1 (CH), 127.0 (3 × CH), 127.2 (6 × CH), 128.2 (CH), 129.4 (6 × 
CH), 129.7 (2 × CH), 141.1 (C), 144.8 (3 × C), 163.2 (d, JC-F 251.5 Hz, C), 173.6 (C), 196.4 (C); m/z (FAB) 
494.2128 (MH+. C32H29FNO3 requires 494.2131), 416 (31%), 258 (6), 243 (100), 166 (34), 150 (35). 
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Methyl (2S,5E)-6-(2’-bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (105)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (1.11 g, 2.25 mmol) and 2-bromobenzaldehyde (0.525 mL, 4.50 
mmol) for 24 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(2’-
bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (105) (0.973 g, 78%) as a colourless oil. Rf 0.17 
(30% diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3021 (NH), 2950 (CH), 1737 (C=O), 1437, 
1204, 1027; [α]D25 +48.6 (c 1.0, CHCl3); δH  (400 MHz, CDCl3) 2.82 (1H, dd, J 15.4, 6.8 Hz, 3-HH), 2.88–
2.97 (2H, m, 3-HH and NH), 3.30 (3H, s, OCH3), 3.78–3.83 (1H, m, 2-H), 6.60 (1H, d, J 16.2 Hz, 5-H), 
7.13–7.33 (11H, m, 4’-H, 5’-H and 9 × ArH), 7.48–7.53 (6H, m, 6 × ArH), 7.59 (2H, td, J 8.0, 1.1 Hz, 
3’-H and 6’-H), 7.85 (1H, d, J 16.2 Hz, 6-H); δC (100 MHz, CDCl3) 45.3 (CH2), 52.1 (CH), 53.8 (CH3), 
71.3 (C), 125.9 (C), 126.6 (3 × CH), 127.8 (CH), 127.9 (CH), 128.0 (6 × CH), 128.9 (6 × CH), 129.1 (CH), 
131.6 (CH), 133.6 (CH), 134.4 (C), 141.7 (CH), 145.8 (3 × C), 174.4 (C), 197.5 (C); m/z (FAB) 554.1322 
(MH+. C32H2979BrNO3 requires 554.1331), 478 (7%), 312 (13), 243 (100), 209 (7), 165 (19). 
 
4-(3’-Nitrophenyl)benzaldehyde (115)76 
 
 
 
To a solution of 4-bromobenzaldehyde (0.111 g, 0.599 mmol) in N,N-dimethylformamide and water 
(3 mL, 19:1) was added 3-nitrophenylboronic acid (0.148 g, 0.887 mmol), potassium carbonate 
(0.204 g, 1.476 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.033 g, 0.029 mmol). The 
reaction mixture was heated to 110 °C and stirred for 4 h. After cooling to room temperature, the 
solution was concentrated in vacuo, redissolved in chloroform (10 mL), filtered through Celite® and 
concentrated in vacuo. The resulting solid was dissolved in diethyl ether (20 mL), washed with water 
(3 × 10 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified via flash 
column chromatography on silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) to 
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give 4-(3’-nitrophenyl)benzaldehyde (115) as an off-white solid (0.139 g, 100%). Mp 113−114 °C 
(lit.,76 114−116 °C); Rf 0.27 (20% ethyl acetate in petroleum ether); δH (400 MHz, CDCl3) 7.68 (1H, t, 
J 8.0 Hz, 5’-H), 7.81 (2H, d, J 8.3 Hz, 3-H and 5-H), 7.95−8.00 (1H, m, 6’-H), 8.03 (2H, d, J 8.3 Hz, 2-H 
and 6-H), 8.26−8.31 (1H, m, 4’-H), 8.51 (1H, t, J 2.0 Hz, 2’-H), 10.10 (1H, s, CHO); δC (101 MHz, CDCl3) 
122.4 (CH), 123.3 (CH), 128.0 (2 × CH), 130.2 (CH), 130.7 (2 × CH), 133.4 (CH), 136.2 (C), 141.6 (C), 
144.5 (C), 149.0 (C), 191.8 (CH); m/z (CI) 228 (MH+. 100%), 198 (10). 
 
Methyl (2S,5E)-6-(3’’-nitrobiphen-4’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (106)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.550 g, 1.11 mmol) and 4-(3’-nitrophenyl)benzaldehyde (115) 
(0.355 g, 1.56 mmol) for 72 h. The crude product was purified via flash column chromatography on 
silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-6-
(3’’-nitrobiphen-4’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (106) (0.556 g, 84%) as a yellow foam. Rf 
0.12 (20% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3030 (NH), 1736 (C=O), 1657 (C=C), 
1603, 1530, 1514, 1348; [α]D23 +61.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.82 (1H, dd, J 15.2, 6.9 Hz, 
3-HH), 2.90–3.02 (2H, m, 3-HH and NH), 3.30 (3H, s, OCH3), 3.77–3.88 (1H, m, 2-H), 6.75 (1H, d, J 
16.2 Hz, 5-H), 7.12–7.32 (9H, m, 9 × ArH), 7.45–7.73 (12H, m, 6-H and 11 × ArH), 7.93 (1H, d, J 7.9 
Hz, 6’’-H), 8.23 (1H, d, J 7.9 Hz, 4’’-H), 8.48 (1H, br s, 2’’-H); δC (100 MHz, CDCl3)45.9 (CH2), 52.1 
(CH3), 53.8 (CH), 71.3 (C), 121.9 (CH), 122.7 (CH), 126.6 (3 × CH), 127.0 (CH), 127.7 (2 × CH), 128.0 
(6 × CH), 128.9 (6 × CH), 129.2 (2 × CH), 130.0 (CH), 132.9 (CH), 134.7 (C), 140.6 (C), 141.7 (C), 142.2 
(CH), 145.8 (3 × C), 148.8 (C), 174.5 (C), 197.4 (C); m/z (FAB) 597.2384 (MH+. C38H33N2O5 requires 
597.2389), 519 (23%), 419 (5), 353 (32), 243 (100), 194 (9), 166 (54). 
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Methyl (2S,5E)-6-(furan-2-yl)-4-oxo-2-(tritylamino)hex-5-enoate (107) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.308 g, 0.622 mmol) and 2-furaldehyde (0.103 mL, 1.24 mmol) 
for 96 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
40% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(furan-2-yl)-4-oxo-2-
(tritylamino)hex-5-enoate (107) (0.234 g, 81%) as a light brown solid. Mp 97–98 °C; Rf 0.20 (40% 
diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3058 (NH), 2951 (CH), 1737 (C=O), 1607; [α]D23 
+42.9 (c 0.3, CHCl3); δH (400 MHz, CDCl3) 2.72 (1H, dd, J 15.1, 7.0 Hz, 3-HH), 2.82–2.94 (2H, m, 3-HH 
and NH), 3.27 (3H, s, OCH3), 3.74–3.81 (1H, m, 2-H), 6.47–6.50 (1H, m, 4’-H), 6.59 (1H, d, J 15.8 Hz, 
5-H), 6.66 (1H, d, J 3.3 Hz, 3’-H), 7.14–7.30 (11H, m, 6-H, 5’-H and 9 × ArH), 7.46–7.52 (6H, m, 6 × 
ArH); δC (101 MHz, CDCl3) 46.2 (CH2), 51.9 (CH3), 53.8 (CH), 71.3 (C), 112.6 (CH), 116.0 (CH), 123.6 
(CH), 126.5 (3 × CH), 128.2 (6 × CH), 128.6 (6 × CH), 129.2 (CH), 145.1 (CH), 145.8 (3 × C), 151.0 (C), 
174.4 (C), 197.0 (C); m/z (FAB) 488.1833 (MNa+. C30H27NO4Na requires 488.1838), 388 (7%), 352 (3), 
243 (100), 166 (18). 
 
Methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (108)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (1.01 g, 2.04 mmol) and butyraldehyde (0.367 mL, 4.08 mmol) 
for 96 h. The crude product was purified via a plug of silica gel, eluting with 20% ethyl acetate in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (108) 
(0.765 g, 85%) as a yellow oil. Rf 0.18 (20% ethyl acetate in petroleum ether); νmax (neat)/cm–1 3316 
(NH), 2955 (CH), 1736 (C=O), 1667, 1443, 1204, 1173; [α]D27 +28.6 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 
0.93 (3H, t, J 7.3 Hz, 9-H3), 1.44–1.53 (2H, m, 8-H2), 2.18 (2H, dtd, J 7.4, 7.0, 1.5 Hz, 7-H2), 2.65 (1H, 
dd, J 15.3, 7.1 Hz, 3-HH), 2.79 (1H, dd, J 15.3, 5.2 Hz, 3-HH), 2.85 (1H, d, J 9.8 Hz, NH), 3.27 (3H, s, 
OCH3), 3.67–3.74 (1H, m, 2-H), 6.04 (1H, dt, J 16.0, 1.5 Hz, 5-H), 6.74 (1H, dt, J 16.0, 7.0 Hz, 6-H), 
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7.08–7.19 (9H, m, 9 × ArH), 7.39–7.41 (6H, m, 6 × ArH); δC (101 MHz, CDCl3) 13.7 (CH3), 21.3 (CH2), 
34.5 (CH2), 44.9 (CH2), 51.9 (CH), 53.6 (CH3), 71.2 (C), 126.5 (3  CH), 127.9 (6  CH), 129.1 (6  CH), 
130.7 (CH), 145.8 (3 × C), 148.3 (CH), 174.6 (C), 198.0 (C); m/z (FAB) 442.2378 (MH+. C29H32NO3 
requires 442.2382), 364 (60%), 243 (100), 198 (64), 165 (43). 
 
Methyl (2S,5E)-2-(tritylamino)-4-oxotetradec-5-enoate (109) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.243 g, 0.574 mmol) and nonanal (0.188 mL, 1.09 mmol) for 
96 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
20% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-2-(tritylamino)-4-
oxotetradec-5-enoate (109) (0.117 g, 40%) as a colourless oil. Rf 0.19 (20% diethyl ether in 
petroleum ether); νmax/cm−1 (neat) 3316 (NH), 2955 (CH), 1736 (C=O), 1667, 1443, 1204, 1173; [α]D26 
+9.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz, 14-H3), 1.21–1.34 (10H, m, 9-H2, 10-H2, 
11-H2, 12-H2 and 13-H2), 1.39–1.49 (2H, m, 8-H2), 2.15–2.23 (2H, m, 7-H2), 2.65 (1H, dd, J 15.3, 7.0 
Hz, 3-HH), 2.76–2.92 (2H, m, 3-HH and NH), 3.26 (3H, s, OCH3), 3.68–3.75 (1H, m, 2-H), 6.03 (1H, dt, 
J 15.9, 1.4 Hz, 5-H), 6.74 (1H, dt, J 15.9, 6.9 Hz, 6-H), 7.14–7.20 (3H, m, 3 × ArH), 7.21–7.29 (6H, m, 
6 × ArH), 7.45–7.52 (6H, m, 6 × ArH); δC (101 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 28.1 (CH2), 29.2 
(CH2), 29.2 (CH2), 29.4 (CH2), 31.8 (CH2), 32.5 (CH2), 44.9 (CH2), 51.9 (CH3), 53.7 (CH), 71.2 (C), 126.5 
(3 × CH), 127.9 (6 × CH), 128.8 (6 × CH), 130.6 (CH), 145.8 (3 × C), 148.6 (CH), 174.6 (C), 197.7 (C); 
m/z (ESI) 534.2955 (MNa+. C34H41NNaO3 requires 534.2979). 
 
Methyl (2S,5E)-6-(2’,4’-dimethoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (158)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (1.11 g, 2.24 mmol) and 2,4-dimethoxybenzaldehyde (0.743 g, 
4.48 mmol) for 120 h. The crude product was purified via flash column chromatography on silica 
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gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-6-(2’,4’-
dimethoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (158)  (0.564 g, 47%) as a yellow foam. Mp 
66–70 °C; Rf 0.15 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 2948 (CH), 1736 (C=O), 
1599 (C=C), 1266, 1210, 1160, 1028, 734, 699; [α]D26 +52.3 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 2.83 
(1H, dd, J 14.9, 6.8 Hz, 3-HH), 2.87–2.95 (2H, m, 3-HH and NH), 3.25 (3H, s, OCH3), 3.75–3.86 (7H, 
m, 2-H and 2 × OCH3), 6.45 (1H, d, J 2.3 Hz, 3’-H), 6.51 (1H, dd, J 8.6, 2.3 Hz, 5’-H), 6.69 (1H, d, J 16.3 
Hz, 5-H), 7.12–7.19 (3H, m, 3 × ArH), 7.20–7.27 (6H, m, 6 × ArH), 7.44–7.54 (7H, m, 6’-H and 6 × 
ArH), 7.82 (1H, d, J 16.3 Hz, 6-H); δC (126 MHz, CDCl3) 45.3 (CH2), 51.8 (CH3), 53.9 (CH), 55.5 (CH3), 
55.5 (CH3), 71.3 (C), 98.4 (CH), 105.5 (CH), 116.5 (C), 124.8 (CH), 126.4 (3 × CH), 127.8 (6 × CH), 128.9 
(6 × CH), 130.2 (CH), 138.8 (CH), 145.9 (3 × C), 160.1 (C), 163.2 (C), 174.6 (C), 198.0 (C); m/z (ESI) 
558.2227 (MNa+. C34H33NNaO5 requires 558.2251). 
 
Methyl (2S,5E)-6-(2H-1’,3’-benzodioxol-5’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (159)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (0.215 g, 0.434 mmol) and piperonal (0.130 g, 0.868 mmol) for 
120 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
20% ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-6-(2H-1’,3’-benzodioxol-
5’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (159)  (0.113 g, 50%) as a yellow oil. Rf 0.12 (20% ethyl 
acetate in petroleum ether); νmax/cm−1 (neat) 3055 (NH), 2898 (CH), 1734 (C=O), 1594 (C=C), 1489, 
1446, 1253, 1034, 699; [α]D26 +49.2 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.75 (1H, dd, J 15.1, 6.8 Hz, 
3-HH), 2.84–2.95 (2H, m, 3-HH and NH), 3.27 (3H, s, OCH3), 3.78 (1H, dt, J 9.3, 6.8 Hz, 2-H), 5.98 (2H, 
s, 2’-H2), 6.52 (1H, d, J 16.1 Hz, 5-H), 6.81 (1H, d, J 7.9 Hz, 7’-H), 6.97–7.04 (2H, m, 4’-H and 6’-H), 
7.13–7.19 (3H, m, 3 × ArH), 7.20–7.29 (6H, m, 6 × ArH), 7.39 (1H, d, J 16.1 Hz, 6-H), 7.47–7.53 (6H, 
m, 6 × ArH); δC (101 MHz, CDCl3) 45.8 (CH2), 51.9 (CH3), 53.8 (CH), 71.3 (C), 101.6 (CH2), 106.6 (CH), 
108.6 (CH), 124.5 (CH), 125.0 (CH), 126.5 (3 × CH), 127.9 (6 × CH), 128.1 (C), 128.8 (6 × CH), 143.1 
(CH), 145.8 (3 × C), 148.5 (C), 150.0 (C), 174.5 (C), 197.2 (C); m/z (ESI) 542.1915 (MNa+. C33H29NNaO5 
requires 542.1938). 
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Methyl (2S,5E)-6-(2’,4’-dinitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (160)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) using methyl (2S)-5-(dimethoxyphosphoryl)-4-
oxo-2-(tritylamino)pentanoate (73) (1.06 g, 2.15 mmol) and 2,4-dinitrobenzaldehyde (0.842 g, 4.29 
mmol) for 1 h. The crude product was purified via flash column chromatography on silica gel, eluting 
with 60% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-6-(2’,4’-
dinitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (160)  (0.801 g, 66%) as an orange solid. Mp 58–
61 °C; Rf 0.25 (60% diethyl ether in petroleum ether); νmax/cm−1 (neat) 3057 (NH), 2952 (CH), 1734 
(C=O), 1530 (C=C), 1447, 1266, 834, 705; [α]D26 +37.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 2.79 (1H, 
dd, J 15.8, 6.8 Hz, 3-HH), 2.85–3.05 (2H, m, 3-HH and NH), 3.35 (3H, s, OCH3), 3.78–3.84 (1H, m, 2-
H), 6.60 (1H, d, J 16.1 Hz, 5-H), 7.15–7.28 (9H, m, 9 × ArH), 7.47–7.52 (6H, m, 6 × ArH), 7.78 (1H, d, 
J 8.6 Hz, 6’-H), 7.86 (1H, d, J 16.1 Hz, 6-H), 8.46 (1H, dd, J 8.6, 2.3 Hz, 5’-H), 8.90 (1H, d, J 2.3 Hz, 3’-
H); δC (126 MHz, CDCl3) 45.5 (CH2), 52.2 (CH3), 53.5 (CH), 71.3 (C), 120.7 (CH), 126.6 (3 × CH), 127.7 
(CH), 128.0 (6 × CH), 128.8 (6 × CH), 130.6 (CH), 133.4 (CH), 136.0 (CH), 136.6 (C), 145.6 (3 × C), 
148.1 (C), 148.2 (C), 174.1 (C), 196.5 (C); m/z (ESI) 588.1714 (MNa+. C32H27N3NaO7 requires 
588.1741). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116)  
 
 
 
To a solution of methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) (0.347 g, 0.730 
mmol) in dichloromethane (7 mL) was added trifluoroacetic acid (0.112 mL, 1.46 mmol). The 
reaction mixture was stirred at room temperature for 2 h before concentrating in vacuo. The 
resulting residue was dissolved in chloroform (2 mL) and petroleum ether (40–60) was added until 
an orange oil formed, at which point the solvent was decanted off. The resulting oil was dissolved 
in dichloromethane (7 mL) and N,N’-diisopropylethylamine (0.320 mL, 1.83 mmol) was added, 
followed by benzyl chloroformate (0.158 mL, 1.10 mmol). The reaction mixture was stirred at room 
temperature for 1 h, before diluting with water (20 mL). The mixture was then extracted with 
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dichloromethane (3 × 10 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified via flash column chromatography on silica gel, eluting with 30% ethyl acetate in petroleum 
ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-
enoate (116) (0.230 g, 86%) as a white solid. Mp 77−78 °C; Rf 0.17 (30% ethyl acetate in petroleum 
ether); νmax/cm−1 (neat) 3333 (NH), 3059, 2951 (CH), 1734 (C=O), 1688 (C=O), 1533 (C=C), 1435, 
1343, 1254, 1090, 980, 748; [α]D26 +26.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.26 (1H, dd, J 17.9, 4.2 
Hz, 3-HH), 3.48 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.75 (3H, s, OCH3), 4.68 (1H, dt, J 8.4, 4.2 Hz, 2-H), 5.12 
(2H, s, OCH2Ph), 5.85 (1H, d, J 8.4 Hz, NH), 6.69 (1H, d, J 16.2 Hz, 5-H), 7.26−7.43 (8H, m, 8 × ArH), 
7.51−7.59 (3H, m, 6-H and 2 × ArH); δC (101 MHz, CDCl3) 42.4 (CH2), 50.2 (CH), 52.9 (CH3) 67.2 (CH2), 
125.6 (CH), 128.2 (2 × CH), 128.3 (CH), 128.6 (4 × CH), 129.2 (2 × CH), 131.0 (CH), 134.2 (C), 136.4 
(C), 144.2 (CH), 156.2 (C), 171.7 (C), 197.6 (C); m/z (CI) 368.1506 (MH+. C21H22NO5 requires 
368.1498), 326 (8%), 260 (23), 234 (21), 219 (18), 181 (6), 147 (17), 107 (16), 85 (100). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-methoxyphenyl)-4-oxohex-5-enoate (117)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(4’-
methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (100) (0.932 g, 1.84 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-
methoxyphenyl)-4-oxohex-5-enoate (117) as a colourless oil (0.636 g, 87%). Rf 0.21 (40% ethyl 
acetate in petroleum ether); νmax/cm−1 (neat) 3347 (NH), 2953 (CH), 1717 (C=O), 1655 (C=O), 1597 
(C=C), 1510 (C=C), 1248, 1208, 1169, 1026, 816; [α]D29 +30.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.23 
(1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.47 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.75 (3H, s, OCH3), 3.85 (3H, s, 
OCH3), 4.67 (1H, dt, J 8.5, 4.2 Hz, 2-H), 5.12 (2H, s, OCH2Ph), 5.88 (1H, d, J 8.5 Hz, NH), 6.58 (1H, d, J 
16.2 Hz, 5-H), 6.92 (2H, d, J 8.8 Hz, 3’-H and 5’-H), 7.27−7.38 (5H, m, Ph), 7.49 (2H, d, J 8.8 Hz, 2’-H 
and 6’-H), 7.52 (1H, d, J 16.2 Hz, 6-H); δC (101 MHz, CDCl3) 42.3 (CH2), 50.3 (CH), 52.8 (CH3), 55.6 
(CH3), 67.1 (CH2), 114.6 (2 × CH), 123.4 (CH), 126.9 (C), 128.1 (2 × CH), 128.2 (CH), 128.6 (2 × CH), 
130.4 (2 × CH), 136.4 (C), 144.0 (CH), 156.2 (C), 162.1 (C), 171.8 (C), 197.4 (C); m/z (EI) 397.1526 
(M+. C22H23NO6 requires 397.1525), 336 (10%), 289 (19), 262 (19), 243 (45), 182 (34), 161 (100), 91 
(32). 
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Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(naphthalen-2’-yl)-4-oxohex-5-enoate (118)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-
(naphthalen-2’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (101) (0.736 g, 1.40 mmol). The crude 
product was purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate 
in petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-
(naphthalen-2’-yl)-4-oxohex-5-enoate (118) (0.497 g, 85%) as a colourless oil. Rf 0.26 (40% ethyl 
acetate in petroleum ether); νmax/cm−1 (neat) 3339 (NH), 2951 (CH), 1717 (C=O), 1659 (C=O), 1505 
(C=C), 1207, 1057, 976, 812; [α]D28 +27.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.31 (1H, dd, J 18.0, 4.2 
Hz, 3-HH), 3.54 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.77 (3H, s, OCH3), 4.71 (1H, dt, J 8.6, 4.2 Hz, 2-H), 5.13 
(2H, s, OCH2Ph), 5.89 (1H, d, J 8.6 Hz, NH), 6.82 (1H, d, J 16.2 Hz, 5-H), 7.28−7.39 (5H, m, Ph), 
7.51−7.58 (2H, m, 6’-H and 7’-H), 7.67 (1H, dd, J 8.6, 1.5 Hz, 3’-H), 7.73 (1H, d, J 16.2 Hz, 6-H), 
7.82−7.90 (3H, m, 4’-H, 5’-H and 8’-H), 7.96 (1H, br s, 1’-H); δC (101 MHz, CDCl3) 42.5 (CH2), 50.2 
(CH), 52.9 (CH3), 67.2 (CH2), 123.6 (CH), 125.7 (CH), 127.0 (CH), 127.7 (CH), 127.9 (CH), 128.1 (2 × 
CH), 128.3 (CH), 128.6 (2 × CH), 128.8 (CH), 129.0 (CH), 130.9 (CH), 131.7 (C), 133.4 (C), 134.6 (C), 
136.4 (C), 144.3 (CH), 156.2 (C), 171.7 (C), 197.5 (C); m/z (CI) 418.1653 (MH+. C25H24NO5 requires 
418.1654), 383 (32%), 310 (48), 275 (20), 147 (30), 107 (29). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-[4’-(dimethylamino)naphthalen-1’-yl]-4-oxohex-
5-enoate (119) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-[4’-
(dimethylamino)naphthalen-1’-yl]-4-oxo-2-(tritylamino)hex-5-enoate (74) (0.188 g, 0.331 mmol). 
The crude product was purified via flash column chromatography on silica gel, eluting with 30% 
ethyl acetate in petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-
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6-[4’-(dimethylamino)naphthalen-1’-yl]-4-oxohex-5-enoate (119) (0.086 g, 56%) as a yellow oil. Rf 
0.12 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3423 (NH), 2953 (CH), 1720 (C=O), 
1558 (C=C), 1209, 1045, 732; [α]D24 +18.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.94 (6H, s, NMe2), 3.31 
(1H, dd, J 17.8, 4.2 Hz, 3-HH), 3.53 (1H, dd, J 17.8, 4.2 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.72 (1H, dt, J 
8.6, 4.2 Hz, 2-H), 5.13 (2H, s, OCH2Ph), 5.94 (1H, d, J 8.6 Hz, NH), 6.73 (1H, d, J 15.8 Hz, 5-H), 7.01 
(1H, d, J 8.0 Hz, 3’-H), 7.25–7.37 (5H, m, Ph), 7.48–7.59 (2H, m, 6’-H and 7’-H), 7.74 (1H, d, J 8.0 Hz, 
2’-H, 8.16 (1H, d, J 8.0 Hz, ArH), 8.20–8.26 (1H, m, ArH), 8.39 (1H, d, J 15.8 Hz, 6-H); δC (101 MHz, 
CDCl3) 42.5 (CH2), 44.8 (2 × CH3), 50.2 (CH), 52.7 (CH3), 67.0 (CH2), 113.3 (CH), 123.4 (CH), 124.9 (C), 
125.3 (2 × CH), 125.3 (CH), 126.0 (CH), 126.9 (CH), 128.0 (2 × CH), 128.1 (CH), 128.3 (C), 128.5 (2 × 
CH), 133.1 (C), 136.3 (C), 140.9 (CH), 154.0 (C), 156.1 (C), 171.8 (C), 197.2 (C); m/z (EI) 460.2003 (M+. 
C27H28N2O5 requires 460.1998). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-nitrophenyl)-4-oxohex-5-enoate (90)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(4’-
nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (102) (1.55 g, 2.97 mmol). The crude product was 
purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate in petroleum 
ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-nitrophenyl)-4-
oxohex-5-enoate (90) (0.943 g, 77%) as an yellow solid. Mp 73−74 °C; Rf 0.41 (40% ethyl acetate in 
petroleum ether); νmax/cm−1 (neat) 3331 (NH), 2953 (CH), 1730 (C=O), 1686 (C=O), 1512 (C=C), 1343, 
1202, 1059, 978, 860; [α]D28 +20.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.30 (1H, dd, J 18.1, 4.2 Hz, 3-
HH), 3.48 (1H, dd, J 18.1, 4.2 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.70 (1H, dt, J 8.4, 4.2 Hz, 2-H), 5.12 (2H, 
s, OCH2Ph), 5.82 (1H, d, J 8.4 Hz, NH), 6.80 (1H, d, J 16.2 Hz, 5-H), 7.29−7.37 (5H, m, Ph), 7.58 (1H, 
d, J 16.2 Hz, 6-H), 7.69 (2H, d, J 8.8 Hz, 2’-H and 6’-H), 8.26 (2H, d, J 8.8 Hz, 3’-H and 5’-H); δC (101 
MHz, CDCl3) 43.0 (CH2), 50.2 (CH), 53.0 (CH3), 67.3 (CH2), 124.4 (2 × CH), 128.2 (2 × CH), 128.4 (CH), 
128.7 (2 × CH), 128.9 (CH), 129.1 (2 × CH), 136.3 (C), 140.4 (C), 140.9 (CH), 149.0 (C), 156.2 (C), 171.5 
(C), 197.0 (C); m/z (CI) 413.1352 (MH+. C21H21N2O7 requires 413.1349), 383 (42%), 348 (38), 305 (30), 
275 (30), 257 (23), 137 (68), 91 (68), 69 (100). 
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Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-fluorophenyl)-4-oxohex-5-enoate (120) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(4-
fluorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (104) (0.367 g, 0.744 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 30% ethyl acetate in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-
fluorophenyl)-4-oxohex-5-enoate (120) (0.174 g, 57%) as a white solid. Mp 66–69 °C; Rf 0.20 (30% 
ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3333 (NH), 2951 (CH), 1685 (C=O), 1508 (C=C), 
1236, 1161, 981, 829, 698; [α]D27 +26.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.24 (1H, dd, J 17.9, 4.2 
Hz, 3-HH), 3.46 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.75 (3H, s, OCH3), 4.68 (1H, dt, J 8.5, 4.2 Hz, 2-H), 5.12 
(2H, s, OCH2Ph), 5.84 (1H, d, J 8.5 Hz, NH), 6.62 (1H, d, J 16.2 Hz, 5-H), 7.06–7.13 (2H, m, 3’-H and 
5’-H), 7.28–7.39 (5H, m, Ph), 7.49–7.58 (3H, m, 6-H, 2’-H and 6’-H); δC (101 MHz, CDCl3) 42.5 (CH2), 
50.2 (CH), 52.9 (CH3), 67.2 (CH2), 116.4 (d, JC-C-F 22.0 Hz, 2 × CH), 125.3 (CH), 128.2 (2 × CH), 128.3 
(CH), 128.7 (2 × CH), 130.5 (C), 130.5 (d, JC-C-C-F 8.5 Hz, 2 × CH), 136.4 (C), 142.9 (CH), 156.2 (C), 164.4 
(d, JC-F 252.6 Hz, C), 171.7 (C), 197.4 (C); m/z (ESI) 408.1201 (MNa+. C21H20FNNaO5 requires 
408.1218). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’-bromophenyl)-4-oxohex-5-enoate (121) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(2’-
bromophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (105) (0.223 g, 0.402 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 30% ethyl acetate in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’-
bromophenyl)-4-oxohex-5-enoate (121) (0.131 g, 73%) as a yellow oil. Rf 0.18 (30% ethyl acetate in 
petroleum ether); νmax/cm−1 (neat) 3338 (NH), 2960 (CH), 1687 (C=O), 1533 (C=C), 1286, 1087, 979, 
746; [α]D27 +22.1 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.30 (1H, dd, J 18.0, 4.1 Hz, 3-HH), 3.52 (1H, dd, 
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J 18.0, 4.1 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.71 (1H, dt, J 8.5, 4.1 Hz, 2-H), 5.12 (2H, s, OCH2Ph), 5.85 
(1H, d, J 8.5 Hz, NH), 6.62 (1H, d, J 16.3 Hz, 5-H), 7.23–7.38 (7H, m, 4’-H, 5’-H and Ph), 7.62 (2H, td, 
J 8.1, 0.9 Hz, 3’-H and 6’-H), 7.94 (1H, d, J 16.3 Hz, 6-H); δC (126 MHz, CDCl3) 42.4 (CH2), 50.2 (CH), 
52.9 (CH3), 67.2 (CH2), 126.0 (C), 127.9 (CH), 128.0 (CH), 128.2 (3 × CH), 128.3 (CH), 128.7 (2 × CH), 
131.9 (CH), 133.7 (CH), 134.2 (C), 136.4 (C), 142.6 (CH), 156.2 (C), 171.7 (C), 197.5 (C); m/z (ESI) 
468.0402 (MNa+. C21H2079BrNNaO5 requires 468.0417). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(3’’-nitrobiphen-4’-yl)-4-oxohex-5-enoate (122)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(3’’-
nitrobiphen-4’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (106) (0.324 g, 0.543 mmol). The crude 
product was purified via flash column chromatography on silica gel, eluting with 50% ethyl acetate 
in petroleum ether (40–60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(3’’-
nitrobiphen-4’-yl)-4-oxohex-5-enoate (122) (0.221 g, 84%) as a pale yellow solid. Mp 102−104 °C; 
Rf 0.50 (50% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3325 (NH), 2953 (CH), 1742 (C=O), 
1683 (C=O), 1664 (C=O), 1529 (C=C), 1342, 1179, 1057, 970, 802; [α]D27 +17.2 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 3.29 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.51 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.77 (3H, s, OCH3), 
4.71 (1H, dt, J 8.5, 4.2 Hz, 2-H), 5.13 (2H, s, OCH2Ph), 5.87 (1H, d, J 8.5 Hz, NH), 6.77 (1H, d, J 16.2 
Hz, 5-H), 7.28−7.39 (5H, m, Ph), 7.61 (1H, d, J 16.2 Hz, 6-H), 7.64−7.70 (5H, m, 2’-H, 3’-H, 5’-H, 6’-H 
and 5”-H), 7.94 (1H, ddd, J 7.8, 2.0, 1.0 Hz, 6”-H), 8.24 (1H, ddd, J 8.2, 2.0, 1.0 Hz, 4”-H), 8.48 (1H, t, 
J 2.0 Hz, 2”-H); δC (101 MHz, CDCl3) 42.6 (CH2), 50.2 (CH), 52.9 (CH3), 67.2 (CH2), 122.0 (CH), 122.8 
(CH), 126.2 (CH), 127.9 (2 × CH), 128.2 (2 × CH), 128.3 (CH), 128.7 (2 × CH), 129.4 (2 × CH), 130.1 
(CH), 133.0 (CH), 134.5 (C), 136.4 (C), 141.0 (C), 141.8 (C), 143.1 (CH), 149.0 (C), 156.2 (C), 171.7 (C), 
197.4 (C); m/z (CI) 489.1664 (MH+. C27H25N2O7 requires 489.1662), 459 (8%), 418 (10), 381 (42), 351 
(23), 338 (32), 310 (19), 275 (10), 181 (15), 147 (26), 91 (100). 
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Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-4-oxonon-5-enoate (123) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-2-
(tritylamino)-4-oxonon-5-enoate (108) (0.398 g, 0.902 mmol). The crude product was purified via 
flash column chromatography on silica gel, eluting with 30% ethyl acetate in petroleum ether (40–
60) to produce methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-4-oxonon-5-enoate (123) (0.201 g, 
67%) as a white solid. Mp 40–42 °C; Rf 0.29 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 
3352 (NH), 2958 (CH), 1723 (C=O), 1502 (C=C), 1209, 1060, 978, 736, 698; [α]D27 +23.7 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 0.94 (3H, t, J 7.4 Hz, 9-H3), 1.44–1.55 (2H, m, 8-H2), 2.20 (2H, qd, J 7.2, 1.4 Hz, 
7-H2), 3.11 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.34 (1H, dd, J 18.0, 4.2 Hz, 3-HH), 3.73 (3H, s, OCH3), 4.62 
(1H, dt, J 8.5, 4.2 Hz, 2-H), 5.11 (2H, s, OCH2Ph), 5.79 (1H, d, J 8.5 Hz, NH), 6.06 (1H, dt, J 15.8, 1.4 
Hz, 5-H), 6.86 (1H, dt, J 15.8, 7.2 Hz, 6-H), 7.28–7.39 (5H, m, Ph); δC (101 MHz, CDCl3) 13.8 (CH3), 
21.4 (CH2), 34.7 (CH2), 41.7 (CH2), 50.1 (CH), 52.8 (CH3), 67.2 (CH2), 128.2 (2 × CH), 128.3 (CH), 128.7 
(2 × CH), 130.1 (CH), 136.4 (C), 149.4 (CH), 156.2 (C), 171.8 (C), 197.8 (C); m/z (ESI) 356.1455 (MNa+. 
C18H23NNaO5 requires 356.1468). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’,4’-dimethoxyphenyl)-4-oxohex-5-enoate 
(161)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(2’,4’-
dimethoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (158) (0.550 g, 1.03 mmol). The crude 
product was purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate 
in petroleum ether (40–60) to give methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’,4’-
dimethoxyphenyl)-4-oxohex-5-enoate (161) (0.168 g, 70%) as a yellow oil. Rf 0.16 (40% ethyl 
acetate in petroleum ether); νmax/cm−1 (neat) 3362 (NH), 2949 (CH), 1722 (C=O), 1600 (C=C), 1504, 
1210, 1028, 698; [α]D26 +19.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.23 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 
3.47 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.73 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.67 
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(1H, dt, J 8.7, 4.2 Hz, 2-H), 5.11 (2H, s, OCH2Ph), 5.91 (1H, d, J 8.7 Hz, NH), 6.44 (1H, d, J 2.3 Hz, 3’-
H), 6.50 (1H, dd, J 8.6, 2.3 Hz, 5’-H), 6.66 (1H, d, J 16.4 Hz, 5-H), 7.27–7.39 (5H, m, Ph), 7.45 (1H, d, 
J 8.6 Hz, 6’-H), 7.84 (1H, d, J 16.4 Hz, 6-H); δC (101 MHz, CDCl3) 41.8 (CH2), 50.2 (CH), 52.6 (CH3), 55.5 
(CH3), 55.5 (CH3), 66.9 (CH2), 98.4 (CH), 105.6 (CH), 116.1 (C), 123.6 (CH), 128.0 (2 × CH), 128.1 (CH), 
128.5 (2 × CH), 130.3 (CH), 136.3 (C), 139.4 (CH), 156.1 (C), 160.1 (C), 163.4 (C), 171.8 (C), 197.8 (C); 
m/z (ESI) 450.1503 (MNa+. C23H25NNaO7 requires 450.1523). 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2H-1’,3’-benzodioxol-5’-yl)-4-oxohex-5-enoate 
(162)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(2H-1’,3’-
benzodioxol-5’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (159) (1.51 g, 2.91 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate in 
petroleum ether (40–60) to give methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2H-1’,3’-
benzodioxol-5’-yl)-4-oxohex-5-enoate (162) (0.972 g, 81%) as a yellow oil. Rf 0.20 (40% ethyl acetate 
in petroleum ether); νmax/cm−1 (neat) 3368 (NH), 2953 (CH), 1720 (C=O), 1502 (C=C), 1252, 980, 928, 
736, 698; [α]D26 +28.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.21 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.43 
(1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.74 (3H, s, OCH3), 4.67 (1H, dt, J 8.6, 4.2 Hz, 2-H), 5.11 (2H, s, OCH2Ph), 
5.88 (1H, d, J 8.6 Hz, NH), 6.01 (2H, s, 2’-H2), 6.52 (1H, d, J 16.1 Hz, 5-H), 6.81 (1H, d, J 8.1 Hz, 7’-H), 
6.99–7.05 (2H, m, 4’-H and 6’-H), 7.28–7.38 (5H, m, Ph), 7.46 (1H, d, J 16.1 Hz, 6-H); δC (101 MHz, 
CDCl3) 42.3 (CH2), 50.1 (CH), 52.7 (CH3), 67.0 (CH2), 101.7 (CH2), 106.6 (CH), 108.7 (CH), 123.5 (CH), 
125.3 (CH), 128.0 (2 × CH), 128.1 (CH), 128.5 (2 × CH), 128.5 (C), 136.3 (C), 143.9 (CH), 148.5 (C), 
150.2 (C), 156.1 (C), 171.7 (C), 197.2 (C); m/z (ESI) 434.1192 (MNa+. C22H21NNaO7 requires 
434.1210). 
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Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’,4’-dinitrophenyl)-4-oxohex-5-enoate (163)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) using methyl (2S,5E)-6-(2’,4’-
dinitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (160) (0.620 g, 1.10 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate in 
petroleum ether (40–60) to give methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(2’,4’-
dinitrophenyl)-4-oxohex-5-enoate (163) (0.293 g, 59%) as a brown solid. Mp 88–91 °C; Rf 0.15 (40% 
ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3382 (NH), 2955 (CH), 1719 (C=O), 1527 (C=C), 
1343, 1211, 835, 735; [α]D27 +19.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.34 (1H, dd, J 18.1, 4.3 Hz, 3-
HH), 3.49 (1H, dd, J 18.1, 4.3 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.74 (1H, dt, J 8.5, 4.3 Hz, 2-H), 5.10 (2H, 
s, OCH2Ph), 5.91 (1H, d, J 8.5 Hz, NH), 6.70 (1H, d, J 16.1 Hz, 5-H), 7.26–7.36 (5H, m, Ph), 7.85 (1H, 
d, J 8.6 Hz, 6’-H), 8.01 (1H, d, J 16.1 Hz, 6-H), 8.49 (1H, dd, J 8.6, 2.3 Hz, 5’-H), 8.89 (1H, d, J 2.3 Hz, 
3’-H); δC (126 MHz, CDCl3) 42.7 (CH2), 49.9 (CH), 52.9 (CH3), 67.0 (CH2), 120.7 (CH), 127.8 (CH), 128.0 
(2 × CH), 128.2 (CH), 128.5 (2 × CH), 130.7 (CH), 132.4 (CH), 136.1 (C), 136.4 (C), 136.9 (CH), 148.1 
(C), 148.2 (C), 156.0 (C), 171.3 (C), 196.5 (C); m/z (ESI) 480.0997 (MNa+. C21H19N3NaO9 requires 
480.1014). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124)  
 
 
 
To a solution of methyl (2S,5E)-4-oxo-6-phenyl-2-(tritylamino)hex-5-enoate (99) (0.214 g, 0.449 
mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (0.344 mL, 4.490 mmol). The 
reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated 
in vacuo, and then the residue was dissolved in water (10 mL) and washed with diethyl ether (2 × 
10 mL). The aqueous layer was concentrated in vacuo, azeotroping with ethyl acetate-chloroform 
to give the TFA salt. The resulting TFA salt was dissolved in dichloromethane (5 mL) and 
triethylamine (0.124 mL, 0.898 mmol) was added followed by di-tert-butyl dicarbonate (0.196 g, 
0.898 mmol). The reaction mixture was stirred at room temperature for 3 h before diluting with 
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water (10 mL). The mixture was then extracted with dichloromethane (3 × 10 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified via flash column chromatography on 
silica gel, eluting with 40% diethyl ether in petroleum ether (40–60) to produce methyl (2S,5E)-2-
(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) (0.097 g, 65%) as a colourless oil. Rf 
0.22 (40% diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 3368 (NH), 2979 (CH), 1747 (C=O), 
1713 (C=O), 1663 (C=C), 1496, 1367, 1168; [α]D17 +56.9 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.44 (9H, 
s, 3 × CH3), 3.33 (1H, dd, J 17.8, 4.3 Hz, 3-HH), 3.44 (1H, dd, J 17.8, 4.1 Hz, 3-HH), 3.75 (3H, s, OCH3), 
4.62 (1H, ddd, J 8.5, 4.3, 4.1 Hz, 2-H), 5.60 (1H, d, J 8.5 Hz, NH), 6.71 (1H, d, J 16.1 Hz, 5-H), 7.38–
7.42 (3H, m, 3 × ArH), 7.52–7.55 (2H, m, 2 × ArH), 7.57 (1H, d, J 16.1 Hz, 6-H); δC (100 MHz, CDCl3) 
28.3 (3 × CH3), 42.4 (CH2), 49.6 (CH), 52.6 (CH3), 79.9 (C), 125.6 (CH), 128.4 (2 × CH), 129.2 (2 × CH), 
130.9 (CH), 134.1 (C), 143.9 (CH), 155.6 (C), 172.0 (C), 197.6 (C); m/z (CI) 334.1653 (MH+. C18H24NO5 
requires 334.1654), 320 (4%), 278 (100), 234 (13). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-methoxyphenyl)-4-oxohex-5-enoate (125) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-(4’-
methoxyphenyl)-4-oxo-2-(tritylamino)hex-5-enoate (100) (0.132 g, 0.261 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 40% diethyl ether in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-
methoxyphenyl)-4-oxohex-5-enoate (125) (0.058 g, 62%) as a colourless oil. Rf 0.11 (40% diethyl 
ether in petroleum ether); νmax/cm−1 (neat) 3367 (NH), 2970 (CH), 1708 (C=O), 1597 (C=C), 1512, 
1249, 1112, 1026, 734; [α]D26 +42.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.44 (9H, s, 3 × CH3), 3.19 
(1H, dd, J 17.7, 4.2 Hz, 3-HH), 3.41 (1H, dd, J 17.7, 4.2 Hz, 3-HH), 3.74 (3H, s, OCH3), 3.84 (3H, s, 
OCH3), 4.60 (1H, dt, J 8.5, 4.2 Hz, 2-H), 5.59 (1H, d, J 8.5 Hz, NH), 6.59 (1H, d, J 16.2 Hz, 5-H), 6.89–
6.94 (2H, m, 3’-H and 5’-H), 7.46–7.56 (3H, m, 6-H, 2’-H and 6’-H); δC (101 MHz, CDCl3) 28.5 (3 × 
CH3), 42.4 (CH2), 49.9 (CH), 52.7 (CH3), 55.6 (CH3), 80.1 (C), 114.7 (2 × CH), 123.5 (CH), 127.0 (C), 
130.4 (2 × CH), 143.9 (CH), 155.7 (C), 162.1 (C), 172.2 (C), 197.7 (C); m/z (ESI) 386.1557 (MNa+. 
C19H25NNaO6 requires 386.1574). 
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Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(naphthalen-2’-yl)-4-oxohex-5-enoate (126) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-
(naphthalen-2’-yl)-4-oxo-2-(tritylamino)hex-5-enoate (101) (0.191 g, 0.363 mmol). The crude 
product was purified via flash column chromatography on silica gel, eluting with 40% diethyl ether 
in petroleum ether (40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-
(naphthalen-2’-yl)-4-oxohex-5-enoate (126) (0.088 g, 64%) as a white solid. Mp 73–75 °C; Rf 0.14 
(40% diethyl ether in petroleum ether); νmax/cm−1 (neat) 3475 (NH), 2951 (CH), 1724 (C=O), 1481, 
1367, 1155, 1091, 817, 750; [α]D26 +40.8 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.45 (9H, s, 3 × CH3), 
3.27 (1H, dd, J 17.7, 4.1 Hz, 3-HH), 3.49 (1H, dd, J 17.7, 4.1 Hz, 3-HH), 3.76 (3H, s, OCH3), 4.61–4.67 
(1H, m, 2-H), 5.61 (1H, d, J 8.5 Hz, NH), 6.82 (1H, d, J 16.2 Hz, 5-H), 7.50–7.57 (2H, m, 6’-H and 7’-
H), 7.67 (1H, dd, J 8.6, 1.5 Hz, 3’-H), 7.73 (1H, d, J 16.2 Hz, 6-H), 7.82–7.90 (3H, m, 4’-H, 5’-H and 8’-
H), 7.96 (1H, br s, 1’-H); δC (126 MHz, CDCl3) 28.5 (3 × CH3), 42.7 (CH2), 49.9 (CH), 52.8 (CH3), 80.2 
(C), 123.6 (CH), 125.9 (CH), 127.0 (CH), 127.7 (CH), 128.0 (CH), 128.8 (CH), 129.0 (CH), 130.9 (CH), 
131.8 (C), 133.5 (C), 134.7 (C), 144.2 (CH), 155.8 (C), 172.2 (C), 197.7 (C); m/z (ESI) 406.1609 (MNa+. 
C22H25NNaO5 requires 406.1625). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-nitrophenyl)-4-oxohex-5-enoate (127) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-(4’-
nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (102) (0.152 g, 0.292 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 60% diethyl ether in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-
nitrophenyl)-4-oxohex-5-enoate (127) (0.087 g, 79%) as an pale yellow oil. Rf 0.23 (60% diethyl 
ether in petroleum ether); νmax/cm−1 (neat) 3365 (NH), 2953 (CH), 1705 (C=O), 1518 (C=C), 1342, 
1161, 862, 744; [α]D26 +36.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.44 (9H, s, 3 × CH3), 3.27 (1H, dd, J 
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17.9, 4.2 Hz, 3-HH), 3.44 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.75 (3H, s, OCH3), 4.63 (1H, dt, J 8.3, 4.2 Hz, 
2-H), 5.55 (1H, d, J 8.3 Hz, NH), 6.81 (1H, d, J 16.3 Hz, 5-H), 7.58 (1H, d, J 16.3 Hz, 6-H), 7.69 (2H, d, 
J 8.8 Hz, 2’-H and 6’-H), 8.26 (2H, d, J 8.8 Hz, 3’-H and 5’-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 43.1 
(CH2), 49.6 (CH), 52.7 (CH3), 80.2 (C), 124.3 (2 × CH), 128.9 (CH), 129.0 (2 × CH), 140.3 (C), 140.6 
(CH), 148.8 (C), 155.5 (C), 171.8 (C), 197.1 (C); m/z (ESI) 401.1305 (MNa+. C18H22N2NaO7 requires 
401.1319). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-fluoro-3’-nitrophenyl)-4-oxohex-5-enoate 
(128) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-(4’-fluoro-
3’-nitrophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (103) (0.272 g, 0.505 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 60% diethyl ether in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-fluoro-3’-
nitrophenyl)-4-oxohex-5-enoate (128) (0.165 g, 82%) as a yellow solid. Mp 90–93 °C; Rf 0.18 (60% 
diethyl ether in petroleum ether); νmax/cm−1 (neat) 3367 (NH), 2989 (CH), 1739 (C=O), 1533 (C=C), 
1153, 989, 825; [α]D26 +37.5 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.44 (9H, s, 3 × CH3), 3.24 (1H, dd, J 
17.9, 4.2 Hz, 3-HH), 3.42 (1H, dd, J 17.9, 4.2 Hz, 3-HH), 3.75 (3H, s, OCH3), 4.62 (1H, dt, J 8.3, 4.2 Hz, 
2-H), 5.54 (1H, d, J 8.3 Hz, NH), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.35 (1H, dd, J 10.1, 8.7 Hz, 5’-H), 7.52 
(1H, d, J 16.2 Hz, 6-H), 7.79 (1H, ddd, J 8.7, 4.0, 2.2 Hz, 6’-H), 8.24 (1H, dd, J 7.0, 2.2 Hz, 2’-H); δC 
(126 MHz, CDCl3) 28.5 (3 × CH3), 43.3 (CH2), 49.8 (CH), 52.9 (CH3), 80.3 (C), 119.5 (d, JC-C-F 21.5 Hz, 
CH), 125.7 (d, JC-C-C-F 2.1 Hz, CH), 127.9 (CH), 131.6 (d, JC-C-F 4.4 Hz, C), 134.8 (d, JC-C-C-F 8.9 Hz, CH), 
138.0 (C), 139.6 (CH), 155.7 (C), 156.5 (d, JC-F 270.0 Hz, C), 171.9 (C), 197.0 (C); m/z (CI) 397.1412 
(MH+. C18H22FN2O7 requires 397.1411), 367 (4%), 340 (100), 311 (13), 296 (14), 267 (5), 157 (3), 71 
(13). 
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Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-fluorophenyl)-4-oxohex-5-enoate (129) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-(4-
fluorophenyl)-4-oxo-2-(tritylamino)hex-5-enoate (104) (0.107 g, 0.217 mmol). The crude product 
was purified via flash column chromatography on silica gel, eluting with 40% diethyl ether in 
petroleum ether (40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(4’-
fluorophenyl)-4-oxohex-5-enoate (129) (0.047 g, 64%) as a pale yellow oil. Rf 0.15 (40% diethyl ether 
in petroleum ether); νmax/cm−1 (neat) 3362 (NH), 2970 (CH), 1708 (C=O), 1508 (C=C), 1365, 1230, 
1159, 817, 736; [α]D26 +41.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.44 (9H, s, 3 × CH3), 3.22 (1H, dd, J 
17.8, 4.1 Hz, 3-HH), 3.42 (1H, dd, J 17.8, 4.1 Hz, 3-HH), 3.74 (3H, s, OCH3), 4.56–4.66 (1H, m, 2-H), 
5.57 (1H, d, J 8.5 Hz, NH), 6.63 (1H, d, J 16.3 Hz, 5-H), 7.05–7.15 (2H, m, 3’-H and 5’-H), 7.48–7.61 
(3H, m, 6-H, 2’-H and 6’-H); δC (126 MHz, CDCl3) 28.3 (3 × CH3), 42.5 (CH2), 49.7 (CH), 52.6 (CH3), 
80.0 (C), 116.2 (d, JC-C-F 22.0 Hz, 2 × CH), 125.3 (CH), 130.4 (d, JC-C-C-F 8.5 Hz, 2 × CH), 137.8 (C), 142.6 
(CH), 155.6 (C), 164.2 (d, JC-F 252.5 Hz, C), 171.9 (C), 197.4 (C); m/z (ESI) 374.1361 (MNa+. 
C18H22FNNaO5 requires 374.1374). 
 
Methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(furan-2-yl)-4-oxohex-5-enoate (130) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S,5E)-
2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-enoate (124) using methyl (2S,5E)-6-(furan-2-
yl)-4-oxo-2-(tritylamino)hex-5-enoate (107) (0.136 g, 0.292 mmol). The crude product was purified 
via flash column chromatography on silica gel, eluting with 50% diethyl ether in petroleum ether 
(40–60) to produce methyl (2S,5E)-2-(tert-butoxycarbonylamino)-6-(furan-2-yl)-4-oxohex-5-enoate 
(130) (0.040 g, 43%) as a yellow oil. Rf 0.23 (50% diethyl ether in petroleum ether); νmax/cm−1 (NaCl) 
3362 (NH), 2978 (CH), 1747 (C=O), 1709 (C=O), 1609 (C=O), 1495 (C=C); [α]D24 +48.6 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 1.44 (9H, s, 3 × CH3), 3.16 (1H, dd, J 18.0, 4.4 Hz, 3-HH), 3.37 (1H, dd, J 18.0, 4.4 
Hz, 3-HH), 3.74 (3H, s, OCH3), 4.59 (1H, m, 2-H), 5.58 (1H, d, J 8.8 Hz, NH), 6.50 (1H, dd, J 3.6, 1.6 Hz, 
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4’-H), 6.60 (1H, d, J 16.0 Hz, 5-H, 6.69 (1H, d, J 3.6 Hz, 3’-H), 7.32 (1H, d, J 16.0 Hz, 6-H), 7.51 (1H, d, 
J 1.6 Hz, 5’-H); δC (101 MHz, CDCl3) 28.3 (3 × CH3), 42.8 (CH2), 49.6 (CH), 52.6 (CH3), 78.0 (C), 112.7 
(CH), 116.5 (CH), 122.7 (CH), 126.7 (CH), 145.4 (CH), 150.7 (C), 155.6 (C), 172.0 (C), 197.2 (C); m/z 
(ESI) 323.1349 (MNa+. C16H21NNaO6 requires 323.1363). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) 
 
 
 
To a solution of methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (116) 
(0.186 g, 0.506 mmol) in ethyl vinyl ether (5 mL) was added tris(6,6,7,7,8,8,8-heptafluoro-2,2-
dimethyl-3,5-octanedionato)ytterbium (0.0269 g, 0.0253 mmol) and the sealed tube purged with 
argon. The reaction mixture was stirred at 110 °C for 96 h. The mixture was then allowed to cool to 
room temperature and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) to produce 
dihydropyran intermediate 133 (0.208 g, 93%). Intermediate 133 (0.208 g, 0.476 mmol) was then 
treated with hydroxylamine hydrochloride (0.166 g, 2.38 mmol) in acetonitrile (5 mL) at 70 °C for 
16 h. The crude product was purified via flash column chromatography on neutral alumina 
(Brockmann V grade), eluting with 1% methanol in dichloromethane to produce methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) (0.132 g, 71%) as a yellow 
oil. Rf 0.79 (1% methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3345 (NH), 2951 (CH), 
1718 (C=O), 1506 (C=C), 1212, 1060, 763, 697; [α]D22 +27.6 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 3.36 
(1H, dd, J 14.9, 5.2 Hz, 3-HH), 3.44 (1H, dd, J 14.9, 5.2 Hz, 3-HH), 3.70 (3H, s, OCH3), 4.81 (1H, dt, J 
8.3, 5.2 Hz, 2-H), 5.10 (1H, d, J 12.4 Hz, OCHHPh), 5.13 (1H, d, J 12.4 Hz, OCHHPh), 6.35 (1H, d, J 8.3 
Hz, NH), 7.29–7.37 (7H, m, 3’-H, 5’-H and Ph), 7.42–7.50 (3H, m, 3 × ArH), 7.56–7.63 (2H, m, 2 × 
ArH), 8.51 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 39.2 (CH2), 52.5 (CH3), 53.6 (CH), 67.0 (CH2), 
120.1 (CH), 121.8 (CH), 127.1 (2 × CH), 128.2 (3 × CH), 128.6 (2 × CH), 129.2 (2 × CH), 129.3 (CH), 
136.6 (C), 138.1 (C), 149.3 (C), 149.7 (CH), 156.2 (C), 157.6 (C), 172.2 (C); m/z (ESI) 413.1461 (MNa+. 
C23H22N2NaO4 requires 413.1472). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoate 
(143) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(4’-methoxyphenyl)-4-oxohex-5-enoate (117) (0.602 g, 1.515 mmol) 
for 168 h. The crude product was purified via flash column chromatography on silica gel, eluting 
with 30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 134 
(0.590 g, 83%). Intermediate 134 (0.590 g, 1.26 mmol) was then treated with hydroxylamine 
hydrochloride (0.438 g, 6.30 mmol) in acetonitrile (12 mL) at 70 °C for 16 h. The crude product was 
purified via flash column chromatography on neutral alumina (Brockmann V grade), eluting with 
1% methanol in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-
methoxyphenyl)pyridin-2’-yl]propanoate (143) (0.254 g, 48%) as a yellow oil. Rf 0.81 (1% methanol 
in dichloromethane on alumina); νmax/cm−1 (neat) 3340 (NH), 2953 (CH), 1718 (C=O), 1602, 1516 
(C=C), 1250, 1179, 1026, 825, 698; [α]D25 +23.0 (c 0.8, CHCl3); δH (500 MHz, CDCl3) 3.33 (1H, dd, J 
14.9, 5.2 Hz, 3-HH), 3.42 (1H, dd, J 14.9, 5.2 Hz, 3-HH), 3.70 (3H, s, OCH3), 3.86 (3H, s, OCH3), 4.80 
(1H, dt, J 8.2, 5.2 Hz, 2-H), 5.09 (1H, d, J 12.3 Hz, OCHHPh), 5.13 (1H, d, J 12.3 Hz, OCHHPh), 6.36 
(1H, d, J 8.2 Hz, NH), 6.97–7.01 (2H, m, 3’’-H and 5’’-H), 7.29–7.35 (7H, m, 3’-H, 5’-H and Ph), 7.55 
(2H, d, J 8.7 Hz, 2’’-H and 6’’-H), 8.47 (1H, d, J 5.2 Hz, 6’-H); δC (126 MHz, CDCl3) 39.2 (CH2), 52.5 
(CH3), 53.6 (CH), 55.6 (CH3), 67.0 (CH2), 114.7 (2 × CH2), 119.6 (CH), 121.2 (CH), 128.2 (3 × CH), 128.3 
(2 × CH), 128.6 (2 × CH), 130.4 (C), 136.6 (C), 148.8 (C), 149.6 (CH), 156.3 (C), 157.5 (C), 160.8 (C), 
172.3 (C); m/z (ESI) 443.1556 (MNa+. C24H24N2NaO5 requires 443.1577). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(naphthalen-2’’-yl)pyridin-2’-yl]propanoate 
(144) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(naphthalen-2’-yl)-4-oxohex-5-enoate (118) (0.110 g, 0.264 mmol) 
for 72 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
40% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 135 (0.129 g, 
83%). Intermediate 135 (0.129 g, 0.264 mmol) was then treated with hydroxylamine hydrochloride 
(0.0917 g, 1.32 mmol) in acetonitrile (3 mL) at 70 °C for 16 h. The crude product was purified via 
flash column chromatography on neutral alumina (Brockmann V grade), eluting with 1% methanol 
in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(naphthalen-2’’-
yl)pyridin-2’-yl]propanoate (144) (0.056 g, 48%) as a yellow solid. Mp 56–60 °C; Rf 0.84 (1% 
methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3345 (NH), 3054 (CH), 2951 (CH), 1716 
(C=O), 1597 (C=C), 1503, 1437, 1210, 1056, 1028; [α]D25 +26.1 (c 0.9, CHCl3); δH (500 MHz, CDCl3) 
3.39 (1H, dd, J 15.0, 5.2 Hz, 3-HH), 3.48 (1H, dd, J 15.0, 5.2 Hz, 3-HH), 3.71 (3H, s, OCH3), 4.84 (1H, 
dt, J 8.4, 5.2 Hz, 2-H), 5.10 (1H, d, J 12.4 Hz, OCHHPh), 5.13 (1H, d, J 12.4 Hz, OCHHPh), 6.37 (1H, d, 
J 8.4 Hz, NH), 7.27–7.37 (5H, m, Ph), 7.45–7.49 (2H, m, 3’-H and 5’-H), 7.52–7.56 (2H, m, 2 × ArH), 
7.70 (1H, dd, J 8.6, 1.5 Hz, 3’’-H), 7.86–7.92 (2H, m, 2 × ArH), 7.94 (1H, d, J 8.6 Hz, 4’’-H), 8.07 (1H, 
br s, 1’’-H), 8.55 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 39.3 (CH2), 52.6 (CH3), 53.6 (CH), 67.1 
(CH2), 120.3 (CH), 121.9 (CH), 124.7 (CH), 126.6 (CH), 126.9 (CH), 127.0 (CH), 127.9 (CH), 128.2 (3 × 
CH), 128.6 (CH), 128.6 (2 × CH), 129.1 (CH), 133.6 (C), 133.6 (C), 135.4 (C), 136.5 (C), 149.2 (C), 149.8 
(CH), 156.3 (C), 157.7 (C), 172.3 (C); m/z (EI) 440.1738 (M+. C27H24N2O4 requires 440.1736), 381 
(17%), 332 (45), 305 (43), 273 (76), 245 (96), 219 (100). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{4’-[4’’-(dimethylamino)naphthalen-1’’-yl]pyridin-
2’-yl}propanoate (145) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-[4’-(dimethylamino)naphthalen-1’-yl]-4-oxohex-5-enoate (119) 
(0.0419 g, 0.0910 mmol) for 168 h. The crude product was purified via flash column 
chromatography on silica gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce 
dihydropyran intermediate 136 (0.048 g, 89%). Intermediate 136 (0.0480 g, 0.0901 mmol) was then 
treated with hydroxylamine hydrochloride (0.0313 g, 0.451 mmol) in acetonitrile (2 mL) at 70 °C for 
16 h. The crude product was purified via flash column chromatography on neutral alumina 
(Brockmann V grade), eluting with 1% methanol in dichloromethane to produce methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-{4’-[4’’-(dimethylamino)naphthalen-1’’-yl]pyridin-2’-yl}propanoate 
(145) (0.0118 g, 27%) as a yellow oil. Rf 0.82 (1% methanol in dichloromethane on alumina); 
νmax/cm−1 (neat) 3349 (NH), 2947 (CH), 1722 (C=O), 1580 (C=C), 1208, 1048, 771; [α]D24 +10.5 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 2.94 (6H, s, NMe3), 3.35 (1H, dd, J 14.9, 5.1 Hz, 3-HH), 3.44 (1H, dd, J 
14.9, 5.1 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.82 (1H, dt, J 8.4, 5.1 Hz, 2-H), 5.10 (1H, d, J 12.6 Hz, 
OCHHPh), 5.14 (1H, d, J 12.6 Hz, OCHHPh), 6.40 (1H, d, J 8.4 Hz, NH), 7.10 (1H, d, J 7.7 Hz, 2’’-H), 
7.23–7.38 (8H, m, 3’-H, 5’-H, 3’’-H and Ph), 7.40–7.46 (1H, m, ArH), 7.51 (1H, ddd, J 8.4, 6.8, 0.9 Hz, 
ArH), 7.79 (1H, d, J 8.4 Hz, ArH), 8.31 (1H, dd, J 8.4, 0.9 Hz, ArH), 8.56 (1H, d, J 5.0 Hz, 6’-H); δC (101 
MHz, CDCl3) 39.0 (CH2), 45.1 (2 × CH3), 52.4 (CH3), 53.5 (CH), 66.9 (CH2), 113.4 (CH), 123.5 (CH), 
124.8 (CH), 125.1 (CH), 125.4 (CH), 125.6 (CH), 126.5 (CH), 127.0 (CH), 128.1 (CH), 128.1 (2 × CH), 
128.5 (2 × CH), 128.8 (C), 131.7 (C), 132.0 (C), 136.4 (C), 149.1 (CH), 149.8 (C), 151.7 (C), 156.1 (C), 
156.9 (C), 172.2 (C); m/z (ESI) 484.2211 (MH+. C29H30N3O4 requires 484.2231). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-nitrophenyl)pyridin-2’-yl]propanoate (146) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(4’-nitrophenyl)-4-oxohex-5-enoate (90) (0.104 g, 0.252 mmol) for 
96 h. The crude product was purified via flash column chromatography on silica gel, eluting with 
30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 137 (0.097 g, 
79%). Intermediate 137 (0.0968 g, 0.199 mmol) was then treated with hydroxylamine hydrochloride 
(0.0691 g, 0.995 mmol) in acetonitrile (2 mL) at 70 °C for 16 h. The crude product was purified via 
flash column chromatography on neutral alumina (Brockmann V grade), eluting with 1% methanol 
in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-
nitrophenyl)pyridin-2’-yl]propanoate (146) (0.035 g, 40%) as a yellow solid. Mp 79–82 °C; Rf 0.79 
(1% methanol in dichloromethane on neutral alumina); νmax/cm−1 (neat) 3349 (NH), 2952 (CH), 1718 
(C=O), 1595 (C=C), 1346 (CH), 1265, 1211, 1175, 1108, 1051; [α]D25 +25.7 (c 1.0, CHCl3); δH (500 MHz, 
CDCl3) 3.40 (1H, dd, J 15.1, 5.1 Hz, 3-HH), 3.48 (1H, dd, J 15.1, 5.1 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.84 
(1H, dt, J 8.4, 5.1 Hz, 2-H), 5.09 (1H, d, J 12.3 Hz, OCHHPh), 5.13 (1H, d, J 12.3 Hz, OCHHPh), 6.21 
(1H, d, J 8.4 Hz, NH), 7.28–7.39 (7H, m, 3’-H, 5’-H and Ph), 7.74 (2H, d, J 8.7 Hz, 2’’-H and 6’’-H), 8.33 
(2H, d, J 8.7 Hz, 3’’-H and 5’’-H), 8.59 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 39.2 (CH2), 52.5 
(CH3), 53.3 (CH), 67.0 (CH2), 120.0 (CH), 121.8 (CH), 124.4 (2 × CH), 128.1 (2 × CH), 128.1 (2 × CH), 
128.2 (CH), 128.5 (2 × CH), 136.3 (C), 144.4 (C), 146.7 (C), 148.3 (C), 150.0 (CH), 156.0 (C), 158.2 (C), 
172.0 (C); m/z (ESI) 434.1347 ([M−H]−. C23H20N3O6 requires 434.1358). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-fluorophenyl)pyridin-2’-yl]propanoate (147) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-4-oxo-6-phenylhex-5-enoate (120) (0.126 g, 0.310 mmol) for 96 h. The 
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crude product was purified via flash column chromatography on silica gel, eluting with 30% ethyl 
acetate in petroleum ether (40–60) to produce dihydropyran intermediate 138 (0.098 g, 70%). 
Intermediate 138 (0.0872 g, 0.191 mmol) was then treated with hydroxylamine hydrochloride 
(0.0616 g, 0.955 mmol) in acetonitrile (2 mL) at 70 °C for 16 h. The crude product was purified via 
flash column chromatography on neutral alumina (Brockmann V grade), eluting with 1% methanol 
in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-
fluorophenyl)pyridin-2’-yl]propanoate (147) (0.047 g, 60%) as a white solid. Mp 48–52 °C; Rf 0.79 
(1% methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3345 (NH), 2952 (CH), 1718 (C=O), 
1605 (C=C), 1513, 1222, 1058, 827, 698; [α]D22 +25.5 (c 0.6, CHCl3); δH (500 MHz, CDCl3) 3.35 (1H, 
dd, J 15.0, 5.2 Hz, 3-HH), 3.44 (1H, dd, J 15.0, 5.2 Hz, 3-HH), 3.70 (3H, s, OCH3), 4.81 (1H, dt, J 8.3, 
5.2 Hz, 2-H), 5.09 (1H, d, J 12.3 Hz, OCHHPh), 5.13 (1H, d, J 12.3 Hz, OCHHPh), 6.31 (1H, d, J 8.3 Hz, 
NH), 7.13–7.19 (2H, m 3’’-H and 5’’-H), 7.28–7.36 (7H, m, 3’-H, 5’-H and Ph), 7.53–7.60 (2H, m, 2’’-
H and 6’’-H), 8.51 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 39.2 (CH2), 52.5 (CH3), 53.5 (CH), 67.1 
(CH2), 116.3 (d, JC-C-F 21.8 Hz, 2 × CH), 120.0 (CH), 121.6 (CH), 128.2 (3 × CH), 128.6 (2 × CH), 128.9 
(d, JC-C-C-F 8.3 Hz, 2 × CH), 134.3 (d, JC-C-C-C-F 3.2 Hz, C), 136.5 (C), 148.2 (C), 149.8 (CH), 156.2 (C), 157.8 
(C), 163.62 (d, JC-F 249.4 Hz, C), 172.2 (C); m/z (ESI) 431.1364 (MNa+. C23H21FN2NaO4 requires 
431.1378). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{4’-[4’’-(3’’’-nitrophenyl)phenyl]pyridin-2’-
yl}propanoate (148) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(3’’-nitrobiphen-4’-yl)-4-oxohex-5-enoate (122) (0.103 g, 0.211 
mmol) for 96 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 
139 (0.095 g, 86%). Intermediate 139 (0.100 g, 0.191 mmol) was then treated with hydroxylamine 
hydrochloride (0.0664 g, 0.955 mmol) in acetonitrile (2 mL) at 70 °C for 16 h. The crude product was 
purified via flash column chromatography on neutral alumina (Brockmann V grade), eluting with 
1% methanol in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{4’-[4’’-
(3’’’-nitrophenyl)phenyl]pyridin-2’-yl}propanoate (148) (0.035 g, 36%) as an off-white solid. Mp 48–
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50 °C; Rf 0.70 (1% methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3339 (NH), 2951 (CH), 
1718 (C=O), 1601 (C=C), 1518, 1349, 1212, 1061, 730; [α]D24 +22.1 (c 0.6, CHCl3); δH (500 MHz, CDCl3) 
3.38 (1H, dd, J 14.9, 5.2 Hz, 3-HH), 3.47 (1H, dd, J 14.9, 5.2 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.83 (1H, 
dt, J 8.3, 5.2 Hz, 2-H), 5.10 (1H, d, J 12.3 Hz, OCHHPh), 5.13 (1H, d, J 12.3 Hz, OCHHPh), 6.34 (1H, d, 
J 8.3 Hz, NH), 7.27–7.36 (5H, m, Ph), 7.37–7.43 (2H, m, 3’-H and 5’-H), 7.65 (1H, t, J 8.0 Hz, 5’’’-H), 
7.71–7.78 (4H, m, 2’’-H, 3’’-H, 5’’-H and 6’’-H), 7.96 (1H, ddd, J 8.0, 1.9, 1.0 Hz, 6’’’-H), 8.24 (1H, ddd, 
J 8.0, 1.9, 1.0 Hz, 4’’’-H), 8.49–8.51 (1H, m, 2’’’-H), 8.55 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 
39.2 (CH2), 52.6 (CH3), 53.5 (CH), 67.0 (CH2), 120.0 (CH), 121.6 (CH), 122.0 (CH), 122.6 (CH), 127.9 (2 
× CH), 128.0 (2 × CH), 128.2 (2 × CH), 128.2 (2 × CH), 128.6 (CH), 130.0 (CH), 133.0 (CH), 136.5 (C), 
138.2 (C), 139.5 (C), 142.0 (C), 148.2 (C), 149.0 (CH), 149.9 (C), 156.2 (C), 157.8 (C), 172.2 (C); m/z 
(EI) 511.1717 (M+. C29H25N3O6 requires 511.1743), 452 (18%), 376 (25), 344 (45), 279 (100), 108 (71), 
79 (62). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(4’-propylpyridin-2’-yl]propanoate (149) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-4-oxonon-5-enoate (123) (0.103 g, 0.309 mmol) for 96 h. The crude 
product was purified via flash column chromatography on silica gel, eluting with 20% ethyl acetate 
in petroleum ether (40–60) to produce dihydropyran intermediate 140 (0.108 g, 86%). Intermediate 
140 (0.107 g, 0.264 mmol) was then treated with hydroxylamine hydrochloride (0.0917 g, 1.32 
mmol) in acetonitrile (3 mL) at 70 °C for 16 h. The crude product was purified via flash column 
chromatography on neutral alumina (Brockmann V grade), eluting with 1% methanol in 
dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(4’-propylpyridin-2’-
yl]propanoate (149) (0.054 g, 58%) as a pale yellow oil. Rf 0.85 (1% methanol in dichloromethane 
on alumina); νmax/cm−1 (neat) 3343 (NH), 2958 (CH), 1720 (C=O), 1605 (C=C), 1506, 1209, 1055, 737, 
697; [α]D22 +18.0 (c 0.7, CHCl3); δH (500 MHz, CDCl3) 0.92 (3H, t, J 7.3 Hz, 3’’-H), 1.57–1.67 (2H, m, 
2’’-H), 2.49–2.56 (2H, m, 1’’-H), 3.23 (1H, dd, J 14.8, 5.2 Hz, 3-HH), 3.32 (1H, dd, J 14.8, 5.2 Hz, 3-
HH), 3.67 (3H, s, OCH3), 4.74 (1H, dt, J 8.2, 5.2 Hz, 2-H), 5.08 (1H, d, J 12.4 Hz, OCHHPh), 5.12 (1H, 
d, J 12.4 Hz, OCHHPh), 6.38 (1H, d, J 8.2 Hz, NH), 6.91–6.97 (2H, m, 3’-H and 5’-H), 7.28–7.37 (5H, 
m, Ph), 8.33 (1H, d, J 5.0 Hz, 6’-H); δC (126 MHz, CDCl3) 13.8 (CH3), 23.5 (CH2), 37.3 (CH2), 38.9 (CH2), 
52.4 (CH3), 53.6 (CH), 66.9 (CH2), 122.3 (CH), 124.0 (CH), 128.2 (2 × CH), 128.2 (CH), 128.6 (2 × CH), 
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136.6 (C), 149.1 (CH), 152.3 (C), 156.2 (C), 156.9 (C), 172.2 (C); m/z (EI) 356.1729 (M+. C20H24N2O4 
requires 356.1736), 297 (36%), 207 (21), 189 (48), 135 (95), 91 (100). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-dimethoxyphenyl)pyridin-2’-
yl]propanoate (167) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(2’,4’-dimethoxyphenyl)-4-oxohex-5-enoate (161) (0.140 g, 0.327 
mmol) for 192 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 
164 (0.135 g, 83%). Intermediate 164 (0.135 g, 0.270 mmol) was then treated with hydroxylamine 
hydrochloride (0.0938 g, 1.35 mmol) in acetonitrile (5 mL) at 70 °C for 16 h. The crude product was 
purified via flash column chromatography on neutral alumina (Brockmann V grade), eluting with 
1% methanol in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-
(2’’,4’’-dimethoxyphenyl)pyridin-2’-yl]propanoate (167) (0.069 g, 57%) as a pale yellow oil. Rf 0.78 
(1% methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3342 (NH), 2951 (CH), 1718 (C=O), 
1508 (C=C), 1207, 1028, 736, 698; [α]D27 +22.9 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.30 (1H, dd, J 
14.8, 5.2 Hz, 3-HH), 3.40 (1H, dd, J 14.8, 5.2 Hz, 3-HH), 3.70 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.85 
(3H, s, OCH3), 4.77 (1H, dt, J 8.2, 5.2 Hz, 2-H), 5.09 (1H, d, J 12.6 Hz, OCHHPh), 5.12 (1H, d, J 12.6 Hz, 
OCHHPh), 6.39 (1H, d, J 8.2 Hz, NH), 6.52–6.60 (2H, m, 3’’-H and 5’’-H), 7.22–7.38 (8H, m, 3’-H, 5’-
H, 6’’-H and Ph), 8.44 (1H, d, J 5.2 Hz, 6’-H); δC (126 MHz, CDCl3) 39.0 (CH2), 52.3 (CH3), 53.5 (CH), 
55.5 (CH3), 55.5 (CH3), 66.9 (CH2), 99.1 (CH), 105.0 (CH), 120.3 (C), 122.4 (CH), 124.0 (CH), 128.0 
(CH), 128.1 (2 × CH), 128.5 (2 × CH), 131.1 (CH), 136.4 (C), 146.8 (C), 148.8 (CH), 156.1 (C), 156.4 (C), 
157.7 (C), 161.5 (C), 172.2 (C); m/z (ESI) 451.1846 (MH+. C25H27N2O6 requires 451.1840). 
 
152 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-
yl]propanoate (168) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(2H-1’,3’-benzodioxol-5’-yl)-4-oxohex-5-enoate (162) (0.972 g, 2.36 
mmol) for 168 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 
165 (0.990 g, 87%). Intermediate 165 (0.990 g, 2.05 mmol) was then treated with hydroxylamine 
hydrochloride (0.711 g, 10.2 mmol) in acetonitrile (20 mL) at 70 °C for 16 h. The crude product was 
purified via flash column chromatography on neutral alumina (Brockmann V grade), eluting with 
1% methanol in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2H-
1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoate (168) (0.530 g, 59%) as an orange oil. Rf 0.80 (1% 
methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3358 (NH), 2953 (CH), 1720 (C=O), 1506 
(C=C), 1475, 1236, 1039, 808; [α]D27 +28.0 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 3.35 (1H, dd, J 15.0, 
5.1 Hz, 3-HH), 3.44 (1H, dd, J 15.0, 5.1 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.82 (1H, dt, J 8.2, 5.1 Hz, 2-H), 
5.11 (1H, d, J 12.5 Hz, OCHHPh), 5.15 (1H, d, J 12.5 Hz, OCHHPh), 6.05 (2H, s, 2’’-H2), 6.35 (1H, d, J 
8.2 Hz, NH), 6.92 (1H, d, J 8.0 Hz, 7’’-H), 7.07–7.15 (2H, m, 4’’-H and 6’’-H), 7.26–7.40 (7H, m, 3’-H, 
5’-H and Ph), 8.49 (1H, d, J 5.2 Hz, 6’-H); δC (101 MHz, CDCl3) 39.1 (CH2), 52.4 (CH3), 53.4 (CH), 66.9 
(CH2), 101.5 (CH2), 107.2 (CH), 108.9 (CH), 119.6 (CH), 121.0 (CH), 121.2 (CH), 128.1 (3 × CH), 128.5 
(2 × CH), 132.1 (C), 136.4 (C), 148.5 (C), 148.6 (C), 148.7 (C), 149.5 (CH), 156.1 (C), 157.4 (C), 172.1 
(C); m/z (ESI) 457.1355 (MNa+. C24H22N2NaO6 requires 457.1370). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoate 
(169) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) using methyl (2S,5E)-2-
[(benzyloxycarbonyl)amino]-6-(2’,4’-dinitrophenyl)-4-oxohex-5-enoate (163) (0.198 g, 0.432 mmol) 
for 168 h. The crude product was purified via flash column chromatography on silica gel, eluting 
with 30% ethyl acetate in petroleum ether (40–60) to produce dihydropyran intermediate 166 
(0.193 g, 84%). Intermediate 166 (0.193 g, 0.365 mmol) was then treated with hydroxylamine 
hydrochloride (0.127 g, 1.83 mmol) in acetonitrile (5 mL) at 70 °C for 16 h. The crude product was 
purified via flash column chromatography on neutral alumina (Brockmann V grade), eluting with 
1% methanol in dichloromethane to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-
(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoate (169) (0.068 g, 38%) as an orange oil. Rf 0.87 (1% 
methanol in dichloromethane on alumina); νmax/cm−1 (neat) 3363 (NH), 2953 (CH), 1720 (C=O), 1531 
(C=C), 1346, 1211, 1055, 833, 740; [α]D27 +19.5 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.38 (1H, dd, J 
15.1, 5.2 Hz, 3-HH), 3.45 (1H, dd, J 15.1, 5.2 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.79–4.86 (1H, m, 2-H), 
5.10 (1H, d, J 12.3 Hz, OCHHPh), 5.13 (1H, d, J 12.3 Hz, OCHHPh), 6.16 (1H, d, J 8.3 Hz, NH), 7.07–
7.11 (2H, m, 3’-H and 5’-H), 7.27–7.39 (5H, m, Ph), 7.59 (1H, d, J 8.4 Hz, 6’’-H), 8.50 (1H, dd, J 8.4, 
2.1 Hz, 5’’-H), 8.60 (1H, d, J 5.7 Hz, 6’-H), 8.83 (1H, d, J 2.1 Hz, 3’’-H); δC (126 MHz, CDCl3) 39.2 (CH2), 
52.6 (CH3), 53.1 (CH), 67.0 (CH2), 120.2 (CH), 120.4 (CH), 122.2 (CH), 127.1 (CH), 128.2 (2 × CH), 
128.2 (CH), 128.5 (2 × CH), 132.9 (CH), 136.3 (C), 139.6 (C), 144.2 (C), 147.8 (C), 148.5 (C), 149.7 
(CH), 156.0 (C), 158.2 (C), 171.8 (C); m/z (ESI) 503.1154 (MNa+. C23H20N4NaO8 requires 503.1173). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-aminophenyl)pyridin-2’-yl]propanoate 
(170) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-nitrophenyl)pyridin-2’-yl]propanoate (146) 
(0.0206 g, 0.0473 mmol) was dissolved in anhydrous methanol (2 mL) and tin(II) chloride dihydrate 
(0.0530 g, 0.235 mmol) was added. The reaction was stirred at room temperature for 2 h. Once the 
reaction was complete, the solution was diluted with ethyl acetate (15 mL) and washed with 
saturated potassium fluoride solution (3 × 10 mL) and brine (10 mL). The organic layer was dried 
over MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 40% ethyl acetate/1% triethylamine in dichloromethane 
to produce methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(4’’-aminophenyl)pyridin-2’-
yl]propanoate (170) (0.0127 g, 65%) as a yellow oil. Rf 0.24 (40% ethyl acetate/1% triethylamine in 
dichloromethane); νmax/cm−1 (neat) 3363 (NH), 2947 (CH), 1720 (C=O), 1597 (C=C), 1519, 1211, 
1056, 825; [α]D26 +25.6 (c 0.5, CHCl3); δH (500 MHz, CDCl3) 3.31 (1H, dd, J 14.8, 5.2 Hz, 3-HH), 3.41 
(1H, dd, J 14.8, 5.2 Hz, 3HH), 3.69 (3H, s, OCH3), 3.89 (2H, br s, NH2), 4.78 (1H, dt, J 8.3, 5.2 Hz, 2-H), 
5.09 (1H, d, J 12.4 Hz, OCHHPh), 5.12 (1H, d, J 12.4 Hz, OCHHPh), 6.40 (1H, d, J 8.3 Hz, NH), 6.74 (2H, 
d, J 8.6 Hz, 3’’-H and 5’’-H), 7.27–7.37 (7H, m, 3’-H, 5’-H and Ph), 7.44 (2H, d, J 8.6 Hz, 2’’-H and 6’’-
H), 8.42 (1H, d, J 5.2 Hz, 6’-H); δC (126 MHz, CDCl3) 38.7 (CH2), 52.4 (CH3), 53.5 (CH), 66.9 (CH2), 115.3 
(2 × CH), 119.0 (CH), 120.6 (CH), 127.2 (C), 128.1 (2 × CH), 128.1 (CH), 128.1 (2 × CH), 128.5 (2 × CH), 
136.4 (C), 147.9 (C), 148.7 (CH), 149.4 (C), 156.2 (C), 156.8 (C), 172.1 (C); m/z (ESI) 406.1745 (MH+. 
C23H24N3O4 requires 406.1761). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-diaminophenyl)pyridin-2’-yl]propanoate 
(171) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(4’’-aminophenyl)pyridin-2’-yl]propanoate (170) using methyl 
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(2S)-2-[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoate (169) 
(0.359 g, 0.0747 mmol). The crude product was purified via flash column chromatography on silica 
gel, eluting with 50% ethyl acetate/1% triethylamine in dichloromethane to produce methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-diaminophenyl)pyridin-2’-yl]propanoate (171) (0.0198 g, 
63%) as a yellow oil. Rf 0.13 (50% ethyl acetate/1% triethylamine in dichloromethane); νmax/cm−1 
(neat) 3364 (NH), 2952 (CH), 1712 (C=O), 1599 (C=C), 1515, 1266, 1213, 1055, 698; [α]D26 +15.8 (c 
1.0, CHCl3); δH (500 MHz, CDCl3) 3.30 (1H, dd, J 14.7, 5.3 Hz, 3-HH), 3.35 (1H, dd, J 14.7, 5.3 Hz, 3-
HH), 3.63–3.78 (7H, m, OCH3 and 2 × NH2), 4.78 (1H, dt, J 8.3, 5.3 Hz, 2-H), 5.07 (1H, d, J 12.3 Hz, 
OCHHPh), 5.11 (1H, d, J 12.3 Hz, OCHHPh), 6.06 (1H, d, J 2.2 Hz, 3’’-H), 6.18 (1H, dd, J 8.2, 2.2 Hz, 
5’’-H), 6.30 (1H, d, J 8.3 Hz, NH), 6.91 (1H, d, J 8.2 Hz, 6’’-H), 7.20–7.24 (2H, m, 3’-H and 5’-H), 7.28–
7.36 (5H, m, Ph), 8.45 (1H, d, J 5.1 Hz, 6’-H); δC (126 MHz, CDCl3) 39.1 (CH2), 52.4 (CH3), 53.5 (CH), 
66.9 (CH2), 101.8 (CH), 106.6 (CH), 115.2 (C), 122.0 (CH), 123.6 (CH), 128.1 (2 × CH), 128.1 (CH), 
128.5 (2 × CH), 131.3 (CH), 136.4 (C), 144.7 (C), 148.2 (C), 148.6 (C), 149.5 (CH), 156.1 (C), 157.1 (C), 
172.2 (C); m/z (ESI) 421.1853 (MH+. C23H25N4O4 requires 421.1870). 
 
(2S)-2-Amino-3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) 
 
 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(4’-phenylpyridin-2’-yl)propanoate (142) (0.0637 g, 
0.163 mmol) was suspended in 6 M hydrochloric acid (5 mL) and heated under reflux for 48 h. The 
mixture was cooled to room temperature and concentrated in vacuo. The crude material was 
purified by trituration with diethyl ether (5 mL) to produce (2S)-2-amino-3-(4’-phenylpyridin-2’-
yl)propanoic acid hydrochloride (150) (0.044 g, 97%) as a brown solid. Mp 110–113 °C; νmax/cm−1 
(neat) 3375 (NH), 2931 (CH), 1633 (C=O), 1479, 1392, 1024, 844, 765; [α]D22 +28.6 (c 1.1, MeOH); δH 
(500 MHz, CD3OD) 3.73–3.84 (2H, m, 3-H2), 4.76 (1H, dd, J 8.4, 6.5 Hz, 2-H), 7.62–7.67 (3H, m, 3 × 
ArH), 8.00–8.07 (2H, m, 2 × ArH), 8.32 (1H, dd, J 6.3, 1.7 Hz, 5’-H), 8.50 (1H, d, J 1.7 Hz, 3’-H), 8.82 
(1H, d, J 6.3 Hz, 6’-H); δC (126 MHz, CD3OD) 35.0 (CH2), 52.9 (CH), 124.3 (CH), 126.6 (CH), 129.3 (2 × 
CH), 130.9 (2 × CH), 133.3 (CH), 135.8 (C), 143.1 (CH), 152.3 (C), 159.4 (C), 169.8 (C); m/z (ESI) 
277.0744 ([M−H]−. C14H1435ClN2O2 requires 277.0749). 
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(2S)-2-Amino-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid hydrochloride (151) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoate (143) (0.0610  g, 
0.145 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid hydrochloride (151) 
(0.043 g, 93%) as a brown solid. Mp 165–167 °C; νmax/cm−1 (neat) 3340 (NH), 2926 (CH), 1737 (C=O), 
1369, 1224, 823; [α]D21 +34.0 (c 0.8, MeOH); δH (500 MHz, CD3OD) 3.67–3.77 (2H, m, 3-H2), 3.91 (3H, 
s, OCH3), 4.71 (1H, t, J 7.3 Hz, 2-H), 7.17 (2H, d, J 8.9 Hz, 3’’-H and 5’’-H), 8.04 (2H, d, J 8.9 Hz, 2’’-H 
and 6’’-H), 8.22 (1H, dd, J 6.3, 1.3 Hz, 5’-H), 8.39 (1H, d, J 1.3 Hz, 3’-H), 8.70 (1H, d, J 6.3 Hz, 6’-H); 
δC (126 MHz, CD3OD) 35.1 (CH2), 52.9 (CH), 56.2 (CH3), 116.4 (2 × CH), 122.8 (CH), 125.0 (CH), 127.6 
(C), 131.1 (2 × CH), 143.1 (CH), 152.1 (C), 158.3 (C), 164.8 (C), 170.0 (C); m/z (ESI) 307.0847 ([M−H]−. 
C15H1635ClN2O3 requires 307.0855). 
 
(2S)-2-Amino-3-[4’-(naphthalen-2’’-yl)pyridin-2’-yl]propanoic acid hydrochloride (152) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(naphthalen-2’’-yl)pyridin-2’-yl]propanoate (144) (0.0260 g, 
0.0590 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(naphthalen-2’’-yl)pyridin-2’-yl]propanoic acid hydrochloride (152) 
(0.019 g, 94%) as a brown solid. Mp 120–124 °C; νmax/cm−1 (neat) 2924 (CH), 1739 (C=O), 1622 (C=C), 
1456, 1365, 1228, 817, 754; [α]D21 +35.9 (c 0.9, MeOH); δH (500 MHz, CD3OD) 3.72–3.82 (2H, m, 3-
H2), 4.72–4.80 (1H, m, 2-H), 7.59–7.68 (2H, m, 6’’-H and 7’’-H), 7.97 (1H, d, J 7.8 Hz, ArH), 8.03–8.13 
(3H, m, 3’’-H, 4’’-H and ArH), 8.38 (1H, br d, J 4.8 Hz, 5’-H), 8.56 (1H, br s, 3’-H), 8.61 (1H, br s, 1’’-
H), 8.81 (1H, d, J 4.8 Hz, 6’-H); δC (126 MHz, CD3OD) 35.3 (CH2), 53.0 (CH), 124.1 (CH), 125.1 (CH), 
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126.3 (CH), 128.4 (CH), 128.9 (CH), 129.6 (CH), 130.2 (CH), 130.3 (CH), 130.8 (CH), 133.1 (C), 134.8 
(C), 136.2 (C), 143.9 (CH), 152.8 (C), 158.4 (C), 170.0 (C); m/z (ESI) 327.0898 ([M−H]−. C18H1635ClN2O2 
requires 327.0906). 
 
(2S)-2-Amino-3-[4’-(4’’-nitrophenyl)pyridin-2’-yl]propanoic acid hydrochloride (154) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(4’’-nitrophenyl)pyridin-2’-yl]propanoate (146) (0.0263 g, 0.0604 
mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to produce 
(2S)-2-amino-3-[4’-(4’’-nitrophenyl)pyridin-2’-yl]propanoic acid hydrochloride (154) (0.017 g, 86%) 
as a brown solid. Mp 140–143 °C; νmax/cm−1 (neat) 3221 (NH), 2853 (CH), 1718 (C=O), 1635 (C=C), 
1529, 1479, 1349, 1263, 1246; [α]D25 +31.9 (c 0.9, MeOH); δH (500 MHz, CD3OD) 3.78 (2H, d, J 6.5 
Hz, 3-H2), 4.75 (1H, t, J 6.5 Hz, 2-H), 8.22 (2H, d, J 8.5 Hz, 2’’-H and 6’’-H), 8.30 (1H, d, J 5.7 Hz, 5’-H), 
8.46 (2H, d, J 8.5 Hz, 3’’-H and 5’’-H), 8.48 (1H, br s, 3’-H), 8.89 (1H, d, J 5.7 Hz, 6’-H); δC (126 MHz, 
CD3OD) 35.4 (CH2), 52.9 (CH), 124.7 (CH), 125.6 (2 × CH), 126.9 (CH), 130.6 (2 × CH), 142.4 (C), 144.8 
(CH), 151.0 (C), 153.9 (C), 155.7 (C), 170.0 (C); m/z (ESI) 322.0593 ([M−H]−. C14H1335ClN3O4 requires 
322.0600). 
 
(2S)-2-Amino-3-[4’-(4’’-fluorophenyl)pyridin-2’-yl]propanoic acid hydrochloride (155) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(4’’-fluorophenyl)pyridin-2’-yl]propanoate (147) (0.0139 g, 
0.0341 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(4’’-fluorophenyl)pyridin-2’-yl]propanoic acid hydrochloride (155) 
(0.010 g, 99%) as a yellow solid. Mp 80–84 °C; νmax/cm−1 (neat) 3360 (NH), 2920 (CH), 1602 (C=O), 
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1516 (C=C), 1236, 1163, 827; [α]D25 +30.8 (c 1.0, MeOH); δH (500 MHz, CD3OD) 3.69–3.79 (2H, m, 3-
H2), 4.72 (1H, t, J 7.2 Hz, 2-H), 7.38 (2H, t, J 8.8 Hz, 3’’-H and 5’’-H), 8.07 (2H, dd, J 8.8, 5.1 Hz, 2’’-H 
and 6’’-H), 8.22 (1H, dd, J 6.1, 1.1 Hz, 5’-H), 8.38 (1H, br s, 3’-H), 8.78 (1H, d, J 6.1 Hz, 6’-H); δC (126 
MHz, CD3OD) 35.3 (CH2), 52.9 (CH), 117.8 (d, JC-C-F 22.3 Hz, 2 × CH), 123.8 (CH), 125.9 (CH), 131.7 (d, 
JC-C-C-F 9.1 Hz, 2 × CH), 132.5 (d, JC-C-C-C-F 3.0 Hz, C), 144.1 (CH), 153.1 (C), 157.2 (C), 166.5 (d, JC-F 252.3 
Hz, C), 170.0 (C); m/z (ESI) 283.0843 (MNa+. C14H13FN2NaO2 requires 283.0853). 
 
(2S)-2-Amino-3-{4’-[4’’(3’’’-nitrophenyl)phenyl]pyridin-2’-yl]}propanoic acid hydrochloride (156) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-{4’-[4’’-(3’’’-nitrophenyl)phenyl]pyridin-2’-yl)propanoate (148) 
(0.0240 g, 0.0469 mmol) for 48 h. The crude material was purified by trituration with diethyl ether 
(5 mL) to produce (2S)-2-amino-3-{4’-[4’’(3’’’-nitrophenyl)phenyl]pyridin-2’-yl]}propanoic acid 
hydrochloride (156) (0.018 g, 98%) as a brown solid. Mp 140–142 °C; νmax/cm−1 (neat) 3414 (NH), 
2922 (CH), 1633 (C=O), 1521 (C=C), 1348, 806, 748; [α]D27 +14.1 (c 0.1, MeOH); δH (400 MHz, CD3OD) 
3.72–3.83 (2H, m, 3-H2), 4.72–4.80 (1H, m, 2-H), 7.77 (1H, t, J 7.8 Hz, ArH), 7.87–8.04 (2H, m, 3’-H 
and ArH), 8.13–8.23 (3H, m, 3 × ArH), 8.24–8.38 (2H, m, 5’-H and ArH), 8.47–8.60 (2H, m, 2 × ArH), 
8.83 (1H, s, 6’-H); δC (126 MHz, CD3OD) 35.3 (CH2), 53.0 (CH), 122.8 (CH), 124.0 (CH), 124.1 (CH), 
126.3 (CH), 129.6 (2 × CH), 130.2 (2 × CH), 131.6 (CH), 134.4 (CH), 136.0 (C), 142.5 (C), 143.4 (C), 
144.0 (CH), 150.4 (C), 153.0 (C), 157.9 (C), 170.0 (C); m/z (ESI) 398.0899 ([M−H]−. C20H1735ClN3O4 
requires 398.0913). 
 
(2S)-2-Amino-3-(4’-propylpyridin-2’-yl]propanoic acid hydrochloride (157) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
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[(benzyloxycarbonyl)amino]-3-(4’-propylpyridin-2’-yl]propanoate (149) (0.0230 g, 0.0645 mmol) 
for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to produce (2S)-2-
amino-3-(4’-propylpyridin-2’-yl]propanoic acid hydrochloride (157) (0.015 g, 97%) as a brown solid. 
Mp 112–116 °C; νmax/cm−1 (neat) 3360 (NH), 2924 (CH), 1635 (C=O), 1506 (C=C), 1226, 1062, 819; 
[α]D22 +27.5 (c 0.9, MeOH); δH (500 MHz, CD3OD) 1.03 (3H, t, J 7.3 Hz, 3’’-H3), 1.77–1.86 (2H, m, 2’’-
H2), 2.91–2.97 (2H, m, 1’’-H2), 3.66 (1H, dd, J 14.8, 8.9 Hz, 3-HH), 3.72 (1H, dd, J 14.8, 6.2 Hz, 3-HH), 
4.65 (1H, dd, J 8.9, 6.2 Hz, 2-H), 7.89 (1H, d, J 5.9 Hz, 5’-H), 8.05 (1H, s, 3’-H), 8.69 (1H, d, J 5.9 Hz, 
6’-H); δC (126 MHz, CD3OD) 13.9 (CH3), 24.1 (CH2), 34.7 (CH2), 38.9 (CH2), 52.8 (CH), 127.3 (CH), 129.5 
(CH), 142.1 (CH), 151.4 (C), 166.6 (C), 169.7 (C); m/z (ESI) 243.0902 ([M−H]−. C11H1635ClN2O2 requires 
243.0906). 
 
(2S)-2-Amino-3-[4’-(2’’,4’’-dimethoxyphenyl)pyridin-2’-yl]propanoic acid hydrochloride (172) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-dimethoxyphenyl)pyridin-2’-yl]propanoate (167) (0.0470 
g, 0.108 mmol) for 16 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(2’’,4’’-dimethoxyphenyl)pyridin-2’-yl]propanoic acid hydrochloride 
(172) (0.308 g, 95%) as a dark brown solid. Mp 180–183 °C; νmax/cm−1 (neat) 3410 (NH), 2931 (CH), 
1743 (C=O), 1597 (C=C), 1211, 1018, 833; [α]D27 +10.1 (c 0.1, MeOH); δH (400 MHz, CD3OD) 3.67–
3.81 (2H, m, 3-H2), 3.91 (3H, s, OCH3), 3.95 (3H, s, OCH3), 4.63–4.74 (1H, m, 2-H), 6.71–6.82 (2H, m, 
3’’-H and 5’’-H), 7.71 (1H, d, J 8.3 Hz, 6’’-H), 8.26 (1H, d, J 6.1 Hz, 5’-H), 8.36 (1H, br s, 3’-H), 8.67 
(1H, d, J 6.1 Hz, 6’-H); δC (101 MHz, CD3OD) 34.9 (CH2), 53.1 (CH), 56.4 (CH3), 56.6 (CH3), 100.0 (CH), 
108.0 (CH), 117.4 (C), 126.1 (CH), 128.0 (CH), 133.8 (CH), 141.7 (CH), 150.7 (C), 158.1 (C), 160.9 (C), 
166.1 (C), 169.9 (C); m/z (ESI) 303.1338 (MH+. C16H19N2O4 requires 303.1339). 
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(2S)-2-Amino-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoic acid hydrochloride (173) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoate (168) 
(0.244 g, 0.562 mmol) for 16 h. The crude material was purified by trituration with diethyl ether (5 
mL) to produce (2S)-2-amino-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoic acid 
hydrochloride (173) (0.179 g, 99%) as a dark brown solid. Mp 197–200 °C; νmax/cm−1 (neat) 3410 
(NH), 2808 (CH), 1735 (C=O), 1612 (C=C), 1111, 1033, 810; [α]D27 +38.5 (c 0.1, MeOH); δH (400 MHz, 
CD3OD) 3.69 (1H, dd, J 12.8, 5.7 Hz, 3-HH), 3.74 (1H, dd, J 12.8, 5.7 Hz, 3-HH), 4.71 (1H, dd, J 8.0, 5.7 
Hz, 2-H), 6.12 (2H, s, 2’’-H2), 7.07 (1H, d, J 8.2 Hz, 7’’-H), 7.55 (1H, d, J 1.9 Hz, 4’’-H), 7.63 (1H, dd, J 
8.2, 1.9 Hz, 6’’-H), 8.20 (1H, dd, J 6.4, 1.9 Hz, 5’-H), 8.35 (1H, d, J 1.9 Hz, 3’-H), 8.71 (1H, d, J 6.4 Hz, 
6’-H); δC (101 MHz, CD3OD) 35.1 (CH2), 52.9 (CH), 103.9 (CH2), 108.8 (CH), 110.4 (CH), 123.4 (CH), 
125.0 (CH), 125.5 (CH), 129.5 (C), 142.9 (CH), 150.9 (C), 152.0 (C), 153.1 (C), 158.7 (C), 169.9 (C); m/z 
(ESI) 287.1029 (MH+. C15H15N2O4 requires 287.1026). 
 
(2S)-2-Amino-3-[4’-(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoic acid hydrochloride (174) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoate (169) (0.0237 g, 
0.0493 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(2’’,4’’-dinitrophenyl)pyridin-2’-yl]propanoic acid hydrochloride (174) 
(0.175 g, 97%) as a yellow solid. Mp 130–134 °C; νmax/cm−1 (neat) 3402 (NH), 3039 (CH), 1743 (C=O), 
1527 (C=C), 1342, 1080, 833, 740; [α]D26 +9.3 (c 1.0, MeOH); δH (500 MHz, CD3OD) 3.55 (1H, dd, J 
16.3, 7.1 Hz, 3-HH), 3.62 (1H, dd, J 16.3, 5.4 Hz, 3-HH), 4.57 (1H, dd, J 7.1, 5.4 Hz, 2-H), 7.53 (1H, dd, 
J 5.3, 1.6 Hz, 5’-H), 7.63 (1H, br s, 3’-H), 7.84 (1H, d, J 8.4 Hz, 6’’-H), 8.64 (1H, dd, J 8.4, 2.3 Hz, 5’’-
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H), 8.71 (1H, d, J 5.3 Hz, 6’-H), 8.95 (1H, d, J 2.3 Hz, 3’’-H); δC (126 MHz, CD3OD) 36.5 (CH2), 52.9 
(CH), 121.4 (CH), 123.6 (CH), 124.9 (CH), 128.7 (CH), 128.7 (CH), 134.5 (C), 139.9 (CH), 149.1 (C), 
149.7 (C), 149.8 (C), 155.0 (C), 170.9 (C); m/z (ESI) 333.0822 (MH+. C14H13N4O6 requires 333.0830). 
 
(2S)-2-Amino-3-[4’-(4’’-aminophenyl)pyridin-2’-yl]propanoic acid hydrochloride (175) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(4’’-aminophenyl)pyridin-2’-yl]propanoate (170) (0.0136 g, 
0.0335 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(4’’-aminophenyl)pyridin-2’-yl]propanoic acid hydrochloride (175) 
(0.00970 g, 98%) as a dark orange solid. Mp 151–154 °C; νmax/cm−1 (neat) 3379 (NH), 2831 (CH), 
1743 (C=O), 1589 (C=C), 1473, 1311, 817; [α]D27 +34.9 (c 0.1, MeOH); δH (400 MHz, CD3OD) 3.70 (2H, 
d, J 7.3 Hz, 3-H2), 4.69 (1H, t, J 7.3 Hz, 2-H), 7.30 (2H, d, J 8.7 Hz, 3’’-H and 5’’-H), 8.04 (2H, d, J 8.7 
Hz, 2’’-H and 6’’-H), 8.15 (1H, dd, J 6.3, 1.7 Hz, 5’-H), 8.33 (1H, d, J 1.7 Hz, 3’-H), 8.68 (1H, d, J 6.3 Hz, 
6’-H); δC (101 MHz, CD3OD) 35.3 (CH2), 53.0 (CH), 121.5 (2 × CH), 122.6 (CH), 124.7 (CH), 131.1 (C), 
131.1 (2 × CH and C), 143.8 (CH), 152.6 (C), 157.1 (C), 170.1 (C); m/z (ESI) 258.1236 (MH+. C14H16N3O2 
requires 258.1237). 
 
(2S)-2-Amino-3-[4’-(2’’,4’’-diaminophenyl)pyridin-2’-yl]propanoic acid hydrochloride (176) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-amino-
3-(4’-phenylpyridin-2’-yl)propanoic acid hydrochloride (150) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[4’-(2’’,4’’-diaminophenyl)pyridin-2’-yl]propanoate (171) (0.0163 g, 
0.0388 mmol) for 48 h. The crude material was purified by trituration with diethyl ether (5 mL) to 
produce (2S)-2-amino-3-[4’-(2’’,4’’-diaminophenyl)pyridin-2’-yl]propanoic acid hydrochloride (176) 
(0.0113 g, 95%) as a dark brown solid. Mp 159–162 °C; νmax/cm−1 (neat) 3332 (NH), 2846 (CH), 1743 
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(C=O), 1620 (C=C), 1473, 1234, 1072, 840; [α]D26 +15.7 (c 1.0, MeOH); δH (400 MHz, CD3OD) 3.70–
3.84 (2H, m, 3-H2), 4.72 (1H, t, J 7.3 Hz, 2-H), 6.94 (1H, dd, J 8.3, 1.9 Hz, 5’’-H), 7.04 (1H, d, J 1.9 Hz, 
3’’-H), 7.51 (1H, d, J 8.3 Hz, 6’’-H), 8.16 (1H, br d, J 6.0 Hz, 5’-H), 8.35 (1H, br s, 3’-H), 8.82 (1H, d, J 
6.0 Hz, 6’-H); δC (126 MHz, CD3OD) 35.0 (CH2), 52.9 (CH), 112.2 (CH), 114.0 (CH), 122.6 (C), 127.0 
(CH), 129.2 (CH), 133.8 (CH), 137.1 (C), 143.2 (CH), 145.9 (C), 152.2 (C), 158.6 (C), 169.8 (C); m/z 
(ESI) 273.1346 (MH+. C14H17N4O2 requires 273.1346). 
 
(2S)-2-[(9H-Fluoren-9-ylmethoxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-
yl]propanoic acid (177) 
 
 
 
(2S)-2-Amino-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid hydrochloride (151) (0.264 g, 
0.0855 mmol) was dissolved in 1,4-dioxane (1.5 mL) followed by the addition of 10% sodium 
carbonate solution (1.5 mL), N,N-diisopropylethylamine (0.0164 mL, 0.0941 mmol) and 9-
fluorenylmethoxycarbonyl chloride (0.0243 g, 0.0941 mmol). The reaction was stirred at room 
temperature for 18 h. Once the reaction was complete, the solution was concentrated in vacuo, 
redissolved in water (5 mL) and acidified to pH 1 with hydrochloric acid (2 M). The aqueous solution 
was washed with dichloromethane (3 × 10 mL) and the organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 3% methanol/1% acetic acid in dichloromethane to produce (2S)-2-[(9H-fluoren-9-
ylmethoxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid (177) (0.0171 g, 
40%) as a brown solid. Mp 90–93 °C; Rf 0.09 (3% methanol/1% acetic acid in dichloromethane); 
νmax/cm−1 (neat) 3326 (NH), 2935 (CH), 1716 (C=O), 1602 (C=C), 1518, 1251, 1182, 1047, 826, 739; 
[α]D21 +60.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.37–3.56 (2H, m, 3-H2), 3.87 (3H, s, OCH3), 4.24 (1H, 
t, J 7.3 Hz, CO2CH2CH), 4.39 (2H, d, J 7.3 Hz, CO2CH2CH), 4.47–4.57 (1H, m, 2-H), 6.31 (1H, d, J 3.4 
Hz, NH), 7.00 (2H, d, J 8.6 Hz, 3’’-H and 5’’-H), 7.32 (2H, t, J 7.4 Hz, 2 × ArH), 7.41 (2H, t, J 7.4 Hz, 2 × 
ArH), 7.55 (1H, d, J 5.6 Hz, 5’-H), 7.58–7.67 (5H, m, 3’-H, 2’’-H, 6’’-H and 2 × ArH), 7.77 (2H, d, J 7.4 
Hz, 2 × ArH), 8.49 (1H, d, J 5.6 Hz, 6’-H); δC (101 MHz, CDCl3) 38.4 (CH2), 47.2 (CH), 53.2 (CH), 55.5 
(CH3), 67.2 (CH2), 114.8 (2 × CH), 120.0 (2 × CH), 120.3 (CH), 122.5 (CH), 125.2 (2 × CH), 127.1 (2 × 
CH), 127.7 (2 × CH), 128.6 (2 × CH), 141.3 (2 × C), 143.8 (2 × C), 143.9 (C), 145.6 (CH), 152.0 (C), 155.7 
(C), 156.1 (C), 161.5 (C), 172.8 (C); m/z (ESI) 495.1901 (MH+. C30H27N2O5 requires 495.1914). 
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(2S)-2-[(9H-Fluoren-9-ylmethoxycarbonyl)amino]-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-
yl]propanoic acid (178) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2S)-2-[(9H-
fluoren-9-ylmethoxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid (177) 
using (2S)-2-amino-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoic acid hydrochloride 
(173) (0.349 g, 1.13 mmol). The crude product was purified via flash column chromatography on 
silica gel, eluting with 5% methanol/1% acetic acid in dichloromethane to produce (2S)-2-[(9H-
fluoren-9-ylmethoxycarbonyl)amino]-3-[4’-(2H-1’’,3’’-benzodioxol-5’’-yl)pyridin-2’-yl]propanoic 
acid (178) (0.304 g, 40%) as a yellow solid. Mp 96–100 °C; Rf 0.24 (5% methanol/1% acetic acid in 
dichloromethane); νmax/cm−1 (neat) 2970 (CH), 1716 (C=O), 1604 (C=C), 1473, 1234, 1033, 738; [α]D26 
+25.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.38–3.57 (2H, m, 3-H2), 4.22 (1H, t, J 7.2 Hz, CO2CH2CH), 
4.33–4.46 (2H, m, CO2CH2CH), 4.54 (1H, s, 2-H), 6.03 (2H, br d, J 5.1 Hz, 2’’-H2), 6.26 (1H, d, J 4.4 Hz, 
NH), 6.88 (1H, d, J 8.1 Hz, 7’’-H), 7.06–7.19 (2H, m, 4’’-H and 6’’-H), 7.27–7.45 (4H, m, 4 × ArH), 7.46–
7.66 (4H, m, 3’-H, 5’-H and 2 × ArH), 7.77 (2H, d, J 7.4 Hz, 2 × ArH), 8.51 (1H, d, J 5.5 Hz, 6’-H); δC 
(101 MHz, CDCl3) 38.5 (CH2), 47.2 (CH), 53.0 (CH), 67.2 (CH2), 101.8 (CH2), 107.3 (CH), 109.1 (CH), 
120.0 (2 × CH), 120.5 (CH), 121.7 (CH), 122.7 (CH), 125.2 (2 × CH), 127.1 (2 × CH), 127.7 (2 × CH), 
130.6 (C), 141.3 (2 × C), 143.8 (2 × C), 145.8 (CH), 148.9 (C), 149.6 (C), 151.9 (C), 155.7 (C), 156.3 (C), 
172.6 (C); m/z (ESI) 531.1517 (MNa+. C30H24N2NaO6 requires 531.1527). 
 
Benzamidine (183)168,169 
 
 
 
Benzamidine hydrochloride (182) (1.09 g, 6.99 mmol) was dissolved in 1 M sodium hydroxide 
solution (10 mL) and left to stir at room temperature for 2 h. The solution was then diluted with 
dichloromethane (15 mL), extracted with dichloromethane (3 × 10 mL), dried over MgSO4 and 
concentrated in vacuo to produce benzamidine (183) (0.689 g, 82%) as a white solid. Spectroscopic 
data was consistent with the literature.168,169 Mp 79–82 °C (lit.,170 Mp 77–79 °C); δH (400 MHz, CDCl3) 
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5.28 (3H, s, NH and NH2), 7.42–7.62 (5H, m, Ph); δC (101 MHz, CDCl3) 125.9 (2 × ArH), 128.5 (2 × 
ArH), 130.2 (ArH), 136.7 (C), 166.3 (C); m/z (ESI) 143 (MNa+, 100%). 
 
Acetamidine (185)171  
 
 
 
Acetamidine hydrochloride (184) (1.07 g, 11.35 mmol) was dissolved in methanol (28 mL, 0.4 M) 
followed by addition of sodium hydroxide (0.45 g, 11.35 mmol) and was left to stir a room 
temperature for 2 h. The solution was then filtered through a pad of Celite® and concentrated in 
vacuo. The crude solid was then triturated with 15% isopropyl alcohol in dichloromethane (10 mL), 
filtered and concentrated in vacuo to give acetamidine (185) (0.59 g, 89%) as a colourless solid. 
Spectroscopic data was consistent with the literature.171 Mp 64–66 °C (lit.,171 Mp 66–67 °C); δH (500 
MHz, CDCl3) 1.99 (3H, s, CH3), 4.88 (1H, s, NH), 7.26 (2H, s, 2 × NH), deuterium exchange with 
hydrogen, the sum of integrals δ 4.88 and δ 7.26 equal to that of δ 1.99; δC (126 MHz, CDCl3) 23.2 
(CH3), 165.4 (C); m/z (ESI) 81 (MNa+, 100%). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6’-(4’’-nitrophenyl)-2’-phenylpyrimidin-4’-
yl]propanoate (186) 
 
 
 
Methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(4’-nitrophenyl)-4-oxohex-5-enoate (90) (0.0456 g, 
0.111 mmol) was dissolved in tetrahydrofuran (1.5 mL) followed by sequential addition of 
benzamidine hydrochloride 182 (0.0262 g, 0.167 mmol), potassium carbonate (0.0184 g, 0.133 
mmol) and ytterbium triflate (0.00680 g, 0.0111 mmol). The mixture was heated under reflux for 
22 h. The mixture was concentrated in vacuo and redissolved in methanol (5 mL) followed by 
addition of thionyl chloride (0.0107 mL, 0.147 mmol). The mixture was stirred at room temperature 
for 24 h. Upon completion, the mixture was concentrated in vauco, redissolved in dichloromethane 
(10 mL), washed with a saturated solution of sodium hydrogen carbonate (5 mL), brine (5 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce 
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methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6’-(4’’-nitrophenyl)-2’-phenylpyrimidin-4’-
yl]propanoate (186) (0.0267 g, 47%) as an orange solid. Mp 66–70 °C; Rf 0.17 (30% ethyl acetate in 
petroleum ether); νmax/cm−1 (neat) 3338 (NH), 2953 (CH), 1720 (C=O), 1541 (C=C), 1348, 1211, 1058, 
748, 694; [α]D24 +44.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.50 (1H, dd, J 16.2, 4.7 Hz, 3-HH), 3.63 
(1H, dd, J 16.2, 4.7 Hz, 3-HH), 3.77 (3H, s, OCH3), 4.90–4.97 (1H, m, 2-H), 5.09 (1H, d, J 12.5 Hz, 
OCHHPh), 5.13 (1H, d, J 12.5 Hz, OCHHPh), 6.05 (1H, d, J 8.2 Hz, NH), 7.26–7.37 (5H, m, Ph), 7.48–
7.55 (4H, m, 5’-H, 2’’-H, 6’’-H, ArH), 8.31–8.39 (4H, m, 4 × ArH), 8.48–8.55 (2H, m, 3’’-H and 5’’-H); 
δC (101 MHz, CDCl3) 39.0 (CH2), 52.0 (CH), 52.7 (CH3), 67.1 (CH2), 115.0 (CH), 124.1 (2 × CH), 128.1 
(2 × CH), 128.2 (3 × CH), 128.4 (2 × CH), 128.5 (2 × CH), 128.7 (2 × CH), 131.3 (CH), 136.1 (C), 137.1 
(C), 142.8 (C), 149.3 (C), 156.0 (C), 161.8 (C), 164.5 (C), 167.2 (C), 171.8 (C); m/z (EI) 535.1563 (MNa+. 
C28H24N4NaO6 requires 535.1588). 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6’-(naphthalen-2’’-yl)-2-phenylpyrimidin-4’-
yl]propanoate (187) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[6’-(4’’-nitrophenyl)-2’-phenylpyrimidin-4’-yl]propanoate (186) 
using methyl (2S,5E)-2-[(benzyloxycarbonyl)amino]-6-(naphthalen-2’-yl)-4-oxohex-5-enoate (118) 
(0.0822 g, 0.197 mmol). The crude product was purified via flash column chromatography on silica 
gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[6’-(naphthalen-2’’-yl)-2-phenylpyrimidin-4’-yl]propanoate (187) 
(0.0112 g, 11%) as a colourless oil. Rf 0.20 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 
3345 (NH), 3054 (CH), 2951 (CH), 1716 (C=O), 1597 (C=C), 1503, 1437, 1210, 1056, 1028; [α]D24 +22.1 
(c 0.6, CHCl3); δH (500 MHz, CDCl3) 3.48 (1H, dd, J 16.0, 4.7 Hz, 3-HH), 3.64 (1H, dd, J 16.0, 4.7 Hz, 3-
HH), 3.76 (3H, s, OCH3), 4.90–4.96 (1H, m, 2-H), 5.12 (2H, s, OCH2Ph), 6.19 (1H, d, J 8.3 Hz, NH), 
7.23–7.37 (5H, m, Ph), 7.49–7.62 (6H, m, 5’-H, 6’’-H, 7’’-H and 3 × ArH), 7.88–7.94 (1H, m, ArH), 
7.97–8.04 (2H, m, 4’’-H and ArH), 8.30 (1H, dd, J 8.6, 1.5 Hz, 3’’-H), 8.55–8.60 (2H, m, 5’’-H and 8’’-
H), 8.69 (1H, br s, 1’’-H); δC (126 MHz, CDCl3) 38.8 (CH2), 52.1 (CH), 52.7 (CH3), 67.0 (CH2), 114.5 (CH), 
124.1 (CH), 126.6 (CH), 127.5 (CH), 127.6 (CH), 127.8 (CH), 128.0 (2 × CH), 128.1 (CH), 128.4 (2 × 
CH), 128.5 (2 × CH), 128.6 (2 × CH), 128.7 (CH), 129.1 (CH), 130.9 (CH), 133.3 (C), 134.2 (C), 134.7 
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(C), 136.2 (C), 137.7 (C), 156.1 (C), 164.2 (C), 166.2 (C), 172.0 (C), 194.4 (C); m/z (EI) 540.1885 (MNa+. 
C32H27N3NaO4 requires 540.1894). 
 
N-Boc-ʟ-Aspartic acid 4-methyl ester (188)172 
 
 
 
ʟ-Aspartic acid (5.00 g, 37.6 mmol) was dissolved in methanol (250 mL) and cooled to −10 °C. Thionyl 
chloride (4.77 mL, 41.4mmol) was added dropwise and the resultant reaction mixture was stirred 
for 0.5 h. The solution was concentrated in vacuo and triturated with diethyl ether to give ʟ-aspartic 
acid 4-methyl ester as a white solid (8.27 g, 89%). This was then dissolved in 1,4-dioxane (100 mL) 
and cooled to 0 °C followed by the addition of di-tert-butyl dicarbonate (9.03 g, 41.4 mmol) and a 
10% aqueous solution of sodium carbonate (100 mL). The resulting reaction mixture was allowed 
to warm to room temperature and stirred for 16 h. Once the reaction had reached completion, the 
mixture was concentrated in vacuo and the residue was then dissolved in saturated aqueous 
ammonium chloride (100 mL), washed with dichloromethane (3 × 50 mL) and acidified to pH 1 with 
1 M aqueous hydrochloric acid. This was extracted with dichloromethane (3 × 50 mL), the organic 
fractions were combined, washed with brine (100 mL), dried (MgSO4), filtered and concentrated 
under reduced pressure to give N-Boc-ʟ-aspartic acid 4-methyl ester (188) as a white solid (8.27 g, 
89%). Mp 54–56 °C (lit.,172 56 °C); δH (500 MHz, CDCl3) 1.45 (9H, s, 3 × CH3), 2.85 (1H, dd, J 17.2, 3.8 
Hz, 3-HH), 3.04 (1H, dd, J 17.2, 3.8 Hz, 3-HH), 3.72 (3H, s, OCH3), 4.55–4.67 (1H, m, 2-H), 5.55 (1H, 
d, J 8.0 Hz, NH); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 36.4 (CH2), 49.9 (CH), 52.3 (CH3), 80.8 (C), 155.8 
(C), 171.8 (C), 175.1 (C); m/z (ESI) 270 (MNa+, 100%). 
 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (189)173 
 
 
 
To a solution of N-Boc-ʟ-aspartic acid 4-methyl ester (188) (8.27 g, 33.5 mmol) in ethyl acetate (200 
mL) at 0 °C was added N-hydroxysuccinimide (4.24 g, 36.9 mmol) and then N,N'-
dicyclohexylcarbodiimide (7.05 g, 34.2 mmol) in ethyl acetate (20 mL) was added dropwise. The 
reaction mixture was allowed to warm to room temperature and stirred for 16 h. Once the reaction 
was complete, the reaction mixture was filtered through Celite®. The filtrate was washed with 
saturated sodium carbonate solution (100 mL), brine (100 mL), dried (MgSO4) and concentrated in 
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vacuo. The resulting residue was then dissolved in tetrahydrofuran (20 mL) and added dropwise to 
a solution of sodium borohydride (2.03 g, 53.6 mmol) in a mixture of tetrahydrofuran and water 
(7.5:1, 85 mL). The reaction mixture was stirred for 0.1 h before quenching with saturated aqueous 
ammonium chloride (5 mL). The reaction mixture was extracted with dichloromethane (3 × 50 mL). 
The organic fractions were combined and washed with brine (100 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 30% ethyl acetate in dichloromethane to produce methyl (3S)-3-(tert-
butoxycarbonylamino)-4-hydroxybutanoate (189) as a clear oil (7.03 g, 90%). Rf 0.22 (40% ethyl 
acetate in dichloromethane); [α]D26 +5.6 (c 1.0, CHCl3), lit.,173 [α]D23 +6.3 (c 0.5, CHCl3); δH (400 MHz, 
CDCl3) 1.42 (9H, s, 3 × CH3), 2.62 (2H, d, J 6.1 Hz, 2-H2), 2.82 (1H, br s, OH), 3.65–3.73 (5H, m, OCH3 
and 4-H2), 3.92–4.04 (1H, m, 3-H), 5.25 (1H, br s, NH); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 35.9 (CH2), 
49.4 (CH), 52.0 (CH3), 64.4 (CH2), 79.9 (C), 155.9 (C), 172.4 (C); m/z (ESI) 256 (MNa+, 100%). 
 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)butanoate (190)174 
 
 
 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (189) (0.0508 g, 0.218 mmol) was 
dissolved in anhydrous dichloromethane (5 mL) and cooled to 0 °C followed by addition of tert-
butyldimethylsilyl chloride (0.0454 mL, 0.262 mmol) and imidazole (0.0223 g, 0.327 mmol). The 
reaction was warmed to room temperature and stirred for 48 h. Once the reaction was complete, 
the solution was diluted with dichloromethane (5 mL) and washed with brine (10 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The crude product was purified via flash 
column chromatography on silica gel eluting with 10% ethyl acetate in petroleum ether (40–60) to 
produce methyl (3S)-3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)butanoate (190) 
(0.0662 g, 88%) as a colourless oil. Rf 0.18 (10% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 
3363 (NH), 2955 (CH), 1716 (C=O), 1365, 1251, 1168, 835, 777; [α]D25 +13.1 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 0.02 (6H, s, Si(CH3)2), 0.87 (9H, s, 3 × CH3), 1.42 (9H, s, 3 × CH3), 2.49–2.64 (2H, m, 2-
H2), 3.56–3.71 (5H, m, OCH3 and 4-H2), 4.00 (1H, s, 3-H), 5.07 (1H, d, J 7.8 Hz, NH); δC (101 MHz, 
CDCl3) −5.6 (CH3), −5.5 (CH3), 18.3 (C), 25.8 (3 × CH3), 28.4 (3 × CH3), 35.6 (CH2), 48.9 (CH), 51.6 (CH3), 
64.1 (CH2), 79.4 (C), 155.2 (C), 172.1 (C); m/z (ESI) 370.2008 (MNa+. C16H33NNaO5Si requires 
370.2020). 
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(2S)-1-(tert-Butyldimethylsilyloxy)-2-(tert-butoxycarbonylamino)-5-
(dimethyloxyphosphoryl)pentan-2-one (191) 
 
 
 
Dimethyl methylphosphonate (0.270 mL, 2.49 mmol) was dissolved in tetrahydrofuran (5 mL) and 
cooled to −78 °C under an argon atmosphere. n-Butyl lithium (2.5 M in hexane, 0.997 mL, 2.493 
mmol) was added dropwise and the mixture was stirred for 0.3 h. A solution of methyl (3S)-3-(tert-
butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)butanoate (190) (0.346 g, 0.997 mmol) in 
tetrahydrofuran (5 mL) was added dropwise. The resulting reaction mixture was then stirred at −78 
°C for 0.5 h and allowed to warm to 0 °C over a period of 1 h. The reaction was quenched with a 
saturated aqueous solution of ammonium chloride (2 mL). Extraction was performed with ethyl 
acetate (2 × 10 mL). The combined organic layers were then combined, washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified via a plug of 
silica gel eluting with 100% ethyl acetate to produce (2S)-1-(tert-butyldimethylsilyloxy)-2-(tert-
butoxycarbonylamino)-5-(dimethyloxyphosphoryl)pentan-2-one (191) (0.338 g, 77%) as a 
colourless oil. Rf 0.38 (100% ethyl acetate); νmax/cm−1 (neat) 3315 (NH), 2955 (CH), 1712 (C=O), 1251, 
1170, 1112, 835, 777; [α]D26 +3.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.04 (6H, s, Si(CH3)2), 0.88 (9H, 
s, 3 × CH3), 1.42 (9H, s, 3 × CH3), 2.85 (2H, d, J 6.2 Hz, 3-H2), 3.09 (2H, dd, J 22.1, 13.1 Hz, 5-HH), 3.18 
(1H, dd, J 21.4, 13.1 Hz, 5-HH), 3.58–3.69 (2H, m, 1-H2), 3.76 (3H, s, OCH3), 3.79 (3H, s, OCH3), 4.04 
(1H, br s, 2-H), 5.01 (1H, br d, J 6.7 Hz, NH); δC (101 MHz, CDCl3) -5.5 (CH3), -5.5 (CH3), 18.3 (C), 25.9 
(3 × CH3), 28.4 (3 × CH3), 41.8 (d, JC-P 127.9 Hz, CH2), 45.1 (CH2), 48.6 (CH), 53.0 (d, JC-O-P 6.5 Hz, CH3), 
53.1 (d, JC-O-P 6.5 Hz, CH3), 64.2 (CH2), 79.4 (C), 155.3 (C), 200.6 (d, JC-C-P 6.4 Hz, C); m/z (ESI) 462.2029 
(MNa+. C18H38NNaO7PSi requires 462.2047). 
 
(2S,5E)-6-Phenyl-1(tert-butyldimethylsilyloxy)-2-(tert-butoxycarbonylamino)-4-oxo-hex-5-ene 
(192)  
 
 
 
(2S)-1-(tert-butyldimethylsilyloxy)-2-(tert-butoxycarbonylamino)-5-
(dimethyloxyphosphoryl)pentan-2-one (191) (0.324 g, 0.737 mmol) was dissolved in anhydrous 
acetonitrile (8 mL) and potassium carbonate (0.122 g, 0.884 mmol) was added. The mixture was 
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stirred at room temperature for 0.5 h followed by addition of benzaldehyde (0.149 mL, 1.474 
mmol). The temperature was increased to 50 °C and stirred for 72 h. Once the reaction was 
complete, the solution was concentrated in vacuo, redissolved in ethyl acetate (10 mL) and washed 
with water (2 × 10 mL) and brine (10 mL). The organic layer was dried over MgSO4 and concentrated 
in vacuo. The crude product was purified via flash column chromatography on silica gel eluting with 
20% diethyl ether in petroleum ether (40–60) to produce (2S,5E)-6-phenyl-1(tert-
butyldimethylsilyloxy)-2-(tert-butoxycarbonylamino)-4-oxo-hex-5-ene (192) (0.277 g, 89%) as a 
white solid. Mp 50–53 °C; Rf 0.16 (20% diethyl ether in petroleum ether); νmax/cm−1 (neat) 3448 
(NH), 2929 (CH), 1710 (C=O), 1494 (C=C), 1251, 1168, 835, 748; [α]D26 +30.6 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 0.04 (6H, s, Si(CH3)2), 0.88 (9H, s, 3 × CH3), 1.43 (9H, s, 3 × CH3), 2.90 (1H, dd, J 16.1, 6.8 
Hz, 3-HH), 3.00 (1H, dd, J 16.1, 3.9 Hz, 3-HH), 3.65 (1H, dd, J 10.0, 5.5 Hz, 1-HH), 3.72 (1H, dd, J 10.0, 
3.9 Hz, 1-HH), 4.05–4.16 (1H, m, 2-H), 5.16 (1H, br d, J 8.0 Hz, NH), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.37–
7.42 (3H, m, 3 × ArH), 7.52–7.61 (3H, m, 2 × ArH and 6-H); δC (101 MHz, CDCl3) -5.5 (CH3), -5.4 (CH3), 
18.3 (C), 25.9 (3 × CH3), 28.4 (3 × CH3), 41.2 (CH2), 49.1 (CH), 63.9 (CH2), 79.3 (C), 126.4 (CH), 128.4 
(2 × CH), 129.0 (2 × CH), 130.6 (CH), 134.4 (C), 143.1 (CH), 155.3 (C), 199.0 (C); m/z (ESI) 442.2367 
(MNa+. C23H37NNaO4Si requires 442.2384). 
 
2-Amidoacetophenone (204)119 
 
 
 
2-Aminoacetophenone hydrochloride (0.0510 g, 0.297 mmol) was suspended in a solution of acetic 
anhydride (0.199 mL, 1.49 M). Sodium acetate (0.0463 g, 0.564 mmol) was added to the mixture 
and the solution was stirred at room temperature for 0.5 h. Water (0.401 mL, 0.74 M) was then 
added dropwise to the solution, which was left to stir for 1 h. The mixture was then diluted with 
ethyl acetate (10 mL), washed with saturated sodium hydrogen carbonate (2 × 5 mL), brine (5 mL), 
dried over MgSO4 and concentrated in vacuo to produce 2-amidoacetophenone (204) (0.047 g, 
90%) as a white solid. Spectroscopic data was consistent with the literature.119 Mp 84–85 °C (lit., 119 
Mp 86–87 °C); δH (400 MHz, CDCl3) 2.09 (3H, s, H3), 4.75 (2H, d, J 4.3 Hz, H2), 6.66 (1H, br s, NH), 
7.43–7.52 (2H, m, 2 × ArH), 7.57–7.65 (1H, m, 1 × ArH), 7.91–8.01 (2H, m, 2 × ArH); δc (101 MHz, 
CDCl3) 23.1 (CH3), 46.5 (CH2), 127.9 (2 × CH), 128.9 (2 × CH), 134.2 (CH), 134.3 (C), 170.2 (C), 194.2 
(C); m/z (ESI) 200 (MNa+, 100%). 
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Methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (240)129 and methyl (2S,6R)-4-oxo-6-
propylpiperidine-2-carboxylate (241)130  
 
 
 
To a solution of methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (108) (0.103 g, 0.23 mmol) in 
methanol (10 mL) was added 2 M hydrochloric acid solution (2.5 mL). The mixture was stirred for 1 
h, then diluted with water (10 mL) and basified to pH 8 with NN-diisopropylethylamine (1.5 mL). 
The mixture was stirred for 18 h then partitioned between ethyl acetate (20 mL) and brine (20 mL). 
The aqueous layer was separated and re-extracted with ethyl acetate (20 mL). The organic layers 
were combined, dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified via flash column chromatography on silica gel, eluting with 40% ethyl acetate/1% 
triethylamine in petroleum ether (40–60) to produce methyl (2S,6S)-4-oxo-6-propylpiperidine-2-
carboxylate (240) (0.026 g, 56%) as a colourless oil. Further elution yielded methyl (2S,6R)-4-oxo-6-
propylpiperidine-2-carboxylate (241) (0.011 g, 24%) as a colourless oil. Data for methyl (2S,6S)-4-
oxo-6-propylpiperidine-2-carboxylate (240): Rf 0.22 (40% ethyl acetate/1% triethylamine in 
petroleum ether); νmax (neat)/cm–1 3330 (NH), 2959, (CH), 2359, 1740 (C=O), 1715 (C=O), 1437, 
1217, 1009; [α]D25 −20.9 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 0.94 (3H, t, J 7.0 Hz, 3’-H3), 1.36–1.63 
(4H, m, 1’-H2 and 2’-H2), 2.09 (2H, dd, J 14.1, 11.7 Hz, 5-H2), 2.39–2.46 (2H, m, 3-HH and NH), 2.69 
(1H, dddd, J 14.4, 3.4, 2.1, 0.6 Hz, 3-HH), 2.83–2.90 (1H, m, 6-H), 3.64 (1H, dd, J 12.2, 3.4 Hz, 2-H), 
3.78 (3H, s, OCH3); δC (101 MHz, CDCl3) 14.0 (CH3), 18.8 (CH2), 38.9 (CH2), 44.5 (CH2), 48.4 (CH2), 52.5 
(CH3), 55.6 (CH), 57.9 (CH), 171.9 (C), 207.3 (C); m/z (EI) 199.1212 (M+. C10H17NO3 requires 
199.1208), 156 (95%), 140 (97), 114 (70), 98 (96). Data for methyl (2S,6R)-4-oxo-6-propylpiperidine-
2-carboxylate (241): Rf 0.11 (40% ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 
(neat) 3325 (NH), 2957 (CH), 1732 (CO), 1717 (CO), 1435, 1120, 1163; [α]D24 −7.5 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3) 0.94 (3H, t, J 7.3 Hz, 3’-H3), 1.22–1.51 (4H, m, 1’-H2 and 2’-H2), 2.16 (1H, ddd, J 
14.5, 9.9, 0.9 Hz, 5-HH), 2.43 (1H, ddd, J 14.5, 3.7, 1.7 Hz, 5-HH), 2.64 (1H, ddd, J 15.0, 6.6, 0.9 Hz, 
3-HH), 2.72 (1H, ddd, J 15.0, 3.9, 1.7 Hz, 3-HH), 3.06–3.10 (1H, m, 6-H), 3.74 (3H, s, OCH3), 4.04 (1H, 
dd, J 6.6, 3.9 Hz, 2-H); δC (101 MHz, CDCl3) 13.9 (CH3), 18.7 (CH2), 38.2 (CH2), 42.1 (CH2), 47.7 (CH2), 
52.3 (CH), 52.4 (CH3), 55.8 (CH), 173.1 (C), 207.1 (C); m/z (CI) 200.1292 (MH+. C10H18NO3 requires 
200.1287), 181 (9%), 164 (7), 156 (4), 140 (5). 
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Methyl (2S,6S)-1-tert-butoxycarbonyl-4-oxo-6-propylpiperidine-2-carboxylate (242)   
 
 
 
Methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (240) (0.134 g, 0.673 mmol) was dissolved 
in dichloromethane (7 mL) and cooled to 0 °C. Triethylamine (0.469 mL, 3.37 mmol) was added 
followed by di-tert-butyl dicarbonate (0.294 g, 1.34 mmol). The solution was heated under reflux 
and stirred for 48 h. Upon completion, the mixture was quenched with an aqueous saturated 
ammonium chloride solution (5 mL), diluted with dichloromethane (5 mL), washed with water (10 
mL), brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified 
via flash column chromatography on silica gel, eluting with 30% ethyl acetate in petroleum ether 
(40–60) to produce methyl (2S,6S)-1-tert-butoxycarbonyl-4-oxo-6-propylpiperidine-2-carboxylate 
(242) (0.140 g, 70%) as a yellow oil. Rf 0.28 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 
2961 (CH), 1690 (C=O), 1395, 1364, 1167, 773; [α]D27 −90.5 (c 1.1, CHCl3); δH (500 MHz, CDCl3) 0.91 
(3H, t, J 7.2 Hz, 3’-H3), 1.33–1.50 (12H, m, 3 × CH3, 2’-H2 and 1’-HH ), 1.64–1.73 (1H, m, 1’-HH), 2.36–
2.48 (1H, m, 5-HH), 2.57–2.73 (2H, m, 3-HH and 5-HH), 2.79–2.93 (1H, m, 3-HH), 3.74 (3H, s, OCH3), 
4.32–4.64 (1H, m, 6-H), 4.71–5.24 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.0 (CH3), 19.8 (CH2), 28.4 (3 
× CH3), 38.1 (CH2), 39.8 (CH2), 44.0 (CH2), 51.8 (CH), 52.6 (CH3), 53.6 (CH), 81.3 (C), 154.9 (C), 172.5 
(C), 205.9 (C); m/z (ESI) 322.1624 (MNa+. C15H25NNaO5 requires 322.1625). 
 
Methyl (2S,4R,6S)-1-tert-butyloxycarbonyl-4-hydroxy-6-propylpiperidine-2-carboxylate (243)   
 
 
 
Methyl (2S,6S)-1-tert-butoxycarbonyl-4-oxo-6-propylpiperidine-2-carboxylate (242) (0.140 g, 0.468 
mmol) was dissolved in methanol (5 mL) and cooled to −10 °C. Sodium borohydride (0.0195 g, 0.515 
mmol) was then added. The mixture was stirred for 0.5 h and quenched with water (3 mL). The 
solution was diluted with ethyl acetate (10 mL) and washed with water (5 mL), brine (5 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 30% ethyl acetate in dichloromethane to produce methyl 
(2S,4R,6S)-1-tert-butyloxycarbonyl-4-hydroxy-6-propylpiperidine-2-carboxylate (243) (0.098 g, 
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70%) as a colourless oil. Rf 0.38 (30% ethyl acetate in dichloromethane); νmax/cm−1 (neat) 3502 (OH), 
2958 (CH), 1670 (C=O), 1365, 1170, 1074, 734; [α]D27 −56.4 (c 0.9, CHCl3); δH (500 MHz, CDCl3) 0.90 
(3H, t, J 7.4 Hz, 3’-H3), 1.29–1.39 (2H, m, 2’-H), 1.46 (9H, s, 3 × CH3), 1.55–1.65 (1H, m, 1’-HH), 1.71–
1.82 (3H, m, 1’-HH and 5-H2), 1.94 (1H, ddd, J 14.3, 7.2, 3.5 Hz, 3-HH), 2.08 (1H, d, J 2.3 Hz, OH), 2.40 
(1H, dt, J 14.3, 3.5 Hz, 3-HH), 3.71 (3H, s, OCH3), 4.08–4.17 (2H, m, 4-H and 6-H), 4.87 (1H, d, J 3.5 
Hz, 2-H); δC (126 MHz, CDCl3) 14.2 (CH3), 20.5 (CH2), 28.5 (3 × CH3), 32.4 (CH2), 33.6 (CH2), 38.0 (CH2), 
49.9 (CH), 50.0 (CH), 52.3 (CH3), 64.1 (CH), 80.3 (C), 155.6 (C), 174.7 (C); m/z (ESI) 324.1792 (MNa+. 
C17H26NNaO5 requires 324.1781). 
 
Methyl (2S,4R,6S)-1-tert-butyloxycarbonyl-4-(methoxymethoxy)-6-propylpiperidine-2-
carboxylate (244)   
 
 
 
Methyl (2S,4R,6S)-1-tert-butyloxycarbonyl-4-hydroxy-6-propylpiperidine-2-carboxylate (243) 
(0.172 g, 0.572 mmol) was dissolved in dichloromethane (10 mL) at room temperature and 
bromomethyl methyl ether (0.0700 mL, 0.858 mmol) was added, followed by N,N-
diisopropylethylamine (0.149 mL, 0.858 mmol). The mixture was allowed to stir at reflux for 48 h. 
Upon completion, the mixture was diluted with dichloromethane (10 mL), washed with water (2 × 
10 mL), brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified 
via flash column chromatography on silica gel, eluting with 20% ethyl acetate in petroleum ether 
(40–60) to produce methyl (2S,4R,6S)-1-tert-butyloxycarbonyl-4-(methoxymethoxy)-6-
propylpiperidine-2-carboxylate (244) (0.169 g, 86%) as a colourless oil. Rf 0.30 (20% ethyl acetate in 
petroleum ether); νmax/cm−1 (neat) 2954 (CH0, 1685 (C=O), 1365, 1174, 1098, 1035, 917, 734; [α]D24 
+13.0 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 0.92 (3H, t, J 7.4 Hz, 3’-H3), 1.30–1.39 (2H, m, J 14.8, 7.4 
Hz, 2’-H2), 1.45 (9H, s, 3 × CH3), 1.56–1.67 (1H, m, 1’-HH), 1.72–1.88 (3H, m, 1’-HH and 5-H2), 1.93 
(1H, ddd, J 14.0, 7.5, 3.3 Hz, 3-HH), 2.40 (1H, dt, J 10.2, 4.6 Hz, 3-HH), 3.33 (3H, s, OCH2OCH3), 3.69 
(3H, s, OCH3), 3.91 (1H, ddd, J 9.2, 5.3, 4.1 Hz, 4-H), 4.10 (1H, td, J 8.6, 2.5 Hz, 6-H), 4.52 (1H, d, J 6.8 
Hz, OCHHOCH3), 4.61 (1H, d, J 6.8 Hz, OCHHOCH3), 4.70–4.77 (1H, m, 2-H); δC (126 MHz, CDCl3) 14.3 
(CH3), 20.4 (CH2), 28.5 (3 × CH3), 29.8 (CH2), 31.7 (CH2), 38.3 (CH2), 50.0 (CH), 51.0 (CH), 51.9 (CH3), 
55.4 (CH3), 67.8 (CH), 80.20 (C), 94.1 (CH2), 155.6 (C), 173.3 (C); m/z (ESI) 368.2027 (MNa+. 
C17H31NNaO6 requires 368.2044). 
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(2S,4R,6S)-1-tert-Butyloxycarbonyl-4-(methoxymethoxy)-6-propylpiperidine-2-hydroxymethyl 
(245)   
 
 
 
Methyl (2S,4R,6S)-1-tert-butyloxycarbonyl-4-(methoxymethoxy)-6-propylpiperidine-2-carboxylate 
(244) (0.078 g, 0.226 mmol) was dissolved in diethyl ether (10 mL) and cooled to 0 °C. 
Diisobutylaluminium hydride solution (0.497 mL, 0.497 mmol, 1.0 M in THF) was added and the 
mixture was allowed to stir for 48 h while warming to room temperature. Upon completion the 
reaction was quenched with saturated potassium sodium tartrate solution (10 mL) and allowed to 
stir vigorously for 1 h. The mixture was diluted with diethyl ether (10 mL), washed with water (5 
mL), brine (5 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified via 
flash column chromatography on silica gel, eluting with 40% ethyl acetate in petroleum ether (40–
60) to produce (2S,4R,6S)-1-tert-butyloxycarbonyl-4-(methoxymethoxy)-6-propylpiperidine-2-
hydroxymethyl (245) (0.055 g, 77%) as a colourless oil. Rf 0.21 (40% ethyl acetate in petroleum 
ether); νmax/cm−1 (neat) 3454 (OH), 2957 (CH), 2930 (CH), 1685 (C=O), 1663, 1466, 1366, 1039; [α]D23 
−24.6 (c 1.2, CHCl3); δH (400 MHz, CDCl3) 0.90 (3H, t, J 7.3 Hz, 3’-H3), 1.23–1.40 (2H, m, 2’-H2), 1.45 
(9H, s, 3 × CH3), 1.59–1.81 (4H, m, 1’-H2, 3-HH and 5-HH), 1.87–1.98 (2H, m, 3-HH and 5-HH), 2.79 
(1H, s, OH), 3.35 (3H, s, OCH3), 3.69 (1H, dd, J 10.8, 6.2 Hz, 1’’-HH), 3.76 (1H, dd, J 10.8, 8.3 Hz, 1’’-
HH) 3.84 (1H, tt, J 6.2, 4.1 Hz, 4-H), 4.12 (1H, ddd, J 15.1, 7.9, 3.5 Hz, 6-H), 4.35 (1H, tdd, J 8.0, 6.3, 
4.4 Hz, 2-H), 4.63 (2H, s, OCH2OCH3); δC (101 MHz, CDCl3) 14.2 (CH3), 20.2 (CH2), 28.6 (3 × CH3), 30.1 
(CH2), 32.1 (CH2), 40.1 (CH2), 49.8 (CH), 51.8 (CH), 55.5 (CH), 67.5 (CH2), 69.8 (CH), 80.3 (C), 95.1 
(CH2), 157.0 (C); m/z (ESI) 340.2085 (MNa+. C16H31NNaO5 requires 340.2094). 
 
(5S,7R,8aS)-7-(Methoxymethoxy)-5-propyl-hexahydro-1H-[1,3]oxazolo[3,4-a]pyridin-3-one (247)   
 
 
 
(2S,4R,6S)-1-tert-Butyloxycarbonyl-4-(methoxymethoxy)-6-propylpiperidine-2-hydroxymethyl 
(245) (0.0276 g, 0.0870 mmol) was dissolved in dichloromethane (5 mL) and cooled to 0 °C. 4-
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(Dimethylamino)pyridine (0.00160 g, 0.0131 mmol), triethylamine (0.0279 mL, 0.200 mmol) and 
methanesulfonyl chloride (0.0108 mL, 0.139 mmol) was added sequentially. The mixture was 
allowed to stir at room temperature for 24 h. Upon completion the mixture was diluted with 
dichloromethane (10 mL), washed with water (5 mL), brine (5 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 40% ethyl acetate/1% triethylamine in petroleum ether (40–60) to produce 
(5S,7R,8aS)-7-(methoxymethoxy)-5-propyl-hexahydro-1H-[1,3]oxazolo[3,4-a]pyridin-3-one (247) 
(0.012 g, 60%) as a colourless oil. Rf 0.13 (40% ethyl acetate/1% triethylamine in petroleum ether); 
νmax/cm−1 (neat) 2958 (CH), 1743 (C=O), 1365, 1224, 1033, 734; [α]D23 −30.7 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 0.95 (3H, t, J 7.4 Hz, 3’-H3), 1.33–1.49 (4H, m, 2’-H2, 3-HH and 5-HH), 1.74 (1H, ddt, J 
13.8, 8.9, 6.6 Hz, 1’-HH), 2.01–2.07 (1H, m, 5-HH), 2.07–2.15 (1H, m, 3-HH), 2.41 (1H, ddt, J 12.9, 
9.7, 6.6 Hz, 1’-HH), 3.05–3.14 (1H, m, 6-H), 3.34–3.40 (3H, m, OCH3), 3.53–3.64 (1H, m, 2-H), 3.68 
(1H, tt, J 11.2, 4.3 Hz, 4-H), 3.87 (1H, dd, J 8.4, 4.8 Hz, 1’’-HH), 4.30 (1H, dd, J 8.4, 7.5 Hz, 1’’-HH), 
4.67 (1H, d, J 7.0 Hz, OCHHCH3), 4.70 (1H, d, J 7.0 Hz, OCHHCH3); δC (101 MHz, CDCl3) 14.1 (CH3), 
19.8 (CH2), 33.4 (CH2), 36.7 (CH2), 37.9 (CH2), 55.0 (CH), 55.6 (CH3), 56.1 (CH), 66.7 (CH2), 73.2 (CH), 
94.9 (CH2), 156.1 (C); m/z (ESI) 266.1356 (MNa+. C12H21NNaO4 requires 266.1363). 
 
Methyl (2S,6S)-1-benzyl-4-oxo-6-propylpiperidine-2-carboxylate (248) 
 
 
 
Methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (240) (0.0414 g, 0.208 mmol) was dissolved 
in acetonitrile (3 mL) followed by addition of potassium carbonate (0.0431 g, 0.312 mmol) and 
benzyl bromide (0.0296 mL, 0.249 mmol). The solution was heated under reflux and stirred for 38 
h. Upon completion, the mixture was diluted with ethyl acetate (5 mL), washed with water (10 mL), 
brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified via 
flash column chromatography on silica gel, eluting with 30% ethyl acetate in petroleum ether (40–
60) to produce methyl (2S,6S)-1-benzyl-4-oxo-6-propylpiperidine-2-carboxylate (248) (0.049 g, 
82%) as a yellow oil. Rf 0.29 (30% ethyl acetate in petroleum ether); [α]D23 −28.7 (c 1.2, CHCl3); 
νmax/cm−1 (neat) 2956 (CH), 1732 (C=O), 1454, 1197, 1166, 1028, 734, 698; δH (400 MHz, CDCl3) 0.83 
(3H, t, J 7.1 Hz, 3’’-H3), 1.15–1.40 (3H, m, 2’’-H2 and 1’’-HH), 1.54–1.67 (1H, m, 1’’-HH), 2.38 (1H, 
ddd, J 15.4, 7.4, 0.9 Hz, 5-HH), 2.48–2.58 (2H, m, 3-HH and 5-HH), 2.78 (1H, ddd, J 15.4, 6.1, 0.9 Hz, 
3-HH), 3.12 (1H, tt, J 7.4, 4.8 Hz, 6-H), 3.57 (3H, s, OCH3), 3.79 (1H, t, J 6.1 Hz, 2-H), 3.92 (1H, d, J 
14.6 Hz, CHHPh), 4.00 (1H, d, J 14.6 Hz, CHHPh), 7.22–7.43 (5H, m, Ph); δC (101 MHz, CDCl3) 14.0 
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(CH3), 19.5 (CH2), 35.5 (CH2), 40.2 (CH2), 43.6 (CH2), 52.0 (CH3), 55.5 (CH2), 59.6 (CH), 60.8 (CH), 127.2 
(CH), 128.3 (2 × CH), 128.6 (2 × CH), 139.0 (C), 173.1 (C), 207.8 (C); m/z (ESI) 312.1558 (MNa+. 
C17H23NNaO3 requires 312.1570). 
 
Methyl (2S,4R,6S)-4-hydroxy-6-propylpiperidine-2-carboxylate (250) 
 
 
 
Methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (240) (0.0728 g, 0.366 mmol) was dissolved 
in methanol (4 mL) and cooled to −10 °C. Sodium borohydride (0.0145 g, 0.384 mmol) was then 
added. The mixture was stirred for 0.5 h and quenched with water (3 mL). The solution was diluted 
with ethyl acetate (10 mL) and washed with water (5 mL), brine (5 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 5% methanol/1% triethylamine in dichloromethane to produce methyl (2S,4R,6S)-
4-hydroxy-6-propylpiperidine-2-carboxylate (250) (0.044 g, 60%) as a yellow oil. Rf 0.26 (5% 
methanol/1% triethylamine in dichloromethane); [α]D23 −15.5 (c 1.0, CHCl3); νmax/cm−1 (neat) 3336 
(NH and OH), 2955 (CH), 1737 (C=O), 1435, 1205, 1159, 1047, 754; δH (500 MHz, CDCl3) 0.92 (3H, t, 
J 7.1 Hz, 3’’-H3), 1.01 (1H, q, J 11.9 Hz, 5-HH), 1.28–1.54 (5H, m, 2’’-H2, 1’’-H2 and 3-HH), 1.99 (1H, 
ddt, J 11.9, 4.6, 2.5 Hz, 5-HH), 2.11 (2H, br s, NH and OH), 2.31 (1H, ddt, J 11.9, 4.6, 2.5 Hz, 3-HH), 
2.57 (1H, dtd, J 8.8, 6.2, 2.5 Hz, 6-H), 3.38 (1H, dd, J 11.9, 2.5 Hz, 2-H), 3.66–3.76 (4H, m, 4-H and 
OCH3); δC (126 MHz, CDCl3) 14.1 (CH3), 19.1 (CH2), 38.4 (CH2), 38.7 (CH2), 41.5 (CH2), 52.2 (CH3), 54.0 
(CH), 57.3 (CH), 68.9 (CH), 173.0 (C); m/z (ESI) 224.1254 (MNa+. C10H19NNaO3 requires 224.1257). 
 
Methyl (2S,4R,6S)-1-benzyl-4-hydroxy-6-propylpiperidine-2-carboxylate (251) 
 
 
 
Methyl (2S,4R,6S)-4-hydroxy-6-propylpiperidine-2-carboxylate (250) (0.103 g, 0.512 mmol) was 
dissolved in acetonitrile (5 mL) followed by addition of potassium carbonate (0.283 g, 2.05 mmol), 
sodium iodide (0.575 g, 3.84 mmol) and benzyl bromide (0.609 mL, 5.12 mmol). The solution was 
heated under reflux and stirred for 36 h. Upon completion, the mixture was diluted with ethyl 
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acetate (10 mL), washed with water (10 mL), brine (10 mL), dried over MgSO4 and concentrated in 
vacuo. The crude product was purified via flash column chromatography on silica gel, eluting with 
5% methanol in dichloromethane to produce methyl (2S,4R,6S)-1-benzyl-4-hydroxy-6-
propylpiperidine-2-carboxylate (251) (0.123 g, 63%) as a yellow oil. Rf 0.28 (5% methanol in 
dichloromethane); [α]D21 +2.6 (c 1.0, CHCl3); νmax/cm−1 (neat) 3385 (NH), 2955 (CH), 1735 (C=O), 
1452, 1281, 1164, 1027, 732, 699; δH (400 MHz, CDCl3) 0.78 (3H, t, J 7.3 Hz, 3’-H), 1.13–1.28 (1H, m, 
2’-HH), 1.29–1.44 (3H, m, 2’-HH, 1’-H2 and 5-HH), 1.60–1.79 (2H, m, 1’-H2 and 3-HH), 1.92–2.00 (1H, 
m, 5-HH), 2.00–2.11 (2H, m, 3-HH and OH), 2.45 (1H, ddt, J 11.1, 8.1, 3.1 Hz, 6-H), 3.30 (1H, dd, J 
11.7, 2.9 Hz, 2-H), 3.48 (3H, s, OCH3), 3.56–3.80 (3H, m, CH2Ph and 4-H), 7.17–7.23 (1H, m, ArH), 
7.27–7.35 (4H, m, ArH); δC (101 MHz, CDCl3) 14.3 (CH3), 19.0 (CH2), 36.3 (CH2), 36.9 (CH2), 38.7 (CH2), 
51.9 (CH3), 54.3 (CH2), 59.8 (CH), 64.8 (CH), 68.0 (CH), 126.8 (CH), 128.0 (2 × CH2), 128.8 (2 × CH2), 
139.0 (C), 173.5 (C); m/z (ESI) 314.1718 (MNa+. C17H25NNaO3 requires 314.1727). 
 
(2S,4R,6S)-1-Benzyl-2-(hydroxymethyl)-6-propylpiperidine-4-ol (252) 
 
 
 
Methyl (2S,4R,6S)-1-benzyl-4-hydroxy-6-propylpiperidine-2-carboxylate (251) (0.0522 g, 0.179 
mmol) was dissolved in acetonitrile (2 mL) and cooled to 0 °C. Lithium borohydride (0.00897 g, 
0.412 mmol) was added and the solution was heated under reflux for 18 h. Upon completion, the 
mixture was diluted with ethyl acetate (10 mL), washed with water (10 mL), brine (10 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 10% methanol in dichloromethane to produce (2S,4R,6S)-
1-benzyl-2-(hydroxymethyl)-6-propylpiperidine-4-ol (252) (0.034 g, 72%) as an off-white solid. Mp 
87–90 °C; Rf 0.26 (10% methanol in dichloromethane); [α]D23 +17.2 (c 1.0, CHCl3); νmax/cm−1 (neat) 
3190 (OH), 2932 (CH), 1454, 1043, 732, 697; δH (400 MHz, CDCl3) 0.87 (3H, t, J 7.2 Hz, 3’’-H3), 1.20–
1.49 (4H, m, 2’’-H2 and 1’’-H2), 1.55 (1H, q, J 11.7 Hz, 3-HH), 1.61–1.80 (2H, m, 5-HH and 3-HH), 
1.91–2.28 (3H, m, 5-HH, NH and OH), 2.62 (1H, ddd, J 11.7, 7.1, 3.5 Hz, 6-H), 2.73–2.83 (1H, m, 2-
H), 3.35 (1H, dd, J 11.7, 5.7 Hz, 1’-HH), 3.50 (1H, dd, J 11.7, 4.1 Hz, 1’-HH), 3.61–3.80 (3H, m, 4-H 
and CH2Ph), 7.21–7.26 (1H, m, ArH), 7.30–7.42 (4H, m, 4 × ArH); δC (101 MHz, CDCl3) 14.3 (CH3), 
19.6 (CH2), 34.5 (CH2), 37.0 (CH2), 37.9 (CH2), 50.5 (CH2), 60.9 (CH), 63.0 (CH), 63.7 (CH2), 68.7 (CH), 
126.9 (CH), 127.5 (2 × CH), 128.7 (2 × CH), 141.4 (C); m/z (ESI) 286.1768 (MNa+. C16H25NNaO2 
requires 286.1778). 
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Methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (255)109 
 
 
 
To a suspension of imidazole (4.11 g, 60.4 mmol) and triphenylphosphine (11.9 g, 45.3 mmol) in a 
mixture of diethyl ether and dichloromethane (2:1, 100 mL) at 0 °C was added iodine (11.5 g, 45.3 
mmol) in three portions over 0.5 h. After stirring for a further 0.2 h, a solution of methyl (3S)-3-
(tert-butoxycarbonylamino)-4-hydroxybutanoate (189) (7.03 g, 30.2 mmol) in a mixture of diethyl 
ether and dichloromethane (2:1, 50 mL) was added and the resulting reaction mixture was stirred 
for 3 h at room temperature. The reaction mixture was filtered through Celite® and the filtrate was 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 30% diethyl ether in petroleum ether (40–60) to produce methyl (3S)-3-(tert-
butoxycarbonylamino)-4-iodobutanoate (255) (9.33 g, 90%) as a clear oil. Spectroscopic data were 
consistent with the literature.109 Rf 0.27 (20% ethyl acetate in petroleum ether); [α]D33 +7.3 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 1.40 (9H, s, 3 × CH3), 2.60 (1H, dd, J 16.4, 6.1 Hz, 2-HH), 2.70 (1H, dd, J 
16.4, 5.6 Hz, 2-HH), 3.28–3.45 (2H, m, 4-H2), 3.66 (3H, s, OCH3), 3.81–3.95 (1H, m, 3-H), 5.11 (1H, d, 
J 7.2 Hz, NH); δC (101 MHz, CDCl3) 11.1 (CH2), 28.4 (3 × CH3), 38.6 (CH2), 47.7 (CH), 52.0 (CH3), 80.0 
(C) 154.7 (C), 171.2 (C); m/z (ESI) 366 (MNa+, 100%). 
 
Methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (256)175 
 
 
 
A solution of methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (255) (9.33 g, 27.2 mmol), 
N,N-diisopropylethylamine (7.11 mL, 40.8 mmol), 10% Pd/C (2.89 g, 2.72 mmol) in methanol (50 
mL) was purged with hydrogen for 0.5 h. The reaction mixture was stirred under an atmosphere of 
hydrogen for 18 h at room temperature. It was then filtered through Celite® and the filtrate was 
concentrated in vacuo. The resulting residue was dissolved in dichloromethane (100 ml) and 
washed with a saturated solution of sodium hydrogen carbonate (50 mL), 1 M hydrochloric acid (50 
ml), brine (50 mL), dried over MgSO4, filtered and the dichloromethane was removed in vacuo  to 
give methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (256) as a clear oil (5.87 g, 99%). 
Spectroscopic data were consistent with the literature.175 Rf 0.17 (20% ethyl acetate in petroleum 
ether); [α]D26 +21.5 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.20 (3H, d, J 6.8 Hz, 4-H3), 1.43 (9H, s, 3 × 
CH3), 2.47 (1H, dd, J 15.5, 6.0 Hz, 2-HH), 2.52 (1H, dd, J 15.5, 5.4 Hz, 2-HH), 3.68 (3H, s, OCH3), 4.03 
178 
 
(1H, br s, 3-H), 4.91 (1H, br s, NH); δC (126 MHz, CDCl3) 20.5 (CH3), 28.4 (3 × CH3), 40.6 (CH2), 43.4 
(CH), 51.6 (CH3), 79.3 (C), 155.0 (C), 172.0 (C); m/z (ESI) 240 (MNa+, 100%). 
 
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (257) 
 
 
 
Dimethyl methylphosphonate (3.74 mL, 34.5 mmol) was dissolved in tetrahydrofuran (100 mL) and 
cooled to −78 °C under an argon atmosphere. n-Butyl lithium (2.5 M, in hexane, 13.8 mL, 34.5 mmol) 
was added dropwise and the mixture was stirred for 0.3 h. A solution of methyl (3R)-3-(tert-
butoxycarbonylamino)butanoate (256) (3.00 g, 13.8 mmol) in tetrahydrofuran (20 mL) was added 
dropwise. The resulting reaction mixture was then stirred at −78 °C for 0.5 h and allowed to warm 
to 0 °C over a period of 1 h. The reaction was quenched with a saturated aqueous solution of 
ammonium chloride (4 mL). Extraction was performed with ethyl acetate (2 × 50 mL). The combined 
organic layers were then combined, washed with brine (100 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude product was purified via flash column chromatography on silica 
gel, eluting with 40% ethyl acetate in dichloromethane to produce (4R)-4-(tert-
butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (257) (2.99 g, 70%) as a clear oil. 
Rf 0.19 (100% ethyl acetate); νmax/cm−1 (neat) 3316 (NH), 2976 (CH), 1704 (C=O), 1700 (C=O), 1248, 
1167, 1023; [α]D31 +38.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H, d, J 6.7 Hz, 5-H3), 1.39 (9H, s, 
3 × CH3), 2.71 (1H, dd, J 16.9, 5.9 Hz, 3-HH), 2.80 (1H, dd, J 16.9, 5.9 Hz, 3-HH), 3.03 (1H, dd, J 22.6, 
13.6 Hz, 1-HH), 3.12 (1H, dd, J 22.6, 13.6 Hz, 1-HH), 3.74 (3H, d, J 0.8 Hz, OCH3), 3.77 (3H, d, J 0.8 
Hz, OCH3), 3.93–4.09 (1H, m, 4-H), 4.92 (1H, br s, NH); δC (101 MHz, CDCl3) 20.6 (CH3), 28.3 (3 × CH3), 
41.8 (d, JC-P 127.5 Hz, CH2), 43.3 (CH), 50.2 (CH2), 53.1 (d, JC-O-P 6.5 Hz, CH3), 53.2 (d, JC-O-P 6.5 Hz, CH3), 
79.3 (C), 155.2 (C), 200.6 (C); m/z (ESI) 332.1225 (MNa+. C12H24NNaO6P requires 332.1233). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (258) 
 
 
 
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (257) (0.421 g, 1.36 
mmol) was dissolved in anhydrous acetonitrile (14 mL) and potassium carbonate (0.225 g, 1.63 
mmol) was added. The mixture was stirred at room temperature for 0.5 h followed by addition of 
butyraldehyde (0.250 mL, 2.72 mmol). The temperature was increased to 50 °C and the mixture 
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was stirred for 72 h. Once the reaction was complete, the solution was concentrated in vacuo, 
redissolved in ethyl acetate (20 mL) and washed with water (2 × 15 mL) and brine (15 mL). The 
organic layer was dried over MgSO4 and concentrated in vacuo. The crude product was purified via 
a plug of silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-2-
(tert-butoxycarbonylamino)-4-oxonona-5-ene (258) as a clear colourless oil (0.301 g, 87%). Rf 0.24 
(20% ethyl acetate/petroleum ether); νmax/cm−1 (neat) 3350 (NH), 2968 (CH), 1689 (C=O), 1516, 
1365, 1166, 1053, 977; [α]D26 +9.3 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 0.94 (3H, t, J 7.3 Hz, 9-H3), 1.20 
(3H, d, J 6.9 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 1.46–1.55 (2H, m, 8-H2), 2.20 (qd, J 6.9, 1.5 Hz, 7-H2), 
2.64 (1H, dd, J 15.9, 6.5 Hz, 3-HH), 2.86 (1H, dd, J 15.9, 4.5 Hz, 3-HH), 3.98–4.09 (1H, m, 2-H), 5.02 
(1H, br s, NH), 6.09 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.86 (1H, dt, J 15.9, 6.9 Hz, 6-H); δC (126 MHz, CDCl3) 
13.7 (CH3), 20.5 (CH3), 21.4 (CH2), 28.4 (3 × CH3), 34.5 (CH2), 43.7 (CH), 45.7 (CH2), 79.1 (C), 130.8 
(CH), 148.2 (CH), 155.2 (C), 199.2 (C); m/z (ESI) 278.1725 (MNa+. C14H25NNaO3 requires 278.1727). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxopentadec-5-ene (259) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.405 g, 1.31 mmol) and decanal (0.5 mL, 2.618 
mmol) for 96 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 30% diethyl ether in petroleum ether (40–60) to produce (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxopentadec-5-ene (259) (0.345 g, 78%) as a colourless oil. Rf 0.25 (30% 
diethyl ether in petroleum ether); νmax/cm−1 (neat) 3327 (NH), 2958 (CH), 1693 (C=O), 1365, 1170, 
1053; [α]D25 +4.2 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.3 Hz, 15-H3), 1.20 (3H, d, J 6.7 
Hz, 1-H3), 1.23–1.34 (12H, m, 9-H2, 10-H2, 11-H2, 12-H2, 13-H2 and 14-H2), 1.39–1.50 (11H, m, 8-H2 
and 3 × CH3), 2.20 (2H, q, J 7.0 Hz, 7-H2), 2.63 (1H, dd, J 15.7, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.7, 4.5 
Hz, 3-HH), 3.96–4.08 (1H, m, 2-H), 4.95 (1H, br s, NH), 6.08 (1H, d, J 15.6 Hz, 5-H), 6.85 (1H, dt, J 
15.6, 7.0 Hz, 6-H); δC (126 MHz, CDCl3) 14.1 (CH3), 20.5 (CH3), 22.7 (CH2), 28.1 (CH2), 28.4 (3 × CH3), 
29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 31.9 (CH2), 32.5 (CH2), 43.7 (CH), 45.7 (CH2), 79.2 (C), 
130.6 (CH), 148.5 (CH), 155.2 (C), 199.2 (C); m/z (ESI) 362.2649 (MNa+. C20H37NNaO3 requires 
362.2666). 
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(2R,5E)-6-Phenyl-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (263)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.251 g, 0.810 mmol) and benzaldehyde (0.160 mL, 
1.62 mmol) for 48 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 20% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-6-phenyl-2-(tert-
butoxycarbonylamino)-4-oxohex-5-ene (263)  (0.227 g, 97%) as a white solid. Mp 59–62 °C; Rf 0.18 
(20% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3345 (NH), 2976 (CH), 1687 (C=O), 1655 
(C=O), 1608 (C=C), 1495, 1365, 1247, 1166; [α]D23 +10.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.25 (3H, 
d, J 6.8 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.77 (1H, dd, J 15.8, 6.8 Hz, 3-HH), 3.00 (1H, dd, J 15.8, 4.6 
Hz, 3-HH), 4.05–4.18 (1H, m, 2-H), 5.04 (1H, br s, NH), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.36–7.41 (3H, m, 
3 × ArH), 7.52–7.54 (2H, m, 2 × ArH), 7.56 (1H, d, J 16.2 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 
28.4 (3 × CH3), 43.8 (CH), 46.6 (CH2), 79.2 (C), 126.4 (CH), 128.4 (2 × CH), 129.0 (2 × CH), 130.6 (CH), 
134.4 (C), 143.2 (CH), 155.2 (C), 198.9 (C); m/z (ESI) 312.1558 (MNa+. C17H23NNaO3 requires 
312.1570). 
 
(2R,5E)-6-(4’-Methoxyphenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (264) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.241 g, 0.781 mmol) and anisaldehyde (0.190 mL, 
1.56 mmol) for 96 h. The crude product was purified via flash column chromatography on silica gel, 
eluting with 20% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-6-(4’-
methoxyphenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (264)  (0.186 g, 75%) as a white 
solid. Mp 102–105 °C; Rf 0.10 (20% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3375 (NH), 
2980 (CH), 1682 (C=O), 1600 (C=C), 1511 (C=C), 1324, 1248, 1163, 1030; [α]D23 +50.1 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 1.24 (3H, d, J 6.8 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.74 (1H, dd, J 15.7, 6.8 Hz, 3-
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HH), 2.97 (1H, dd, J 15.7, 4.5 Hz, 3-HH), 3.84 (3H, s, OCH3), 4.04–4.16 (1H, m, 2-H), 5.03 (1H, br s, 
NH), 6.62 (1H, d, J 16.1 Hz, 5-H), 6.91 (2H, d, J 8.7 Hz, 3’-H and 5’-H), 7.50 (2H, d, J 8.7 Hz, 2’-H and 
6’-H), 7.54 (1H, d, J 16.1 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 43.9 (CH), 46.4 
(CH2), 55.4 (CH3), 79.2 (C), 114.4 (2 × CH), 124.2 (CH), 127.0 (C), 130.1 (2 × CH), 143.1 (CH), 155.2 
(C), 161.7 (C), 198.8 (C); m/z (ESI) 342.1661 (MNa+. C18H25NNaO4 requires 342.1676). 
 
(2R,5E)-6-(Naphthalen-2’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (265) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.262 g, 0.849 mmol) and 2-naphthaldehyde (0.265 
g, 1.70 mmol) for 48 h. The crude product was purified via flash column chromatography on silica 
gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-6-(naphthalen-
2’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (265) (0.231 g, 80%) as a white solid. Mp 103–
106 °C; Rf 0.35 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3358 (NH), 2972 (CH), 1683 
(C=O), 1518 (C=C), 1364, 1247, 1168, 1050; [α]D23 +30.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.27 (3H, 
d, J 6.7 Hz, 1-H3), 1.44 (9H, s, 3 × CH3), 2.81 (1H, dd, J 15.9, 6.7 Hz, 3-HH), 3.04 (1H, dd, J 15.9, 4.4 
Hz, 3-HH), 4.07–4.21 (1H, m, 2-H), 5.00 (1H, br s, NH), 6.85 (1H, d, J 16.1 Hz, 5-H), 7.48–7.56 (2H, m, 
6’-H and 7’-H), 7.68 (1H, dd, J 8.6, 1.2 Hz, 3’-H), 7.75 (1H, d, J 16.1 Hz, 6-H), 7.81–7.90 (3H, m, 4’-H, 
5’-H and 8’-H), 7.97 (1H, br s, 1’-H); δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 43.9 (CH), 46.7 
(CH2), 79.2 (C), 123.5 (CH), 126.4 (CH), 126.8 (CH), 127.4 (CH), 127.8 (CH), 128.6 (CH), 128.7 (CH), 
130.5 (CH), 131.9 (C), 133.3 (C), 134.4 (C), 143.2 (CH), 155.2 (C), 198.8 (C); m/z (ESI) 362.1710 (MNa+. 
C21H25NNaO3 requires 362.1727). 
 
(2R,5E)-6-(4’-Nitrophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (266) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
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(dimethyloxyphosphoryl)pentan-2-one (257) (0.209 g, 0.676 mmol) and 4-nitrobenzaldehyde 
(0.204 g, 1.35 mmol) for 6 h. The crude product was purified via flash column chromatography on 
silica gel, eluting with 30% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-6-(4’-
nitrophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (266)  (0.143 g, 63%) as a pale yellow 
solid. Mp 122–126 °C; Rf 0.19 (30% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3365 (NH), 
2980 (CH), 1683 (C=O), 1612 (C=O), 1514, 1348, 1168, 1047; [α]D26 +14.7 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 1.27 (3H, d, J 6.7 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.80 (1H, dd, J 15.8, 6.7 Hz, 3-HH), 3.06 (1H, 
dd, J 15.8, 4.2 Hz, 3-HH), 4.07–4.20 (1H, m, 2-H), 4.94 (1H, br s, NH), 6.86 (1H, d, J 16.2 Hz, 5-H), 
7.63 (1H, d, J 16.2 Hz, 6-H), 7.72 (2H, d, J 8.8 Hz, 2’-H and 6’-H), 8.26 (2H, d, J 8.8 Hz, 3’-H and 5’-H); 
δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 43.8 (CH), 47.4 (CH2), 79.4 (C), 124.2 (2 × CH), 128.9 
(2 × CH), 129.6 (CH), 140.0 (CH), 140.7 (C), 148.6 (C), 155.2 (C), 198.2 (C); m/z (ESI) 357.1405 (MNa+. 
C17H22N2NaO5 requires 357.1421). 
 
(2R,5E)-6-(Pyridin-3’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (267) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.212 g, 0.687 mmol) and 3-pyridinecarboxaldehyde 
(0.130 mL, 1.37 mmol) for 24 h. The crude product was purified via flash column chromatography 
on silica gel, eluting with 40% ethyl acetate in dichloromethane to produce (2R,5E)-6-(pyridin-3’-
yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (267) (0.130 g, 65%) as an off-white solid. Mp 93–
96 °C; Rf 0.1 (40% ethyl acetate in dichloromethane); νmax/cm−1 (neat) 3362 (NH), 2970 (CH), 1678 
(C=O), 1519 (C=C), 1365, 1251, 1165, 1057, 977; [α]D26 +6.0 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.26 
(3H, d, J 6.8 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.78 (1H, dd, J 15.8, 6.8 Hz, 3-HH), 3.03 (1H, dd, J 15.8, 
4.6 Hz, 3-HH), 4.06–4.19 (1H, m, 2-H), 5.03 (1H, br s, NH), 6.81 (1H, d, J 16.3 Hz, 5-H), 7.35 (1H, dd, 
J 7.9, 4.1 Hz, 5’-H), 7.59 (1H, d, J 16.3 Hz, 6-H), 7.85–7.91 (1H, m, 4’-H), 8.62 (1H, d, J 4.1 Hz, 6’-H), 
8.77 (1H, br s, 2’-H); δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 43.8 (CH), 47.1 (CH2), 79.3 (C), 
123.8 (CH), 128.0 (CH), 130.3 (C), 134.4 (CH), 139.3 (CH), 150.1 (CH), 151.2 (CH), 155.2 (C), 198.3 
(C); m/z (ESI) 313.1513 (MNa+. C16H22N2NaO3 requires 313.1523). 
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(2R,5E)-8-Phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-ene (268) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.349 g, 1.13 mmol) and hydrocinnamaldehyde 
(0.300 mL, 2.26 mmol) for 48 h. The crude product was purified via flash column chromatography 
on silica gel, eluting with 20% ethyl acetate in petroleum ether (40–60) to produce (2R,5E)-8-
phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-ene (268) (0.288 g, 80%) as a pale yellow oil. Rf 
0.19 (20% ethyl acetate in petroleum ether); νmax/cm−1 (neat) 3353 (NH), 2976 (CH), 1692 (C=O), 
1496 (C=C), 1247, 1221, 1054; [α]D23 +4.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H, d, J 6.7 Hz, 1-
H3), 1.43 (9H, s, 3 × CH3), 2.53 (2H, q, J 6.8 Hz, 7-H2), 2.60 (1H, dd, J 15.7, 7.8 Hz, 3-HH), 2.77 (2H, t, 
J 6.8 Hz, 8-H2), 2.84 (1H, dd, J 15.7, 4.5 Hz, 3-HH), 3.95–4.08 (1H, m, 2-H), 4.99 (1H, br s, NH), 6.09 
(1H, d, J 15.9 Hz, 5-H), 6.87 (1H, dt, J 15.9, 6.8 Hz, 6-H), 7.14–7.23 (3H, m, 3 × ArH), 7.25–7.32 (2H, 
m, 2 × ArH); δC (101 MHz, CDCl3) 20.5 (CH3), 28.4 (3 × CH3), 34.2 (CH2), 34.3 (CH2), 43.7 (CH), 45.8 
(CH2), 79.1 (C), 126.2 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 131.0 (CH), 140.6 (C), 146.9 (CH), 155.1 
(C), 198.9 (C); m/z (ESI) 340.1868 (MNa+. C19H27NNaO3 requires 340.1883). 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxohepta-5-ene (269) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxonona-5-ene (258) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (257) (0.386 g, 1.25 mmol) and acetaldehyde (0.140 mL, 
2.49 mmol) for 48 h. The crude product was purified via a plug of silica gel, eluting with 30% ethyl 
acetate in petroleum ether (40–60) producing (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxohepta-
5-ene (269) (0.197 g, 70%) as a pale yellow oil. Rf 0.27 (30% ethyl acetate in petroleum ether); 
νmax/cm−1 (neat) 3359 (NH), 2975 (CH), 1690 (C=O), 1517, 1365, 1247, 1166, 1052, 970; [α]D23 +2.6 
(c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.20 (3H, d, J 6.7 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 1.91 (3H, d, J 6.8 
Hz, 7-H3), 2.62 (1H, dd, J 15.7, 6.7 Hz, 3-HH), 2.86 (1H, dd, J 15.7, 4.6 Hz, 3-HH), 3.96–4.09 (1H, m, 
2-H), 5.02 (1H, br s, NH), 6.12 (1H, d, J 15.8 Hz, 5-H), 6.88 (1H, dq, J 15.8, 6.8 Hz, 6-H); δC (101 MHz, 
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CDCl3) 18.3 (CH3), 20.5 (CH3), 28.4 (3 × CH3), 43.8 (CH), 45.7 (CH2), 79.1 (C), 132.3 (CH), 143.5 (CH), 
155.2 (C), 198.9 (C); m/z (ESI) 250.1405 (MNa+. C12H21NNaO3 requires 250.1414). 
 
(2R,6S)-2-Methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one 
(261) 
 
 
 
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxonona-5-ene (258) (0.298 g, 1.17 mmol) was dissolved 
in dichloromethane (12 mL) and trifluoroacetic acid (0.890 mL, 11.7 mmol) was added dropwise. 
The mixture was stirred for 1.5 h at room temperature. Once the reaction was complete, the 
mixture was concentrated in vacuo and the crude residue was redissolved in methanol (12 mL) and 
cooled to 0 °C. N,N-Diisopropylethylamine (0.300 mL, 1.75 mmol) was added dropwise and the 
mixture was allowed to warm to room temperature and left to stir for 2 h. Upon completion, the 
mixture was diluted with ethyl acetate (15 mL) and washed with a saturated aqueous solution of 
sodium hydrogen carbonate (10 mL) and brine (10 mL). The organic layer was dried over MgSO4 
and concentrated in vacuo. The crude product was purified via flash column chromatography on 
silica gel (soaked with 1% triethylamine/dichloromethane), with a gradient elution from 40% ethyl 
acetate/10% dichloromethane/1% triethylamine in petroleum ether (40–60) to 40% ethyl 
acetate/30% dichloromethane/1% triethylamine in petroleum ether (40–60) to produce (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) (0.0780 g, 43%) as a dark orange oil. Further elution yielded 
(2R,6R)-2-methyl-6-propylpiperidin-4-one (261) (0.0760 g, 42%) as a dark orange oil. Data for 
(2R,6S)-2-methyl-6-propylpiperidin-4-one (260): Rf 0.47 (40% ethyl acetate/30% 
dichloromethane/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3302 (NH), 2962 (CH), 
1658 (C=O), 1527, 1458, 1257; [α]D26 +9.8 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 0.93 (3H, t, J 7.2 Hz, 
3’’-H3), 1.21 (3H, d, J 6.2 Hz, 1’-H3), 1.29–1.68 (5H, m, 1’’-H2, 2’’-H2 and NH), 1.99–2.12 (2H, m, 3-HH 
and 5-HH), 2.30–2.39 (2H, m, 3-HH and 5-HH), 2.85 (1H, tdd, J 9.1, 6.2, 2.9 Hz, 6-H), 2.96 (1H, dqd, 
J 12.4, 6.2, 2.9 Hz, 2-H); δC (101 MHz, CDCl3) 14.1 (CH3), 18.9 (CH2), 22.7 (CH3), 39.2 (CH2), 48.2 (CH2), 
50.2 (CH2), 52.1 (CH), 56.3 (CH), 209.6 (C); m/z (ESI) 156.1377 (MH+. C9H18NO requires 156.1383). 
Data for (2R,6R)-2-methyl-6-propylpiperidin-4-one (261): Rf 0.23 (40% ethyl acetate/30% 
dichloromethane/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3271 (NH), 2954 (CH), 
1720 (C=O), 1535, 1458, 964; [α]D26 −7.9 (c 0.1, CHCl3); δH (400 MHz, CDCl3) 0.92 (3H, t, J 7.1 Hz, 3’’-
H3), 1.16 (3H, d, J 6.5 Hz, 1’-H3), 1.23–1.52 (4H, m, 1’’-H2 and 2’’-H2), 1.61 (1H, br s, NH), 2.14 (2H, 
dddd, J 13.6, 11.6, 6.0, 1.6 Hz, 3-HH and 5-HH), 2.47 (2H, dddd, J 15.6, 14.0, 5.2, 1.6 Hz, 3-HH and 
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5-HH),3.27–3.36 (1H, m, 6-H), 3.39–3.49 (1H, m, 2-H); δC (101 MHz, CDCl3) 13.9 (CH3), 19.3 (CH2), 
21.6 (CH3), 36.9 (CH2), 47.8 (CH2 and CH), 49.6 (CH2), 52.3 (CH), 210.0 (C); m/z (ESI) 156.1378 (MH+. 
C9H18NO requires 156.1383). 
 
(2R,6S)-2-Methyl-6-nonylpiperidin-4-one (239)144 and (2R,6R)-2-methyl-6-nonylpiperidin-4-one 
(262)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxopentadec-5-ene (259) (0.302 g, 0.889 mmol). The 
crude product was purified via flash column chromatography on silica gel, (soaked with 1% 
triethylamine/petroleum ether) eluting with 20% ethyl acetate/1% triethylamine in petroleum 
ether (40–60) to produce (2R,6S)-2-methyl-6-nonylpiperidin-4-one (239) (0.0950 g, 45%) as an 
orange oil. Further elution yielded (2R,6R)-2-methyl-6-nonylpiperidin-4-one (262) (0.0930 g, 44%) 
as an orange oil. Data for (2R,6S)-2-methyl-6-nonylpiperidin-4-one (239): Rf 0.22 (20% ethyl 
acetate/1% triethylamine in petroleum ether); [α]D26 −2.4 (c 1.0, CHCl3), lit.,144 [α]D22 −1.5 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.2 Hz, 9’’-H3), 1.21 (3H, d, J 5.8 Hz, 1’-H3), 1.23–1.61 (17H, 
m, 1’’-H2, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2, 8’’-H2 and NH), 1.99–2.12 (2H, m, 3-HH and 5-
HH), 2.24–2.45 (2H, m, 3-HH and 5-HH), 2.77–2.89 (1H, m, 6-H), 2.90–3.04 (1H, m, 2-H); δC (101 
MHz, CDCl3) 14.1 (CH3), 22.7 (CH3 and CH2), 25.7 (CH2), 29.3 (CH2), 29.5 (2 × CH2), 29.6 (CH2), 31.9 
(CH2), 37.1 (CH2), 48.2 (CH2), 50.2 (CH2), 52.1 (CH), 56.6 (CH), 209.6 (C); m/z (ESI) 240 (MH+, 100%). 
Data for (2R,6R)-2-methyl-6-nonylpiperidin-4-one (262): Rf 0.07 (20% ethyl acetate/1% 
triethylamine in petroleum ether); νmax/cm−1 (neat) 3300 (NH), 2958 (CH), 1710 (C=O), 1458, 1377, 
1327; [α]D26 −3.5 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.3 Hz, 9’’-H3), 1.16 (3H, d, J 6.4 
Hz, 1’-H3), 1.20–1.54 (17H, m, 1’’-H2, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2, 8’’-H2 and NH), 2.09–
2.20 (2H, m, 3-HH and 5-HH), 2.42–2.54 (2H, m, 3-HH and 5-HH), 3.24–3.34 (1H, m, 6-H), 3.39–3.49 
(1H, m, 2-H); δC (101 MHz, CDCl3) 14.1 (CH3), 21.7 (CH3), 22.7 (CH2), 26.1 (CH2), 29.3 (CH2), 29.5 (CH2), 
29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 34.8 (CH2), 47.8 (CH), 47.8 (CH2), 49.6 (CH2), 52.7 (CH), 210.0 (C); 
m/z (ESI) 240.2316 (MH+. C15H30NO requires 240.2322). 
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(2R,6R)-2-Methyl-6-phenylpiperidin-4-one (270)139 and (2R,6S)-2-methyl-6-phenylpiperidin-4-
one (271) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-6-phenyl-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (263) (0.105 g, 0.365 mmol), 
dichloromethane (4 mL) and trifluoroacetic acid (0.279 mL, 3.65 mmol). The crude product was 
purified via flash column chromatography on silica gel (soaked with 1% triethylamine/petroleum 
ether), with a gradient elution from 30% ethyl acetate/1% triethylamine in petroleum ether (40–
60) to 60% ethyl acetate/1% triethylamine in petroleum ether (40–60) to produce (2R,6R)-2-
methyl-6-phenylpiperidin-4-one (270) (0.0290 g, 42%) as an orange solid. Further elution yielded 
(2R,6S)-2-methyl-6-phenylpiperidin-4-one (271) (0.0280 g, 40%) as an orange solid. Data for 
(2R,6R)-2-methyl-6-phenylpiperidin-4-one (270): Mp 58–61 °C; Rf 0.30 (30% ethyl acetate/1% 
triethylamine in petroleum ether); [α]D26 +63.4 (c 0.9, CHCl3), lit.,139 [α]D20 +72.2 (c 0.9, CHCl3); δH 
(400 MHz, CDCl3) 1.26 (3H, d, J 6.1 Hz, 1’-H3), 1.80 (1H, br s, NH), 2.23 (1H, dd, J 14.0, 11.9 Hz, 3-
HH), 2.41 (1H, dd, J 14.0, 2.7 Hz, 3-HH), 2.47–2.52 (2H, m, 5-H2), 3.12 (1H, dqd, J 11.9, 6.1, 2.7 Hz, 
2-H), 3.96 (1H, dt, J 11.9, 8.0 Hz, 6-H), 7.27–7.43 (5H, m, Ph); δC (101 MHz, CDCl3) 22.7 (CH3), 49.8 
(CH2), 50.0 (CH2), 52.4 (CH), 61.1 (CH), 126.5 (2 × CH), 127.9 (CH), 128.8 (2 × CH), 142.7 (C), 208.9 
(C); m/z (ESI) 190 (MH+, 100%). Data for (2R,6S)-2-methyl-6-phenylpiperidin-4-one (271): Mp 65–
69 °C; Rf 0.06 (30% ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3309 (NH), 
2962 (CH), 1712 (C=O), 1450 (C=C), 1242, 756, 702; [α]D26 +8.2 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 
1.19 (3H, d, J 6.4 Hz, 1’-H3), 1.82 (1H, br s, NH), 2.23 (1H, ddd, J 14.2, 6.4, 1.1 Hz, 3-HH), 2.59–2.73 
(3H, m, 3-HH and 5-H2), 3.41–3.51 (1H, m, 2-H), 4.48 (1H, t, J 8.0 Hz, 6-H), 7.25–7.41 (5H, m, Ph) ; δC 
(101 MHz, CDCl3) 21.2 (CH3), 47.8 (CH), 47.8 (CH2), 48.9 (CH2), 55.6 (CH), 126.9 (2 × CH), 127.6 (CH), 
128.7 (2 × CH), 142.7 (C), 209.5 (C); m/z (ESI) 190.1226 (MH+. C12H16NO requires 190.1226). 
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(2R,6R)-2-Methyl-6-(4’’-methoxyphenyl)piperidin-4-one (272) and (2R,6S)-2-methyl-6-(4’’-
methoxyphenyl)piperidin-4-one (273) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-6-(4’-methoxyphenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (264) (0.178 g, 0.558 
mmol). The crude product was purified via flash column chromatography on silica gel (soaked with 
1% triethylamine/petroleum ether), with a gradient elution from 40% ethyl acetate/1% 
triethylamine in petroleum ether (40–60) to 80% ethyl acetate/1% triethylamine in petroleum ether 
(40–60) to produce (2R,6R)-2-methyl-6-(4’’-methoxyphenyl)piperidin-4-one (272) (0.0560 g, 46%) 
as an orange solid. Further elution yielded (2R,6S)-2-methyl-6-(4’’-methoxyphenyl)piperidin-4-one 
(273) (0.0450 g, 37%) as a red solid. Data for (2R,6R)-2-methyl-6-(4’’-methoxyphenyl)piperidin-4-
one (272): Mp 83–85 °C; Rf 0.22 (40% ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 
(neat) 3300 (NH), 2966 (CH), 1708 (C=O), 1510 (C=C), 1301, 1242, 1028, 823, 788; [α]D26 +65.3 (c 
1.0, CHCl3); δH (500 MHz, CDCl3) 1.25 (3H, d, J 6.2 Hz, 1’-H3), 1.79 (1H, br s, NH), 2.21 (1H, dd, J 14.0, 
11.9 Hz, 3-HH), 2.39 (1H, dd, J 14.0, 2.6 Hz, 3-HH), 2.44–2.51 (2H, m, 5-H2), 3.10 (1H, dqd, J 11.9, 
6.2, 2.6 Hz, 2-H), 3.80 (3H, s, OCH3), 3.90 (1H, dd, J 8.6, 6.2 Hz, 6-H), 6.87–6.91 (2H, m, 3’’-H and 5’’-
H), 7.30–7.34 (2H, m, 2’’-H and 6’’-H); δC (126 MHz, CDCl3) 22.6 (CH3), 49.8 (CH2), 50.1 (CH2), 52.3 
(CH), 55.3 (CH3), 60.5 (CH), 114.1 (2 × CH), 127.7 (2 × CH), 134.9 (C), 159.2 (C), 209.0 (C); m/z (ESI) 
220.1327 (MH+. C13H18NO2 requires 220.1332). Data for (2R,6S)-2-methyl-6-(4’’-
methoxyphenyl)piperidin-4-one (273): Mp 78–80 °C; Rf 0.070 (40% ethyl acetate/1% triethylamine 
in petroleum ether); νmax/cm−1 (neat) 3300 (NH), 2823 (CH), 1705 (C=O), 1512 (C=C), 1141, 1026, 
825, 786; [α]D26 +34.7 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 1.18 (3H, d, J 6.5 Hz, 1’-H3), 1.76 (1H, br s, 
NH), 2.22 (1H, ddd, J 14.2, 6.5, 1.1 Hz, 3-HH), 2.58–2.70 (3H, m, 3-HH and 5-H2), 3.39–3.48 (1H, m, 
2-H), 3.80 (3H, s, OCH3), 4.44 (1H, t, J 6.5 Hz, 6-H), 6.85–6.90 (2H, m, 3’’-H and 5’’-H), 7.23–7.29 (2H, 
m, 2’’-H and 6’’-H); δC (101 MHz, CDCl3) 21.2 (CH3), 47.7 (CH), 48.0 (CH2), 48.9 (CH2), 55.1 (CH3), 55.3 
(CH), 114.0 (2 × CH), 128.0 (2 × CH), 134.8 (C), 158.9 (C), 209.7 (C); m/z (ESI) 220.1331 (MH+. 
C13H18NO2 requires 220.1332). 
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(2R,6R)-2-Methyl-6-(naphthalen-2’’-yl)piperidin-4-one (274) and (2R,6S)-2-methyl-6-
(naphthalen-2’’-yl)piperidin-4-one (275) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-6-(naphthalen-2’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (265) (0.132 g, 0.390 
mmol). The crude product was purified via flash column chromatography on silica gel (soaked with 
1% triethylamine/petroleum ether), with a gradient elution from 40% ethyl acetate/1% 
triethylamine in petroleum ether (40–60) to 1% triethylamine in ethyl acetate to produce (2R,6R)-
2-methyl-6-(naphthalen-2’’-yl)piperidin-4-one (274) (0.0410 g, 44%) as an orange oil. Further 
elution yielded (2R,6S)-2-methyl-6-(naphthalen-2’’-yl)piperidin-4-one (275) (0.0390 g, 42%) as an 
orange oil. Data for (2R,6R)-2-methyl-6-(naphthalen-2’’-yl)piperidin-4-one (274): Rf 0.39 (40% ethyl 
acetate/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3311 (NH), 2970 (CH), 1714 (C=O), 
1373, 1303, 1232, 860; [α]D26 +65.9 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.29 (3H, d, J 6.2 Hz, 1’-H3), 
1.91 (1H, br s, NH), 2.27 (1H, dd, J 14.0, 11.9 Hz, 3-HH), 2.44 (1H, dd, J 14.0, 2.7 Hz, 3-HH), 2.57 (2H, 
d, J 8.0 Hz, 5-H2), 3.17 (1H, dqd, J 11.9, 6.2, 2.7 Hz, 2-H), 4.08–4.15 (1H, m, 6-H), 7.45–7.51 (2H, m, 
6’’-H and 7’’-H), 7.52 (1H, dd, J 8.6, 1.5 Hz, 3’’-H), 7.80–7.86 (4H, m, 1’’-H, 4’’-H, 5’’-H and 8’’-H); δC 
(126 MHz, CDCl3) 22.7 (CH3), 49.8 (CH2), 49.9 (CH2), 52.4 (CH), 61.1 (CH), 124.7 (CH), 125.1 (CH), 
126.0 (CH), 126.3 (CH), 127.7 (CH), 127.9 (CH), 128.5 (CH), 133.1 (C), 133.4 (C), 140.0 (C), 208.7 (C); 
m/z (ESI) 240.1379 (MH+. C16H18NO requires 240.1383). Data for (2R,6S)-2-methyl-6-(naphthalen-
2’’-yl)piperidin-4-one (275): Rf 0.10 (40% ethyl acetate/1% triethylamine in petroleum ether); 
νmax/cm−1 (neat) 3315 (NH), 2964 (CH), 1708 (C=O), 1506 (C=C), 1305, 1236, 858, 619; [α]D26 −58.7 
(c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.20 (3H, d, J 6.6 Hz, 1’-H3), 1.86 (1H, br s, NH), 2.26 (1H, ddd, J 
14.2, 6.6, 1.4 Hz, 3-HH), 2.65 (1H, ddd, J 14.2, 4.9, 1.4 Hz, 3-HH), 2.74 (1H, ddd, J 14.4, 5.3, 1.4 Hz, 
5-HH), 2.81 (1H, ddd, J 14.4, 6.9, 1.4 Hz, 5-HH), 3.41–3.49 (1H, m, 2-H), 4.65 (1H, dd, J 6.9, 5.3 Hz, 
6-H), 7.45–7.51 (3H, m, 3’’-H, 6’’-H and 7’’-H), 7.75 (1H, br s, 1’’-H), 7.79–7.86 (3H, m, 4’’-H, 5’’-H 
and 8’’-H); δC (101 MHz, CDCl3) 21.1 (CH3), 47.4 (CH2), 47.8 (CH), 48.8 (CH2), 55.7 (CH), 125.1 (CH), 
125.6 (CH), 126.1 (CH), 126.4 (CH), 127.6 (CH), 128.0 (CH), 128.6 (CH), 132.8 (C), 133.2 (C), 139.5 
(C), 208.6 (C); m/z (ESI) 240.1385 (MH+. C16H18NO requires 240.1383). 
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(2R,6R)-2-Methyl-6-(4’’-nitrophenyl)piperidin-4-one (276) and (2R,6S)-2-methyl-6-(4’’-
nitrophenyl)piperidin-4-one (277) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-6-(4’-nitrophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (266) (0.103 g, 0.309 
mmol). The crude product was purified via flash column chromatography on silica gel (soaked with 
1% triethylamine/petroleum ether), eluting with 40% ethyl acetate/1% triethylamine in petroleum 
ether (40–60) to produce (2R,6R)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-one (276) (0.0310 g, 43%) 
as a red solid. Further elution yielded (2R,6S)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-one (277) 
(0.0300 g, 41%) as a brown solid. Data for (2R,6R)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-one 
(276): Mp 117–120 °C; Rf 0.21 (40% ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 
(neat) 3321 (NH), 2968 (CH), 1705 (C=O), 1510, 1346, 1305, 1292, 858; [α]D26 +62.4 (c 1.0, CHCl3); 
δH (500 MHz, CDCl3) 1.29 (3H, d, J 6.1 Hz, 1’-H3), 1.86 (1H, br s, NH), 2.25 (1H, ddd, J 14.0, 12.0, 0.8 
Hz, 3-HH), 2.37–2.54 (3H, m, 3-HH and 5-H2), 3.15 (1H, dqd, J 12.0, 6.1, 2.9 Hz, 2-H), 4.09 (1H, dd, J 
11.8, 3.2 Hz, 6-H), 7.58–7.64 (2H, m, 2’’-H and 6’’-H), 8.19–8.26 (2H, m, 3’’-H and 5’’-H); δC (126 
MHz, CDCl3) 22.6 (CH3), 49.6 (CH2), 49.7 (CH2), 52.2 (CH), 60.3 (CH), 124.1 (2 × CH), 127.4 (2 × CH), 
147.5 (C), 149.9 (C), 207.4 (C); m/z (ESI) 235.1073 (MH+. C12H15N2O3 requires 235.1077). Data for 
(2R,6S)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-one (277): Mp 88–91 °C; Rf 0.07 (40% ethyl 
acetate/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3300 (NH), 2962 (CH), 1707 (C=O), 
1508, 1344, 1236, 1170, 854, 700; [α]D26 +11.1 (c 0.2, CHCl3); δH (500 MHz, CDCl3) 1.22 (3H, d, J 6.6 
Hz, 1’-H3), 1.82 (1H, br s, NH), 2.26 (1H, ddd, J 14.0, 6.1, 1.0 Hz, 3-HH), 2.61–2.72 (3H, m, 3-HH and 
5-H2), 3.42–3.50 (1H, m, 2-H), 4.59 (1H, t, J 5.0 Hz, 6-H), 7.55–7.60 (2H, m, 2’’-H and 6’’-H), 8.18–
8.23 (2H, m, 3’’-H and 5’’-H); δC (126 MHz, CDCl3) 21.1 (CH3), 47.7 (CH2), 48.2 (CH), 48.9 (CH2), 55.2 
(CH), 123.9 (2 × CH), 127.8 (2 × CH), 147.3 (C), 150.0 (C), 208.3 (C); m/z (ESI) 235.1075 (MH+. 
C12H15N2O3 requires 235.1077). 
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(2R,6R)-2-Methyl-6-(pyridin-3’’-yl)piperidin-4-one (278) and (2R,6S)-2-methyl-6-(pyridin-3’’-
yl)piperidin-4-one (279) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-6-(pyridin-3’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (267) (0.0961 g, 0.331 
mmol). The crude product was purified via flash column chromatography on silica gel (soaked with 
1% triethylamine/dichloromethane), eluting with 2% methanol/50% dichloromethane/1% 
triethylamine in petroleum ether (40–60) to produce (2R,6R)-2-methyl-6-(pyridin-3’’-yl)piperidin-
4-one (278) (0.0260 g, 41%) as an orange oil. Further elution yielded (2R,6S)-2-methyl-6-( pyridin-
3’’-yl)piperidin-4-one (279) (0.0250 g, 39%) as an orange oil. Data for (2R,6R)-2-methyl-6-(pyridin-
3’’-yl)piperidin-4-one (278): Rf 0.22 (2% methanol/50% dichloromethane/1% triethylamine in 
petroleum ether); νmax/cm−1 (neat) 3285 (NH), 2965 (CH), 1709 (C=O), 1426, 1304, 1026, 713; [α]D26 
+70.5 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.27 (3H, d, J 6.1 Hz, 1’-H3), 1.85 (1H, br s, NH), 2.23 (1H, 
dd, J 14.0, 10.6 Hz, 3-HH), 2.40–2.54 (3H, m, 3-HH and 5-H2), 3.14 (1H, dqd, J 12.2, 6.1, 2.9 Hz, 2-H), 
4.01 (1H, dd, J 10.6, 4.4 Hz, 6-H), 7.31 (1H, dd, J 7.9, 4.8 Hz, 5’’-H), 7.77 (1H, dt, J 7.9, 1.9 Hz, 4’’-H), 
8.56 (1H, dd, J 4.8, 1.9 Hz, 6’’-H), 8.64 (1H, br d, J 1.9 Hz, 2’’-H); δC (126 MHz, CDCl3) 22.6 (CH3), 49.6 
(CH2), 49.6 (CH2), 52.4 (CH), 58.6 (CH), 123.7 (CH), 134.2 (CH), 138.0 (C), 148.5 (CH), 149.5 (CH), 
207.9 (C); m/z (ESI) 191.1181 (MH+. C11H15N2O requires 191.1179). Data for (2R,6S)-2-methyl-6-
(pyridin-3’’-yl)piperidin-4-one (279): Rf 0.11 (2% methanol/50% dichloromethane/1% triethylamine 
in petroleum ether); νmax/cm−1 (neat) 3263 (NH), 2962 (CH), 1705 (C=O), 1419, 1026, 802, 709; [α]D26 
+38.9 (c 0.2, CHCl3); δH (400 MHz, CDCl3) 1.22 (3H, d, J 6.4 Hz, 1’-H3), 1.69 (1H, br s, NH), 2.26 (1H, 
dd, J 14.1, 6.4 Hz, 3-HH), 2.62–2.70 (3H, m, 3-HH and 5-H2), 3.42–3.52 (1H, m, 2-H), 4.54 (1H, t, J 6.2 
Hz, 6-H), 7.28 (1H, dd, J 7.9, 4.8 Hz, 5’’-H), 7.70 (1H, dt, J 7.9, 1.8 Hz, 4’’-H), 8.54 (1H, dd, J 4.8, 1.8 
Hz, 6’’-H), 8.64 (1H, d, J 1.8 Hz, 2’’-H); δC (101 MHz, CDCl3) 21.0 (CH3), 47.5 (CH2), 48.1 (CH), 48.8 
(CH2), 53.6 (CH), 123.5 (CH), 134.4 (CH), 137.8 (C), 148.9 (CH), 149.1 (CH), 208.4 (C); m/z (ESI) 
191.1178 (MH+. C11H15N2O requires 191.1179). 
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(2R,6S)-2-Methyl-6-(2’’-phenylethyl)piperidin-4-one (280) and (2R,6R)-2-methyl-6-(2’’-
phenylethyl)piperidin-4-one (281) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,6S)-2-
methyl-6-propylpiperidin-4-one (260) and (2R,6R)-2-methyl-6-propylpiperidin-4-one (261) using 
(2R,5E)-8-phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-ene (268) (0.133 g, 0.420 mmol). The 
crude product was purified via flash column chromatography on silica gel (soaked with 1% 
triethylamine/petroleum ether), with a gradient elution from 60% ethyl acetate/1% triethylamine 
in petroleum ether (40–60) to 90% ethyl acetate/1% triethylamine in petroleum ether (40–60) to 
produce (2R,6S)-2-methyl-6-(2’’-phenylethyl)piperidin-4-one (280) (0.0380 g, 42%) as a brown oil. 
Further elution yielded (2R,6R)-2-methyl-6-(2’’-phenylethyl)piperidin-4-one (281) (0.0360 g, 40%) 
as a brown oil. Data for (2R,6S)-2-methyl-6-(2’’-phenylethyl)piperidin-4-one (280): Rf 0.32 (60% 
ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3300 (NH), 2960 (CH), 1714 
(C=O), 1454, 1365, 1217, 750; [α]D26 +2.2 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 1.20 (3H, d, J 6.2 Hz, 1’-
H3), 1.67 (1H, br s, NH), 1.75–1.91 (2H, m, 1’’-H2), 2.04–2.14 (2H, m, 3-HH and 5-HH), 2.34 (1H, dt, J 
15.0, 5.0 Hz, 3-HH), 2.41 (1H, dt, J 15.0, 5.0 Hz, 5-HH), 2.70 (2H, t, J 8.0 Hz, 2’’-H2), 2.84–2.98 (2H, 
m, 2-H and 6-H), 7.15–7.32 (5H, m, Ph); δC (126 MHz, CDCl3) 22.6 (CH3), 32.2 (CH2), 38.6 (CH2), 48.1 
(CH2), 50.2 (CH2), 52.0 (CH), 56.1 (CH), 126.1 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.4 (C), 209.2 
(C); m/z (ESI) 218.1540 (MH+. C14H20NO requires 218.1539). Data for (2R,6R)-2-methyl-6-(2’’-
phenylethyl)piperidin-4-one (281): Rf 0.11 (60% ethyl acetate/1% triethylamine in petroleum 
ether); νmax/cm−1 (neat) 3300 (NH), 2926 (CH), 1708 (C=O), 1454, 1379, 1232, 748; [α]D26 +6.0 (c 1.0, 
CHCl3); δH (500 MHz, CDCl3) 1.14 (3H, d, J 6.5 Hz, 1’-H3), 1.68–1.86 (3H, m, 1’’-H2 and NH), 2.13 (1H, 
ddd, J 13.8, 7.3, 1.4 Hz, 3-HH), 2.21 (1H, ddd, J 13.8, 6.0, 1.4 Hz, 5-HH), 2.47 (1H, ddd, J 13.8, 4.6, 
1.4 Hz, 3-HH), 2.52 (1H, ddd, J 13.8, 5.1, 1.4 Hz, 5-HH), 2.61–2.73 (2H, m, 2’’-H2), 3.31–3.38 (1H, m, 
6-H), 3.40–3.48 (1H, m, 2-H), 7.15–7.31 (5H, m, Ph); δC (126 MHz, CDCl3) 21.6 (CH3), 32.5 (CH2), 36.2 
(CH2), 47.8 (CH2), 47.8 (CH), 49.7 (CH2), 52.3 (CH), 126.0 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.4 
(C), 209.6 (C); m/z (ESI) 218.1537 (MH+. C14H20NO requires 218.1539). 
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(2R,4S,6S)-2-Methyl-6-propylpiperidin-4-ol (229)132 
 
 
 
(2R,6S)-2-Methyl-6-propylpiperidin-4-one (260) (0.094 g, 0.061 mmol) was dissolved in anhydrous 
methanol (2 mL) and cooled to −15 °C. Sodium borohydride (0.0046 g, 0.12 mmol) was added and 
the solution was stirred rapidly for 0.25 h. Once the reaction was complete, brine (1 mL) was added 
to quench the reaction and the mixture was diluted with ethyl acetate (10 mL). The organic layer 
was washed with brine (5 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified via flash column chromatography on silica gel, eluting with 30% methanol/1% 
triethylamine in ethyl acetate to produce (2R,4S,6S)-2-methyl-6-propylpiperidin-4-ol (229) (0.080 
g, 87%) as an off-white solid. Spectroscopic data was coJnsistent with the literature.132 Mp 74–76 
°C; Rf 0.25 (30% methanol/1% triethylamine in ethyl acetate); [α]D26 +9.0 (c 0.7, MeOH), lit.,132 [α]D20 
+8.8 (c 0.4, MeOH); δH (400 MHz, CDCl3) 0.91 (3H, t, J 7.1 Hz, 3’’-H3), 0.98 (1H, q, J 11.8 Hz, 5-HH), 
1.03 (1H, q, J 11.8 Hz, 3-HH), 1.12 (3H, d, J 6.3 Hz, 1’-H3), 1.29–1.46 (4H, m, 1’’-H2 and 2’’-H2), 1.86 
(2H, br s, NH and OH), 1.91–2.01 (2H, m, 3-HH and 5-HH), 2.52–2.61 (1H, m, 6-H), 2.69 (1H, dqd, J 
12.6, 6.3, 2.4 Hz, 2-H), 3.65 (1H, tt, J 11.0, 4.5 Hz, 4-H); δC (101 MHz, CDCl3) 14.2 (CH3), 19.2 (CH2), 
22.4 (CH3), 39.0 (CH2), 41.6 (CH2), 43.9 (CH2), 50.2 (CH), 54.6 (CH), 69.3 (CH); m/z (ESI) 158 (MH+, 
100%). 
 
(2R,4S,6S)-2-Methyl-6-nonylpiperidin-4-ol (234)142 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6S)-2-methyl-6-nonylpiperidin-4-one (239) (0.028 g, 
0.12 mmol). The crude product was purified via flash column chromatography on silica gel, eluting 
with 10% methanol/1% triethylamine in ethyl acetate to produce (2R,4S,6S)-2-methyl-6-
nonylpiperidin-4-ol (234) (0.023 g, 84%) as an off-white solid. Spectroscopic data was consistent 
with the literature.142 Mp 86–88 °C; Rf 0.16 (10% methanol/1% triethylamine in ethyl acetate); [α]D26 
+7.9 (c 1.0, MeOH), lit.,142 [α]D25 +7.0 (c 1.0, MeOH); δH (500 MHz, CDCl3) 0.88 (3H, t, J 7.0 Hz, 9’’-
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H3), 0.93–1.06 (2H, m, 3-HH and 5-HH), 1.12 (3H, d, J 6.3 Hz, 1’-H3), 1.20–1.48 (16H, m, 1’’-H2, 2’’-
H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2 and 8’’-H2), 1.63 (2H, br s, NH and OH), 1.97 (1H, q, J 11.8 Hz, 
3-HH), 2.02 (1H, q, J 11.8 Hz, 5-HH), 2.50–2.58 (1H, m, 6-H), 2.68 (1H, dqd, J 11.8, 6.3, 2.4 Hz, 2-H), 
3.65 (1H, tt, J 11.0, 4.6 Hz, 4-H); δC (126 MHz, CDCl3) 14.1 (CH3), 22.5 (CH3), 22.7 (CH2), 26.1 (CH2), 
29.3 (CH2), 29.6 (CH2), 29.6 (CH2), 29.8 (CH2), 31.9 (CH2), 36.8 (CH2), 41.8 (CH2), 43.9 (CH2), 50.2 (CH), 
54.9 (CH), 69.4 (CH); m/z (ESI) 242 (MH+, 100%). 
 
(2R,4S,6R)-2-Methyl-6-phenylpiperidin-4-ol (282)158  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6R)-2-methyl-6-phenylpiperidin-4-one (270) (0.0146 
g, 0.0770 mmol). The crude product was purified via flash column chromatography on silica gel, 
eluting with 1% methanol/1% triethylamine in dichloromethane to produce (2R,4S,6R)-2-methyl-6-
phenylpiperidin-4-ol (282) (0.013 g, 91%) as an off white solid. Spectroscopic data was consistent 
with the literature.158 Mp 92–94 °C; Rf 0.19 (1% methanol/1% triethylamine in dichloromethane); 
[α]D26 +27.6 (c 1.0, CHCl3), lit.,158 [α]D20 +29.0 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 1.10–1.21 (4H, m, 
1’-H3 and 3-HH), 1.45 (1H, q, J 11.8 Hz, 5-HH), 1.58 (2H, br s, NH and OH), 2.00 (1H, ddt, J 11.8, 4.6, 
2.4 Hz, 3-HH), 2.10 (1H, ddt, J 11.8, 4.6, 2.4 Hz, 5-HH), 2.86 (1H, dqd, J 11.8, 6.3, 2.4 Hz, 2-H), 3.69 
(1H, dd, J 11.8, 2.4 Hz, 6-H), 3.81 (1H, tt, J 11.8, 4.6 Hz, 4-H), 7.23–7.41 (5H, m, Ph); δC (101 MHz, 
CDCl3) 22.5 (CH3), 43.4 (CH2), 43.4 (CH2), 50.7 (CH), 59.8 (CH), 69.8 (CH), 126.8 (2 × CH), 127.3 (CH), 
128.5 (2 × CH), 144.0 (C); m/z (ESI) 192.1385 (MH+. C12H18NO requires 192.1383). 
 
(2R,4S,6R)-2-Methyl-6-(4’’-methoxyphenyl)piperidin-4-ol (283)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6R)-2-methyl-6-(4’’-methoxyphenyl)piperidin-4-one 
194 
 
(272) (0.0170 g, 0.0780 mmol). The crude product was purified via flash column chromatography 
on silica gel, eluting with 70% ethyl acetate/1% triethylamine in dichloromethane to produce 
(2R,4S,6R)-2-methyl-6-(4’’-methoxyphenyl)piperidin-4-ol (283) (0.015 g, 85%) as a white solid. Mp 
85–90 °C; Rf 0.11 (70% ethyl acetate/1% triethylamine in dichloromethane); νmax/cm−1 (neat) 3340 
(NH and OH), 2933 (CH), 1514 (C=C), 1303, 1244, 1178, 1033, 827, 734; [α]D26 +21.3 (c 1.0, CHCl3); 
δH (500 MHz, CDCl3) 1.09–1.19 (4H, m, 1’-H3 and 3-HH), 1.43 (1H, q, J 12.0 Hz, 5-HH), 1.61 (2H, br s, 
NH and OH), 1.99 (1H, ddt, J 12.0, 4.4, 2.3 Hz, 3-HH), 2.07 (1H, ddt, J 12.0, 4.4, 2.3 Hz, 5-HH), 2.84 
(1H, dqd, J 12.0, 6.2, 2.3 Hz, 2-H), 3.64 (1H, dd, J 12.0, 2.3 Hz, 6-H), 3.75–3.83 (4H, m, OCH3 and 4-
H), 6.83–6.89 (2H, m, 3’’-H and 5’’-H), 7.27–7.32 (2H, m, 2’’-H and 6’’-H); δC (126 MHz, CDCl3) 22.5 
(CH3), 43.4 (2 × CH2), 50.7 (CH), 55.3 (CH3), 59.1 (CH), 69.8 (CH), 113.8 (2 × CH), 127.8 (2 × CH), 136.3 
(C), 158.8 (C); m/z (ESI) 222.1487 (MH+. C13H20NO2 requires 222.1489). 
 
(2R,4S,6R)-2-Methyl-6-(naphthalen-2’’-yl)piperidin-4-ol (284)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6R)-2-methyl-6-(naphthalen-2’’-yl)piperidin-4-one 
(274) (0.0363 g, 0.152 mmol). The crude product was purified via flash column chromatography on 
silica gel, eluting with 80% ethyl acetate/1% triethylamine in dichloromethane to produce 
(2R,4S,6R)-2-methyl-6-(naphthalen-2’’-yl)piperidin-4-ol (284) (0.032 g, 87%) as a white solid. Mp 
157–160 °C; Rf 0.21 (80% ethyl acetate/1% triethylamine in dichloromethane); νmax/cm−1 (neat) 
3284 (NH and OH), 2926 (CH), 1599 (C=C), 1371, 1303, 1087, 1035, 817, 746; [α]D26 +6.9 (c 1.0, 
CHCl3); δH (400 MHz, CDCl3) 1.12–1.26 (4H, m, 1’-H3 and 3-HH), 1.53 (1H, q, J 12.2 Hz, 5-HH), 1.68 
(2H, br s, NH and OH), 2.03 (1H, ddt, J 12.2, 4.5, 2.3 Hz, 3-HH), 2.18 (1H, ddt, J 12.2, 4.5, 2.3 Hz, 5-
HH), 2.90 (1H, dqd, J 12.2, 6.3, 2.3 Hz, 2-H), 3.80–3.90 (2H, m, 4-H and 6-H), 7.41–7.53 (3H, m, 3’’-
H, 6’’-H and 7’’-H), 7.77–7.86 (4H, m, 1’’-H, 4’’-H, 5’’-H and 8’’-H); δC (101 MHz, CDCl3) 22.5 (CH3), 
43.5 (CH2), 43.5 (CH2), 50.8 (CH), 59.8 (CH), 69.8 (CH), 125.0 (CH), 125.3 (CH), 125.6 (CH), 126.0 (CH), 
127.6 (CH), 127.9 (CH), 128.1 (CH), 132.9 (C), 133.5 (C), 141.5 (C); m/z (ESI) 242.1538 (MH+. C16H20NO 
requires 242.1539). 
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(2R,4S,6R)-2-Methyl-6-(4’’-nitrophenyl)piperidin-4-ol (285)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6R)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-one 
(276) (0.0192 g, 0.0820 mmol). The crude product was purified via flash column chromatography 
on silica gel, eluting with 70% ethyl acetate/1% triethylamine in petroleum ether (40–60) to 
produce (2R,4S,6R)-2-methyl-6-(4’’-nitrophenyl)piperidin-4-ol (285) (0.015 g, 75%) as a yellow oil. 
Rf 0.12 (70% ethyl acetate/1% triethylamine in petroleum ether); νmax/cm−1 (neat) 3298 (NH and 
OH), 2935 (CH), 1516, 1344, 1087, 1033, 854, 698; [α]D26 +20.0 (c 0.9, CHCl3); δH (500 MHz, CDCl3) 
1.12–1.22 (4H, m, 1’-H3 and 3-HH), 1.37 (1H, q, J 12.3 Hz, 5-HH), 1.58 (2H, br s, NH and OH), 2.03 
(1H, ddt, J 12.3, 4.5, 2.4 Hz, 3-HH), 2.10 (1H, ddt, J 12.3, 4.5, 2.4 Hz, 5-HH), 2.89 (1H, dqd, J 12.3, 6.2, 
2.4 Hz, 2-H), 3.79–3.88 (2H, m, 4-H and 6-H), 7.54–7.58 (2H, m, 2’’-H and 6’’-H), 8.16–8.21 (2H, m, 
3’’-H and 5’’-H); δC (126 MHz, CDCl3) 22.5 (CH3), 43.1 (CH2), 43.5 (CH2), 50.5 (CH), 59.2 (CH), 69.4 
(CH), 123.8 (2 × CH), 127.6 (2 × CH), 147.2 (C), 151.6 (C); m/z (ESI) 237.1239 (MH+. C12H17N2O3 
requires 237.1234). 
 
(2R,4S,6R)-2-Methyl-6-(pyridin-3’’-yl)piperidin-4-ol (286)  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6R)-2-methyl-6-(pyridin-3’’-yl)piperidin-4-one (278) 
(0.0176 g, 0.0920 mmol). The crude product was purified via flash column chromatography on silica 
gel, eluting with 5% methanol/1% triethylamine in dichloromethane to produce (2R,4S,6R)-2-
methyl-6-(pyridin-3’’-yl)piperidin-4-ol (286) (0.012 g, 68%) as a pale yellow oil. Rf 0.23 (5% 
methanol/1% triethylamine in dichloromethane); νmax/cm−1 (neat) 3254 (NH and OH), 2933 (CH), 
1425, 1305, 1089, 1028, 804, 711; [α]D26 +17.7 (c 0.8, CHCl3); δH (400 MHz, CDCl3) 1.10–1.23 (4H, m, 
1’-H3 and 3-HH), 1.44 (1H, q, J 12.2 Hz, 5-HH), 1.87 (2H, br s, NH and OH), 2.02 (1H, ddt, J 12.2, 4.5, 
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2.3 Hz, 5-HH), 2.09 (1H, ddt, J 12.2, 4.5, 2.3 Hz, 3-HH), 2.88 (1H, dqd, J 12.2, 6.2, 2.3 Hz, 2-H), 3.74 
(1H, dd, J 12.2, 2.3 Hz, 6-H), 3.82 (1H, tt, J 12.2, 4.5 Hz, 4-H), 7.26 (1H, dd, J 7.9, 4.8 Hz, 5’’-H), 7.74 
(1H, dt, J 7.9, 1.8 Hz, 4’’-H), 8.50 (1H, dd, J 4.8, 1.8 Hz, 6’’-H), 8.58 (1H, d, J 1.8 Hz, 2’’-H); δC (101 
MHz, CDCl3) 22.5 (CH3), 43.2 (2 × CH2), 50.7 (CH), 57.3 (CH), 69.4 (CH), 123.6 (CH), 134.4 (CH), 139.4 
(C), 148.7 (CH), 148.8 (CH); m/z (ESI) 193.1339 (MH+. C11H17N2O requires 193.1335). 
 
(2R,4S,6S)-2-Methyl-6-(2’’-phenylethyl)piperidin-4-ol (287)146  
 
 
 
The reaction was carried out according to the above procedure for the synthesis of (2R,4S,6S)-2-
methyl-6-propylpiperidin-4-ol (229) using (2R,6S)-2-methyl-6-(2’’-phenylethyl)piperidin-4-one 
(280) (0.0136 g, 0.0630 mmol). The crude product was purified via flash column chromatography 
on silica gel, eluting with 1% methanol/1% triethylamine in dichloromethane to produce (2R,4S,6S)-
2-methyl-6-(2’’-phenylethyl)piperidin-4-ol (287) (0.011 g, 80%) as an off-white solid. Spectroscopic 
data was consistent with the literature.146 Mp 98–102 °C; Rf 0.19 (1% methanol/1% triethylamine 
in dichloromethane); [α]D26 +7.0 (c 0.6, CHCl3); δH (400 MHz, CDCl3) 1.02 (1H, q, J 11.7 Hz, 5-HH), 
1.04 (1H, q, J 11.7 Hz, 3-HH), 1.12 (3H, d, J 6.3 Hz, 1’-H3), 1.47 (2H, br s, NH and OH), 1.67–1.83 (2H, 
m, 1’’-H2), 1.95 (1H, ddt, J 11.7, 4.5, 2.2 Hz, 5-HH), 2.03 (1H, ddt, J 11.7, 4.5, 2.2 Hz, 3-HH), 2.56–
2.72 (4H, m, 2-H, 6-H and 2’’-H2), 3.66 (1H, tt, J 11.7, 4.5 Hz, 4-H), 7.16–7.21 (3H, m, 3 × ArH), 7.25–
7.31 (2H, m, 2 × ArH); δC (101 MHz, CDCl3) 22.6 (CH3), 32.6 (CH2), 38.6 (CH2), 41.8 (CH2), 44.1 (CH2), 
50.3 (CH), 54.5 (CH), 69.5 (CH), 126.0 (CH), 128.5 (2 × CH), 128.6 (2 × CH), 142.1 (C); m/z (ESI) 220 
(MH+, 100%). 
 
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (288) 
 
 
 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (258) (0.101 g, 0.396 mmol) was dissolved 
in methanol (9.9 mL, 0.04 M). Addition of 2 M hydrochloric acid in diethyl ether (0.198 mL, 0.396 
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mmol) followed and the solution was allowed to stir at room temperature for 1 h. Upon completion, 
the mixture was concentrated in vacuo. The crude product was purified via flash column 
chromatography on silica gel, eluting with 30% diethyl ether in petroleum ether (40–60) to produce 
tert-butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (288) (0.0404 g, 40%) as a 
colourless oil. Rf 0.21 (30% diethyl ether in petroleum ether); νmax/cm−1 (neat) 2962 (CH), 1658 
(C=O), 1527, 1458, 1257; [α]D24 +30.1 (c 0.9, CHCl3); δH (400 MHz, CDCl3) 0.91 (3H, t, J 7.2 Hz, 3’’-H3), 
1.23–1.39 (6H, m, 1’-H3, 1’’-HH and 2’’-H2 ), 1.50 (9H, s, 3 × CH3), 1.66–1.79 (1H, m, 1’’-HH), 2.36 
(1H, dd, J 17.7, 2.0 Hz, 3-HH), 2.53 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.72 (1H, ddd, J 17.9, 6.3, 1.4 Hz, 
5-HH), 2.82 (1H, dd, J 17.7, 6.3 Hz, 3-HH), 4.11–4.23 (1H, m, 6-H), 4.30–4.41 (1H, m, 2-H); δC (101 
MHz, CDCl3) 13.8 (CH3), 19.9 (CH2), 22.7 (CH3), 28.5 (3 × CH3), 39.3 (CH2), 41.3 (CH2), 44.6 (CH2), 46.5 
(CH), 50.9 (CH), 79.9 (C), 154.6 (C), 208.1 (C); m/z (ESI) 278.1730 (MNa+. C14H25NNaO3 requires 
278.1727). 
 
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-nonylpiperidine-1-carboxylate (290) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (288) using (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxopentadec-5-ene (259) (0.0504 g, 0.148 mmol). The crude product was 
purified via flash column chromatography on silica gel, eluting with 20% diethyl ether in petroleum 
ether (40–60) to produce tert-butyl (2R,6R)-2-methyl-4-oxo-6-nonylpiperidine-1-carboxylate (290) 
(0.0269 g, 53%) as a colourless oil. Rf 0.14 (20% diethyl ether in petroleum ether); νmax/cm−1 (neat) 
2958 (CH), 1710 (C=O), 1458, 1377, 1327; [α]D24 +19.6 (c 1.5, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, 
t, J 6.8 Hz, 9’’-H3), 1.17–1.36 (18H, m, 1’-H3, 1’’-HH, 2’’-H2, 3’’-H2, 4’’-H2, 5’’-H2, 6’’-H2, 7’’-H2 and 8’’-
H2), 1.50 (9H, s, 3 × CH3), 1.69–1.81 (1H, m, 1’’-HH), 2.36 (1H, dd, J 17.7, 1.8 Hz, 3-HH), 2.53 (1H, dd, 
J 18.0, 1.8 Hz, 5-HH), 2.72 (1H, dd, J 18.0, 5.5 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.4 Hz, 3-HH), 4.09–
4.20 (1H, m, 6-H), 4.30–4.42 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 22.7 (CH3), 
26.8 (CH2), 28.5 (3 × CH3), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 37.2 (CH2), 41.3 
(CH2), 44.6 (CH2), 46.5 (CH), 51.2 (CH), 79.9 (C), 154.6 (C), 208.1 (C); m/z (ESI) 362.2662 (MNa+. 
C20H37NNaO3 requires 362.2666). 
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tert-Butyl (2R,6R)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-carboxylate (291) 
 
 
 
The reaction was carried out according to the above procedure for the synthesis of tert-butyl 
(2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxylate (288) using (2R,5E)-8-phenyl-2-(tert-
butoxycarbonylamino)-4-oxooct-5-ene (268) (0.0354 g, 0.111 mmol). The crude product was 
purified via flash column chromatography on silica gel, eluting with 20% ethyl acetate in petroleum 
ether (40–60) to produce tert-butyl (2R,6R)-2-methyl-4-oxo-6-(2’’-phenylethyl)piperidine-1-
carboxylate (291) (0.0156 g, 44%) as a white solid. Mp 88–90 °C; Rf 0.15 (20% ethyl acetate in 
petroleum ether); νmax/cm−1 (neat) 2958 (CH), 1710 (C=O), 1458, 1377, 1327; [α]D24 +19.6 (c 1.5, 
CHCl3); δH (400 MHz, CDCl3) 1.27 (3H, d, J 6.7 Hz, 1’-H3), 1.49 (9H, s, 3 × CH3), 1.64 (1H, dtd, J 13.4, 
9.9, 6.1 Hz, 1’’-HH), 2.04–2.16 (1H, m, 1’’-HH), 2.38 (1H, dd, J 17.8, 2.0 Hz, 3-HH), 2.54–2.69 (3H, m, 
5-HH), 2.72–2.86 (2H, m, 3-HH and 5-HH), 4.20–4.30 (1H, m, 6-H), 4.31–4.42 (1H, m, 2-H), 7.12–
7.32 (5H, m, Ph); δC (101 MHz, CDCl3) 22.7 (CH3), 28.5 (3 × CH3), 33.2 (CH2), 39.0 (CH2), 41.4 (CH2), 
44.6 (CH2), 46.6 (CH), 50.9 (CH), 80.1 (C), 126.1 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.0 (C), 154.5 
(C), 207.7 (C); m/z (ESI) 340.1876 (MNa+. C19H27NNaO3 requires 340.1883). 
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4.3 Experimental for the Synthesis of Hexapeptide 181 
 
 
 
Pentapeptide 180 was synthesised on a Biotage Initiator+ Alstra peptide synthesiser using an 
Fmoc/tBu protecting group strategy on a 0.1 mmol synthetic scale using Rink Amide ChemMatrix® 
resin. Resin bound peptide 180 was synthesised by first loading Fmoc-Lys(Boc)-OH to the resin and 
by introducing the amino acids (4 equivalents) successively with a combination of 0.5 M HCTU in 
DMF (4 equivalents) and 2 M DIPEA in NMP (8 equivalents). Fmoc groups were removed using 20% 
piperidine in DMF. 
 
 
 
Resin bound pentapeptide 180 (0.0889 g, 0.0300 mmol) was treated with 20% piperidine in DMF (2 
mL) and shaken for 0.25 h. The solution was decanted and the resin bound peptide was washed 
with dichloromethane (3 × 2 mL), isopropanol (3 × 2 mL) and dimethylformamide (3 × 2 mL). The 
resin bound peptide was suspended in dimethylformamide (2 mL) followed by addition of (2S)-2-
[(9H-fluoren-9-ylmethoxycarbonyl)amino]-3-[4’-(4’’-methoxyphenyl)pyridin-2’-yl]propanoic acid 
(177) (0.0297 g, 0.0600 mmol), diisoproptlethylamine (0.0209 mL, 0.120 mmol), 0.5 M 2-(6-chloro-
1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate in dimethylformamide 
(0.120 mL, 0.0600 mmol). The mixture was shaken for 4 h. The solution was decanted and the resin 
bound peptide was washed with dichloromethane (3 × 2 mL), isopropanol (3 × 2 mL) and 
dimethylformamide (3 × 2 mL). The resin bound peptide was treated with 20% piperidine in DMF 
(2 mL) and shaken for 0.25 h. The solution was decanted and the resin bound peptide was washed 
with dichloromethane (3 × 2 mL), isopropanol (3 × 2 mL) and dimethylformamide (3 × 2 mL). The 
resin bound peptide was suspended in dimethylformamide (1.50 mL) followed by sequential 
addition of acetic anhydride (0.190 mL) and diisopropylethylamine (0.190 mL). The mixture was 
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shaken for 1 h. The solution was decanted and the resin bound peptide was washed with 
dichloromethane (3 × 2 mL), isopropanol (3 × 2 mL) and dimethylformamide (3 × 2 mL). The resin 
bound peptide was treated with trifluoroacetic acid/water/triisopropylsilane (2 mL, 95:2.5:2.5) and 
shaken for 2 h. The cleavage cocktail was evaporated using a stream of nitrogen and peptide 181 
was precipitated from a solution of ice cold diethyl ether (2 mL), centrifuged at 3700 rpm for 5 
minutes and the precipitate was washed with ice cold diethyl ether (3 × 2 mL). Peptide 181 was 
purified on a reverse-phase Dionex HPLC system equipped with Dionex P680 pumps and a Dionex 
UVD170U UV-Vis detector (monitoring at 214 nm and 280 nm), using a Phenomenex, Gemini, C18, 
5 um, 250 × 21.2 mm column. Gradients were run using a solvent system consisting of A (H2O + 
0.1% TFA) and B (MeCN + 0.1% TFA), and collected fractions were lyophilised on a Christ Alpha 2-4 
LO plus freeze dryer. Pure peptide 181 was analysed on a Shimadzu reverse-phase HPLC (RP-HPLC) 
system equipped with Shimadzu LC-20AT pumps, a Shimadzu SIL-20A autosampler and a Shimadzu 
SPD-20A UV-Vis detector (monitoring at 214 nm and 280 nm) using a Phenomenex, Aeris, 5 μm, 
peptide XB-C18, 150 × 4.6 mm column at a flow rate of 1 mL/minute. RP-HPLC gradients were run 
using a solvent system consisting of solution A (5% MeCN in H2O + 0.1% TFA) and B (5% H2O in 
MeCN + 0.1% TFA). Two gradients were used to characterise peptide 181; a gradient from 0–100% 
solution B over 20 minutes (Figure 53) and a gradient from 0–100% solution B over 50 minutes 
(Figure 54). Analytical RP-HPLC data is reported as column retention time (tR) in minutes (Table 4). 
High resolution mass spectrometry (HRMS) was performed on a Bruker microTOF-Q II (ESI+). HRMS 
data are reported as mass to charge ratio (m/z) = observed / MW. 
 
 
Table 4: RP-HPLC gradients and HRMS data. 
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Figure 53: Analytical HPLC 20 minute gradient. 
 
 
Figure 54: Analytical HPLC 50 minute gradient. 
 
4.4 Cell-Hexapeptide 181 Study 
15 × 104 human foreskin fibroblast cells immortalised with hTERT (human telomerase reverse 
transcriptase) were plated onto ibidi® μ-Slide VI 0.4 six-chamber plates and grown for 72 h in 
Dulbecco’s Modified Eagle’s Medium (DMEM) complemented with medium 199 (18%), fetal bovine 
serum (FBS) (9%), penicillin/streptomycin (2%) and sodium pyruvate (1%) in a 5% CO2 atmosphere 
at 37 °C. Fresh growth media was applied every 24 h. Cells were treated with 120 μL of 100 μM 
hexapeptide 181 and were visualised immediately using a fluorescence microsope.  
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Appendix 2 - Pentapeptide Test Cleavage Data 
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